# Pharmacokinetic-markers-of-clinical-outcomes-in-severe-mental-illness-a-systematic-review.---source
Respository for the screened data

|title| year | journal | volume | issue | pages | authors | doi |
|--- | --- |--- | --- |--- | --- |--- | --- |
|	Venlafaxine pharmacogenetics:Â a comprehensive review.	|	2019	|	Pharmacogenomics	|	20	|	11	|	829-845	|	SuwaÅ‚a J and Machowska M and Wiela-HojeÅ„ska A	|	10.2217/pgs-2019-0031	|
|	Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.	|	2019	|	Pharmacogenomics	|	20	|	1	|	37-47	|	Bousman CA and Arandjelovic K and Mancuso SG and Eyre HA and Dunlop BW	|	10.2217/pgs-2018-0142	|
|	Review and Consensus on Pharmacogenomic Testing in Psychiatry.	|	2021	|	Pharmacopsychiatry	|	54	|	1	|	17-May	|	Bousman CA and Bengesser SA and Aitchison KJ and Amare AT and Aschauer H and Baune BT and Asl BB and Bishop JR and Burmeister M and Chaumette B and Chen LS and Cordner ZA and Deckert J and Degenhardt F and DeLisi LE and Folkersen L and Kennedy JL and Klein TE and McClay JL and McMahon FJ and Musil R and Saccone NL and Sangkuhl K and Stowe RM and Tan EC and Tiwari AK and Zai CC and Zai G and Zhang J and Gaedigk A and MÃ¼ller DJ	|	10.1055/a-1288-1061	|
|	Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.	|	2017	|	The Journal of clinical psychiatry	|	78	|	6	|	720-729	|	Rosenblat JD and Lee Y and McIntyre RS	|	10.4088/JCP.15r10583	|
|	Biomarker-Guided Tailored Therapy.	|	2019	|	Advances in experimental medicine and biology	|	1192	|		|	199-224	|	Lydiard J and Nemeroff CB	|	10.1007/978-981-32-9721-0_10	|
|	The pharmacogenetics of treatment with olanzapine.	|	2021	|	Pharmacogenomics	|	22	|	14	|	939-958	|	Zubiaur P and Soria-Chacartegui P and Villapalos-GarcÃ­a G and Gordillo-Perdomo JJ and Abad-Santos F	|	10.2217/pgs-2021-0051	|
|	Pharmacogenomics and Biomarkers of Depression.	|	2019	|	Handbook of experimental pharmacology	|	250	|		|	101-113	|	Jha MK and Trivedi MH	|	10.1007/164_2018_171	|
|	Pharmacogenomic Biomarkers and Their Applications in Psychiatry.	|	2020	|	Genes	|	11	|	12	|		|	Kam H and Jeong H	|	10.3390/genes11121445	|
|	Antidepressant pharmacogenetics.	|	2014	|	Current opinion in psychiatry	|	27	|	1	|	43-51	|	Singh AB and Bousman CA and Ng C and Berk M	|	10.1097/YCO.0000000000000023	|
|	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.	|	2022	|	JAMA	|	328	|	2	|	151-161	|	Oslin DW and Lynch KG and Shih MC and Ingram EP and Wray LO and Chapman SR and Kranzler HR and Gelernter J and Pyne JM and Stone A and DuVall SL and Lehmann LS and Thase ME and Aslam M and Batki SL and Bjork JM and Blow FC and Brenner LA and Chen P and Desai S and Dieperink EW and Fears SC and Fuller MA and Goodman CS and Graham DP and Haas GL and Hamner MB and Helstrom AW and Hurley RA and Icardi MS and Jurjus GJ and Kilbourne AM and Kreyenbuhl J and Lache DJ and Lieske SP and Lynch JA and Meyer LJ and Montalvo C and Muralidhar S and Ostacher MJ and Paschall GY and Pfeiffer PN and Prieto S and Przygodzki RM and Ranganathan M and Rodriguez-Suarez MM and Roggenkamp H and Schichman SA and Schneeweis JS and Simonetti JA and Steinhauer SR and Suppes T and Umbert MA and Vassy JL and Voora D and Wiechers IR and Wood AE	|	10.1001/jama.2022.9805	|
|	Pharmacogenetics and schizophrenia.	|	2007	|	The Psychiatric clinics of North America	|	30	|	3	|	417-35	|	Foster A and Miller DD and Buckley PF	|	10.1016/j.psc.2007.04.004	|
|	Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia.	|	2021	|	Drug development research	|	82	|	5	|	678-684	|	Maes MS and Lu JY and Tiwari AK and Freeman N and de Luca V and MÃ¼ller DJ and Voineskos AN and Potkin SG and Lieberman JA and Meltzer HY and Remington G and Kennedy JL and Zai CC	|	10.1002/ddr.21681	|
|	Iloperidone for schizophrenia.	|	2010	|	Expert opinion on pharmacotherapy	|	11	|	12	|	2087-93	|	Rado J and Janicak PG	|	10.1517/14656566.2010.502889	|
|	Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.	|	2018	|	The lancet. Psychiatry	|	5	|	4	|	327-338	|	Yu H and Yan H and Wang L and Li J and Tan L and Deng W and Chen Q and Yang G and Zhang F and Lu T and Yang J and Li K and Lv L and Tan Q and Zhang H and Xiao X and Li M and Ma X and Yang F and Li L and Wang C and Li T and Zhang D and Yue W	|	10.1016/S2215-0366(18)30049-X	|
|	Pharmacogenomics of ketamine: A systematic review.	|	2021	|	Journal of psychiatric research	|	145	|		|	27-34	|	Meshkat S and Rodrigues NB and Di Vincenzo JD and Ceban F and Jaberi S and McIntyre RS and Lui LMW and Rosenblat JD	|	10.1016/j.jpsychires.2021.11.036	|
|	Genomics and pharmacogenomics of schizophrenia.	|	2011	|	CNS neuroscience & therapeutics	|	17	|	5	|	541-65	|	Cacabelos R and MartÃ­nez-Bouza R	|	10.1111/j.1755-5949.2010.00187.x	|
|	[Pharmacogenetics in psychiatry: state of the art].	|	2018	|	Der Nervenarzt	|	89	|	3	|	290-299	|	MÃ¼ller DJ and Brandl EJ and Degenhardt F and Domschke K and Grabe H and Gruber O and Hebebrand J and Maier W and Menke A and Riemenschneider M and Rietschel M and Rujescu D and Schulze TG and Tebartz van Elst L and TÃ¼scher O and Deckert J	|	10.1007/s00115-017-0479-8	|
|	Genetic contributions to bipolar disorder: current status and future directions.	|	2021	|	Psychological medicine	|	51	|	13	|	2156-2167	|	O'Connell KS and Coombes BJ	|	10.1017/S0033291721001252	|
|	Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.	|	2015	|	Psychiatry research	|	230	|	2	|	121-9	|	Helton SG and Lohoff FW	|	10.1016/j.psychres.2015.09.019	|
|	Lithium Pharmacogenetics: Where Do We Stand?	|	2016	|	Drug development research	|	77	|	7	|	368-373	|	Pisanu C and Melis C and Squassina A	|	10.1002/ddr.21341	|
|	Pharmacogenomics and schizophrenia.	|	2000	|	European journal of pharmacology	|	410	|	2	|	227-241	|	Kawanishi Y and Tachikawa H and Suzuki T	|	10.1016/s0014-2999(00)00817-7	|
|	Advances in biomarkers of major depressive disorder.	|	2015	|	Advances in clinical chemistry	|	68	|		|	177-204	|	Huang TL and Lin CC	|	10.1016/bs.acc.2014.11.003	|
|	Personalized medicine in major depressive disorder -- opportunities and pitfalls.	|	2013	|	Metabolism: clinical and experimental	|	62	|		|	S34-9	|	Miller DB and O'Callaghan JP	|	10.1016/j.metabol.2012.08.021	|
|	The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.	|	2018	|	Molecular diagnosis & therapy	|	22	|	4	|	409-420	|	Pisanu C and Heilbronner U and Squassina A	|	10.1007/s40291-018-0335-y	|
|	Exploring pharmacogenetic variation in a Bulgarian psychiatric cohort.	|	2021	|	Folia medica	|	63	|	3	|	365-371	|	Ivanov HY and Velinov B and Kyosovksa G and Grigorova D and Shopov P	|	10.3897/folmed.63.e61484	|
|	The inflammatory cytokines: molecular biomarkers for major depressive disorder?	|	2015	|	Biomarkers in medicine	|	9	|	2	|	169-80	|	Martin C and Tansey KE and Schalkwyk LC and Powell TR	|	10.2217/bmm.14.29	|
|	Pharmacogenetics of schizophrenia.	|	2000	|	American journal of medical genetics	|	97	|	1	|	98-106	|	Cichon S and NÃ¶then MM and Rietschel M and Propping P	|	10.1002/(sici)1096-8628(200021)97:1<98::aid-ajmg12>3.0.co;2-w	|
|	The promise of psychiatric pharmacogenomics.	|	2015	|	Biological psychiatry	|	77	|	1	|	29-35	|	Hamilton SP	|	10.1016/j.biopsych.2014.09.009	|
|	Progress and prospects in pharmacogenetics of antidepressant drugs.	|	2016	|	Expert opinion on drug metabolism & toxicology	|	12	|	10	|	1157-68	|	Fabbri C and Crisafulli C and CalabrÃ² M and Spina E and Serretti A	|	10.1080/17425255.2016.1202237	|
|	Genetic Variations Associated with Long-Term Treatment Response in Bipolar Depression.	|	2021	|	Genes	|	12	|	8	|		|	Anmella G and Vilches S and Espadaler-Mazo J and Murru A and Pacchiarotti I and Tuson M and Garriga M and SolÃ© E and Brat M and Fico G and Vieta E	|	10.3390/genes12081259	|
|	Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.	|	2007	|	Molecular psychiatry	|	12	|	8	|	707-47	|	Arranz MJ and de Leon J	|	10.1038/sj.mp.4002009	|
|	From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.	|	2014	|	Canadian journal of psychiatry. Revue canadienne de psychiatrie	|	59	|	2	|	62-75	|	Fabbri C and Porcelli S and Serretti A	|	10.1177/070674371405900202	|
|	Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.	|	2015	|	Current psychiatry reports	|	17	|	7	|	50	|	Fabbri C and Serretti A	|	10.1007/s11920-015-0594-9	|
|	Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates.	|	2019	|	Frontiers in pharmacology	|	10	|		|	402	|	Vita A and Minelli A and Barlati S and Deste G and Giacopuzzi E and Valsecchi P and Turrina C and Gennarelli M	|	10.3389/fphar.2019.00402	|
|	Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research.	|	2013	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	162	|	6	|	487-520	|	Fabbri C and Di Girolamo G and Serretti A	|	10.1002/ajmg.b.32184	|
|	Prediction of response to drug therapy in psychiatric disorders.	|	2018	|	Open biology	|	8	|	5	|		|	Stern S and Linker S and Vadodaria KC and Marchetto MC and Gage FH	|	10.1098/rsob.180031	|
|	Epigenetic Modifications of Major Depressive Disorder.	|	2016	|	International journal of molecular sciences	|	17	|	8	|		|	Saavedra K and Molina-MÃ¡rquez AM and Saavedra N and Zambrano T and Salazar LA	|	10.3390/ijms17081279	|
|	Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future.	|	2020	|	Clinical psychopharmacology and neuroscience : the official scientific journal of           the Korean College of Neuropsychopharmacology	|	18	|	1	|	9-Jan	|	Fabbri C and Serretti A	|	10.9758/cpn.2020.18.1.1	|
|	Moving pharmacoepigenetics tools for depression toward clinical use.	|	2019	|	Journal of affective disorders	|	249	|		|	336-346	|	Hack LM and Fries GR and Eyre HA and Bousman CA and Singh AB and Quevedo J and John VP and Baune BT and Dunlop BW	|	10.1016/j.jad.2019.02.009	|
|	Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.	|	2022	|	Methods in molecular biology (Clifton, N.J.)	|	2547	|		|	389-425	|	Elsheikh SSM and MÃ¼ller DJ and Pouget JG	|	10.1007/978-1-0716-2573-6_14	|
|	Pharmacogenetics and antipsychotic treatment response.	|	2015	|	Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski           nauki)	|	36	|	1	|	53-67	|	Naumovska Z and Nestorovska AK and Filipce A and Sterjev Z and Brezovska K and Dimovski A and Suturkova LJ	|		|
|	Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.	|	2011	|	Expert opinion on drug metabolism & toxicology	|	7	|	1	|	Sep-37	|	Zhang JP and Malhotra AK	|	10.1517/17425255.2011.532787	|
|	Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs.	|	2021	|	Molecular psychiatry	|	26	|	7	|	2776-2804	|	Le-Niculescu H and Roseberry K and Gill SS and Levey DF and Phalen PL and Mullen J and Williams A and Bhairo S and Voegtline T and Davis H and Shekhar A and Kurian SM and Niculescu AB	|	10.1038/s41380-021-01061-w	|
|	TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response.	|	2021	|	Molecular psychiatry	|	26	|	7	|	3122-3133	|	Ho MF and Zhang C and Zhang L and Wei L and Zhou Y and Moon I and Geske JR and Choi DS and Biernacka J and Frye M and Wen Z and Karpyak VM and Li H and Weinshilboum R	|	10.1038/s41380-020-0855-9	|
|	miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.	|	2022	|	The pharmacogenomics journal	|	22	|	4	|	211-222	|	Tsermpini EE and Kalogirou CI and Kyriakopoulos GC and Patrinos GP and Stathopoulos C	|	10.1038/s41397-022-00283-7	|
|	Pharmacogenetics and outcome with antipsychotic drugs.	|	2014	|	Dialogues in clinical neuroscience	|	16	|	4	|	555-66	|	Pouget JG and Shams TA and Tiwari AK and MÃ¼ller DJ	|	10.31887/DCNS.2014.16.4/jpouget	|
|	Pharmacogenomics in psychiatry: implications for practice.	|	2014	|	Recent patents on biotechnology	|	8	|	2	|	152-9	|	Moore TR and Hill AM and Panguluri SK	|	10.2174/1872208309666140904113615	|
|	Possible biomarkers modulating haloperidol efficacy and/or tolerability.	|	2016	|	Pharmacogenomics	|	17	|	5	|	507-29	|	Porcelli S and Crisafulli C and CalabrÃ² M and Serretti A and Rujescu D	|	10.2217/pgs.16.5	|
|	The ethics of elective psychopharmacology.	|	2012	|	The international journal of neuropsychopharmacology	|	15	|	4	|	559-71	|	Mohamed AD and Sahakian BJ	|	10.1017/S146114571100037X	|
|	Economic evaluation in psychiatric pharmacogenomics: a systematic review.	|	2021	|	The pharmacogenomics journal	|	21	|	4	|	533-541	|	Karamperis K and Koromina M and Papantoniou P and Skokou M and Kanellakis F and Mitropoulos K and Vozikis A and MÃ¼ller DJ and Patrinos GP and Mitropoulou C	|	10.1038/s41397-021-00249-1	|
|	Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study.	|	2021	|	Bipolar disorders	|	23	|	8	|	821-831	|	Lin Y and Maihofer AX and Stapp E and Ritchey M and Alliey-Rodriguez N and Anand A and Balaraman Y and Berrettini WH and Bertram H and Bhattacharjee A and Calkin CV and Conroy C and Coryell W and D'Arcangelo N and DeModena A and Biernacka JM and Fisher C and Frazier N and Frye M and Gao K and Garnham J and Gershon E and Glazer K and Goes FS and Goto T and Karberg E and Harrington G and Jakobsen P and Kamali M and Kelly M and Leckband SG and Lohoff FW and Stautland A and McCarthy MJ and McInnis MG and Mondimore F and Morken G and Nurnberger JI and Oedegaard KJ and Syrstad VEG and Ryan K and Schinagle M and Schoeyen H and Andreassen OA and Shaw M and Shilling PD and Slaney C and Tarwater B and Calabrese JR and Alda M and Nievergelt CM and Zandi PP and Kelsoe JR	|	10.1111/bdi.13078	|
|	Sleep- and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder.	|	2015	|	Expert opinion on therapeutic targets	|	19	|	6	|	747-63	|	Bellivier F and Geoffroy PA and Etain B and Scott J	|	10.1517/14728222.2015.1018822	|
|	Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics.	|	2021	|	Pharmacogenomics	|	22	|	8	|	485-503	|	Shalimova A and Babasieva V and Chubarev VN and Tarasov VV and SchiÃ¶th HB and Mwinyi J	|	10.2217/pgs-2020-0157	|
|	Pharmacogenetics of antipsychotics: recent progress and methodological issues.	|	2013	|	Expert opinion on drug metabolism & toxicology	|	9	|	2	|	183-91	|	Zhang JP and Malhotra AK	|	10.1517/17425255.2013.736964	|
|	Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.	|	2020	|	Brain sciences	|	10	|	11	|		|	Dragoi AM and Radulescu I and NÄƒsui BA and Pop AL and Varlas VN and Trifu S	|	10.3390/brainsci10110840	|
|	Twenty years of Lithium pharmacogenetics: A systematic review.	|	2019	|	Psychiatry research	|	278	|		|	42-50	|	Pagani R and Gasparini A and Ielmini M and Caselli I and Poloni N and Ferrari M and Marino F and Callegari C	|	10.1016/j.psychres.2019.05.036	|
|	Clinically meaningful biomarkers for psychosis: a systematic and quantitative review.	|	2014	|	Neuroscience and biobehavioral reviews	|	45	|		|	134-41	|	Prata D and Mechelli A and Kapur S	|	10.1016/j.neubiorev.2014.05.010	|
|	Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia.	|	2017	|	Pharmacotherapy	|	37	|	9	|	1122-1130	|	Ward KM and Kraal AZ and Flowers SA and Ellingrod VL	|	10.1002/phar.1968	|
|	Pharmacogenetic-guided cannabis usage in the community pharmacy: evaluation of a pilot program.	|	2020	|	Journal of cannabis research	|	2	|	1	|	24	|	Papastergiou J and Li W and Sterling C and van den Bemt B	|	10.1186/s42238-020-00033-1	|
|	Pharmacogenetics in psychosis.	|	2003	|	Drug news & perspectives	|	16	|	3	|	159-65	|	Collier DA	|	10.1358/dnp.2003.16.3.737958	|
|		|	2020	|		|		|		|		|	Li KX and Loshak H	|		|
|	Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.	|	2010	|	Molecular psychiatry	|	15	|	5	|	473-500	|	Kato M and Serretti A	|	10.1038/mp.2008.116	|
|	Pharmacogenomic testing and personalized treatment of depression.	|	2014	|	Clinical chemistry	|	60	|	1	|	53-9	|	Perlis RH	|	10.1373/clinchem.2013.204446	|
|	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.	|	2018	|	Pharmacogenomics	|	19	|	16	|	1269-1284	|	Chang DD and Eyreeuro HA and Abbott R and Coudreaut M and Baune BT and Shaman JA and Lavretsky H and Lenze EJ and Merrill DA and Singh AB and Mulsant BH and Reynolds CF 3rd and MÃ¼ller DJ and Bousman C	|	10.2217/pgs-2018-0099	|
|	Molecular genetics of bipolar disorder and depression.	|	2007	|	Psychiatry and clinical neurosciences	|	61	|	1	|	19-Mar	|	Kato T	|	10.1111/j.1440-1819.2007.01604.x	|
|	Pharmacogenetic Decision Support Tools: A New Paradigm for Late-Life Depression?	|	2018	|	The American journal of geriatric psychiatry : official journal of the American           Association for Geriatric Psychiatry	|	26	|	2	|	125-133	|	Abbott R and Chang DD and Eyre HA and Bousman CA and Merrill DA and Lavretsky H	|	10.1016/j.jagp.2017.05.012	|
|	Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.	|	2013	|	Discovery medicine	|	16	|	87	|	113-22	|	Murphy E and McMahon FJ	|		|
|	Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.	|	2015	|	Pharmacogenomics	|	16	|	5	|	541-53	|	Helton SG and Lohoff FW	|	10.2217/pgs.15.15	|
|	Negative symptoms in schizophrenia: correlation with clinical and genetic factors.	|	2021	|	Pharmacogenomics	|	22	|	7	|	389-399	|	Hajj A and Hallit S and Chamoun K and Sacre H and Obeid S and Haddad C and Dollfus S and Khabbaz LR	|	10.2217/pgs-2020-0171	|
|	Clinical utility of pharmacogenetic testing in the treatment of bipolar disorder of Chinese patients.	|	2020	|	Pharmacogenomics	|	21	|	11	|	761-770	|	Huilei X and Siyu C and Jianghua X and Jidong R and Yi R	|	10.2217/pgs-2020-0050	|
|	Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial.	|	2021	|	Contemporary clinical trials	|	101	|		|	106247	|	Oslin DW and Chapman S and Duvall SL and Gelernter J and Ingram EP and Kranzler HR and Lehmann LS and Lynch JA and Lynch KG and Pyne JM and Shih MC and Stone A and Thase ME and Wray LO	|	10.1016/j.cct.2020.106247	|
|	Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection.	|	2020	|	International journal of bipolar disorders	|	8	|	1	|	23	|	CuÃ©llar-Barboza AB and McElroy SL and Veldic M and Singh B and Kung S and Romo-Nava F and Nunez NA and Cabello-Arreola A and Coombes BJ and Prieto M and Betcher HK and Moore KM and Winham SJ and Biernacka JM and Frye MA	|	10.1186/s40345-020-00184-3	|
|	Gene expression: biomarker of antidepressant therapy?	|	2013	|	International review of psychiatry (Abingdon, England)	|	25	|	5	|	579-91	|	Menke A	|	10.3109/09540261.2013.825580	|
|	Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.	|	2016	|	Pharmacogenomics and personalized medicine	|	9	|		|	117-129	|	Lally J and Gaughran F and Timms P and Curran SR	|	10.2147/PGPM.S115741	|
|	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors.	|	2020	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	21	|	1	|	72-77	|	Boiko AS and Ivanova SA and Pozhidaev IV and Freidin MB and Osmanova DZ and Fedorenko OY and Semke AV and Bokhan NA and Wilffert B and Loonen AJM	|	10.1080/15622975.2018.1548780	|
|	Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.	|	2016	|	Journal of neural transmission (Vienna, Austria : 1996)	|	123	|	11	|	1347-1354	|	Amitai M and Kronenberg S and Carmel M and Michaelovsky E and Frisch A and Brent D and Apter A and Chen A and Weizman A and Fennig S	|	10.1007/s00702-016-1585-7	|
|	Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.	|	2014	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	15	|	2	|	135-44	|	Mamdani F and Berlim MT and Beaulieu MM and Turecki G	|	10.3109/15622975.2013.766762	|
|	Mechanisms of the placebo effect in pain and psychiatric disorders.	|	2016	|	The pharmacogenomics journal	|	16	|	6	|	491-500	|	Holmes RD and Tiwari AK and Kennedy JL	|	10.1038/tpj.2016.15	|
|	TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.	|	2016	|	Molecular psychiatry	|	21	|	12	|	1717-1725	|	Gupta M and Neavin D and Liu D and Biernacka J and Hall-Flavin D and Bobo WV and Frye MA and Skime M and Jenkins GD and Batzler A and Kalari K and Matson W and Bhasin SS and Zhu H and Mushiroda T and Nakamura Y and Kubo M and Wang L and Kaddurah-Daouk R and Weinshilboum RM	|	10.1038/mp.2016.6	|
|	Olanzapine-Associated Rhabdomyolysis: A Case Report.	|	2021	|	Cureus	|	13	|	1	|	e12568	|	Skryabin VY and Zastrozhin M and Sychev DA	|	10.7759/cureus.12568	|
|	Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.	|	2018	|	Journal of managed care & specialty pharmacy	|	24	|	8	|	726-734	|	Groessl EJ and Tally SR and Hillery N and Maciel A and Garces JA	|	10.18553/jmcp.2018.24.8.726	|
|	Integrative proteomics and pharmacogenomics analysis of methylphenidate treatment response.	|	2019	|	Translational psychiatry	|	9	|	1	|	308	|	da Silva BS and Leffa DT and Beys-da-Silva WO and Torres ILS and Rovaris DL and Victor MM and Rohde LA and Mota NR and Oliveira C and Berger M and Yates JR 3rd and Sabnis R and PeÃ±a RD and Campos AR and Grevet EH and Santi L and Bau CHD and Contini V	|	10.1038/s41398-019-0649-5	|
|	Impact of TCF4 on the genetics of schizophrenia.	|	2011	|	European archives of psychiatry and clinical neuroscience	|	261	|		|	S161-5	|	Lennertz L and Quednow BB and Benninghoff J and Wagner M and Maier W and MÃ¶ssner R	|	10.1007/s00406-011-0256-9	|
|	Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models.	|	2019	|	Translational psychiatry	|	9	|	1	|	187	|	Paul R and Andlauer TFM and Czamara D and Hoehn D and Lucae S and PÃ¼tz B and Lewis CM and Uher R and MÃ¼ller-Myhsok B and Ising M and SÃ¤mann PG	|	10.1038/s41398-019-0524-4	|
|	Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.	|	2018	|	Neuromolecular medicine	|	20	|	1	|	17-Jan	|	Politi C and Ciccacci C and Novelli G and Borgiani P	|	10.1007/s12017-017-8473-7	|
|	The Potential Role of Pharmacogenomics in Optimizing Drug Regimens for Older People with Major Depressive Disorder.	|	2021	|	The Senior care pharmacist	|	36	|	6	|	276-283	|	Cox JM and Marshall LL	|	10.4140/TCP.n.2021.276	|
|	Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders.	|	2019	|	Journal of neural transmission (Vienna, Austria : 1996)	|	126	|	1	|	101-107	|	Blasco-Fontecilla H	|	10.1007/s00702-018-1882-4	|
|	Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders.	|	2015	|	Schizophrenia research	|	164	|	1	|	115-21	|	Grove T and Taylor S and Dalack G and Ellingrod V	|	10.1016/j.schres.2015.02.006	|
|	Pharmacogenetics of antidepressant response: A polygenic approach.	|	2017	|	Progress in neuro-psychopharmacology & biological psychiatry	|	75	|		|	128-134	|	GarcÃ­a-GonzÃ¡lez J and Tansey KE and Hauser J and Henigsberg N and Maier W and Mors O and Placentino A and Rietschel M and Souery D and Å½agar T and Czerski PM and Jerman B and ButtenschÃ¸n HN and Schulze TG and Zobel A and Farmer A and Aitchison KJ and Craig I and McGuffin P and Giupponi M and Perroud N and Bondolfi G and Evans D and O'Donovan M and Peters TJ and Wendland JR and Lewis G and Kapur S and Perlis R and Arolt V and Domschke K and Breen G and Curtis C and Sang-Hyuk L and Kan C and Newhouse S and Patel H and Baune BT and Uher R and Lewis CM and Fabbri C	|	10.1016/j.pnpbp.2017.01.011	|
|	Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder.	|	2020	|	Journal of affective disorders	|	273	|		|	254-264	|	Ren F and Ma Y and Zhu X and Guo R and Wang J and He L	|	10.1016/j.jad.2020.04.058	|
|	Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population.	|	2019	|	Neuroscience bulletin	|	35	|	3	|	561-580	|	Luo C and Liu J and Wang X and Mao X and Zhou H and Liu Z	|	10.1007/s12264-018-0323-6	|
|	Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication.	|	2019	|	Clinical pharmacology and therapeutics	|	106	|	4	|	855-865	|	Athreya AP and Neavin D and Carrillo-Roa T and Skime M and Biernacka J and Frye MA and Rush AJ and Wang L and Binder EB and Iyer RK and Weinshilboum RM and Bobo WV	|	10.1002/cpt.1482	|
|	Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment.	|	2013	|	International review of psychiatry (Abingdon, England)	|	25	|	5	|	572-8	|	Frieling H and TadiÄ‡ A	|	10.3109/09540261.2013.816657	|
|	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.	|	2020	|	Psychiatry research	|	290	|		|	113017	|	Shelton RC and Parikh SV and Law RA and Rothschild AJ and Thase ME and Dunlop BW and DeBattista C and Conway CR and Forester BP and Macaluso M and Hain DT and Aguilar AL and Brown K and Lewis DJ and Jablonski MR and Greden JF	|	10.1016/j.psychres.2020.113017	|
|	Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future.	|	2006	|	Journal of psychopharmacology (Oxford, England)	|	20	|	4	|	85-94	|	Preskorn SH	|	10.1177/1359786806066070	|
|	Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.	|	2016	|	Dialogues in clinical neuroscience	|	18	|	3	|	313-322	|	Eap CB	|	10.31887/DCNS.2016.18.3/ceap	|
|	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.	|	2021	|	Psychiatry research	|	296	|		|	113649	|	Rothschild AJ and Parikh SV and Hain D and Law R and Thase ME and Dunlop BW and DeBattista C and Conway CR and Forester BP and Shelton RC and Macaluso M and Brown K and Lewis D and Gutin A and Jablonski MR and Greden JF	|	10.1016/j.psychres.2020.113649	|
|	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders.	|	2021	|	Scientific reports	|	11	|	1	|	17823	|	Le Clerc S and Lombardi L and Baune BT and Amare AT and Schubert KO and Hou L and Clark SR and Papiol S and Cearns M and Heilbronner U and Degenhardt F and Tekola-Ayele F and Hsu YH and Shekhtman T and Adli M and Akula N and Akiyama K and Ardau R and Arias B and Aubry JM and Backlund L and Bhattacharjee AK and Bellivier F and Benabarre A and Bengesser S and Biernacka JM and Birner A and Brichant-Petitjean C and Cervantes P and Chen HC and Chillotti C and Cichon S and Cruceanu C and Czerski PM and Dalkner N and Dayer A and Del Zompo M and DePaulo JR and Ã‰tain B and Jamain S and Falkai P and Forstner AJ and Frisen L and Frye MA and Fullerton JM and Gard S and Garnham JS and Goes FS and Grigoroiu-Serbanescu M and Grof P and Hashimoto R and Hauser J and Herms S and Hoffmann P and JimÃ©nez E and Kahn JP and Kassem L and Kuo PH and Kato T and Kelsoe JR and Kittel-Schneider S and Ferensztajn-Rochowiak E and KÃ¶nig B and Kusumi I and Laje G and LandÃ©n M and Lavebratt C and Leckband SG and Tortorella A and Manchia M and Martinsson L and McCarthy MJ and McElroy SL and Colom F and Millischer V and Mitjans M and Mondimore FM and Monteleone P and Nievergelt CM and NÃ¶then MM and NovÃ¡k T and O'Donovan C and Ozaki N and Ã–sby U and Pfennig A and Potash JB and Reif A and Reininghaus E and Rouleau GA and Rybakowski JK and Schalling M and Schofield PR and Schweizer BW and Severino G and Shilling PD and Shimoda K and Simhandl C and Slaney CM and Pisanu C and Squassina A and Stamm T and Stopkova P and Maj M and Turecki G and Vieta E and Veeh J and Witt SH and Wright A and Zandi PP and Mitchell PB and Bauer M and Alda M and Rietschel M and McMahon FJ and Schulze TG and Spadoni JL and Boukouaci W and Richard JR and Le Corvoisier P and Barrau C and Zagury JF and Leboyer M and Tamouza R	|	10.1038/s41598-021-97140-7	|
|	Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis.	|	2021	|	Journal of personalized medicine	|	11	|	12	|		|	Stein K and Maruf AA and MÃ¼ller DJ and Bishop JR and Bousman CA	|	10.3390/jpm11121334	|
|	Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis.	|	2021	|	Drug development research	|	82	|	5	|	685-694	|	Ortega-VÃ¡zquez A and Mayen-Lobo YG and DÃ¡vila-Ortiz de Montellano DJ and TristÃ¡n-LÃ³pez L and AviÃ±a-Cervantes CL and RÃ­os C and LÃ³pez-LÃ³pez M and Monroy-Jaramillo N	|	10.1002/ddr.21774	|
|	Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.	|	2016	|	Schizophrenia bulletin	|	42	|	6	|	1418-1437	|	Zhang JP and Lencz T and Zhang RX and Nitta M and Maayan L and John M and Robinson DG and Fleischhacker WW and Kahn RS and Ophoff RA and Kane JM and Malhotra AK and Correll CU	|	10.1093/schbul/sbw058	|
|	Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study.	|	2018	|	Depression and anxiety	|	35	|	10	|	946-952	|	Perlis RH and Mehta R and Edwards AM and Tiwari A and Imbens GW	|	10.1002/da.22742	|
|	Pharmacogenomics with antidepressants in the STAR*D study.	|	2008	|	Pharmacogenomics	|	9	|	7	|	935-46	|	Lin E and Chen PS	|	10.2217/14622416.9.7.935	|
|	Genome-wide association studies in pharmacogenomics of antidepressants.	|	2015	|	Pharmacogenomics	|	16	|	5	|	555-66	|	Lin E and Lane HY	|	10.2217/pgs.15.5	|
|	Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach.	|	2017	|	Scientific reports	|	7	|	1	|	12460	|	Gaspar HA and Breen G	|	10.1038/s41598-017-12325-3	|
|	Pharmacokinetics of haloperidol: an update.	|	1999	|	Clinical pharmacokinetics	|	37	|	6	|	435-56	|	Kudo S and Ishizaki T	|	10.2165/00003088-199937060-00001	|
|	[Customized pharmacotherapies in schizophrenia].	|	2010	|	Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology	|	30	|	2	|	77-81	|	Suzuki Y and Fukui N and Watanabe J and Ono S and Sugai T and Tsuneyama N and Someya T	|		|
|	Unlocking the molecular mechanisms of antipsychotics - a new frontier for discovery.	|	2016	|	Swiss medical weekly	|	146	|		|	w14314	|	Bowling H and Santini E	|	10.4414/smw.2016.14314	|
|	Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.	|	2016	|	Omics : a journal of integrative biology	|	20	|	10	|	593-603	|	Alessandrini M and Chaudhry M and Dodgen TM and Pepper MS	|	10.1089/omi.2016.0122	|
|	Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients.	|	2021	|	Pharmacogenomics and personalized medicine	|	14	|		|	1015-1025	|	Carrascal-Laso L and Franco-MartÃ­n MÃ and Marcos-Vadillo E and Ramos-Gallego I and GarcÃ­a-Berrocal B and Mayor-Toranzo E and SÃ¡nchez-Iglesias S and Lorenzo C and Sevillano-JimÃ©nez A and SÃ¡nchez-MartÃ­n A and GarcÃ­a-Salgado MJ and Isidoro-GarcÃ­a M	|	10.2147/PGPM.S320816	|
|	A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.	|	2021	|	Journal of psychopharmacology (Oxford, England)	|	35	|	8	|	992-1002	|	McCarthy MJ and Chen Y and Demodena A and Leckband SG and Fischer E and Golshan S and Suppes T and Kelsoe JR	|	10.1177/02698811211015224	|
|	Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.	|	2011	|	Expert review of clinical pharmacology	|	4	|	3	|	389-405	|	Arranz MJ and Munro JC	|	10.1586/ecp.11.16	|
|	Glucocorticoid Receptor Genetic Variants and Response to Fluoxetine in Major Depressive Disorder.	|	2018	|	The Journal of neuropsychiatry and clinical neurosciences	|	30	|	1	|	45-50	|	Nouraei H and Firouzabadi N and Mandegary A and Zomorrodian K and Bahramali E and Shayesteh MRH and Ansari S	|	10.1176/appi.neuropsych.16120322	|
|	Genetic disposition to inflammation and response to antidepressants in major depressive disorder.	|	2018	|	Journal of psychiatric research	|	105	|		|	17-22	|	Zwicker A and Fabbri C and Rietschel M and Hauser J and Mors O and Maier W and Zobel A and Farmer A and Aitchison KJ and McGuffin P and Lewis CM and Uher R	|	10.1016/j.jpsychires.2018.08.011	|
|	Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications.	|	2011	|	Pharmacogenomics	|	12	|	7	|	999-1016	|	Lee AK and Bishop JR	|	10.2217/pgs.11.45	|
|	Convergent Functional Genomics of bipolar disorder: from animal model pharmacogenomics to human genetics and biomarkers.	|	2007	|	Neuroscience and biobehavioral reviews	|	31	|	6	|	897-903	|	Le-Niculescu H and McFarland MJ and Mamidipalli S and Ogden CA and Kuczenski R and Kurian SM and Salomon DR and Tsuang MT and Nurnberger JI Jr and Niculescu AB	|	10.1016/j.neubiorev.2007.05.008	|
|	Pharmacogenetics in psychiatry: are we ready for widespread clinical use?	|	2008	|	Schizophrenia bulletin	|	34	|	6	|	1130-44	|	Arranz MJ and Kapur S	|	10.1093/schbul/sbn114	|
|	The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis.	|	2010	|	Bipolar disorders	|	12	|	7	|	702-6	|	Daray FM and Thommi SB and Ghaemi SN	|	10.1111/j.1399-5618.2010.00864.x	|
|	The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.	|	2018	|	Journal of affective disorders	|	241	|		|	484-491	|	Rosenblat JD and Lee Y and McIntyre RS	|	10.1016/j.jad.2018.08.056	|
|	Genomics and the future of pharmacotherapy in psychiatry.	|	2007	|	International review of psychiatry (Abingdon, England)	|	19	|	5	|	523-30	|	Malhotra AK and Lencz T and Correll CU and Kane JM	|	10.1080/09540260701563460	|
|	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis.	|	2016	|	The international journal of neuropsychopharmacology	|	19	|	5	|		|	Huang E and Zai CC and Lisoway A and Maciukiewicz M and Felsky D and Tiwari AK and Bishop JR and Ikeda M and Molero P and Ortuno F and Porcelli S and Samochowiec J and Mierzejewski P and Gao S and Crespo-Facorro B and Pelayo-TerÃ¡n JM and Kaur H and Kukreti R and Meltzer HY and Lieberman JA and Potkin SG and MÃ¼ller DJ and Kennedy JL	|	10.1093/ijnp/pyv132	|
|	Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines.	|	2016	|	The pharmacogenomics journal	|	16	|	5	|	446-53	|	Breen MS and White CH and Shekhtman T and Lin K and Looney D and Woelk CH and Kelsoe JR	|	10.1038/tpj.2016.50	|
|	The promise of biological markers for treatment response in first-episode psychosis: a systematic review.	|	2015	|	Schizophrenia bulletin	|	41	|	3	|	559-73	|	Fond G and d'Albis MA and Jamain S and Tamouza R and Arango C and Fleischhacker WW and GlenthÃ¸j B and Leweke M and Lewis S and McGuire P and Meyer-Lindenberg A and Sommer IE and Winter-van Rossum I and Kapur S and Kahn RS and Rujescu D and Leboyer M	|	10.1093/schbul/sbv002	|
|	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?	|	2020	|	Frontiers in psychiatry	|	11	|		|	94	|	van Westrhenen R and Aitchison KJ and Ingelman-Sundberg M and JukiÄ‡ MM	|	10.3389/fpsyt.2020.00094	|
|	Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.	|	2017	|	Psychopharmacology	|	234	|	11	|	1649-1661	|	Peterson K and Dieperink E and Anderson J and Boundy E and Ferguson L and Helfand M	|	10.1007/s00213-017-4622-9	|
|	Genetic variation in CYP3A43 is associated with response to antipsychotic medication.	|	2015	|	Journal of neural transmission (Vienna, Austria : 1996)	|	122	|	1	|	29-34	|	Brandl EJ and Chowdhury NI and Tiwari AK and Lett TA and Meltzer HY and Kennedy JL and MÃ¼ller DJ	|	10.1007/s00702-014-1298-8	|
|	Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder.	|	2020	|	Psychiatric genetics	|	30	|	1	|	19-29	|	Simoons M and Mulder H and Appeldoorn JTY and Risselada AJ and Schene AH and van Schaik RHN and van Roon EN and RuhÃ© EG	|	10.1097/YPG.0000000000000244	|
|	Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.	|	2010	|	Expert opinion on drug metabolism & toxicology	|	6	|	1	|	43-53	|	Filopanti M and Lania AG and Spada A	|	10.1517/17425250903352501	|
|	Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective.	|	2014	|	Neurotherapeutics : the journal of the American Society for Experimental           NeuroTherapeutics	|	11	|	1	|	111-6	|	Payami H and Factor SA	|	10.1007/s13311-013-0237-y	|
|	Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta).	|	2009	|	Current medicinal chemistry	|	16	|	15	|	1917-48	|	Serretti A and Drago A and De Ronchi D	|	10.2174/092986709788186101	|
|	Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association.	|	2012	|	Journal of affective disorders	|	136	|	1	|	e21-e29	|	Biernacka JM and McElroy SL and Crow S and Sharp A and Benitez J and Veldic M and Kung S and Cunningham JM and Post RM and Mrazek D and Frye MA	|	10.1016/j.jad.2011.05.038	|
|	Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?	|	2013	|	Molecular diagnosis & therapy	|	17	|	1	|	21-30	|	Burghardt KJ and Ellingrod VL	|	10.1007/s40291-013-0017-8	|
|	Pharmacogenetics of psychotropic drug response.	|	2004	|	The American journal of psychiatry	|	161	|	5	|	780-96	|	Malhotra AK and Murphy GM Jr and Kennedy JL	|	10.1176/appi.ajp.161.5.780	|
|	Personalized antipsychotic treatment: the adverse effects perspectives.	|	2010	|	Psychiatria Danubina	|	22	|	2	|	329-34	|	Plesnicar BK	|		|
|	Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.	|	2004	|	Current medicinal chemistry	|	11	|	3	|	297-312	|	Albers LJ and Ozdemir V	|	10.2174/0929867043456052	|
|	Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.	|	2014	|	Pharmacogenomics and personalized medicine	|	7	|		|	317-28	|	Chang FC and Fung VS	|	10.2147/PGPM.S52806	|
|	Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.	|	2005	|	Pharmacogenomics	|	6	|	2	|	139-49	|	Lane HY and Lee CC and Liu YC and Chang WH	|	10.1517/14622416.6.2.139	|
|	Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.	|	2007	|	Current psychiatry reports	|	9	|	4	|	313-8	|	Nnadi CU and Malhotra AK	|	10.1007/s11920-007-0038-2	|
|	Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment.	|	2020	|	Pharmacogenomics	|	21	|	8	|	533-540	|	Pisanu C and Congiu D and Manchia M and Caria P and Cocco C and Dettori T and Frau DV and Manca E and Meloni A and Nieddu M and Noli B and Pinna F and Robledo R and Sogos V and Ferri GL and Carpiniello B and Vanni R and Bocchetta A and Severino G and Ardau R and Chillotti C and Zompo MD and Squassina A	|	10.2217/pgs-2020-0028	|
|	Gene Ã— environment interactions in the prediction of response to antidepressant treatment.	|	2013	|	The international journal of neuropsychopharmacology	|	16	|	3	|	701-11	|	Klengel T and Binder EB	|	10.1017/S1461145712001459	|
|	Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.	|	2022	|	Clinical drug investigation	|	42	|	9	|	733-746	|	Carta A and Del Zompo M and Meloni A and Mola F and Paribello P and Pinna F and Pinna M and Pisanu C and Manchia M and Squassina A and Carpiniello B and Conversano C	|	10.1007/s40261-022-01182-2	|
|	The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis.	|	2020	|	Pharmacogenomics	|	21	|	8	|	559-569	|	Brown L and Vranjkovic O and Li J and Yu K and Al Habbab T and Johnson H and Brown K and Jablonski MR and Dechairo B	|	10.2217/pgs-2019-0157	|
|	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response.	|	2017	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	18	|	1	|	28-May	|	Fabbri C and Hosak L and MÃ¶ssner R and Giegling I and Mandelli L and Bellivier F and Claes S and Collier DA and Corrales A and Delisi LE and Gallo C and Gill M and Kennedy JL and Leboyer M and Lisoway A and Maier W and Marquez M and Massat I and Mors O and Muglia P and NÃ¶then MM and O'Donovan MC and Ospina-Duque J and Propping P and Shi Y and St Clair D and Thibaut F and Cichon S and Mendlewicz J and Rujescu D and Serretti A	|	10.1080/15622975.2016.1208843	|
|	Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.	|	2018	|	The American journal of psychiatry	|	175	|	9	|	873-886	|	Zeier Z and Carpenter LL and Kalin NH and Rodriguez CI and McDonald WM and Widge AS and Nemeroff CB	|	10.1176/appi.ajp.2018.17111282	|
|	Genetic Determinants of Clozapine-Induced Metabolic Side Effects.	|	2017	|	Canadian journal of psychiatry. Revue canadienne de psychiatrie	|	62	|	2	|	138-149	|	Vasudev K and Choi YH and Norman R and Kim RB and Schwarz UI	|	10.1177/0706743716670128	|
|	Pharmacogenetics of antipsychoatics.	|	2004	|	Nagoya journal of medical science	|	67	|	1	|	7-Jan	|	Ozaki N	|		|
|	Genetics of antipsychotic-induced side effects and agranulocytosis.	|	2011	|	Current psychiatry reports	|	13	|	2	|	156-65	|	Chowdhury NI and Remington G and Kennedy JL	|	10.1007/s11920-011-0185-3	|
|	A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics.	|	2022	|	Clinical pharmacology and therapeutics	|	111	|	4	|	919-930	|	Johnson D and Wilke MAP and Lyle SM and Kowalec K and Jorgensen A and Wright GEB and DrÃ¶gemÃ¶ller BI	|	10.1002/cpt.2520	|
|	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review.	|	2022	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	55	|		|	112-157	|	Pisanu C and Severino G and De Toma I and Dierssen M and Fusar-Poli P and Gennarelli M and Lio P and Maffioletti E and Maron E and Mehta D and Minelli A and Potier MC and Serretti A and Stacey D and van Westrhenen R and Xicota L and Baune BT and Squassina A	|	10.1016/j.euroneuro.2021.12.005	|
|	Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.	|	2020	|	Drug development research	|	81	|	6	|	754-761	|	Maffioletti E and Valsecchi P and Minelli A and Magri C and Bonvicini C and Barlati S and Sacchetti E and Vita A and Gennarelli M	|	10.1002/ddr.21686	|
|	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.	|	2018	|	Neuroscience letters	|	686	|		|	17-22	|	Lu JY and Tiwari AK and Zai GC and Rastogi A and Shaikh SA and MÃ¼ller DJ and Voineskos AN and Potkin SG and Lieberman JA and Meltzer HY and Remington G and Wong AHC and Kennedy JL and Zai CC	|	10.1016/j.neulet.2018.08.007	|
|	The intersection of pharmacology, imaging, and genetics in the development of personalized medicine.	|	2009	|	Dialogues in clinical neuroscience	|	11	|	4	|	363-76	|	Gerretsen P and MÃ¼ller DJ and Tiwari A and Mamo D and Pollock BG	|	10.31887/DCNS.2009.11.4/pgerretsen	|
|	Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics.	|	2008	|	Pharmacogenomics	|	9	|	9	|	1353-8	|	Tsai SJ and Hong CJ and Liou YJ	|	10.2217/14622416.9.9.1353	|
|	SNP alleles in human disease and evolution.	|	2002	|	Journal of human genetics	|	47	|	11	|	561-6	|	Shastry BS	|	10.1007/s100380200086	|
|	Bayesian logistic regression in detection of gene-steroid interaction for cancer at PDLIM5 locus.	|	2016	|	Journal of genetics	|	95	|	2	|	331-40	|	Wang KS and Owusu D and Pan Y and Xie C	|	10.1007/s12041-016-0642-1	|
|	Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions.	|	2002	|	The international journal of neuropsychopharmacology	|	5	|	3	|	255-75	|	Lerer B and Macciardi F	|	10.1017/S1461145702002936	|
|	Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.	|	2016	|	Translational psychiatry	|	6	|	2	|	e739	|	Stevenson JM and Reilly JL and Harris MS and Patel SR and Weiden PJ and Prasad KM and Badner JA and Nimgaonkar VL and Keshavan MS and Sweeney JA and Bishop JR	|	10.1038/tp.2016.10	|
|	Gene expression biomarkers of response to citalopram treatment in major depressive disorder.	|	2011	|	Translational psychiatry	|	1	|	6	|	e13	|	Mamdani F and Berlim MT and Beaulieu MM and Labbe A and Merette C and Turecki G	|	10.1038/tp.2011.12	|
|	Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.	|	2008	|	Molecular diagnosis & therapy	|	12	|	5	|	321-30	|	Lekman M and Paddock S and McMahon FJ	|	10.1007/BF03256297	|
|	Precision medicine for suicidality: from universality to subtypes and personalization.	|	2017	|	Molecular psychiatry	|	22	|	9	|	1250-1273	|	Niculescu AB and Le-Niculescu H and Levey DF and Phalen PL and Dainton HL and Roseberry K and Niculescu EM and Niezer JO and Williams A and Graham DL and Jones TJ and Venugopal V and Ballew A and Yard M and Gelbart T and Kurian SM and Shekhar A and Schork NJ and Sandusky GE and Salomon DR	|	10.1038/mp.2017.128	|
|	Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review.	|	2020	|	Ethnicity & disease	|	30	|		|	229-240	|	Jerome RN and Pulley JM and Sathe NA and Krishnaswami S and Dickerson AB and Worley KJ and Wilkins CH	|	10.18865/ed.30.S1.229	|
|	The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.	|	2010	|	Health technology assessment (Winchester, England)	|	14	|	3	|	1-157, iii	|	Fleeman N and McLeod C and Bagust A and Beale S and Boland A and Dundar Y and Jorgensen A and Payne K and Pirmohamed M and Pushpakom S and Walley T and de Warren-Penny P and Dickson R	|	10.3310/hta14030	|
|	Integration of complementary biomarkers in patients with first episode psychosis: research protocol of a prospective follow up study.	|	2019	|	Psychiatria Danubina	|	31	|	2	|	162-171	|	Rojnic Kuzman M and Makaric P and Bosnjak Kuharic D and Kekin I and Rossini Gajsak L and Boban M and Bozina N and Bozina T and Celic Ruzic M and Darmopil S and Filipcic I and Ganoci L and Hladnik A and Madzarac Z and Malojcic B and Mihaljevic Peles A and Mueller DJ and Ostojic D and Petanjek Z and Petrovic R and Vogrinc Z and Savic A and Silic A and Sagud M and Zivkovic M and Bajic Z	|	10.24869/psyd.2019.162	|
|	Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia.	|	2019	|	Pharmacogenomics	|	20	|	17	|	1199-1223	|	Loonen AJ and Wilffert B and Ivanova SA	|	10.2217/pgs-2019-0100	|
|	Investigation of the impact of an ADCY2 polymorphism as a predictive biomarker in bipolar disorder, suicide tendency and response to lithium carbonate therapy: the first report from Iran.	|	2020	|	Pharmacogenomics	|	21	|	14	|	1011-1020	|	Aghabozorg Afjeh SS and Shams J and Hamednia S and Boshehri B and Olfat A and Omrani MD	|	10.2217/pgs-2020-0058	|
|	A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.	|	2022	|	Epilepsia	|	63	|	6	|	1563-1570	|	Campbell C and McCormack M and Patel S and Stapleton C and Bobbili D and Krause R and Depondt C and Sills GJ and Koeleman BP and Striano P and Zara F and Sander JW and Lerche H and Kunz WS and Stefansson K and Stefansson H and Doherty CP and Heinzen EL and Scheffer IE and Goldstein DB and O'Brien T and Cotter D and Berkovic SF and Sisodiya SM and Delanty N and Cavalleri GL	|	10.1111/epi.17228	|
|	Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis.	|	2017	|	CNS spectrums	|	22	|	4	|	315-324	|	Espadaler J and Tuson M and Lopez-Ibor JM and Lopez-Ibor F and Lopez-Ibor MI	|	10.1017/S1092852915000711	|
|	Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients.	|	2018	|	Psychiatry research	|	269	|		|	746-752	|	MiljeviÄ‡ ÄŒD and NikoliÄ‡-KokiÄ‡ A and BlagojeviÄ‡ D and MilovanoviÄ‡ M and Munjiza A and JukiÄ‡ MM and PeÅ¡iÄ‡ V and LeÄiÄ‡-ToÅ¡evski D and SpasiÄ‡ MB	|	10.1016/j.psychres.2018.09.009	|
|	The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.	|	2020	|	British journal of clinical pharmacology	|	86	|	10	|	2051-2062	|	Koller D and Saiz-RodrÃ­guez M and Zubiaur P and Ochoa D and Almenara S and RomÃ¡n M and Romero-PalaciÃ¡n D and de Miguel-CÃ¡ceres A and MartÃ­n S and Navares-GÃ³mez M and MejÃ­a G and Wojnicz A and Abad-Santos F	|	10.1111/bcp.14300	|
|	Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?	|	2002	|	Clinical pharmacokinetics	|	41	|	7	|	453-70	|	Dahl ML	|	10.2165/00003088-200241070-00001	|
|	Pharmacogenetic Tests in Reducing Accesses to Emergency Services and Days of Hospitalization in Bipolar Disorder: A 2-Year Mirror Analysis.	|	2019	|	Journal of personalized medicine	|	9	|	2	|		|	Callegari C and Isella C and Caselli I and Poloni N and Ielmini M	|	10.3390/jpm9020022	|
|	5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.	|	2010	|	International clinical psychopharmacology	|	25	|	4	|	228-31	|	Noro M and Antonijevic I and Forray C and Kasper S and Kocabas NA and Lecrubier Y and Linotte S and Mendlewicz J and Montgomery S and Snyder L and Souery D and Verbanck P and Zohar J and Massat I	|	10.1097/YIC.0b013e328338bcf4	|
|	The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.	|	2016	|	BMC psychiatry	|	16	|		|	129	|	Oedegaard KJ and Alda M and Anand A and Andreassen OA and Balaraman Y and Berrettini WH and Bhattacharjee A and Brennand KJ and Burdick KE and Calabrese JR and Calkin CV and Claasen A and Coryell WH and Craig D and DeModena A and Frye M and Gage FH and Gao K and Garnham J and Gershon E and Jakobsen P and Leckband SG and McCarthy MJ and McInnis MG and Maihofer AX and Mertens J and Morken G and Nievergelt CM and Nurnberger J and Pham S and Schoeyen H and Shekhtman T and Shilling PD and Szelinger S and Tarwater B and Yao J and Zandi PP and Kelsoe JR	|	10.1186/s12888-016-0732-x	|
|	Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.	|	2013	|	Expert opinion on drug metabolism & toxicology	|	9	|	9	|	1115-37	|	Perera V and Gross AS and Polasek TM and Qin Y and Rao G and Forrest A and Xu J and McLachlan AJ	|	10.1517/17425255.2013.795540	|
|	Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine.	|	2000	|	Biological psychiatry	|	47	|	3	|	252-66	|	Masellis M and Basile VS and Ozdemir V and Meltzer HY and Macciardi FM and Kennedy JL	|	10.1016/s0006-3223(99)00298-x	|
|	Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis.	|	2022	|	The pharmacogenomics journal	|	22	|	4	|	230-240	|	Islam F and Hain D and Lewis D and Law R and Brown LC and Tanner JA and MÃ¼ller DJ	|	10.1038/s41397-022-00281-9	|
|	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis.	|	2016	|	The international journal of neuropsychopharmacology	|	19	|	5	|		|	Takekita Y and Fabbri C and Kato M and Koshikawa Y and Tajika A and Kinoshita T and Serretti A	|	10.1093/ijnp/pyv125	|
|	Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.	|	2010	|	The pharmacogenomics journal	|	10	|	1	|	20-9	|	Laika B and Leucht S and Heres S and Schneider H and Steimer W	|	10.1038/tpj.2009.32	|
|	Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.	|	2014	|	Pharmacogenomics	|	15	|	1	|	61-7	|	Vassas TJ and Burghardt KJ and Ellingrod VL	|	10.2217/pgs.13.157	|
|	Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.	|	2021	|	Ontario health technology assessment series	|	21	|	13	|	1-214	|		|		|
|	ABCB1 and DRD3 polymorphism as a response predicting biomarker and tool for pharmacogenetically guided clozapine dosing in Asian Indian treatment resistant schizophrenia patients.	|	2020	|	Asian journal of psychiatry	|	48	|		|	101918	|	M N and Patil AN and Pattanaik S and Kaur A and Banerjee D and Grover S	|	10.1016/j.ajp.2019.101918	|
|	Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia.	|	2013	|	Schizophrenia research	|	146	|	1	|	279-84	|	Scarr E and Um JY and Cowie TF and Dean B	|	10.1016/j.schres.2013.01.023	|
|	Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms.	|	2011	|	Translational psychiatry	|	1	|	5	|	e9	|	Le-Niculescu H and Balaraman Y and Patel SD and Ayalew M and Gupta J and Kuczenski R and Shekhar A and Schork N and Geyer MA and Niculescu AB	|	10.1038/tp.2011.9	|
|	Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.	|	2008	|	Pharmacogenomics	|	9	|	9	|	1285-306	|	Thelma B and Srivastava V and Tiwari AK	|	10.2217/14622416.9.9.1285	|
|	Pharmacogenomics: a path to predictive medicine for schizophrenia.	|	2006	|	Pharmacogenomics	|	7	|	1	|	31-47	|	Gupta S and Jain S and Brahmachari SK and Kukreti R	|	10.2217/14622416.7.1.31	|
|	Pharmacogenetic Testing of Cytochrome P450 Drug Metabolizing Enzymes in a Case Series of Patients with Prader-Willi Syndrome.	|	2021	|	Genes	|	12	|	2	|		|	Forster J and Duis J and Butler MG	|	10.3390/genes12020152	|
|	Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs).	|	2011	|	Schizophrenia research	|	130	|	1	|	20-6	|	Ellingrod VL and Taylor SF and Brook RD and Evans SJ and ZÃ¶llner SK and Grove TB and Gardner KM and Bly MJ and Pop-Busui R and Dalack G	|	10.1016/j.schres.2011.03.031	|
|	Molecular network-selected pharmacogenomics in a case of bipolar spectrum disorder.	|	2017	|	Pharmacogenomics	|	18	|	18	|	1631-1642	|	Fortinguerra S and Buriani A and Sorrenti V and Lenzi M and Giusti P	|	10.2217/pgs-2017-0133	|
|	Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.	|	2008	|	Schizophrenia research	|	100	|	1	|	70-85	|	Jin H and Meyer JM and Mudaliar S and Jeste DV	|	10.1016/j.schres.2007.11.026	|
|	Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder.	|	2009	|	Schizophrenia research	|	114	|	1	|	50-6	|	Irvin MR and Wiener HW and Perry RP and Savage RM and Go RC	|	10.1016/j.schres.2009.07.008	|
|	Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance.	|	2016	|	Bipolar disorders	|	18	|	5	|	423-32	|	Burghardt KJ and Goodrich JM and Dolinoy DC and Ellingrod VL	|	10.1111/bdi.12422	|
|	Genetic and Epigenetic Markers of Lithium Response.	|	2022	|	International journal of molecular sciences	|	23	|	3	|		|	Pisanu C and Meloni A and Severino G and Squassina A	|	10.3390/ijms23031555	|
|	Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.	|	2013	|	The American journal of psychiatry	|	170	|	2	|	207-17	|		|	10.1176/appi.ajp.2012.12020237	|
|	Evaluation of Correlation Between the Pharmacogenetic Profiles of Risperidone Treated Psychiatry Patients with Plasma and Urine Concentration of Risperidone and its Active Moiety 9-OH Risperidone Determined with Optimized Bioanalytical LC Method.	|	2018	|	Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski           nauki)	|	39	|	2	|	97-106	|	Filipce A and Naumovska Z and Nestorovska AK and Sterjev Z and Brezovska K and Tonic-Ribarska J and Grozdanova A and Suturkova L and Raleva M	|	10.2478/prilozi-2018-0047	|
|	Identification of 34 genes conferring genetic and pharmacological risk for the comorbidity of schizophrenia and smoking behaviors.	|	2020	|	Aging	|	12	|	3	|	2169-2225	|	Ma Y and Li J and Xu Y and Wang Y and Yao Y and Liu Q and Wang M and Zhao X and Fan R and Chen J and Zhang B and Cai Z and Han H and Yang Z and Yuan W and Zhong Y and Chen X and Ma JZ and Payne TJ and Xu Y and Ning Y and Cui W and Li MD	|	10.18632/aging.102735	|
|	Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia.	|	2011	|	Current molecular medicine	|	11	|	9	|	732-43	|	Gupta M and Kaur H and Jajodia A and Jain S and Satyamoorthy K and Mukerji M and Thirthalli J and Kukreti R	|	10.2174/156652411798062386	|
|	Some biological correlates of drug resistance in schizophrenia: a multidimensional approach.	|	2005	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	6	|		|	23-30	|	Altamura AC and Bassetti R and Cattaneo E and Vismara S	|	10.1080/15622970510030027	|
|	Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.	|	2010	|	Neuropsychobiology	|	61	|	2	|	57-63	|	Okumura T and Kishi T and Okochi T and Ikeda M and Kitajima T and Yamanouchi Y and Kinoshita Y and Kawashima K and Tsunoka T and Inada T and Ozaki N and Iwata N	|	10.1159/000265130	|
|	Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.	|	2012	|	Journal of clinical psychopharmacology	|	32	|	2	|	261-5	|	Ellingrod VL and Taylor SF and Dalack G and Grove TB and Bly MJ and Brook RD and ZÃ¶llner SK and Pop-Busui R	|	10.1097/JCP.0b013e3182485888	|
|	Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia.	|	2016	|	Omics : a journal of integrative biology	|	20	|	5	|	283-9	|	TurÄin A and DolÅ¾an V and Porcelli S and Serretti A and PlesniÄar BK	|	10.1089/omi.2016.0003	|
|	Identifying blood biomarkers for mood disorders using convergent functional genomics.	|	2009	|	Molecular psychiatry	|	14	|	2	|	156-74	|	Le-Niculescu H and Kurian SM and Yehyawi N and Dike C and Patel SD and Edenberg HJ and Tsuang MT and Salomon DR and Nurnberger JI Jr and Niculescu AB	|	10.1038/mp.2008.11	|
|	The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.	|	2010	|	International clinical psychopharmacology	|	25	|	4	|	218-27	|	Kocabas NA and Faghel C and Barreto M and Kasper S and Linotte S and Mendlewicz J and Noro M and Oswald P and Souery D and Zohar J and Massat I	|	10.1097/YIC.0b013e328338b884	|
|	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance.	|	2018	|	Progress in neuro-psychopharmacology & biological psychiatry	|	81	|		|	203-210	|	Fabbri C and Corponi F and Albani D and Raimondi I and Forloni G and Schruers K and Kasper S and Kautzky A and Zohar J and Souery D and Montgomery S and Cristalli CP and Mantovani V and Mendlewicz J and Serretti A	|	10.1016/j.pnpbp.2017.10.005	|
|	A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.	|	2013	|	Journal of clinical psychopharmacology	|	33	|	1	|	10-Mar	|	Potkin SG and Preskorn S and Hochfeld M and Meng X	|	10.1097/JCP.0b013e31827c0314	|
|	Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning.	|	2018	|	F1000Research	|	7	|		|	474	|	Eugene AR and Masiak J and Eugene B	|	10.12688/f1000research.14451.3	|
|	Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.	|	2022	|	General psychiatry	|	35	|	1	|	e100685	|	Lin P and Sun J and Lou X and Li D and Shi Y and Li Z and Ma P and Li P and Chen S and Jin W and Liu S and Chen Q and Gao Q and Zhu L and Xu J and Zhu M and Wang M and Liang K and Zhao L and Xu H and Dong K and Li Q and Cheng X and Chen J and Guo X	|	10.1136/gpsych-2021-100685	|
|	Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.	|	2021	|	Scientific reports	|	11	|	1	|	23150	|	Wang S and Li J and Song M and Yan P and Ju X and Liu J and Wang C and Shi J	|	10.1038/s41598-021-02628-x	|
|	Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.	|	2012	|	Progress in neuro-psychopharmacology & biological psychiatry	|	36	|	1	|	147-54	|	Olgiati P and Bajo E and Bigelli M and De Ronchi D and Serretti A	|	10.1016/j.pnpbp.2011.08.013	|
|	Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.	|	2012	|	Psychopharmacology	|	224	|	3	|	441-9	|	Rajkumar AP and Poonkuzhali B and Kuruvilla A and Srivastava A and Jacob M and Jacob KS	|	10.1007/s00213-012-2773-2	|
|	Is Pharmacogenetics Useful in Antidepressant Treatment?	|	2019	|	Clinical pharmacology and therapeutics	|	106	|	5	|	916-918	|	Fabbri C and Serretti A	|	10.1002/cpt.1451	|
|	Pharmacogenetics studies in STAR*D: strengths, limitations, and results.	|	2009	|	Psychiatric services (Washington, D.C.)	|	60	|	11	|	1446-57	|	Laje G and Perlis RH and Rush AJ and McMahon FJ	|	10.1176/appi.ps.60.11.1446	|
|	Rare Functional Variants Associated with Antidepressant Remission in Mexican-Americans: Short title: Antidepressant remission and pharmacogenetics in Mexican-Americans.	|	2021	|	Journal of affective disorders	|	279	|		|	491-500	|	Wong ML and Arcos-Burgos M and Liu S and Licinio AW and Yu C and Chin EWM and Yao WD and Lu XY and Bornstein SR and Licinio J	|	10.1016/j.jad.2020.10.027	|
|	Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement.	|	2020	|	Current topics in medicinal chemistry	|	20	|	15	|	1398-1414	|	Lowe DJE and MÃ¼ller DJ and George TP	|	10.2174/1568026620666200423094423	|
|	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.	|	2019	|	BMC psychiatry	|	19	|	1	|	420	|	Dunlop BW and Parikh SV and Rothschild AJ and Thase ME and DeBattista C and Conway CR and Forester BP and Mondimore FM and Shelton RC and Macaluso M and Logan J and Traxler P and Li J and Johnson H and Greden JF	|	10.1186/s12888-019-2410-2	|
|	Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.	|	2010	|	Psychiatria Danubina	|	22	|	2	|	335-7	|	MihaljeviÄ‡-Peles A and Sagud M and Bozina N and ZivkoviÄ‡ M and JovanoviÄ‡ N	|		|
|	The role of pharmacogenetics in treating central nervous system disorders.	|	2008	|	Experimental biology and medicine (Maywood, N.J.)	|	233	|	12	|	1504-9	|	Patnaik M and Renda MJ and Athanasiou MC and Reed CR	|	10.3181/0806-S-195	|
|	Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in CYP2D6 Poor Metabolizers Diagnosed With Bipolar Disorder.	|	2016	|	Medicine	|	95	|	6	|	e2473	|	SÃ¡nchez-Iglesias S and GarcÃ­a-Solaesa V and GarcÃ­a-Berrocal B and Sanchez-MartÃ­n A and Lorenzo-Romo C and MartÃ­n-Pinto T and Gaedigk A and GonzÃ¡lez-Buitrago JM and Isidoro-GarcÃ­a M	|	10.1097/MD.0000000000002473	|
|	Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine.	|	2015	|	Journal of psychopharmacology (Oxford, England)	|	29	|	5	|	615-22	|	Chang HS and Won ES and Lee HY and Ham BJ and Kim YG and Lee MS	|	10.1177/0269881114554273	|
|	Pharmacogenetics in major depression: a comprehensive meta-analysis.	|	2013	|	Progress in neuro-psychopharmacology & biological psychiatry	|	45	|		|	183-94	|	Niitsu T and Fabbri C and Bentini F and Serretti A	|	10.1016/j.pnpbp.2013.05.011	|
|	SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.	|	2014	|	Pharmacogenomics	|	15	|	12	|	1557-64	|	Wang D and Li Q and Favis R and Jadwin A and Chung H and Fu DJ and Savitz A and Gopal S and Cohen N	|	10.2217/pgs.14.105	|
|	Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine.	|	2017	|	Progress in neuro-psychopharmacology & biological psychiatry	|	75	|		|	28-34	|	GassÃ³ P and RodrÃ­guez N and BlÃ¡zquez A and Monteagudo A and Boloc D and Plana MT and Lafuente A and LÃ¡zaro L and Arnaiz JA and Mas S	|	10.1016/j.pnpbp.2016.12.003	|
|	Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics.	|	2012	|	Journal of psychiatric research	|	46	|	8	|	1073-80	|	Schuhmacher A and Becker T and Rujescu D and Quednow BB and Lennertz L and Wagner M and Benninghoff J and Rietschel M and HÃ¤fner H and Franke P and WÃ¶lwer W and Gaebel W and Maier W and MÃ¶ssner R	|	10.1016/j.jpsychires.2012.04.021	|
|	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.	|	2018	|	The pharmacogenomics journal	|	18	|	3	|	413-421	|	Fabbri C and Tansey KE and Perlis RH and Hauser J and Henigsberg N and Maier W and Mors O and Placentino A and Rietschel M and Souery D and Breen G and Curtis C and Sang-Hyuk L and Newhouse S and Patel H and Guipponi M and Perroud N and Bondolfi G and O'Donovan M and Lewis G and Biernacka JM and Weinshilboum RM and Farmer A and Aitchison KJ and Craig I and McGuffin P and Uher R and Lewis CM	|	10.1038/tpj.2017.44	|
|	Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies.	|	2019	|	Pharmaceutics	|	11	|	9	|		|	Vilches S and Tuson M and Vieta E and Ãlvarez E and Espadaler J	|	10.3390/pharmaceutics11090453	|
|	The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.	|	2017	|	The pharmacogenomics journal	|	17	|	2	|	146-154	|	Sacchetti E and Magri C and Minelli A and Valsecchi P and Traversa M and Calza S and Vita A and Gennarelli M	|	10.1038/tpj.2015.90	|
|	The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.	|	2005	|	Progress in neuro-psychopharmacology & biological psychiatry	|	29	|	6	|	1021-8	|	Reynolds GP and Templeman LA and Zhang ZJ	|	10.1016/j.pnpbp.2005.03.019	|
|	Clinical and pharmacogenetic studies of iloperidone.	|	2008	|	Personalized medicine	|	5	|	4	|	367-375	|	Nnadi CU and Malhotra AK	|	10.2217/17410541.5.4.367	|
|	SOD2 genetic polymorphism (rs4880) has no impact on 6-month response to antidepressant treatment and inflammatory biomarkers in depressed patients.	|	2020	|	Basic & clinical pharmacology & toxicology	|	126	|	3	|	289-295	|	Ait Tayeb AEK and Becquemont L and El-Asmar K and Mahmoudi K and Colle R and Trabado S and Gressier F and Feve B and Corruble E and Verstuyft C	|	10.1111/bcpt.13385	|
|	DNA microarrays: translation of the genome from laboratory to clinic.	|	2003	|	The Lancet. Neurology	|	2	|	5	|	275-82	|	Geschwind DH	|	10.1016/s1474-4422(03)00379-x	|
|	The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.	|	2015	|	Translational psychiatry	|	5	|	4	|	e553	|	Biernacka JM and Sangkuhl K and Jenkins G and Whaley RM and Barman P and Batzler A and Altman RB and Arolt V and BrockmÃ¶ller J and Chen CH and Domschke K and Hall-Flavin DK and Hong CJ and Illi A and Ji Y and Kampman O and Kinoshita T and Leinonen E and Liou YJ and Mushiroda T and Nonen S and Skime MK and Wang L and Baune BT and Kato M and Liu YL and Praphanphoj V and Stingl JC and Tsai SJ and Kubo M and Klein TE and Weinshilboum R	|	10.1038/tp.2015.47	|
|	Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.	|	2010	|	Biological psychiatry	|	67	|	3	|	263-9	|	Ikeda M and Tomita Y and Mouri A and Koga M and Okochi T and Yoshimura R and Yamanouchi Y and Kinoshita Y and Hashimoto R and Williams HJ and Takeda M and Nakamura J and Nabeshima T and Owen MJ and O'Donovan MC and Honda H and Arinami T and Ozaki N and Iwata N	|	10.1016/j.biopsych.2009.08.030	|
|	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.	|	2020	|	Psychopharmacology	|	237	|	7	|	2151-2159	|	Boloc D and RodrÃ­guez N and Torres T and GarcÃ­a-Cerro S and Parellada M and Saiz-Ruiz J and Cuesta MJ and Bernardo M and GassÃ³ P and Lafuente A and Mas S and Arnaiz JA	|	10.1007/s00213-020-05526-8	|
|	A systematic review of genome-wide association studies of antipsychotic response.	|	2019	|	Pharmacogenomics	|	20	|	4	|	291-306	|	Allen JD and Bishop JR	|	10.2217/pgs-2018-0163	|
|	[Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].	|	2010	|	Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology	|	30	|	2	|	83-92	|	Kato M	|		|
|	[Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].	|	2010	|	Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology	|	30	|	2	|	71-6	|	Higuchi H	|		|
|	Label-free, live optical imaging of reprogrammed bipolar disorder patient-derived cells reveals a functional correlate of lithium responsiveness.	|	2014	|	Translational psychiatry	|	4	|	8	|	e428	|	Wang JL and Shamah SM and Sun AX and Waldman ID and Haggarty SJ and Perlis RH	|	10.1038/tp.2014.72	|
|	Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.	|	2019	|	Human psychopharmacology	|	34	|	4	|	e2699	|	Xiong Z and Cheng M and Zhu P and Huang S and Guo J and Zhang W and Zhou H and Shu Y and Li Q	|	10.1002/hup.2699	|
|	Somatostatin Interneurons Control a Key Component of Mismatch Negativity in Mouse Visual Cortex.	|	2016	|	Cell reports	|	16	|	3	|	597-604	|	Hamm JP and Yuste R	|	10.1016/j.celrep.2016.06.037	|
|	On the Marketing and Use of Pharmacogenetic Tests for Psychiatric Treatment.	|	2018	|	JAMA psychiatry	|	75	|	8	|	769-770	|	Zubenko GS and Sommer BR and Cohen BM	|	10.1001/jamapsychiatry.2018.0834	|
|	[Polymorphism of RGS2 gene: genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency].	|	2013	|	Molekuliarnaia biologiia	|	47	|	6	|	934-41	|	Gareeva AE and Zakirov DF and Valinurov RG and Khusnutdinova EK	|		|
|	Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.	|	2016	|	The international journal of neuropsychopharmacology	|	19	|	12	|		|	TÃ³th K and Csukly G and Sirok D and Belic A and Kiss Ã and HÃ¡fra E and DÃ©ri M and Menus Ã and Bitter I and Monostory K	|	10.1093/ijnp/pyw083	|
|	Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.	|	2020	|	Basic & clinical pharmacology & toxicology	|	126	|	3	|	236-246	|	Koller D and Belmonte C and Saiz-RodrÃ­guez M and Zubiaur P and RomÃ¡n M and Ochoa D and Abad-Santos F	|	10.1111/bcpt.13323	|
|	Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.	|	2013	|	The pharmacogenomics journal	|	13	|	5	|	456-63	|	Ji Y and Biernacka JM and Hebbring S and Chai Y and Jenkins GD and Batzler A and Snyder KA and Drews MS and Desta Z and Flockhart D and Mushiroda T and Kubo M and Nakamura Y and Kamatani N and Schaid D and Weinshilboum RM and Mrazek DA	|	10.1038/tpj.2012.32	|
|	Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes.	|	2012	|	Pharmacogenetics and genomics	|	22	|	11	|	807-11	|	Teo C and Zai C and Borlido C and Tomasetti C and Strauss J and Shinkai T and Le Foll B and Wong A and Kennedy JL and De Luca V	|	10.1097/FPC.0b013e3283586c04	|
|	Lithium response and genetic variation in the CREB family of genes.	|	2008	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	147	|	4	|	500-4	|	Mamdani F and Alda M and Grof P and Young LT and Rouleau G and Turecki G	|	10.1002/ajmg.b.30617	|
|	Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder.	|	2010	|	Journal of affective disorders	|	126	|	3	|	430-5	|	Chi MH and Chang HH and Lee SY and Lee IH and Gean PW and Yang YK and Lu RB and Chen PS	|	10.1016/j.jad.2010.07.006	|
|	Two Novel Loci of RELN Associated With Antipsychotics Response in Chinese Han Population.	|	2020	|	Frontiers in pharmacology	|	11	|		|	7	|	Xu Q and Li M and Qin S and Li Y and Ning A and Fu Y and Wang D and Zeng D and Li H and Yu W and Yu S	|	10.3389/fphar.2020.00007	|
|	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.	|	2013	|	European archives of psychiatry and clinical neuroscience	|	263	|	1	|	65-74	|	Giegling I and Balzarro B and Porcelli S and SchÃ¤fer M and Hartmann AM and Friedl M and Konte B and KrÃ¤mer P and MÃ¶ller HJ and De Ronchi D and Stassen HH and Serretti A and Rujescu D	|	10.1007/s00406-012-0348-1	|
|	The association of Î²-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients.	|	2018	|	Progress in neuro-psychopharmacology & biological psychiatry	|	81	|		|	74-79	|	Petit AC and El Asmar K and David DJ and Gardier AM and Becquemont L and FÃ¨ve B and Verstuyft C and Corruble E	|	10.1016/j.pnpbp.2017.10.006	|
|	Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.	|	2012	|	CNS spectrums	|	17	|	2	|	76-86	|	Mischoulon D and Lamon-Fava S and Selhub J and Katz J and Papakostas GI and Iosifescu DV and Yeung AS and Dording CM and Farabaugh AH and Clain AJ and Baer L and Alpert JE and Nierenberg AA and Fava M	|	10.1017/S1092852912000430	|
|	Systematic pharmacogenomics analysis of a Malay whole genome: proof of concept for personalized medicine.	|	2013	|	PloS one	|	8	|	8	|	e71554	|	Salleh MZ and Teh LK and Lee LS and Ismet RI and Patowary A and Joshi K and Pasha A and Ahmed AZ and Janor RM and Hamzah AS and Adam A and Yusoff K and Hoh BP and Hatta FH and Ismail MI and Scaria V and Sivasubbu S	|	10.1371/journal.pone.0071554	|
|	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.	|	2017	|	Molecular neuropsychiatry	|	2	|	4	|	185-197	|	Taylor DL and Tiwari AK and Lieberman JA and Potkin SG and Meltzer HY and Knight J and Remington G and MÃ¼ller DJ and Kennedy JL	|	10.1159/000449224	|
|	Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.	|	2016	|	Human psychopharmacology	|	31	|	3	|	185-92	|	Bobo WV and AnglerÃ³ GC and Jenkins G and Hall-Flavin DK and Weinshilboum R and Biernacka JM	|	10.1002/hup.2526	|
|	Epigenetic alterations of the dopaminergic system in major psychiatric disorders.	|	2008	|	Methods in molecular biology (Clifton, N.J.)	|	448	|		|	187-212	|	Abdolmaleky HM and Smith CL and Zhou JR and Thiagalingam S	|	10.1007/978-1-59745-205-2_9	|
|	Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder.	|	2008	|	The pharmacogenomics journal	|	8	|	6	|	384-90	|	Tsai SJ and Liou YJ and Hong CJ and Yu YW and Chen TJ	|	10.1038/sj.tpj.6500486	|
|	Implications of de novo mutations in guiding drug discovery: A study of four neuropsychiatric disorders.	|	2019	|	Journal of psychiatric research	|	110	|		|	83-92	|	So HC and Wong YH	|	10.1016/j.jpsychires.2018.12.015	|
|	A meta-analysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia.	|	2012	|	PloS one	|	7	|	8	|	e43423	|	Singh JP and Volavka J and Czobor P and Van Dorn RA	|	10.1371/journal.pone.0043423	|
|	BDNF Val66Met polymorphism and lithium response: a meta-analysis.	|	2013	|	Personalized medicine	|	10	|	8	|	777-784	|	Ehret MJ and Baker W and O'Neill H	|	10.2217/pme.13.74	|
|	A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.	|	2011	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	12	|	7	|	501-15	|	Serretti A and Olgiati P and Bajo E and Bigelli M and De Ronchi D	|	10.3109/15622975.2011.572998	|
|	Is response to prophylactic lithium a familial trait?	|	2002	|	The Journal of clinical psychiatry	|	63	|	10	|	942-7	|	Grof P and Duffy A and Cavazzoni P and Grof E and Garnham J and MacDougall M and O'Donovan C and Alda M	|	10.4088/jcp.v63n1013	|
|	Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).	|	2015	|	Trials	|	16	|		|	37	|	Berm EJ and Hak E and Postma M and Boshuisen M and Breuning L and Brouwers JR and Dhondt T and Jansen PA and Kok RM and Maring JG and van Marum R and Mulder H and Voshaar RC and Risselada AJ and Venema H and Vleugel L and Wilffert B	|	10.1186/s13063-015-0561-0	|
|	Association study of polymorphisms within inflammatory genes and methylation status in treatment response in major depression.	|	2019	|	European psychiatry : the journal of the Association of European Psychiatrists	|	60	|		|	13-Jul	|	Draganov M and Arranz MJ and Salazar J and de Diego-AdeliÃ±o J and Gallego-Fabrega C and Jubero M and Carceller-Sindreu M and Portella MJ	|	10.1016/j.eurpsy.2019.05.003	|
|	Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach.	|	2004	|	Molecular psychiatry	|	9	|	11	|	1007-29	|	Ogden CA and Rich ME and Schork NJ and Paulus MP and Geyer MA and Lohr JB and Kuczenski R and Niculescu AB	|	10.1038/sj.mp.4001547	|
|	Novel integrative genomic tool for interrogating lithium response in bipolar disorder.	|	2015	|	Translational psychiatry	|	5	|	2	|	e504	|	Hunsberger JG and Chibane FL and Elkahloun AG and Henderson R and Singh R and Lawson J and Cruceanu C and Nagarajan V and Turecki G and Squassina A and Medeiros CD and Del Zompo M and Rouleau GA and Alda M and Chuang DM	|	10.1038/tp.2014.139	|
|	Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils.	|	2007	|	Depression and anxiety	|	24	|	5	|	350-7	|	Rasmussen-Torvik LJ and McAlpine DD	|	10.1002/da.20251	|
|	Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?	|	2014	|	Journal of psychopharmacology (Oxford, England)	|	28	|	7	|	665-70	|	Koola MM and Tsapakis EM and Wright P and Smith S and Kerwin Rip RW and Nugent KL and Aitchison KJ	|	10.1177/0269881114523861	|
|	ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients.	|	2009	|	Pharmacogenomics	|	10	|	8	|	1267-76	|	Consoli G and Lastella M and Ciapparelli A and Catena Dell'Osso M and Ciofi L and Guidotti E and Danesi R and Dell'Osso L and Del Tacca M and Di Paolo A	|	10.2217/pgs.09.51	|
|	Systems genetics analysis of pharmacogenomics variation during antidepressant treatment.	|	2018	|	The pharmacogenomics journal	|	18	|	1	|	144-152	|	Madsen MB and Kogelman LJA and Kadarmideen HN and Rasmussen HB	|	10.1038/tpj.2016.68	|
|	Neuronal cell adhesion genes and antidepressant response in three independent samples.	|	2015	|	The pharmacogenomics journal	|	15	|	6	|	538-48	|	Fabbri C and Crisafulli C and Gurwitz D and Stingl J and Calati R and Albani D and Forloni G and CalabrÃ² M and Martines R and Kasper S and Zohar J and Juven-Wetzler A and Souery D and Montgomery S and Mendlewicz J and Girolamo GD and Serretti A	|	10.1038/tpj.2015.15	|
|	[How Far is "Personalized Medicine" for Depression from Clinical Use?].	|	2016	|	Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica	|	118	|	8	|	615-624	|	Kato M	|		|
|	Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy.	|	2013	|	Journal of clinical psychopharmacology	|	33	|	2	|	221-5	|	Wei Z and Wang L and Yu T and Wang Y and Sun L and Wang T and Huo R and Li Y and Wu X and Qin S and Xu Y and Feng G and He L and Xing Q	|	10.1097/JCP.0b013e318283963b	|
|	Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.	|	2009	|	Psychiatry research	|	169	|	2	|	113-7	|	Tsai SJ and Hong CJ and Liou YJ and Chen TJ and Chen ML and Hou SJ and Yen FC and Yu YW	|	10.1016/j.psychres.2008.06.028	|
|	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.	|	2019	|	The Journal of clinical psychiatry	|	80	|	6	|		|	Thase ME and Parikh SV and Rothschild AJ and Dunlop BW and DeBattista C and Conway CR and Forester BP and Mondimore FM and Shelton RC and Macaluso M and Li J and Brown K and Jablonski MR and Greden JF	|	10.4088/JCP.19m12910	|
|	Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report.	|	2018	|	Clinical psychopharmacology and neuroscience : the official scientific journal of           the Korean College of Neuropsychopharmacology	|	16	|	3	|	349-357	|	Franco-Martin MA and Sans F and GarcÃ­a-Berrocal B and Blanco C and Llanes-Alvarez C and Isidoro-GarcÃ­a M	|	10.9758/cpn.2018.16.3.349	|
|	Selected summaries from the XVI World Congress of Psychiatric Genetics, Osaka, Japan, 11-15 October 2008.	|	2009	|	Psychiatric genetics	|	19	|	5	|	219-36	|	Bergen S and Chen J and Dagdan E and Foon TS and Goes FS and Houlihan LM and Kloiber S and Kumar RA and Kuzman MR and Menke A and Pedroso I and Videtic A and Villafuerte S and DeLisi LE	|	10.1097/YPG.0b013e32832cec32	|
|	TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs.	|	2016	|	The international journal of neuropsychopharmacology	|	19	|	11	|		|	Xu Z and Reynolds GP and Yuan Y and Shi Y and Pu M and Zhang Z	|	10.1093/ijnp/pyw070	|
|	Haplotype analysis of GSK-3Î² gene polymorphisms in bipolar disorder lithium responders and nonresponders.	|	2014	|	Clinical neuropharmacology	|	37	|	4	|	108-10	|	Iwahashi K and Nishizawa D and Narita S and Numajiri M and Murayama O and Yoshihara E and Onozawa Y and Nagahori K and Fukamauchi F and Ikeda K and Ishigooka J	|	10.1097/WNF.0000000000000039	|
|	Towards understanding the schizophrenia code: an expanded convergent functional genomics approach.	|	2007	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	144	|	2	|	129-58	|	Le-Niculescu H and Balaraman Y and Patel S and Tan J and Sidhu K and Jerome RE and Edenberg HJ and Kuczenski R and Geyer MA and Nurnberger JI Jr and Faraone SV and Tsuang MT and Niculescu AB	|	10.1002/ajmg.b.30481	|
|	Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response.	|	2015	|	Journal of neural transmission (Vienna, Austria : 1996)	|	122	|	1	|	99-108	|	Domschke K and Tidow N and Schwarte K and Ziegler C and Lesch KP and Deckert J and Arolt V and Zwanzger P and Baune BT	|	10.1007/s00702-014-1227-x	|
|	Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.	|	2007	|	Progress in neuro-psychopharmacology & biological psychiatry	|	31	|	6	|	1317-21	|	Kang RH and Wong ML and Choi MJ and Paik JW and Lee MS	|	10.1016/j.pnpbp.2007.05.018	|
|	Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups.	|	2002	|	The Journal of clinical psychiatry	|	63	|	1	|	14-Sep	|	Emsley RA and Roberts MC and Rataemane S and Pretorius J and Oosthuizen PP and Turner J and Niehaus DJ and Keyter N and Stein DJ	|	10.4088/jcp.v63n0103	|
|	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.	|	2018	|	Schizophrenia bulletin	|	44	|	2	|	317-327	|	Conus P and Seidman LJ and Fournier M and Xin L and Cleusix M and Baumann PS and Ferrari C and Cousins A and Alameda L and Gholam-Rezaee M and Golay P and Jenni R and Woo TW and Keshavan MS and Eap CB and Wojcik J and Cuenod M and Buclin T and Gruetter R and Do KQ	|	10.1093/schbul/sbx093	|
|	The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response.	|	2011	|	Schizophrenia research	|	132	|	2	|	121-4	|	Lett TA and Tiwari AK and Meltzer HY and Lieberman JA and Potkin SG and Voineskos AN and Kennedy JL and MÃ¼ller DJ	|	10.1016/j.schres.2011.08.007	|
|	Personalized treatment with atypical antipsychotic medications.	|	2007	|	Advances in therapy	|	24	|	4	|	721-40	|	Kim E and Levy R and Pikalov A	|	10.1007/BF02849966	|
|	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.	|	2011	|	Molecular psychiatry	|	16	|	1	|	76-85	|	McClay JL and Adkins DE and Aberg K and Stroup S and Perkins DO and Vladimirov VI and Lieberman JA and Sullivan PF and van den Oord EJ	|	10.1038/mp.2009.89	|
|	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.	|	2017	|	The American journal of psychiatry	|	174	|	5	|	468-475	|	Marshe VS and Maciukiewicz M and Rej S and Tiwari AK and Sibille E and Blumberger DM and Karp JF and Lenze EJ and Reynolds CF 3rd and Kennedy JL and Mulsant BH and MÃ¼ller DJ	|	10.1176/appi.ajp.2016.16050617	|
|	Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.	|	2018	|	Schizophrenia research	|	199	|		|	203-213	|	Li J and Loebel A and Meltzer HY	|	10.1016/j.schres.2018.04.006	|
|	Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans.	|	2009	|	Molecular psychiatry	|	14	|	12	|	1105-18	|	Dong C and Wong ML and Licinio J	|	10.1038/mp.2009.92	|
|	DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs.	|	2012	|	Schizophrenia research	|	142	|	1	|	206-8	|	Ota VK and SpÃ­ndola LN and Gadelha A and dos Santos Filho AF and Santoro ML and Christofolini DM and Bellucco FT and Ribeiro-dos-Santos Ã‚K and Santos S and Mari Jde J and Melaragno MI and Bressan RA and Smith Mde A and Belangero SI	|	10.1016/j.schres.2012.08.003	|
|	Managing Psychotropic Medications in Complex, Real-World Patients Using Comprehensive Therapeutic Drug Monitoring.	|	2017	|	ACS chemical neuroscience	|	8	|	8	|	1641-1644	|	Sutherland JJ and Morrison RD and Daniels JS and Milne SB and Ryan TP	|	10.1021/acschemneuro.7b00209	|
|	Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine.	|	2022	|	Personalized medicine	|	19	|	3	|	181-192	|	SangÃ¼esa E and Cirujeda C and Concha J and Padilla PP and GarcÃ­a CB and Ribate MP	|	10.2217/pme-2021-0029	|
|	Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.	|	2011	|	Clinical pharmacology and therapeutics	|	89	|	1	|	97-104	|	Ji Y and Hebbring S and Zhu H and Jenkins GD and Biernacka J and Snyder K and Drews M and Fiehn O and Zeng Z and Schaid D and Mrazek DA and Kaddurah-Daouk R and Weinshilboum RM	|	10.1038/clpt.2010.250	|
|	Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.	|	2011	|	Journal of psychopharmacology (Oxford, England)	|	25	|	7	|	896-907	|	Nikisch G and Baumann P and Oneda B and Kiessling B and Weisser H and MathÃ© AA and Yoshitake T and Kehr J and Wiedemann G and Eap CB	|	10.1177/0269881110389208	|
|	Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter.	|	2004	|	Psychopharmacology	|	174	|	4	|	512-24	|	Neumeister A and Young T and Stastny J	|	10.1007/s00213-004-1950-3	|
|	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.	|	2017	|	European archives of psychiatry and clinical neuroscience	|	267	|	8	|	723-735	|	Fabbri C and Crisafulli C and Calati R and Albani D and Forloni G and CalabrÃ² M and Martines R and Kasper S and Zohar J and Juven-Wetzler A and Souery D and Montgomery S and Mendlewicz J and Serretti A	|	10.1007/s00406-017-0766-1	|
|	Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker.	|	2011	|	Pharmacogenomics	|	12	|	2	|	171-84	|	Morag A and Pasmanik-Chor M and Oron-Karni V and Rehavi M and Stingl JC and Gurwitz D	|	10.2217/pgs.10.185	|
|	Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis.	|	2014	|	Journal of affective disorders	|	168	|		|	430-8	|	Lin JY and Jiang MY and Kan ZM and Chu Y	|	10.1016/j.jad.2014.06.012	|
|	Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.	|	2004	|	Archives of general psychiatry	|	61	|	11	|	1163-9	|	Murphy GM Jr and Hollander SB and Rodrigues HE and Kremer C and Schatzberg AF	|	10.1001/archpsyc.61.11.1163	|
|	Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.	|	2015	|	The pharmacogenomics journal	|	15	|	5	|	443-51	|	Altar CA and Carhart JM and Allen JD and Hall-Flavin DK and Dechairo BM and Winner JG	|	10.1038/tpj.2014.85	|
|	Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.	|	2010	|	The American journal of psychiatry	|	167	|	5	|	555-64	|	Uher R and Perroud N and Ng MY and Hauser J and Henigsberg N and Maier W and Mors O and Placentino A and Rietschel M and Souery D and Zagar T and Czerski PM and Jerman B and Larsen ER and Schulze TG and Zobel A and Cohen-Woods S and Pirlo K and Butler AW and Muglia P and Barnes MR and Lathrop M and Farmer A and Breen G and Aitchison KJ and Craig I and Lewis CM and McGuffin P	|	10.1176/appi.ajp.2009.09070932	|
|	Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.	|	2012	|	Biological psychiatry	|	72	|	4	|	331-8	|	Zarate CA Jr and Brutsche N and Laje G and Luckenbaugh DA and Venkata SL and Ramamoorthy A and Moaddel R and Wainer IW	|	10.1016/j.biopsych.2012.03.004	|
|	Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients.	|	2009	|	Pharmacogenetics and genomics	|	19	|	9	|	666-74	|	Laje G and Allen AS and Akula N and Manji H and John Rush A and McMahon FJ	|	10.1097/FPC.0b013e32832e4bcd	|
|	Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response.	|	2009	|	Archives of general psychiatry	|	66	|	5	|	488-97	|	Licinio J and Dong C and Wong ML	|	10.1001/archgenpsychiatry.2009.38	|
|	Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: focus on antiepileptic drugs.	|	2006	|	Personalized medicine	|	3	|	2	|	139-149	|	Clarke W and McMillin G	|	10.2217/17410541.3.2.139	|
|	Norepinephrine and serotonin transporter genes: impact on treatment response in depression.	|	2010	|	Neuropsychobiology	|	62	|	2	|	121-31	|	Baffa A and Hohoff C and Baune BT and MÃ¼ller-Tidow C and Tidow N and Freitag C and Zwanzger P and Deckert J and Arolt V and Domschke K	|	10.1159/000317285	|
|	Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder.	|	2009	|	Brain research	|	1262	|		|	6-Jan	|	Lee HY and Kang RH and Paik JW and Jeong YJ and Chang HS and Han SW and Lee MS	|	10.1016/j.brainres.2009.01.013	|
|	Personalized treatment of schizophrenia in everyday clinical practice: reality or fiction?	|	2015	|	Psychiatria Danubina	|	27	|	3	|	314-8	|	PlesniÄar BK	|		|
|	Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder.	|	2003	|	The international journal of neuropsychopharmacology	|	6	|	4	|	421-4	|	Washizuka S and Ikeda A and Kato N and Kato T	|	10.1017/S1461145703003778	|
|	Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.	|	2013	|	The pharmacogenomics journal	|	13	|	3	|	280-5	|	Perlis RH and Fijal B and Dharia S and Houston JP	|	10.1038/tpj.2011.62	|
|	Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.	|	2005	|	Journal of clinical psychopharmacology	|	25	|	5	|	427-34	|	Perlis RH and Ganz DA and Avorn J and Schneeweiss S and Glynn RJ and Smoller JW and Wang PS	|	10.1097/01.jcp.0000177553.59455.24	|
|	Association analysis between polymorphisms in the myo-inositol monophosphatase 2 (IMPA2) gene and bipolar disorder.	|	2010	|	Progress in neuro-psychopharmacology & biological psychiatry	|	34	|	8	|	1515-9	|	Bloch PJ and Weller AE and Doyle GA and Ferraro TN and Berrettini WH and Hodge R and Lohoff FW	|	10.1016/j.pnpbp.2010.08.015	|
|	Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.	|	2016	|	Pharmacogenomics	|	17	|	9	|	1029-40	|	Noordam R and Avery CL and Visser LE and Stricker BH	|	10.2217/pgs-2016-0024	|
|	Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients.	|	2018	|	Neuroscience letters	|	683	|		|	202-206	|	Zhou W and Chang W and Yan Y and Shen L and Li W and Yi Z and Qin S	|	10.1016/j.neulet.2018.08.002	|
|	Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.	|	2009	|	Pharmacogenomics	|	10	|	3	|	385-97	|	Gupta M and Bhatnagar P and Grover S and Kaur H and Baghel R and Bhasin Y and Chauhan C and Verma B and Manduva V and Mukherjee O and Purushottam M and Sharma A and Jain S and Brahmachari SK and Kukreti R	|	10.2217/14622416.10.3.385	|
|	Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders.	|	2006	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	16	|	7	|	498-503	|	Yu YW and Tsai SJ and Liou YJ and Hong CJ and Chen TJ	|	10.1016/j.euroneuro.2005.12.004	|
|	Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.	|	2008	|	The American journal of psychiatry	|	165	|	10	|	1251-5	|	Henry NL and Stearns V and Flockhart DA and Hayes DF and Riba M	|	10.1176/appi.ajp.2008.08040482	|
|	Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.	|	2018	|	Addiction (Abingdon, England)	|	113	|	3	|	509-523	|	Chenoweth MJ and Ware JJ and Zhu AZX and Cole CB and Cox LS and Nollen N and Ahluwalia JS and Benowitz NL and Schnoll RA and Hawk LW Jr and Cinciripini PM and George TP and Lerman C and Knight J and Tyndale RF	|	10.1111/add.14032	|
|	Estimating the Potential Impact of CYP2C19 and CYP2D6 Genetic Testing on Protocol-Based Care for Depression in Canada and the United States.	|	2020	|	Molecular neuropsychiatry	|	5	|		|	27-33	|	Fan M and Bousman CA	|	10.1159/000504253	|
|	A genomewide association study of citalopram response in major depressive disorder.	|	2010	|	Biological psychiatry	|	67	|	2	|	133-8	|	Garriock HA and Kraft JB and Shyn SI and Peters EJ and Yokoyama JS and Jenkins GD and Reinalda MS and Slager SL and McGrath PJ and Hamilton SP	|	10.1016/j.biopsych.2009.08.029	|
|	Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.	|	2006	|	Expert opinion on pharmacotherapy	|	7	|	2	|	119-33	|	Ozdemir V and Aklillu E and Mee S and Bertilsson L and Albers LJ and Graham JE and Caligiuri M and Lohr JB and Reist C	|	10.1517/14656566.7.2.119	|
|	Genetic prediction of antidepressant drug response and nonresponse in Korean patients.	|	2014	|	PloS one	|	9	|	9	|	e107098	|	Lim SW and Won HH and Kim H and Myung W and Kim S and Kim KK and Carroll BJ and Kim JW and Kim DK	|	10.1371/journal.pone.0107098	|
|	Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia.	|	2018	|	Neuropsychiatric disease and treatment	|	14	|		|	2981-2987	|	Escamilla R and Camarena B and Saracco-Alvarez R and FresÃ¡n A and HernÃ¡ndez S and Aguilar-GarcÃ­a A	|	10.2147/NDT.S176455	|
|	Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.	|	2013	|	Pharmacogenetics and genomics	|	23	|	2	|	69-77	|	Clark SL and Souza RP and Adkins DE and Aberg K and BukszÃ¡r J and McClay JL and Sullivan PF and van den Oord EJ	|	10.1097/FPC.0b013e32835ca260	|
|	Microarray analysis in drug discovery: an uplifting view of depression.	|	2003	|	Science's STKE : signal transduction knowledge environment	|	2003	|	206	|	pe46	|	Levy SE	|	10.1126/stke.2003.206.pe46	|
|	Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients.	|	2010	|	Neuropsychobiology	|	61	|	2	|	71-8	|	Zou YF and Wang Y and Liu P and Feng XL and Wang BY and Zang TH and Yu X and Wei J and Liu ZC and Liu Y and Tao M and Li HC and Li KQ and Hu J and Li M and Zhang KR and Ye DQ and Xu XP	|	10.1159/000265132	|
|	Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.	|	2015	|	The pharmacogenomics journal	|	15	|	5	|	461-6	|	Verbelen M and Collier DA and Cohen D and MacCabe JH and Lewis CM	|	10.1038/tpj.2015.5	|
|	Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects.	|	2004	|	Dialogues in clinical neuroscience	|	6	|	1	|	71-7	|	Ackenheil M and Weber K	|	10.31887/DCNS.2004.6.1/mackenheil	|
|	When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study.	|	2009	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	34	|	10	|	2227-36	|	Perlis RH and Patrick A and Smoller JW and Wang PS	|	10.1038/npp.2009.50	|
|	The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms.	|	2012	|	European archives of psychiatry and clinical neuroscience	|	262	|	3	|	193-7	|	MÃ¶ssner R and Schuhmacher A and Wagner M and Lennertz L and Steinbrecher A and Quednow BB and Rujescu D and Rietschel M and Maier W	|	10.1007/s00406-011-0235-1	|
|	Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism.	|	2018	|	Journal of child and adolescent psychopharmacology	|	28	|	10	|	711-718	|	GassÃ³ P and BlÃ¡zquez A and RodrÃ­guez N and Boloc D and Torres T and Mas S and Lafuente A and LÃ¡zaro L	|	10.1089/cap.2018.0004	|
|	Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.	|	2008	|	Schizophrenia research	|	98	|	1	|	47-54	|	Ellingrod VL and Miller DD and Taylor SF and Moline J and Holman T and Kerr J	|	10.1016/j.schres.2007.09.030	|
|	Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales.	|	2022	|	The Journal of clinical psychiatry	|	83	|	4	|		|	Zhang C and Virani S and Mayes T and Carmody T and Croarkin PE and Weinshilboum R and Rush AJ and Trivedi M and Athreya AP and Bobo WV	|	10.4088/JCP.21m14239	|
|	Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial.	|	2016	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	26	|	10	|	1683-9	|	Labad J and Martorell L and Huerta-Ramos E and Cobo J and Vilella E and Rubio-Abadal E and Garcia-Pares G and Creus M and NÃºÃ±ez C and Ortega L and Miquel E and Usall J	|	10.1016/j.euroneuro.2016.08.006	|
|	Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment.	|	2012	|	Brain : a journal of neurology	|	135	|		|	1436-45	|	Tan HY and Chen AG and Kolachana B and Apud JA and Mattay VS and Callicott JH and Chen Q and Weinberger DR	|	10.1093/brain/aws068	|
|	Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials - Challenges and future perspectives. A critical review.	|	2022	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	59	|		|	68-81	|	Minelli A and Barlati S and Baune BT	|	10.1016/j.euroneuro.2022.04.007	|
|	Variation in GNB3 predicts response and adverse reactions to antidepressants.	|	2011	|	Journal of psychopharmacology (Oxford, England)	|	25	|	7	|	867-74	|	Keers R and Bonvicini C and Scassellati C and Uher R and Placentino A and Giovannini C and Rietschel M and Henigsberg N and Kozel D and Mors O and Maier W and Hauser J and Souery D and Mendlewicz J and SchmÃ¤l C and Zobel A and Larsen ER and Szczepankiewicz A and Kovacic Z and Elkin A and Craig I and McGuffin P and Farmer AE and Aitchison KJ and Gennarelli M	|	10.1177/0269881110376683	|
|	Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response.	|	2008	|	Pharmacogenetics and genomics	|	18	|	10	|	869-75	|	Tsai SJ and Hong CJ and Liou YJ and Yu YW and Chen TJ	|	10.1097/FPC.0b013e328308bbc0	|
|	A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.	|	2015	|	Journal of neural transmission (Vienna, Austria : 1996)	|	122	|	3	|	465-75	|	Drago A and Cocchi E and Crisafulli C and Serretti A	|	10.1007/s00702-014-1267-2	|
|	Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia.	|	2014	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	39	|	9	|	2170-8	|	Jenkins A and Apud JA and Zhang F and Decot H and Weinberger DR and Law AJ	|	10.1038/npp.2014.65	|
|	A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder.	|	2008	|	Progress in neuro-psychopharmacology & biological psychiatry	|	32	|	1	|	204-8	|	Masui T and Hashimoto R and Kusumi I and Suzuki K and Tanaka T and Nakagawa S and Suzuki T and Iwata N and Ozaki N and Kato T and Takeda M and Kunugi H and Koyama T	|	10.1016/j.pnpbp.2007.08.010	|
|	The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.	|	2005	|	The Journal of clinical psychiatry	|	66	|	1	|	15-27	|	de Leon J and Susce MT and Pan RM and Fairchild M and Koch WH and Wedlund PJ	|	10.4088/jcp.v66n0103	|
|	Common functional mineralocorticoid receptor polymorphisms modulate the cortisol awakening response: Interaction with SSRIs.	|	2011	|	Psychoneuroendocrinology	|	36	|	4	|	484-94	|	Klok MD and Vreeburg SA and Penninx BW and Zitman FG and de Kloet ER and DeRijk RH	|	10.1016/j.psyneuen.2010.07.024	|
|	QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.	|	2018	|	European archives of psychiatry and clinical neuroscience	|	268	|	4	|	383-390	|	Spellmann I and Reinhard MA and Veverka D and Zill P and Obermeier M and Dehning S and Schennach R and MÃ¼ller N and MÃ¶ller HJ and Riedel M and Musil R	|	10.1007/s00406-018-0880-8	|
|	Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.	|	2014	|	The American journal of psychiatry	|	171	|	12	|	1297-309	|	Wong ML and Dong C and Flores DL and Ehrhart-Bornstein M and Bornstein S and Arcos-Burgos M and Licinio J	|	10.1176/appi.ajp.2014.12091165	|
|	Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders.	|	2022	|	Psychiatry research	|	311	|		|	114482	|	Ielmini M and Caselli I and Critelli F and Mattia M and Bellini A and Callegari C	|	10.1016/j.psychres.2022.114482	|
|	Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.	|	2009	|	The Journal of clinical psychiatry	|	70	|	6	|	801-9	|	Volpi S and Potkin SG and Malhotra AK and Licamele L and Lavedan C	|	10.4088/jcp.08m04391	|
|	Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.	|	2016	|	Journal of affective disorders	|	198	|		|	43-9	|	Quteineh L and Preisig M and Rivera M and Milaneschi Y and Castelao E and Gholam-Rezaee M and Vandenberghe F and Saigi-Morgui N and DelacrÃ©taz A and Cardinaux JR and Willemsen G and Boomsma DI and Penninx BW and Ching-LÃ³pez A and Conus P and Eap CB	|	10.1016/j.jad.2016.03.031	|
|	Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment.	|	2013	|	Pharmacogenetics and genomics	|	23	|	12	|	666-74	|	DrÃ¶gemÃ¶ller BI and Wright GE and Niehaus DJ and Emsley R and Warnich L	|	10.1097/FPC.0000000000000006	|
|	Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians.	|	2009	|	Pharmacogenomics	|	10	|	9	|	1457-66	|	Kohlrausch FB and Gama CS and Lobato MI and Belmonte-de-Abreu P and Gesteira A and Barros F and Carracedo A and Hutz MH	|	10.2217/pgs.09.76	|
|	Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study.	|	2010	|	European journal of human genetics : EJHG	|	18	|	6	|	707-12	|	Xu M and Li S and Xing Q and Gao R and Feng G and Lin Z and St Clair D and He L	|	10.1038/ejhg.2009.238	|
|	A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression.	|	2009	|	Archives of general psychiatry	|	66	|	9	|	966-975	|	Ising M and Lucae S and Binder EB and Bettecken T and Uhr M and Ripke S and Kohli MA and Hennings JM and Horstmann S and Kloiber S and Menke A and Bondy B and Rupprecht R and Domschke K and Baune BT and Arolt V and Rush AJ and Holsboer F and MÃ¼ller-Myhsok B	|	10.1001/archgenpsychiatry.2009.95	|
|	TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.	|	2015	|	Pharmacopsychiatry	|	48	|	3	|	95-103	|	Yin L and Zhang YY and Zhang X and Yu T and He G and Sun XL	|	10.1055/s-0034-1398508	|
|	Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome.	|	2003	|	AAPS pharmSci	|	5	|	4	|	E29	|	Pinsonneault J and SadÃ©e W	|	10.1208/ps050429	|
|	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia.	|	2019	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	20	|	1	|	91-95	|	Zai CC and Tiwari AK and Chowdhury NI and Yilmaz Z and de Luca V and MÃ¼ller DJ and Potkin SG and Lieberman JA and Meltzer HY and Voineskos AN and Remington G and Kennedy JL	|	10.1080/15622975.2017.1301681	|
|	Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.	|	2013	|	Psychiatry research	|	208	|	3	|	285-7	|	Hopkins SC and Reasner DS and Koblan KS	|	10.1016/j.psychres.2013.04.021	|
|	Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.	|	2016	|	The pharmacogenomics journal	|	16	|	4	|	357-65	|	Xu Q and Wu X and Li M and Huang H and Minica C and Yi Z and Wang G and Shen L and Xing Q and Shi Y and He L and Qin S	|	10.1038/tpj.2015.61	|
|	Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.	|	2012	|	Translational psychiatry	|	2	|	7	|	e129	|	Adkins DE and Clark SL and Ã…berg K and Hettema JM and BukszÃ¡r J and McClay JL and Souza RP and van den Oord EJ	|	10.1038/tp.2012.57	|
|	[5-HT1A gene polymorphisms contributed to antidepressant response in major depression].	|	2009	|	Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology	|	29	|	1	|	23-31	|	Kato M and Fukuda T and Wakeno M and Okugawa G and Takekita Y and Serretti A and Azuma J and Kinoshita T	|		|
|	Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population.	|	2008	|	Neuroscience letters	|	435	|	2	|	95-8	|	Ji X and Takahashi N and Saito S and Ishihara R and Maeno N and Inada T and Ozaki N	|	10.1016/j.neulet.2008.01.083	|
|	COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine.	|	2015	|	Pharmacogenomics	|	16	|	1	|	35-44	|	Bosia M and Lorenzi C and Pirovano A and Guglielmino C and Cocchi F and Spangaro M and Bramanti P and Smeraldi E and Cavallaro R	|	10.2217/pgs.14.150	|
|	CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study.	|	2015	|	Pharmacogenomics	|	16	|	7	|	689-701	|	Probst-Schendzielorz K and Scholl C and Efimkina O and Ersfeld E and Viviani R and Serretti A and Fabbri C and Gurwitz D and Lucae S and Ising M and Paul AM and Lehmann ML and Steffens M and Crisafulli C and CalabrÃ² M and Holsboer F and Stingl J	|	10.2217/pgs.15.31	|
|	Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?	|	2008	|	Neuroscience letters	|	436	|	2	|	111-5	|	Baune BT and Hohoff C and Roehrs T and Deckert J and Arolt V and Domschke K	|	10.1016/j.neulet.2008.03.001	|
|	Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.	|	2012	|	The pharmacogenomics journal	|	12	|	1	|	78-85	|	Ji Y and Biernacka J and Snyder K and Drews M and Pelleymounter LL and Colby C and Wang L and Mrazek DA and Weinshilboum RM	|	10.1038/tpj.2010.69	|
|	Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia.	|	2007	|	Biological psychiatry	|	61	|	10	|	1195-9	|	Wood LS and Pickering EH and Dechairo BM	|	10.1016/j.biopsych.2006.07.005	|
|	Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.	|	2010	|	Progress in neuro-psychopharmacology & biological psychiatry	|	34	|	6	|	1026-32	|	Xu M and Xing Q and Li S and Zheng Y and Wu S and Gao R and Yu L and Guo T and Yang Y and Liu J and Zhang A and Zhao X and He G and Zhou J and Wang L and Xuan J and Du J and Li X and Feng G and Lin Z and Xu Y and St Clair D and Lin Z and He L	|	10.1016/j.pnpbp.2010.05.017	|
|	Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.	|	2007	|	The American journal of psychiatry	|	164	|	8	|	1181-8	|	Paddock S and Laje G and Charney D and Rush AJ and Wilson AF and Sorant AJ and Lipsky R and Wisniewski SR and Manji H and McMahon FJ	|	10.1176/appi.ajp.2007.06111790	|
|	Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.	|	2011	|	Molecular psychiatry	|	16	|	3	|	321-32	|	Adkins DE and Aberg K and McClay JL and BukszÃ¡r J and Zhao Z and Jia P and Stroup TS and Perkins D and McEvoy JP and Lieberman JA and Sullivan PF and van den Oord EJ	|	10.1038/mp.2010.14	|
|	A genetic locus in 7p12.2 associated with treatment resistant schizophrenia.	|	2014	|	Schizophrenia research	|	159	|	2	|	333-9	|	Li J and Meltzer HY	|	10.1016/j.schres.2014.08.018	|
|	The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression.	|	2014	|	Journal of psychiatric research	|	53	|		|	47-53	|	Okada S and Morinobu S and Fuchikami M and Segawa M and Yokomaku K and Kataoka T and Okamoto Y and Yamawaki S and Inoue T and Kusumi I and Koyama T and Tsuchiyama K and Terao T and Kokubo Y and Mimura M	|	10.1016/j.jpsychires.2014.02.002	|
|	A genome-wide association study of a sustained pattern of antidepressant response.	|	2013	|	Journal of psychiatric research	|	47	|	9	|	1157-65	|	Hunter AM and Leuchter AF and Power RA and MuthÃ©n B and McGrath PJ and Lewis CM and Cook IA and Garriock HA and McGuffin P and Uher R and Hamilton SP	|	10.1016/j.jpsychires.2013.05.002	|
|	Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder.	|	1997	|	Pharmacogenetics	|	7	|	5	|	349-53	|	Li T and Vallada H and Curtis D and Arranz M and Xu K and Cai G and Deng H and Liu J and Murray R and Liu X and Collier DA	|	10.1097/00008571-199710000-00002	|
|	Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.	|	2000	|	The Journal of clinical psychiatry	|	61	|	3	|	209-14	|	Lane HY and Chiu WC and Chou JC and Wu ST and Su MH and Chang WH	|	10.4088/jcp.v61n0311	|
|	Genetic markers of suicidal ideation emerging during citalopram treatment of major depression.	|	2007	|	The American journal of psychiatry	|	164	|	10	|	1530-8	|	Laje G and Paddock S and Manji H and Rush AJ and Wilson AF and Charney D and McMahon FJ	|	10.1176/appi.ajp.2007.06122018	|
|	Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.	|	2008	|	Biological psychiatry	|	63	|	1	|	32-41	|	Campbell DB and Ebert PJ and Skelly T and Stroup TS and Lieberman J and Levitt P and Sullivan PF	|	10.1016/j.biopsych.2007.04.018	|
|	Genetic studies of drug response and side effects in the STAR*D study, part 1.	|	2009	|	The Journal of clinical psychiatry	|	70	|	8	|	1186-7	|	Garriock HA and Hamilton SP	|	10.4088/JCP.09ac05519	|
|	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.	|	2016	|	The pharmacogenomics journal	|	16	|	5	|	439-45	|	Mas S and GassÃ³ P and Lafuente A and Bioque M and Lobo A and GonzÃ lez-Pinto A and Olmeda MS and Corripio I and Llerena A and Cabrera B and Saiz-Ruiz J and Bernardo M	|	10.1038/tpj.2016.44	|
|	Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.	|	2009	|	Progress in neuro-psychopharmacology & biological psychiatry	|	33	|	3	|	470-4	|	Chen SF and Shen YC and Chen CH	|	10.1016/j.pnpbp.2009.01.007	|
|	Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone.	|	2015	|	Journal of psychopharmacology (Oxford, England)	|	29	|	4	|	372-82	|	Geerts H and Roberts P and Spiros A and Potkin S	|	10.1177/0269881114568042	|
|	A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.	|	2017	|	The pharmacogenomics journal	|	17	|	2	|	155-161	|	Chen PS and Chang HH and Huang CC and Lee CC and Lee SY and Chen SL and Huang SY and Yang YK and Lu RB	|	10.1038/tpj.2015.96	|
|	[Recent advances in the genetics of schizophrenia and the practical implications of the results].	|	2008	|	Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata	|	23	|	3	|	152-65	|	RÃ©thelyi J and PolgÃ¡r P and Czobor P and Bitter I	|		|
|	The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.	|	2017	|	Basic & clinical pharmacology & toxicology	|	121	|	5	|	435-441	|	Taranu A and Asmar KE and Colle R and Ferreri F and Polosan M and David D and Becquemont L and Corruble E and Verstuyft C	|	10.1111/bcpt.12827	|
|	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.	|	2009	|	European journal of human genetics : EJHG	|	17	|	7	|	946-57	|	Need AC and Keefe RS and Ge D and Grossman I and Dickson S and McEvoy JP and Goldstein DB	|	10.1038/ejhg.2008.264	|
|	The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.	|	2008	|	Biological psychiatry	|	63	|	12	|	1103-10	|	Lekman M and Laje G and Charney D and Rush AJ and Wilson AF and Sorant AJ and Lipsky R and Wisniewski SR and Manji H and McMahon FJ and Paddock S	|	10.1016/j.biopsych.2007.10.026	|
|	Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in Korean patients with major depression.	|	2014	|	Neuropsychobiology	|	69	|	4	|	210-9	|	Kim YG and Chang HS and Won ES and Ham BJ and Lee MS	|	10.1159/000362241	|
|	Meta-analysis of dopamine receptor D1 rs4532 polymorphism and susceptibility to antipsychotic treatment response.	|	2015	|	Psychiatry research	|	229	|	1	|	586-8	|	de Matos LP and Santana CV and Souza RP	|	10.1016/j.psychres.2015.07.054	|
|	Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder.	|	2009	|	Pharmacopsychiatry	|	42	|	1	|	20-2	|	Rybakowski JK and Dmitrzak-Weglarz M and Suwalska A and Leszczynska-Rodziewicz A and Hauser J	|	10.1055/s-0028-1085441	|
|	Sequence variants and haplotype analysis of serotonin transporter gene and association with bipolar affective disorder in Taiwan.	|	2004	|	Pharmacogenetics	|	14	|	3	|	173-9	|	Sun HS and Wang HC and Lai TJ and Wang TJ and Li CM	|	10.1097/00008571-200403000-00005	|
|	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.	|	2012	|	The pharmacogenomics journal	|	12	|	3	|	255-9	|	Mas S and GassÃ² P and Alvarez S and Parellada E and Bernardo M and Lafuente A	|	10.1038/tpj.2010.91	|
|	Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.	|	2009	|	The pharmacogenomics journal	|	9	|	5	|	311-8	|	Fijal BA and Kinon BJ and Kapur S and Stauffer VL and Conley RR and Jamal HH and Kane JM and Witte MM and Houston JP	|	10.1038/tpj.2009.24	|
|	Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.	|	2001	|	Journal of biochemical and biophysical methods	|	47	|	1	|	151-7	|	Ozdemir V and Basile VS and Masellis M and Kennedy JL	|	10.1016/s0165-022x(00)00161-5	|
|	CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.	|	2013	|	Pharmacogenetics and genomics	|	23	|	11	|	627-30	|	Almoguera B and Riveiro-Alvarez R and Lopez-Castroman J and Dorado P and Vaquero-Lorenzo C and Fernandez-Piqueras J and Llerena A and Abad-Santos F and Baca-GarcÃ­a E and Dal-RÃ© R and Ayuso C	|	10.1097/FPC.0b013e3283659a94	|
|	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.	|	2008	|	Progress in neuro-psychopharmacology & biological psychiatry	|	32	|	2	|	398-404	|	Kato M and Fukuda T and Serretti A and Wakeno M and Okugawa G and Ikenaga Y and Hosoi Y and Takekita Y and Mandelli L and Azuma J and Kinoshita T	|	10.1016/j.pnpbp.2007.09.003	|
|	Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India.	|	2017	|	Asian journal of psychiatry	|	29	|		|	174-182	|	Kaur G and Gupta D and Chavan BS and Sinhmar V and Prasad R and Tripathi A and Garg PD and Gupta R and Khurana H and Gautam S and Margoob MA and Aneja J	|	10.1016/j.ajp.2017.07.026	|
|	Improving lithium dose prediction using population pharmacokinetics and pharmacogenomics: a cohort genome-wide association study in Sweden.	|	2022	|	The lancet. Psychiatry	|	9	|	6	|	447-457	|	Millischer V and Matheson GJ and Bergen SE and Coombes BJ and Ponzer K and WikstrÃ¶m F and Jagiello K and Lundberg M and Stenvinkel P and Biernacka JM and Breuer O and Martinsson L and LandÃ©n M and Backlund L and Lavebratt C and Schalling M	|	10.1016/S2215-0366(22)00100-6	|
|	DAT1 polymorphism determines L-DOPA effects on learning about others' prosociality.	|	2013	|	PloS one	|	8	|	7	|	e67820	|	Eisenegger C and Pedroni A and Rieskamp J and Zehnder C and Ebstein R and Fehr E and Knoch D	|	10.1371/journal.pone.0067820	|
|	Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis.	|	2017	|	The pharmacogenomics journal	|	17	|	1	|	92-97	|	Zhang C and Zhang Y and Cai J and Chen M and Song L	|	10.1038/tpj.2015.68	|
|	The future of psychiatric pharmacogenomics.	|	2011	|	Pharmacogenomics	|	12	|	7	|	927-9	|	Lohoff FW	|	10.2217/pgs.11.60	|
|	Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.	|	2010	|	Annals of human genetics	|	74	|	4	|	340-50	|	Wright GE and Niehaus DJ and DrÃ¶gemÃ¶ller BI and Koen L and Gaedigk A and Warnich L	|	10.1111/j.1469-1809.2010.00585.x	|
|	The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).	|	2008	|	Therapeutic drug monitoring	|	30	|	1	|	35-40	|	Nozawa M and Ohnuma T and Matsubara Y and Sakai Y and Hatano T and Hanzawa R and Shibata N and Arai H	|	10.1097/FTD.0b013e31816336fd	|
|	Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study.	|	2012	|	Pharmacogenomics	|	13	|	11	|	1227-37	|	Liu Q and Jamba M and Patrick C 3rd and Padmanabhan S and Brennan MD	|	10.2217/pgs.12.105	|
|	Clinical insights into pharmacogenetics and schizophrenia, part 1.	|	2008	|	The Journal of clinical psychiatry	|	69	|	3	|	487-94	|		|	10.4088/jcp.v69n0322	|
|	Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.	|	2009	|	Psychopharmacology	|	206	|	3	|	491-9	|	Alkelai A and Greenbaum L and Rigbi A and Kanyas K and Lerer B	|	10.1007/s00213-009-1627-z	|
|	The Influence of Genotype Information on Psychiatrists' Treatment Recommendations: More Experienced Clinicians Know Better What to Ignore.	|	2017	|	Value in health : the journal of the International Society for Pharmacoeconomics           and Outcomes Research	|	20	|	1	|	126-131	|	McMichael AJ and Boeri M and Rolison JJ and Kane J and O'Neill FA and Scarpa R and Kee F	|	10.1016/j.jval.2016.09.2395	|
|	Schizophrenia: from brain morphology to psychopathology.	|	2007	|	Current psychiatry reports	|	9	|	4	|	337-42	|	Foster A and Usman M and Stirewalt E and Buckley P	|	10.1007/s11920-007-0042-6	|
|	Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients.	|	2010	|	Biological psychiatry	|	67	|	11	|	1110-3	|	Perlis RH and Fijal B and Dharia S and Heinloth AN and Houston JP	|	10.1016/j.biopsych.2009.12.010	|
|	Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.	|	2011	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	36	|	3	|	616-26	|	McClay JL and Adkins DE and Aberg K and BukszÃ¡r J and Khachane AN and Keefe RS and Perkins DO and McEvoy JP and Stroup TS and Vann RE and Beardsley PM and Lieberman JA and Sullivan PF and van den Oord EJ	|	10.1038/npp.2010.193	|
|	A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients.	|	2012	|	Journal of psychopharmacology (Oxford, England)	|	26	|	6	|	813-8	|	Wei Z and Wang L and Zhang M and Xuan J and Wang Y and Liu B and Shao L and Li J and Zeng Z and Li T and Liu J and Wang T and Zhang M and Qin S and Xu Y and Feng G and He L and Xing Q	|	10.1177/0269881111405358	|
|	rs7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride.	|	2017	|	Human psychopharmacology	|	32	|	2	|		|	Kang SG and Chee IS and Lee K and Lee J	|	10.1002/hup.2562	|
|	Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study.	|	2016	|	Journal of psychiatric research	|	73	|		|	86-95	|	Breitenstein B and Scheuer S and BrÃ¼ckl TM and Meyer J and Ising M and Uhr M and Holsboer F	|	10.1016/j.jpsychires.2015.11.010	|
|	Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms.	|	2006	|	Pharmacogenetics and genomics	|	16	|	2	|	111-7	|	Srivastava V and Varma PG and Prasad S and Semwal P and Nimgaonkar VL and Lerer B and Deshpande SN and BK T	|	10.1097/01.fpc.0000184957.98150.0f	|
|	Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.	|	2006	|	Progress in neuro-psychopharmacology & biological psychiatry	|	30	|	2	|	286-91	|	Yasui-Furukori N and Saito M and Nakagami T and Kaneda A and Tateishi T and Kaneko S	|	10.1016/j.pnpbp.2005.06.019	|
|	Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.	|	2014	|	Schizophrenia research	|	160	|	1	|	73-9	|	Ramsey TL and Brennan MD	|	10.1016/j.schres.2014.09.038	|
|	Gene expression in blood is associated with risperidone response in children with autism spectrum disorders.	|	2012	|	The pharmacogenomics journal	|	12	|	5	|	368-71	|	Lit L and Sharp FR and Bertoglio K and Stamova B and Ander BP and Sossong AD and Hendren RL	|	10.1038/tpj.2011.23	|
|	Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.	|	2012	|	The pharmacogenomics journal	|	12	|	3	|	246-54	|	Liu W and Downing AC and Munsie LM and Chen P and Reed MR and Ruble CL and Landschulz KT and Kinon BJ and Nisenbaum LK	|	10.1038/tpj.2010.90	|
|	Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective.	|	2012	|	Pharmacogenomics	|	13	|	10	|	1119-27	|	Vijayan NN and Mathew A and Balan S and Natarajan C and Nair CM and Allencherry PM and Banerjee M	|	10.2217/pgs.12.86	|
|	Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.	|	2007	|	Psychopharmacology bulletin	|	40	|	1	|	57-62	|	Ellingrod VL and Bishop JR and Moline J and Lin YC and Miller DD	|		|
|	The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness.	|	1998	|	Pharmacogenetics	|	8	|	3	|	259-68	|	Steen VM and LÃ¸vlie R and Osher Y and Belmaker RH and Berle JO and Gulbrandsen AK	|		|
|	Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia.	|	2012	|	Pharmacogenomics	|	13	|	8	|	843-6	|	Kuzman MR and MÃ¼ller DJ	|	10.2217/pgs.12.64	|
|	DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study.	|	2003	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	13	|	3	|	183-5	|	Zalsman G and Frisch A and Lev-Ran S and Martin A and Michaelovsky E and Bensason D and Gothelf D and Nahshoni E and Tyano S and Weizman A	|	10.1016/s0924-977x(03)00006-3	|
|	The NDE1 genomic locus can affect treatment of psychiatric illness through gene expression changes related to microRNA-484.	|	2017	|	Open biology	|	7	|	11	|		|	Bradshaw NJ and Ukkola-Vuoti L and Pankakoski M and Zheutlin AB and Ortega-Alonso A and Torniainen-Holm M and Sinha V and Therman S and Paunio T and Suvisaari J and LÃ¶nnqvist J and Cannon TD and Haukka J and Hennah W	|	10.1098/rsob.170153	|
|	Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder.	|	2012	|	Psychiatry research	|	198	|	1	|	112-5	|	Narasimhan S and Aquino TD and Multani PK and Rickels K and Lohoff FW	|	10.1016/j.psychres.2011.12.034	|
|	BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population.	|	2008	|	Pharmacogenetics and genomics	|	18	|	6	|	449-57	|	Xu MQ and St Clair D and Feng GY and Lin ZG and He G and Li X and He L	|	10.1097/FPC.0b013e3282f85e26	|
|	Postmortem brain tissue for drug discovery in psychiatric research.	|	2009	|	Schizophrenia bulletin	|	35	|	6	|	1031-3	|	Kim S and Webster MJ	|	10.1093/schbul/sbp106	|
|	Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics.	|	2015	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	40	|	7	|	1600-8	|	Blasi G and Selvaggi P and Fazio L and Antonucci LA and Taurisano P and Masellis R and Romano R and Mancini M and Zhang F and Caforio G and Popolizio T and Apud J and Weinberger DR and Bertolino A	|	10.1038/npp.2015.5	|
|	Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia.	|	2006	|	Pharmacogenetics and genomics	|	16	|	3	|	151-7	|	Liou YJ and Lai IC and Lin MW and Bai YM and Lin CC and Liao DL and Chen JY and Lin CY and Wang YC	|	10.1097/01.fpc.0000184958.05775.66	|
|	Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.	|	2005	|	Neuroscience letters	|	376	|	1	|	51-5	|	Benedetti F and Serretti A and Pontiggia A and Bernasconi A and Lorenzi C and Colombo C and Smeraldi E	|	10.1016/j.neulet.2004.11.022	|
|	Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder.	|	2013	|	Human psychopharmacology	|	28	|	3	|	258-62	|	Cooper AJ and Rickels K and Lohoff FW	|	10.1002/hup.2317	|
|	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.	|	2022	|	Translational psychiatry	|	12	|	1	|	101	|	Tiwari AK and Zai CC and Altar CA and Tanner JA and Davies PE and Traxler P and Li J and Cogan ES and Kucera MT and Gugila A and Braganza N and Emmerson H and Zai G and MÃ¼ller DJ and Levitan R and Kloiber S and Daskalakis ZJ and Frey BN and Bowen JM and Tarride JE and Tytus R and Chandrasena R and Voudouris N and Taylor VH and Tempier R and Sharma V and Vasudev A and Dzongowski P and Pliamm L and Greenspoon T and Dechairo BM and Kennedy JL	|	10.1038/s41398-022-01847-8	|
|	Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors.	|	2015	|	Journal of neural transmission (Vienna, Austria : 1996)	|	122	|	1	|	35-42	|	Gressier F and Verstuyft C and Hardy P and Becquemont L and Corruble E	|	10.1007/s00702-014-1273-4	|
|	HTR2A gene variation is involved in antidepressant treatment response.	|	2010	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	20	|	1	|	65-8	|	Lucae S and Ising M and Horstmann S and Baune BT and Arolt V and MÃ¼ller-Myhsok B and Holsboer F and Domschke K	|	10.1016/j.euroneuro.2009.08.006	|
|	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.	|	2017	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	27	|	7	|	647-656	|	Mas S and GassÃ³ P and Torra M and Bioque M and Lobo A and GonzÃ¡lez-Pinto A and Olmeda MS and Corripio I and Vieta E and Castro-Fornieles J and Rodriguez-Jimenez R and Bobes J and Usall J and Llerena A and Saiz-Ruiz J and Bernardo M and Lafuente A and PEPs Group	|	10.1016/j.euroneuro.2017.03.012	|
|	The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression.	|	2010	|	Biological psychiatry	|	67	|	6	|	543-9	|	Baune BT and Dannlowski U and Domschke K and Janssen DG and Jordan MA and Ohrmann P and Bauer J and Biros E and Arolt V and Kugel H and Baxter AG and Suslow T	|	10.1016/j.biopsych.2009.11.004	|
|	Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study.	|	2012	|	Psychiatric genetics	|	22	|	6	|	298-9	|	Zhao QZ and Liu BC and Zhang J and Wang L and Li XW and Wang Y and Ji J and Yang FP and Wan CL and Xu YF and Feng GY and He L and He G	|	10.1097/YPG.0b013e328358629a	|
|	Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.	|	2013	|	The pharmacogenomics journal	|	13	|	2	|	197-204	|	Almoguera B and Riveiro-Alvarez R and Lopez-Castroman J and Dorado P and Vaquero-Lorenzo C and Fernandez-Piqueras J and Llerena A and Abad-Santos F and Baca-GarcÃ­a E and Dal-RÃ© R and Ayuso C	|	10.1038/tpj.2011.57	|
|	The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.	|	2006	|	Therapeutic drug monitoring	|	28	|	5	|	668-72	|	Lin YC and Ellingrod VL and Bishop JR and Miller DD	|	10.1097/01.ftd.0000246761.82377.a6	|
|	[Brain neurotransmitter systems gene Polymorphism: the Search for pharmacogenetic markers of efficacy of haloperidol in Russians and Tatars].	|	2015	|	Molekuliarnaia biologiia	|	49	|	6	|	959-67	|	Gareeva AE and Kinyasheva KO and Galaktionova DY and Sabirov ET and Valinourov RG and Chudinov AV and Zasedatelev AS and Nasedkina TV and Khusnutdinova EK	|	10.7868/S0026898415050079	|
|	Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder.	|	2011	|	Pharmacogenomics	|	12	|	11	|	1559-69	|	Squassina A and Manchia M and Borg J and Congiu D and Costa M and Georgitsi M and Chillotti C and Ardau R and Mitropoulos K and Severino G and Del Zompo M and Patrinos GP	|	10.2217/pgs.11.102	|
|	Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response.	|	2011	|	Pharmacogenomics	|	12	|	4	|	471-80	|	Ramsey TL and Meltzer HY and Brock GN and Mehrotra B and Jayathilake K and Bobo WV and Brennan MD	|	10.2217/pgs.10.205	|
|	Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression.	|	2007	|	International journal of psychiatry in medicine	|	37	|	3	|	315-29	|	Kang RH and Choi MJ and Paik JW and Hahn SW and Lee MS	|	10.2190/PM.37.3.h	|
|	Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.	|	2005	|	Pharmacogenetics and genomics	|	15	|	4	|	195-200	|	Templeman LA and Reynolds GP and Arranz B and San L	|	10.1097/01213011-200504000-00002	|
|	Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.	|	2004	|	The American journal of psychiatry	|	161	|	9	|	1575-80	|	Yoshida K and Takahashi H and Higuchi H and Kamata M and Ito K and Sato K and Naito S and Shimizu T and Itoh K and Inoue K and Suzuki T and Nemeroff CB	|	10.1176/appi.ajp.161.9.1575	|
|	Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample.	|	2016	|	The pharmacogenomics journal	|	16	|	4	|	352-6	|	Brandl EJ and Tiwari AK and Zai CC and Nurmi EL and Chowdhury NI and Arenovich T and Sanches M and Goncalves VF and Shen JJ and Lieberman JA and Meltzer HY and Kennedy JL and MÃ¼ller DJ	|	10.1038/tpj.2015.59	|
|	Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.	|	2009	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	19	|	6	|	451-6	|	Maron E and Tammiste A and Kallassalu K and Eller T and Vasar V and Nutt DJ and Metspalu A	|	10.1016/j.euroneuro.2009.01.010	|
|	Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis.	|	2009	|	Pharmacogenomics	|	10	|	6	|	989-95	|	SÃ¡nchez-Romero MA and Dorado P and Guarino E and Llerena A	|	10.2217/pgs.09.44	|
|	Network analysis of gene expression in peripheral blood identifies mTOR and NF-ÎºB pathways involved in antipsychotic-induced extrapyramidal symptoms.	|	2015	|	The pharmacogenomics journal	|	15	|	5	|	452-60	|	Mas S and GassÃ³ P and Parellada E and Bernardo M and Lafuente A	|	10.1038/tpj.2014.84	|
|	Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data.	|	2008	|	Computer methods and programs in biomedicine	|	91	|	2	|	91-9	|	Lin CC and Wang YC and Chen JY and Liou YJ and Bai YM and Lai IC and Chen TT and Chiu HW and Li YC	|	10.1016/j.cmpb.2008.02.004	|
|	A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia.	|	2003	|	Pharmacogenetics	|	13	|	5	|	271-8	|	Itokawa M and Yamada K and Yoshitsugu K and Toyota T and Suga T and Ohba H and Watanabe A and Hattori E and Shimizu H and Kumakura T and Ebihara M and Meerabux JM and Toru M and Yoshikawa T	|	10.1097/00008571-200305000-00006	|
|	Polymorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin.	|	2010	|	Schizophrenia research	|	121	|	1	|	213-7	|	FernÃ¡ndez E and Carrizo E and FernÃ¡ndez V and Connell L and Sandia I and Prieto D and MogollÃ³n J and Valbuena D and FernÃ¡ndez I and de Baptista EA and Baptista T	|	10.1016/j.schres.2010.06.001	|
|	Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene.	|	2022	|	Frontiers in psychiatry	|	13	|		|	942268	|	StÃ¤uble CK and Meier R and Lampert ML and Mikoteit T and Hatzinger M and Allemann SS and Hersberger KE and Meyer Zu Schwabedissen HE	|	10.3389/fpsyt.2022.942268	|
|	Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients.	|	2009	|	Progress in neuro-psychopharmacology & biological psychiatry	|	33	|	3	|	547-51	|	Wei Z and Wang L and Xuan J and Che R and Du J and Qin S and Xing Y and Gu B and Yang L and Li H and Li J and Feng G and He L and Xing Q	|	10.1016/j.pnpbp.2009.02.008	|
|	The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression.	|	2012	|	Pharmacopsychiatry	|	45	|	3	|	108-13	|	DreimÃ¼ller N and TadiÄ‡ A and Dragicevic A and Boland K and Bondy B and Lieb K and Laux G and Maier W and MÃ¼ller MJ and Rao ML and Rietschel M and RÃ¶schke J and Zill P and Hiemke C	|	10.1055/s-0031-1291347	|
|	[Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].	|	2006	|	Praxis	|	95	|	17	|	671-8	|	Stephan PL and Etzensberger M and Jaquenoud Sirot E	|	10.1024/0369-8394.95.17.671	|
|	The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.	|	2013	|	Journal of clinical psychopharmacology	|	33	|	5	|	593-9	|	ZivkoviÄ‡ M and MihaljeviÄ‡-Peles A and Bozina N and Sagud M and Nikolac-Perkovic M and Vuksan-Cusa B and Muck-Seler D	|	10.1097/JCP.0b013e31829abec9	|
|	Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder.	|	2011	|	Neuroscience letters	|	503	|	3	|	200-2	|	Narasimhan S and Aquino TD and Hodge R and Rickels K and Lohoff FW	|	10.1016/j.neulet.2011.08.035	|
|	Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.	|	2012	|	Biological psychiatry	|	72	|	8	|	700-6	|	Zhang XY and Zhang WF and Zhou DF and Chen DC and Xiu MH and Wu HR and Haile CN and Kosten TA and Kosten TR	|	10.1016/j.biopsych.2012.04.032	|
|	Twenty-one-base-pair insertion polymorphism creates an enhancer element and potentiates SLC6A1 GABA transporter promoter activity.	|	2009	|	Pharmacogenetics and genomics	|	19	|	1	|	53-65	|	Hirunsatit R and George ED and Lipska BK and Elwafi HM and Sander L and Yrigollen CM and Gelernter J and Grigorenko EL and Lappalainen J and Mane S and Nairn AC and Kleinman JE and Simen AA	|	10.1097/FPC.0b013e328318b21a	|
|	A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients.	|	2014	|	Progress in neuro-psychopharmacology & biological psychiatry	|	51	|		|	153-8	|	Xiong Y and Wei Z and Huo R and Wu X and Shen L and Li Y and Gong X and Wu Z and Feng G and Li W and He L and Xing Q and Qin S	|	10.1016/j.pnpbp.2014.01.017	|
|	Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.	|	2012	|	Psychological medicine	|	42	|	6	|	1151-62	|	Clark SL and Adkins DE and Aberg K and Hettema JM and McClay JL and Souza RP and van den Oord EJ	|	10.1017/S003329171100239X	|
|	Keeping our depressed patients in the right treatment long enough for them to get better: some hopeful findings.	|	2007	|	The American journal of psychiatry	|	164	|	8	|	1136-9	|	Badaracco MA	|	10.1176/appi.ajp.2007.07050829	|
|	Haplotype-based pharmacogenetic analysis for longitudinal quantitative traits in the presence of dropout.	|	2010	|	Journal of biopharmaceutical statistics	|	20	|	2	|	334-50	|	Tzeng JY and Lu W and Farmen MW and Liu Y and Sullivan PF	|	10.1080/10543400903572787	|
|	Comparison of two approaches to amitriptyline dose individualisation.	|	1999	|	European journal of drug metabolism and pharmacokinetics	|	24	|	2	|	163-8	|	JankoviÄ‡ SM and TimotijeviÄ‡ I and MihajloviÄ‡ GS and DukiÄ‡-DejanoviÄ‡ S	|	10.1007/BF03190364	|
|	Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression.	|	2008	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	18	|	10	|	751-9	|	Domschke K and Dannlowski U and Ohrmann P and Lawford B and Bauer J and Kugel H and Heindel W and Young R and Morris P and Arolt V and Deckert J and Suslow T and Baune BT	|	10.1016/j.euroneuro.2008.05.003	|
|	[Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].	|	2006	|	Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica	|	108	|	6	|	633-41	|	Suzuki Y and Sawamura H and Someya T	|		|
|	A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications.	|	2009	|	Journal of proteome research	|	8	|	7	|	3633-41	|	Ji B and La Y and Gao L and Zhu H and Tian N and Zhang M and Yang Y and Zhao X and Tang R and Ma G and Zhou J and Meng J and Ma J and Zhang Z and Li H and Feng G and Wang Y and He L and Wan C	|	10.1021/pr800876z	|
|	Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.	|	2012	|	The Journal of clinical psychiatry	|	73	|	3	|	367-71	|	Fijal BA and Stauffer VL and Kinon BJ and Conley RR and Hoffmann VP and Witte MM and Zhao F and Houston JP	|	10.4088/JCP.10m06507	|
|	The influence of TNIK gene polymorphisms on risperidone response in aÂ Chinese Han population.	|	2022	|	Pharmacogenomics	|	23	|	10	|	575-583	|	Xu Q and Li Y and Li M and Qin S and Ning A and Yuan R and Fu Y and Wang D and Zhang R and Zeng D and Yu W and Li H and Yu S	|	10.2217/pgs-2022-0052	|
|	DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.	|	2006	|	The American journal of psychiatry	|	163	|	3	|	529-31	|	Lencz T and Robinson DG and Xu K and Ekholm J and Sevy S and Gunduz-Bruce H and Woerner MG and Kane JM and Goldman D and Malhotra AK	|	10.1176/appi.ajp.163.3.529	|
|	Pharmacogenetics: defining the genetic basis of drug action and inositol trisphosphate analysis.	|	2006	|	Methods in molecular biology (Clifton, N.J.)	|	346	|		|	517-34	|	Adley KE and Keim M and Williams RS	|	10.1385/1-59745-144-4:517	|
|	Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers.	|	2012	|	Pharmacogenomics	|	13	|	10	|	1129-39	|	Oved K and Morag A and Pasmanik-Chor M and Oron-Karni V and Shomron N and Rehavi M and Stingl JC and Gurwitz D	|	10.2217/pgs.12.93	|
|	Population features of alleles and genotypes frequency distribution of polymorphic genetic markers of antipsychotic medications pharmacokinetics in the Kazakh population.	|	2022	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	189	|	3	|	100-107	|	Saduakassova KZ and Svyatova GS	|	10.1002/ajmg.b.32893	|
|	Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.	|	2005	|	Schizophrenia research	|	75	|	1	|	21-6	|	Tiwari AK and Deshpande SN and Rao AR and Bhatia T and Lerer B and Nimgaonkar VL and Thelma BK	|	10.1016/j.schres.2004.12.011	|
|	The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis.	|	2000	|	Drug metabolism and drug interactions	|	16	|	1	|	15-38	|	Aitchison KJ and Jordan BD and Sharma T	|	10.1515/dmdi.2000.16.1.15	|
|	Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population.	|	2007	|	Journal of clinical psychopharmacology	|	27	|	3	|	246-51	|	Zhang XY and Tan YL and Zhou DF and Haile CN and Cao LY and Xu Q and Shen Y and Kosten TA and Kosten TR	|	10.1097/jcp.0b013e3180582412	|
|	Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.	|	2008	|	Human psychopharmacology	|	23	|	1	|	61-7	|	Kim B and Choi EY and Kim CY and Song K and Joo YH	|	10.1002/hup.897	|
|	Genetic studies of drug response and side effects in the STAR*D study, part 2.	|	2009	|	The Journal of clinical psychiatry	|	70	|	9	|	1323-5	|	Garriock HA and Hamilton SP	|	10.4088/JCP.09ac05522	|
|	[Pharmacogenetic research in clinical psychiatry].	|	1976	|	Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)	|	76	|	4	|	597-604	|	Diukov VA	|		|
|	The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.	|	2000	|	Pharmacogenetics	|	10	|	4	|	335-41	|	Suzuki A and Mihara K and Kondo T and Tanaka O and Nagashima U and Otani K and Kaneko S	|	10.1097/00008571-200006000-00007	|
|	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole.	|	2010	|	Psychiatry research	|	178	|	2	|	430-2	|	Pae CU and Chiesa A and Serretti A	|	10.1016/j.psychres.2010.04.017	|
|	Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.	|	2010	|	Journal of psychiatric practice	|	16	|	3	|	177-82	|	Preskorn SH	|	10.1097/01.pra.0000375714.93078.a8	|
|	An African patient with ziprasidone intolerance.	|	2005	|	The Journal of clinical psychiatry	|	66	|	6	|	800	|	Hein J and Gregor A and BartholomÃ¤ A and Heinz A and Juckel G	|	10.4088/jcp.v66n0621a	|
|	The impact of MDR1 polymorphisms on prolactin concentrations in patients treated with risperidone.	|	2008	|	Progress in neuro-psychopharmacology & biological psychiatry	|	32	|	2	|	593-4	|	Al Hadithy AF and Wilffert B and Bruggeman R and Brouwers JR	|	10.1016/j.pnpbp.2007.10.019	|
|	Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.	|	2012	|	Journal of comparative effectiveness research	|	1	|	2	|	171-80	|	Basu A and Meltzer HY	|	10.2217/cer.12.8	|
|	Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis.	|	2008	|	Progress in neuro-psychopharmacology & biological psychiatry	|	32	|	8	|	1848-53	|	Souza RP and De Luca V and Muscettola G and Rosa DV and de Bartolomeis A and Romano Silva M and Kennedy JL	|	10.1016/j.pnpbp.2008.08.014	|
|	Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections.	|	2006	|	Electrophoresis	|	27	|	19	|	3856-63	|	Minarik M and Benesova L and Fantova L and Horacek J and Heracek J and Loukola A	|	10.1002/elps.200600289	|
|	Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.	|	2001	|	Archives of general psychiatry	|	58	|	1	|	93-4	|	Dettling M and Cascorbi I and Roots I and Mueller-Oerlinghausen B	|	10.1001/archpsyc.58.1.93	|
|	Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis.	|	2011	|	Psychiatry research	|	185	|	1	|	286-9	|	Pelayo-TerÃ¡n JM and PÃ©rez-Iglesias R and VÃ¡zquez-Bourgon J and Mata I and Carrasco-MarÃ­n E and VÃ¡zquez-Barquero JL and Crespo-Facorro B	|	10.1016/j.psychres.2010.06.006	|
|	Methylation in schizophrenics: a pharmacogenetic study.	|	1972	|	Journal of psychiatric research	|	9	|	4	|	345-51	|	Price J	|	10.1016/0022-3956(72)90032-5	|
|	Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response.	|	1998	|	Pharmacogenetics	|	8	|	6	|	481-4	|	Arranz MJ and Li T and Munro J and Liu X and Murray R and Collier DA and Kerwin RW	|	10.1097/00008571-199812000-00004	|
|	Pharmacogenetic determinant of vholinesterase and its implications.	|	1972	|	Michigan medicine	|	71	|	24	|	701-2	|	Man PL	|		|
|	[Pharmacogenetics. Some genetically restricted, unusual drug reactions].	|	1968	|	Munchener medizinische Wochenschrift (1950)	|	110	|	20	|	1225-33	|	Lenz W	|		|
|	The prognostic and clinical significance of neuroimagistic and neurobiological vulnerability markers in correlation with the molecular pharmacogenetic testing in psychoses and ultra high-risk categories.	|	2016	|	Romanian journal of morphology and embryology = Revue roumaine de morphologie et           embryologie	|	57	|	3	|	959-967	|	Nussbaum LA and Hogea LM and Andreescu NI and GrÄƒdinaru RC and Puiu M and Todica A	|		|
|	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report.	|	2021	|	Psychoneuroendocrinology	|	132	|		|	105348	|	Suh JS and Fiori LM and Ali M and Harkness KL and Ramonas M and Minuzzi L and Hassel S and Strother SC and Zamyadi M and Arnott SR and Farzan F and Foster JA and Lam RW and MacQueen GM and Milev R and MÃ¼ller DJ and Parikh SV and Rotzinger S and Sassi RB and Soares CN and Uher R and Kennedy SH and Turecki G and Frey BN	|	10.1016/j.psyneuen.2021.105348	|
|	[Pharmacogenetics and treatment response in schizophrenia].	|	2007	|	L'Encephale	|	33	|	6	|	954-64	|	Moulier V and Januel D	|	10.1016/j.encep.2007.01.004	|
|	Convergent analysis of genome-wide genotyping and transcriptomic data suggests association of zinc finger genes with lithium response in bipolar disorder.	|	2018	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	177	|	7	|	658-664	|	Pisanu C and Congiu D and Costa M and Chillotti C and Ardau R and Severino G and Angius A and Heilbronner U and Hou L and McMahon FJ and Schulze TG and Del Zompo M and Squassina A	|	10.1002/ajmg.b.32663	|
|	Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients.	|	1997	|	Pharmacogenetics	|	7	|	5	|	415-8	|	Suzuki A and Otani K and Mihara K and Yasui N and Kaneko S and Inoue Y and Hayashi K	|	10.1097/00008571-199710000-00013	|
|	Pharmacogenetics in schizophrenia: a review of clozapine studies.	|	2013	|	Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)	|	35	|	3	|	305-17	|	Kohlrausch FB	|	10.1590/1516-4446-2012-0970	|
|	Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients.	|	2019	|	Frontiers in pharmacology	|	10	|		|	177	|	Zhou W and Xu Y and Lv Q and Sheng YH and Chen L and Li M and Shen L and Huai C and Yi Z and Cui D and Qin S	|	10.3389/fphar.2019.00177	|
|	Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.	|	2021	|	Behavioral sciences (Basel, Switzerland)	|	11	|	7	|		|	Shad MU	|	10.3390/bs11070097	|
|	Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affective patients.	|	2001	|	Pharmacogenetics	|	11	|	1	|	21-7	|	Niesler B and Weiss B and Fischer C and NÃ¶then MM and Propping P and Bondy B and Rietschel M and Maier W and Albus M and Franzek E and Rappold GA	|	10.1097/00008571-200102000-00003	|
|	Molecular genetics of schizophrenia: a critical review.	|	2003	|	Journal of psychiatry & neuroscience : JPN	|	28	|	6	|	415-29	|	Berry N and Jobanputra V and Pal H	|		|
|	Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.	|	2010	|	Pharmacogenomics	|	11	|	4	|	537-46	|	Tsai MH and Lin KM and Hsiao MC and Shen WW and Lu ML and Tang HS and Fang CK and Wu CS and Lu SC and Liu SC and Chen CY and Liu YL	|	10.2217/pgs.09.168	|
|	Vilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depression.	|	2009	|	Personalized medicine	|	6	|	2	|	217-224	|	Rickels K and Athanasiou M and Reed C	|	10.2217/17410541.6.2.217	|
|	Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage.	|	2016	|	Pharmacogenomics	|	17	|	3	|	199-208	|	Hettige NC and de Moraes GH and Kennedy JL and De Luca V	|	10.2217/pgs.15.171	|
|	Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis.	|	2020	|	Progress in neuro-psychopharmacology & biological psychiatry	|	102	|		|	109952	|	Yoshida K and Maciukiewicz M and Zai CC and GonÃ§alves VF and Brandl EJ and Lieberman JA and Meltzer HY and Tiwari AK and Kennedy JL and MÃ¼ller DJ	|	10.1016/j.pnpbp.2020.109952	|
|	Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.	|	2002	|	The pharmacogenomics journal	|	2	|	6	|	400-7	|	Nikoloff D and Shim JC and Fairchild M and Patten N and Fijal BA and Koch WH and MacPherson A and Flockhart D and Yoon YR and Yoon JS and Kim YH and Shin JG	|	10.1038/sj.tpj.6500138	|
|	Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants.	|	1999	|	Pharmacogenetics	|	9	|	1	|	17-23	|	Cravchik A and Sibley DR and Gejman PV	|	10.1097/00008571-199902000-00003	|
|	The pharmacogenetics of lithium response depends upon clinical co-morbidity.	|	2007	|	Molecular diagnosis & therapy	|	11	|	3	|	161-70	|	Bremer T and Diamond C and McKinney R and Shehktman T and Barrett TB and Herold C and Kelsoe JR	|	10.1007/BF03256238	|
|	Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor.	|	1999	|	Pharmacogenetics	|	9	|	1	|	95-102	|	BrÃ¼ss M and BÃ¶nisch H and BÃ¼hlen M and NÃ¶then MM and Propping P and GÃ¶thert M	|		|
|	Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.	|	2014	|	Journal of psychiatric research	|	54	|		|	36-42	|	Kao AC and Rojnic Kuzman M and Tiwari AK and Zivkovic MV and Chowdhury NI and Medved V and Kekin I and Zai CC and Lieberman JA and Meltzer HY and Bozina T and Bozina N and Kennedy JL and Sertic J and MÃ¼ller DJ	|	10.1016/j.jpsychires.2014.03.012	|
|	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression.	|	2013	|	Journal of psychopharmacology (Oxford, England)	|	27	|	10	|	915-20	|	Tammiste A and Jiang T and Fischer K and MÃ¤gi R and KrjutÅ¡kov K and Pettai K and Esko T and Li Y and Tansey KE and Carroll LS and Uher R and McGuffin P and VÃµsa U and TÅ¡ernikova N and Saria A and Ng PC and Eller T and Vasar V and Nutt DJ and Maron E and Wang J and Metspalu A	|	10.1177/0269881113499829	|
|	Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?	|	2019	|	Psychiatry research	|	271	|		|	604-613	|	Solomon HV and Cates KW and Li KJ	|	10.1016/j.psychres.2018.12.053	|
|	Genome-wide association study of major recurrent depression in the U.K. population.	|	2010	|	The American journal of psychiatry	|	167	|	8	|	949-57	|	Lewis CM and Ng MY and Butler AW and Cohen-Woods S and Uher R and Pirlo K and Weale ME and Schosser A and Paredes UM and Rivera M and Craddock N and Owen MJ and Jones L and Jones I and Korszun A and Aitchison KJ and Shi J and Quinn JP and Mackenzie A and Vollenweider P and Waeber G and Heath S and Lathrop M and Muglia P and Barnes MR and Whittaker JC and Tozzi F and Holsboer F and Preisig M and Farmer AE and Breen G and Craig IW and McGuffin P	|	10.1176/appi.ajp.2010.09091380	|
|	Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry.	|	2001	|	Pharmacogenetics	|	11	|	2	|	135-41	|	Dettling M and Schaub RT and Mueller-Oerlinghausen B and Roots I and Cascorbi I	|	10.1097/00008571-200103000-00004	|
|	Risperidone Therapy and CYP2D6 Genotype.	|	2012	|		|		|		|		|	Dean L	|		|
|	Treatment-Resistant Schizophrenia: Insights From Genetic Studies and Machine Learning Approaches.	|	2019	|	Frontiers in pharmacology	|	10	|		|	617	|	Pisanu C and Squassina A	|	10.3389/fphar.2019.00617	|
|	Post-traumatic stress disorder in the Canadian Longitudinal Study on Aging: A genome-wide association study.	|	2022	|	Journal of psychiatric research	|	154	|		|	209-218	|	Zai CC and Cheema SY and Zai GC and Tiwari AK and Kennedy JL	|	10.1016/j.jpsychires.2022.07.049	|
|	Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration.	|	2012	|	BMC medical genetics	|	13	|		|	91	|	Zain MA and Jahan SN and Reynolds GP and Zainal NZ and Kanagasundram S and Mohamed Z	|	10.1186/1471-2350-13-91	|
|	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.	|	2016	|	International journal of clinical pharmacy	|	38	|	2	|	388-94	|	Yuce-Artun N and Baskak B and Ozel-Kizil ET and Ozdemir H and Uckun Z and Devrimci-Ozguven H and Suzen HS	|	10.1007/s11096-016-0259-8	|
|	Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam.	|	1995	|	Pharmacogenetics	|	5	|	5	|	287-97	|	Patel M and Tang BK and Grant DM and Kalow W	|	10.1097/00008571-199510000-00004	|
|	Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.	|	2011	|	Biomarkers in medicine	|	5	|	4	|	439-49	|	RuaÃ±o G and Villagra D and Szarek B and Windemuth A and Kocherla M and Gorowski K and Berrezueta C and Schwartz HI and Goethe J	|	10.2217/bmm.11.33	|
|	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach.	|	2019	|	Progress in neuro-psychopharmacology & biological psychiatry	|	94	|		|	109659	|	Alkelai A and Greenbaum L and Heinzen EL and Baugh EH and Teitelbaum A and Zhu X and Strous RD and Tatarskyy P and Zai CC and Tiwari AK and Tampakeras M and Freeman N and MÃ¼ller DJ and Voineskos AN and Lieberman JA and Delaney SL and Meltzer HY and Remington G and Kennedy JL and Pulver AE and Peabody EP and Levy DL and Lerer B	|	10.1016/j.pnpbp.2019.109659	|
|	Genome-wide association studies of placebo and duloxetine response in major depressive disorder.	|	2018	|	The pharmacogenomics journal	|	18	|	3	|	406-412	|	Maciukiewicz M and Marshe VS and Tiwari AK and Fonseka TM and Freeman N and Kennedy JL and Rotzinger S and Foster JA and Kennedy SH and MÃ¼ller DJ	|	10.1038/tpj.2017.29	|
|	Genetic influences on pharmacodynamic properties of psychotropic drugs.	|	1979	|	Pharmacology	|	19	|	1	|	4-Jan	|	Propping P and Friedl W	|	10.1159/000137276	|
|	Clozapine Therapy and CYP Genotype.	|	2012	|		|		|		|		|	Dean L and Kane M	|		|
|	Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine.	|	2018	|	Combinatorial chemistry & high throughput screening	|	21	|	5	|	374-380	|	Yenilmez ED and Tamam L and Karaytug O and Tuli A	|	10.2174/1386207321666180619164726	|
|	The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.	|	2020	|	Basic & clinical pharmacology & toxicology	|	126	|	5	|	444-447	|	Baumann P and Eap CB and Gastpar M	|	10.1111/bcpt.13373	|
|	Genetic variants in major depressive disorder: From pathophysiology to therapy.	|	2019	|	Pharmacology & therapeutics	|	194	|		|	22-43	|	Gonda X and Petschner P and Eszlari N and Baksa D and Edes A and Antal P and Juhasz G and Bagdy G	|	10.1016/j.pharmthera.2018.09.002	|
|	The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.	|	2001	|	Pharmacogenetics	|	11	|	6	|	545-50	|	Suzuki A and Kondo T and Mihara K and Yasui-Furukori N and Ishida M and Furukori H and Kaneko S and Inoue Y and Otani K	|	10.1097/00008571-200108000-00009	|
|	Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study.	|	2007	|	Pharmacogenomics	|	8	|	10	|	1337-45	|	Zhang A and Xing Q and Wang L and Du J and Yu L and Lin Z and Li X and Feng G and He L	|	10.2217/14622416.8.10.1337	|
|	The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.	|	2008	|	Journal of psychopharmacology (Oxford, England)	|	22	|	8	|	904-9	|	Wang L and Fang C and Zhang A and Du J and Yu L and Ma J and Feng G and Xing Q and He L	|	10.1177/0269881107081522	|
|	Impairment of signal transduction in response to stimulation of the naturally occurring Pro279Leu variant of the h5-HT7(a) receptor.	|	2003	|	Pharmacogenetics	|	13	|	2	|	119-26	|	Kiel S and BÃ¶nisch H and BrÃ¼ss M and GÃ¶thert M	|	10.1097/00008571-200302000-00008	|
|	Pharmacogenetics in Psychiatry: Perceived Value and Opinions in a Chilean Sample of Practitioners.	|	2021	|	Frontiers in pharmacology	|	12	|		|	657985	|	Undurraga J and BÃ³rquez-Infante I and Crossley NA and Prieto ML and Repetto GM	|	10.3389/fphar.2021.657985	|
|	Roadmap for Routine Pharmacogenetic Testing in a Psychiatric University Hospital.	|	2020	|	Pharmacopsychiatry	|	53	|	4	|	179-183	|	Menke A and Weber H and Deckert J	|	10.1055/a-0914-3234	|
|	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.	|	2016	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	17	|	3	|	221-9	|	Tiwari AK and Brandl EJ and Zai CC and Goncalves VF and Chowdhury NI and Freeman N and Lieberman JA and Meltzer HY and Kennedy JL and MÃ¼ller DJ	|	10.3109/15622975.2015.1076173	|
|	Mutation screening of the Wolfram syndrome gene in psychiatric patients.	|	2001	|	Molecular psychiatry	|	6	|	1	|	39-43	|	Torres R and Leroy E and Hu X and Katrivanou A and Gourzis P and Papachatzopoulou A and Athanassiadou A and Beratis S and Collier D and Polymeropoulos MH	|	10.1038/sj.mp.4000787	|
|	The complement system in schizophrenia: where are we now and what's next?	|	2020	|	Molecular psychiatry	|	25	|	1	|	114-130	|	Woo JJ and Pouget JG and Zai CC and Kennedy JL	|	10.1038/s41380-019-0479-0	|
|	Investigation of the HSPG2 Gene in Tardive Dyskinesia - New Data and Meta-Analysis.	|	2018	|	Frontiers in pharmacology	|	9	|		|	974	|	Zai CC and Lee FH and Tiwari AK and Lu JY and de Luca V and Maes MS and Herbert D and Shahmirian A and Cheema SY and Zai GC and Atukuri A and Sherman M and Shaikh SA and Tampakeras M and Freeman N and King N and MÃ¼ller DJ and Greenbaum L and Lerer B and Voineskos AN and Potkin SG and Lieberman JA and Meltzer HY and Remington G and Kennedy JL	|	10.3389/fphar.2018.00974	|
|	Polymorphisms in the BDNF and BDNFOS genes are associated with hypothalamus-pituitary axis regulation in major depression.	|	2019	|	Progress in neuro-psychopharmacology & biological psychiatry	|	95	|		|	109686	|	Hennings JM and Kohli MA and Uhr M and Holsboer F and Ising M and Lucae S	|	10.1016/j.pnpbp.2019.109686	|
|	Pharmacogenetics of Ketamine-Induced Emergence Phenomena: A Pilot Study.	|	2017	|	Nursing research	|	66	|	2	|	105-114	|	Aroke EN and Crawford SL and Dungan JR	|	10.1097/NNR.0000000000000197	|
|	CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People.	|	2020	|	Frontiers in pharmacology	|	11	|		|	936	|	Cui Y and Yan H and Su Y and Wang L and Lu T and Zhang D and Yue W	|	10.3389/fphar.2020.00936	|
|	Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain.	|	2016	|	Neuropsychobiology	|	74	|	3	|	169-175	|	Zai CC and Tiwari AK and Chowdhury NI and Brandl EJ and Shaikh SA and Freeman N and Lieberman JA and Meltzer HY and Kennedy JL and MÃ¼ller DJ	|	10.1159/000457903	|
|	No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone.	|	2010	|	International journal of psychiatry in clinical practice	|	14	|	3	|	228-32	|	Pae CU and Chiesa A and Patkar AA and Serretti A	|	10.3109/13651501.2010.486902	|
|	Polymorphism of the SNAP25 gene is associated with symptom improvement in schizophrenic patients treated with amisulpride.	|	2017	|	Neuroscience letters	|	661	|		|	46-50	|	Kang SG and Chee IS and Chang HS and Na KS and Lee K and Lee J	|	10.1016/j.neulet.2017.09.041	|
|	The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.	|	2004	|	Schizophrenia bulletin	|	30	|	3	|	577-86	|	Alphs L and Anand R and Islam MZ and Meltzer HY and Kane JM and Krishnan R and Green AI and Potkin S and Chouinard G and Lindenmayer JP and Kerwin R	|	10.1093/oxfordjournals.schbul.a007102	|
|	Network-assisted investigation of antipsychotic drugs and their targets.	|	2012	|	Chemistry & biodiversity	|	9	|	5	|	900-10	|	Sun J and Xu H and Zhao Z	|	10.1002/cbdv.201100356	|
|	Treatment-Resistant Depression Revisited: A Glimmer of Hope.	|	2021	|	Journal of personalized medicine	|	11	|	2	|		|	Halaris A and Sohl E and Whitham EA	|	10.3390/jpm11020155	|
|	Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.	|	2004	|	Pharmacogenetics	|	14	|	3	|	165-72	|	Kurzwelly D and Barann M and Kostanian A and Combrink S and BÃ¶nisch H and GÃ¶thert M and BrÃ¼ss M	|	10.1097/00008571-200403000-00004	|
|	DNA Sequence Analysis in Clinical Medicine, Proceeding Cautiously.	|	2017	|	Frontiers in molecular biosciences	|	4	|		|	24	|	Smith M	|	10.3389/fmolb.2017.00024	|
|	The Potential Role of Regulatory Genes (DNMT3A, HDAC5, and HDAC9) in Antipsychotic Treatment Response in South African Schizophrenia Patients.	|	2019	|	Frontiers in genetics	|	10	|		|	641	|	O'Connell KS and McGregor NW and Emsley R and Seedat S and Warnich L	|	10.3389/fgene.2019.00641	|
|	Identifying a predictive model for response to atypical antipsychotic monotherapy treatment in south Indian schizophrenia patients.	|	2013	|	Genomics	|	102	|	2	|	131-5	|	Gupta M and Moily NS and Kaur H and Jajodia A and Jain S and Kukreti R	|	10.1016/j.ygeno.2013.02.002	|
|	Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics.	|	2018	|	Neuroscience letters	|	669	|		|	24-31	|	Pisanu C and Papadima EM and Del Zompo M and Squassina A	|	10.1016/j.neulet.2016.06.045	|
|	Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study.	|	2021	|	The pharmacogenomics journal	|	21	|	5	|	574-585	|	Fjukstad KK and Athanasiu L and Bahrami S and O'Connell KS and van der Meer D and Bettella F and Dieset I and Steen NE and Djurovic S and Spigset O and Andreassen OA	|	10.1038/s41397-021-00234-8	|
|	Individualized Drugs' Selection by Evaluation of Drug Properties, Pharmacogenomics and Clinical Parameters: Performance of a Bioinformatic Tool Compared to a Clinically Established Counselling Process.	|	2021	|	Pharmacogenomics and personalized medicine	|	14	|		|	955-962	|	Borro M and Gentile G and Preissner SH and Pomes LM and Gohlke BO and Del Casale A and Eckert A and Marchetti P and Preissner S and Preissner R and Simmaco M	|	10.2147/PGPM.S316556	|
|	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.	|	2013	|	Journal of psychiatric research	|	47	|	11	|	1760-5	|	Zai CC and Tiwari AK and Mazzoco M and de Luca V and MÃ¼ller DJ and Shaikh SA and Lohoff FW and Freeman N and Voineskos AN and Potkin SG and Lieberman JA and Meltzer HY and Remington G and Kennedy JL	|	10.1016/j.jpsychires.2013.07.025	|
|	Genetic Profiles Playing Opposite Roles of Pathogenesis in Schizophrenia and Glioma.	|	2020	|	Journal of oncology	|	2020	|		|	3656841	|	Wen YD and Xia ZW and Li DJ and Cheng Q and Zhao Q and Cao H	|	10.1155/2020/3656841	|
|	Cre-Activation in ErbB4-Positive Neurons of Floxed Grin1/NMDA Receptor Mice Is Not Associated With Major Behavioral Impairment.	|	2021	|	Frontiers in psychiatry	|	12	|		|	750106	|	Mallien AS and Pfeiffer N and Vogt MA and Chourbaji S and Sprengel R and Gass P and Inta D	|	10.3389/fpsyt.2021.750106	|
|	Genomic structure and sequence analysis of a human inositol polyphosphate 1-phosphatase gene (INPP1).	|	1999	|	Pharmacogenetics	|	9	|	4	|	517-28	|	LÃ¸vlie R and Gulbrandsen AK and Molven A and Steen VM	|		|
|	A glutamatergic network mediates lithium response in bipolar disorder as defined by epigenome pathway analysis.	|	2015	|	Pharmacogenomics	|	16	|	14	|	1547-63	|	Higgins GA and Allyn-Feuer A and Barbour E and Athey BD	|	10.2217/pgs.15.106	|
|	Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism.	|	2019	|	The American journal of psychiatry	|	176	|	6	|	477-486	|	PardiÃ±as AF and Nalmpanti M and Pocklington AJ and Legge SE and Medway C and King A and Jansen J and Helthuis M and Zammit S and MacCabe J and Owen MJ and O'Donovan MC and Walters JTR	|	10.1176/appi.ajp.2019.18050589	|
|	PDLIM5 gene polymorphisms and short term antidepressant response in Chinese major depressive disorders.	|	2013	|	International journal of clinical and experimental medicine	|	6	|	8	|	677-82	|	Liu Z and Zhu F and Yao L and Yang C and Xiao L and Zhu J and Wang H and Wang G and Liu W and Xiao Z	|		|
|	Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.	|	2017	|	The EPMA journal	|	8	|	3	|	211-227	|	Amare AT and Schubert KO and Baune BT	|	10.1007/s13167-017-0112-8	|
|	Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization.	|	1998	|	Biological psychiatry	|	44	|	8	|	659-66	|	Goei VL and Choi J and Ahn J and Bowlus CL and Raha-Chowdhury R and Gruen JR	|	10.1016/s0006-3223(98)00244-3	|
|	Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.	|	2005	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	15	|	2	|	143-51	|	Reynolds GP and Yao Z and Zhang X and Sun J and Zhang Z	|	10.1016/j.euroneuro.2004.07.001	|
|	Phenotype of mice with inducible ablation of GluA1 AMPA receptors during late adolescence: relevance for mental disorders.	|	2014	|	Hippocampus	|	24	|	4	|	424-35	|	Inta D and Vogt MA and Elkin H and Weber T and Lima-Ojeda JM and Schneider M and Luoni A and Riva MA and Gertz K and Hellmann-Regen J and Kronenberg G and Meyer-Lindenberg A and Sprengel R and Gass P	|	10.1002/hipo.22236	|
|	Increased DNA methylation in the parvalbumin gene promoter is associated with methamphetamine dependence.	|	2017	|	Pharmacogenomics	|	18	|	14	|	1317-1322	|	Veerasakul S and Watiktinkorn P and Thanoi S and Dalton CF and Fachim HA and Nudmamud-Thanoi S and Reynolds GP	|	10.2217/pgs-2016-0188	|
|	The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review.	|	2013	|	Therapeutic advances in drug safety	|	4	|	6	|	246-53	|	Kaniwa N and Saito Y	|	10.1177/2042098613499791	|
|	[Genetic and clinical predictors of treatment efficacy in depressive disorders].	|	2017	|	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova	|	117	|	10	|	55-64	|	Ivanets NN and Kinkulkina MA and Tikhonova YG and Izumina TA and Avdeeva TI and Morozov DI	|	10.17116/jnevro201711710155-64	|
|	CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.	|	2019	|	Journal of child and adolescent psychopharmacology	|	29	|	5	|	340-347	|	Strawn JR and Poweleit EA and Ramsey LB	|	10.1089/cap.2018.0160	|
|	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine.	|	2016	|	Human psychopharmacology	|	31	|	2	|	121-34	|	Taylor DL and Tiwari AK and Lieberman JA and Potkin SG and Meltzer HY and Knight J and Remington G and MÃ¼ller DJ and Kennedy JL	|	10.1002/hup.2519	|
|	Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder.	|	2021	|	Psychiatric genetics	|	31	|	5	|	186-193	|	Pinna M and Manchia M and Pisanu C and Pinna F and Paribello P and Carta A and Meloni A and Conversano C and Del Zompo M and Mola F and Squassina A and Carpiniello B	|	10.1097/YPG.0000000000000293	|
|	Comparing self-reported ethnicity and structure-determined ethnicity: analysis of antipsychotic-induced weight gain.	|	2013	|	Pharmacogenomics	|	14	|	16	|	1943	|	De Luca V and Monda M and Chan LF	|	10.2217/pgs.13.206	|
|	Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics.	|	2021	|	Frontiers in psychiatry	|	12	|		|	623143	|	Ward KM and Burghardt K and Kraal AZ and Jaeger A and Yeomans L and McHugh C and Karnovsky A and Stringer KA and Ellingrod VL	|	10.3389/fpsyt.2021.623143	|
|	Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.	|	2010	|	Pharmacogenomics	|	11	|	6	|	773-80	|	Opgen-Rhein C and Brandl EJ and MÃ¼ller DJ and Neuhaus AH and Tiwari AK and Sander T and Dettling M	|	10.2217/pgs.10.50	|
|	[Meta-analysis of candidate genes in attention-deficit hyperactivity disorder].	|	2005	|	L'Encephale	|	31	|	4	|	437-47	|	Wohl M and Purper-Ouakil D and Mouren MC and AdÃ¨s J and Gorwood P	|	10.1016/s0013-7006(05)82405-4	|
|	Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials.	|	2022	|	Clinical pharmacology and therapeutics	|		|		|		|	Brown LC and Stanton JD and Bharthi K and Maruf A and MÃ¼ller DJ and Bousman CA	|	10.1002/cpt.2748	|
|	The Genetics of Response to and Side Effects of Lithium Treatment in Bipolar Disorder: Future Research Perspectives.	|	2021	|	Frontiers in pharmacology	|	12	|		|	638882	|	Senner F and Kohshour MO and Abdalla S and Papiol S and Schulze TG	|	10.3389/fphar.2021.638882	|
|	Genetic counselling for psychiatric disorders.	|	2006	|	The Medical journal of Australia	|	185	|	9	|	507-10	|	Hill MK and Sahhar M	|	10.5694/j.1326-5377.2006.tb00666.x	|
|	The DRD2 gene in psychiatric and neurological disorders and its phenotypes.	|	2000	|	Pharmacogenomics	|	1	|	3	|	309-33	|	Noble EP	|	10.1517/14622416.1.3.309	|
|	Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.	|	2015	|	Schizophrenia bulletin	|	41	|	6	|	1248-55	|	Zhang JP and Robinson DG and Gallego JA and John M and Yu J and Addington J and Tohen M and Kane JM and Malhotra AK and Lencz T	|	10.1093/schbul/sbv116	|
|	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.	|	2020	|	The American journal of geriatric psychiatry : official journal of the American           Association for Geriatric Psychiatry	|	28	|	9	|	933-945	|	Forester BP and Parikh SV and Weisenbach S and Ajilore O and Vahia I and Rothschild AJ and Thase ME and Dunlop BW and DeBattista C and Conway CR and Shelton RC and Macaluso M and Li J and Traxler P and Logan J and Brown L and Dechairo B and Greden JF	|	10.1016/j.jagp.2020.05.005	|
|	MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant.	|	2014	|	The Journal of biological chemistry	|	289	|	19	|	13434-44	|	Shi S and Leites C and He D and Schwartz D and Moy W and Shi J and Duan J	|	10.1074/jbc.M113.535203	|
|	Iloperidone: A new drug for the treatment of schizophrenia.	|	2011	|	American journal of health-system pharmacy : AJHP : official journal of the           American Society of Health-System Pharmacists	|	68	|	4	|	301-8	|	Arif SA and Mitchell MM	|	10.2146/ajhp100079	|
|	Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis.	|	2006	|	Medical hypotheses	|	67	|	5	|	1090-4	|	Alisky JM and Chertkova EL and Iczkowski KA	|	10.1016/j.mehy.2006.01.059	|
|	Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.	|	2012	|	Journal of clinical psychopharmacology	|	32	|	4	|	441-8	|	Lee ST and Ryu S and Kim SR and Kim MJ and Kim S and Kim JW and Lee SY and Hong KS	|	10.1097/JCP.0b013e31825ac35c	|
|	Towards personalised antidepressive medicine based on "big data": an up-to-date review on robust factors affecting treatment response.	|	2022	|	Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet           lapja = official journal of the Hungarian Association of Psychopharmacology	|	24	|	1	|	17-28	|	Jambor T and Juhasz G and Eszlari N	|		|
|	Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments.	|	2021	|	Clinical psychopharmacology and neuroscience : the official scientific journal of           the Korean College of Neuropsychopharmacology	|	19	|	4	|	577-588	|	Lin E and Lin CH and Lane HY	|	10.9758/cpn.2021.19.4.577	|
|	Is It Possible to Predict the Future in First-Episode Psychosis?	|	2018	|	Frontiers in psychiatry	|	9	|		|	580	|	Suvisaari J and Mantere O and KeinÃ¤nen J and MÃ¤ntylÃ¤ T and Rikandi E and Lindgren M and KieseppÃ¤ T and Raij TT	|	10.3389/fpsyt.2018.00580	|
|	Epigenomic mapping and effect sizes of noncoding variants associated with psychotropic drug response.	|	2015	|	Pharmacogenomics	|	16	|	14	|	1565-83	|	Higgins GA and Allyn-Feuer A and Athey BD	|	10.2217/pgs.15.105	|
|	Whole-genome sequencing reveals KRTAP1-1 as a novel genetic variant associated with antidepressant treatment outcomes.	|	2021	|	Scientific reports	|	11	|	1	|	4552	|	Park JH and Lim SW and Myung W and Park I and Jang HJ and Kim S and Lee MS and Chang HS and Yum D and Suh YL and Kim JW and Kim DK	|	10.1038/s41598-021-83887-6	|
|	Neurostructural phenotypes of CACNA1C rs1006737 in adolescents with bipolar disorder and healthy controls.	|	2021	|	Progress in neuro-psychopharmacology & biological psychiatry	|	104	|		|	110071	|	Shonibare DO and Patel RR and Islam AH and Metcalfe AWS and Fiksenbaum L and Freeman N and MacIntosh BJ and Kennedy JL and Goldstein BI	|	10.1016/j.pnpbp.2020.110071	|
|	African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addiction.	|	2016	|	Pharmacogenomics	|	17	|	9	|	995-1003	|	Levran O and Randesi M and Peles E and Correa da Rosa J and Ott J and Rotrosen J and Adelson M and Kreek MJ	|	10.2217/pgs-2016-0028	|
|	Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.	|	2016	|	The pharmacogenomics journal	|	16	|	3	|	293-300	|	Mas S and GassÃ³ P and Boloc D and Rodriguez N and MÃ¡rmol F and SÃ¡nchez J and Bernardo M and Lafuente A	|	10.1038/tpj.2015.48	|
|	Olanzapine Reversed Brain Gene Expression Changes Induced by Phencyclidine Treatment in Non-Human Primates.	|	2015	|	Molecular neuropsychiatry	|	1	|	2	|	82-93	|	Martin MV and Mirnics K and Nisenbaum LK and Vawter MP	|	10.1159/000430786	|
|	Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population.	|	2016	|	Biological psychiatry	|	80	|	8	|	636-42	|	Saito T and Ikeda M and Mushiroda T and Ozeki T and Kondo K and Shimasaki A and Kawase K and Hashimoto S and Yamamori H and Yasuda Y and Fujimoto M and Ohi K and Takeda M and Kamatani Y and Numata S and Ohmori T and Ueno S and Makinodan M and Nishihata Y and Kubota M and Kimura T and Kanahara N and Hashimoto N and Fujita K and Nemoto K and Fukao T and Suwa T and Noda T and Yada Y and Takaki M and Kida N and Otsuru T and Murakami M and Takahashi A and Kubo M and Hashimoto R and Iwata N	|	10.1016/j.biopsych.2015.12.006	|
|	Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications.	|	2019	|	Frontiers in pharmacology	|	10	|		|	83	|	Veldic M and Ahmed AT and Blacker CJ and Geske JR and Biernacka JM and Borreggine KL and Moore KM and Prieto ML and Vande Voort JL and Croarkin PE and Hoberg AA and Kung S and Alarcon RD and Keeth N and Singh B and Bobo WV and Frye MA	|	10.3389/fphar.2019.00083	|
|	Family association study of Transforming Growth Factor Beta1 gene polymorphisms in schizophrenia.	|	2016	|	Psychiatria polska	|	50	|	4	|	761-770	|	Kapelski P and SkibiÅ„ska M and Maciukiewicz M and Zaremba D and Jasiak M and Hauser J	|	10.12740/PP/61273	|
|	The AmpliChipÂ® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.	|	2012	|	Genetic testing and molecular biomarkers	|	16	|	8	|	897-903	|	MÃ¼ller DJ and Brandl EJ and Hwang R and Tiwari AK and Sturgess JE and Zai CC and Lieberman JA and Kennedy JL and Richter MA	|	10.1089/gtmb.2011.0327	|
|	Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data.	|	2021	|	Frontiers in pharmacology	|	12	|		|	729474	|	MartÃ­nez-PinteÃ±o A and GassÃ³ P and Prohens L and Segura AG and Parellada M and Saiz-Ruiz J and Cuesta MJ and Bernardo M and Lafuente A and Mas S and RodrÃ­guez N	|	10.3389/fphar.2021.729474	|
|	Structural neuroimaging phenotypes of a novel multi-gene risk score in youth bipolar disorder.	|	2021	|	Journal of affective disorders	|	289	|		|	135-143	|	Cazes J and Dimick MK and Kennedy KG and Fiksenbaum L and Zai CC and Patel R and Islam AH and Tampakeras M and Freeman N and Kennedy JL and MacIntosh BJ and Goldstein BI	|	10.1016/j.jad.2021.04.040	|
|	Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain.	|	2020	|	Acta neuropsychiatrica	|	32	|	2	|	72-83	|	Corfitsen HT and Krantz B and Larsen A and Drago A	|	10.1017/neu.2019.41	|
|	Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects.	|	2015	|	International clinical psychopharmacology	|	30	|	2	|	82-8	|	Cabaleiro T and LÃ³pez-RodrÃ­guez R and RomÃ¡n M and Ochoa D and Novalbos J and Borobia A and Carcas A and Abad-Santos F	|	10.1097/YIC.0000000000000047	|
|	[Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts].	|	2006	|	Der Nervenarzt	|	77	|		|	S65-74; quiz S75-6	|	Falkai P and Maier W	|	10.1007/s00115-006-2197-5	|
|	A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder.	|	2022	|	Journal of personalized medicine	|	12	|	6	|		|	Honeycutt DC and DelBello MP and Strawn JR and Ramsey LB and Patino LR and Hinman K and Welge J and Miklowitz DJ and Jo B and Blom TJ and Bruns KM and Hamill Skoch SK and Starace N and Tallman MJ and Singh MK	|	10.3390/jpm12061006	|
|	Antipsychotic medication in schizophrenia: a review.	|	2015	|	British medical bulletin	|	114	|	1	|	169-79	|	Lally J and MacCabe JH	|	10.1093/bmb/ldv017	|
|	TMS-EEG Research to Elucidate the Pathophysiological Neural Bases in Patients with Schizophrenia: A Systematic Review.	|	2021	|	Journal of personalized medicine	|	11	|	5	|		|	Li X and Honda S and Nakajima S and Wada M and Yoshida K and Daskalakis ZJ and Mimura M and Noda Y	|	10.3390/jpm11050388	|
|	Can Psychological, Social and Demographical Factors Predict Clinical Characteristics Symptomatology of Bipolar Affective Disorder and Schizophrenia?	|	2016	|	The Psychiatric quarterly	|	87	|	3	|	501-13	|	Maciukiewicz M and Pawlak J and Kapelski P and ÅabÄ™dzka M and Skibinska M and Zaremba D and Leszczynska-Rodziewicz A and Dmitrzak-Weglarz M and Hauser J	|	10.1007/s11126-015-9405-z	|
|	Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine.	|	2019	|	The pharmacogenomics journal	|	19	|	2	|	211-218	|	Girardin FR and Poncet A and Perrier A and Vernaz N and Pletscher M and F Samer C and Lieberman JA and Villard J	|	10.1038/s41397-017-0004-2	|
|	Anterior cingulate Glutamate-Glutamine cycle metabolites are altered in euthymic bipolar I disorder.	|	2015	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	25	|	12	|	2221-9	|	Soeiro-de-Souza MG and Henning A and Machado-Vieira R and Moreno RA and Pastorello BF and da Costa Leite C and Vallada H and Otaduy MC	|	10.1016/j.euroneuro.2015.09.020	|
|	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.	|	2014	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	15	|	5	|	404-10	|	Garfield LD and MÃ¼ller DJ and Kennedy JL and Mulsant BH and Reynolds CF 3rd and Teitelbaum SL and Civitelli R and Dixon D and Todorov AA and Lenze EJ	|	10.3109/15622975.2013.832380	|
|	Neuropsychiatric Genetics of Psychosis in the Mexican Population: A Genome-Wide Association Study Protocol for Schizophrenia, Schizoaffective, and Bipolar Disorder Patients and Controls.	|	2021	|	Complex psychiatry	|	7	|	3	|	60-70	|	Camarena B and Atkinson EG and Baker M and Becerra-Palars C and Chibnik LB and Escamilla-Orozco R and JimÃ©nez-PavÃ³n J and Koenig Z and MÃ¡rquez-Luna C and Martin AR and Morales-Cedillo IP and Olivares AM and Ortega-Ortiz H and Rodriguez-RamÃ­rez AM and Saracco-Alvarez R and Basaldua RE and Sena BF and Koenen KC	|	10.1159/000518926	|
|	Genaissance pharmaceuticals, inc.	|	2002	|	Pharmacogenomics	|	3	|	2	|	273-6	|	Oestreicher P	|	10.1517/14622416.3.2.273	|
|	Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction.	|	2020	|	Frontiers in pharmacology	|	11	|		|	614048	|	Nguyen TTL and Liu D and Ho MF and Athreya AP and Weinshilboum R	|	10.3389/fphar.2020.614048	|
|	Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes.	|	2018	|	Schizophrenia research	|	192	|		|	194-204	|	Li J and Yoshikawa A and Brennan MD and Ramsey TL and Meltzer HY	|	10.1016/j.schres.2017.04.009	|
|	Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment?	|	2013	|	Pharmacogenomics	|	14	|	11	|	1273-81	|	Chan LF and Zai C and Monda M and Potkin S and Kennedy JL and Remington G and Lieberman J and Meltzer HY and De Luca V	|	10.2217/pgs.13.127	|
|	Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology.	|	2021	|	Biological psychiatry	|	90	|	9	|	652-660	|	Da Silva T and Guma E and Hafizi S and Koppel A and Rusjan P and Kennedy JL and Chakravarty MM and Mizrahi R	|	10.1016/j.biopsych.2021.06.021	|
|	Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance.	|	2019	|	Science China. Life sciences	|	62	|	4	|	535-543	|	Zhang Y and Ren H and Wang Q and Deng W and Yue W and Yan H and Tan L and Chen Q and Yang G and Lu T and Wang L and Zhang F and Yang J and Li K and Lv L and Tan Q and Zhang H and Ma X and Yang F and Li L and Wang C and Zhang D and Zhao L and Wang H and Li X and Guo W and Hu X and Tian Y and Ma X and Li T	|	10.1007/s11427-018-9489-x	|
|	Effect of 5-HT2C receptor gene polymorphism (HTR2C-759C/T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone.	|	2021	|	Pharmacoepidemiology and drug safety	|	30	|	6	|	806-813	|	Vanwong N and Puangpetch A and Unaharassamee W and Jiratjintana N and Na Nakorn C and Hongkaew Y and Sukasem C	|	10.1002/pds.5224	|
|	An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care.	|	2019	|	The pharmacogenomics journal	|	19	|	5	|	480-489	|	Sluiter RL and Janzing JGE and van der Wilt GJ and Kievit W and Teichert M	|	10.1038/s41397-019-0070-8	|
|	Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.	|	2017	|	Drug metabolism and personalized therapy	|	32	|	3	|	129-136	|	Sychev DA and Zastrozhin MS and Miroshnichenko II and Baymeeva NV and Smirnov VV and Grishina EA and Ryzhikova KA and Mirzaev KB and Markov DD and Skryabin VY and Snalina NE and Nosikova PG and Savchenko LM and Bryun EA	|	10.1515/dmpt-2017-0021	|
|	Pharmacogenetic aspect of red blood cell lithium index in manic-depressive psychosis.	|	1977	|	Biological psychiatry	|	12	|	3	|	425-9	|	Rybakowski J	|		|
|	Curidium Medica, plc.	|	2008	|	Personalized medicine	|	5	|	3	|	219-223	|	Caffo NA	|	10.2217/17410541.5.3.219	|
|	[Treatment of resistant depression with the citalopram-lithium combination. Methodology of a double-blind multicenter study and preliminary results].	|	1991	|	L'Encephale	|	17	|	3	|	213-9	|	Souche A and Montaldi S and Uehlinger C and Kasas A and Reymond MJ and Reymond P and Baumann P and Dufour H	|		|
|	GWAS analysis of treatment resistant schizophrenia: interaction effect of childhood trauma.	|	2017	|	Pharmacogenomics	|	18	|	7	|	663-671	|	Koga A and Bani-Fatemi A and Hettige N and Borlido C and Zai C and Strauss J and Gerretsen P and Graff A and Remington G and De Luca V	|	10.2217/pgs-2016-0137	|
|	[What to consider when choosing an antidepressant to treat unipolar depression].	|	2019	|	Vertex (Buenos Aires, Argentina)	|		|	145	|	172-181	|	Halsband S and Barembaum R and Barbosa Eyler GE	|		|
|	Association of polymorphisms in GAD1 and GAD2 genes with methamphetamine dependence.	|	2017	|	Pharmacogenomics	|	18	|	1	|	17-22	|	Veerasakul S and Watiktinkorn P and Thanoi S and Reynolds GP and Nudmamud-Thanoi S	|	10.2217/pgs-2016-0101	|
|	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.	|	2022	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	56	|		|	100-111	|	CalabrÃ² M and Fabbri C and Kasper S and Zohar J and Souery D and Montgomery S and Albani D and Forloni G and Ferentinos P and Rujescu D and Mendlewicz J and De Ronchi D and Serretti A and Crisafulli C	|	10.1016/j.euroneuro.2022.01.008	|
|	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.	|	2013	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	23	|	8	|	887-94	|	Drago A and Giegling I and SchÃ¤fer M and Hartmann AM and Friedl M and Konte B and MÃ¶ller HJ and De Ronchi D and Stassen HH and Serretti A and Rujescu D	|	10.1016/j.euroneuro.2012.08.013	|
|	Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine.	|	2020	|	Psychiatria Danubina	|	32	|	1	|	84-91	|	Zivkovic M and Mihaljevic-Peles A and Muck-Seler D and Sagud M and Ganoci L and Vlatkovic S and Tudor L and Pivac N and Bozina N	|	10.24869/psyd.2020.84	|
|	Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes.	|	2015	|	Pharmacogenomics	|	16	|	1	|	22-May	|	Pouget JG and GonÃ§alves VF and Nurmi EL and P Laughlin C and Mallya KS and McCracken JT and Aman MG and McDougle CJ and Scahill L and Misener VL and Tiwari AK and Zai CC and Brandl EJ and Felsky D and Leung AQ and Lieberman JA and Meltzer HY and Potkin SG and Niedling C and Steimer W and Leucht S and Knight J and MÃ¼ller DJ and Kennedy JL	|	10.2217/pgs.14.158	|
|	BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence.	|	2015	|	Pharmacogenomics	|	16	|	14	|	1541-5	|	Iamjan SA and Thanoi S and Watiktinkorn P and Nudmamud-Thanoi S and Reynolds GP	|	10.2217/pgs.15.96	|
|	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs).	|	2013	|	Revista de psiquiatria y salud mental	|	6	|	1	|	16-Apr	|	Bernardo M and Bioque M and Parellada M and Saiz Ruiz J and Cuesta MJ and Llerena A and SanjuÃ¡n J and Castro-Fornieles J and Arango C and Cabrera B	|	10.1016/j.rpsm.2012.11.001	|
|	Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.	|	2005	|	The pharmacogenomics journal	|	5	|	1	|	60-9	|	Tiwari AK and Deshpande SN and Rao AR and Bhatia T and Mukit SR and Shriharsh V and Lerer B and Nimagaonkar VL and Thelma BK	|	10.1038/sj.tpj.6500282	|
|	Linkage and candidate gene analysis of 14q22-24 in bipolar disorder: support for GCHI as a novel susceptibility gene.	|	2005	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	136	|	1	|	75-80	|	Kealey C and Roche S and Claffey E and McKeon P	|	10.1002/ajmg.b.30192	|
|	Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients.	|	2020	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	37	|		|	64-69	|	Smith RL and Tveito M and KyllesÃ¸ L and Jukic MM and Ingelman-Sundberg M and Andreassen OA and Molden E	|	10.1016/j.euroneuro.2020.06.007	|
|	Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study.	|	2009	|	Current pharmacogenomics and personalized medicine	|	7	|	3	|	164-188	|	Glatt SJ and Chandler SD and Bousman CA and Chana G and Lucero GR and Tatro E and May T and Lohr JB and Kremen WS and Everall IP and Tsuang MT	|	10.2174/1875692110907030164	|
|	CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.	|	2006	|	International journal of geriatric psychiatry	|	21	|	6	|	542-9	|	Whyte EM and Romkes M and Mulsant BH and Kirshne MA and Begley AE and Reynolds CF 3rd and Pollock BG	|	10.1002/gps.1522	|
|	Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia.	|	2022	|	Diagnostics (Basel, Switzerland)	|	12	|	7	|		|	Fedorenko OY and Paderina DZ and Kornetova EG and Poltavskaya EG and Pozhidaev IV and Goncharova AA and Freidin MB and Bocharova AV and Bokhan NA and Loonen AJM and Ivanova SA	|	10.3390/diagnostics12071521	|
|	Response to sertraline is influenced by GNÎ²3 gene G-350A variant in patients with major depressive disorder.	|	2019	|	European journal of clinical pharmacology	|	75	|	2	|	189-194	|	Firouzabadi D and Firouzabadi N and Kalani K and Zomorrodian K and Tehrani ES	|	10.1007/s00228-018-2577-3	|
|	Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms.	|	2017	|	Pharmacogenomics	|	18	|	2	|	105-120	|	Ovenden ES and DrÃ¶gemÃ¶ller BI and van der Merwe L and Chiliza B and Asmal L and Emsley RA and Warnich L	|	10.2217/pgs-2016-0108	|
|	[Pharmacogenetic strategies].	|	2001	|	Fortschritte der Neurologie-Psychiatrie	|	69	|		|	S62-4	|	Rietschel M	|	10.1055/s-2001-16532	|
|	Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report.	|	2016	|	Journal of medical case reports	|	10	|	1	|	242	|	Tucker MG and Kekulawala S and Kent M and Mostafa S and Harvey R	|	10.1186/s13256-016-1031-3	|
|	Genetic association between the DRD4 promoter polymorphism and clozapine-induced sialorrhea.	|	2014	|	Psychiatric genetics	|	24	|	6	|	273-6	|	Rajagopal V and Sundaresan L and Rajkumar AP and Chittybabu C and Kuruvilla A and Srivastava A and Balasubramanian P and Jacob KS and Jacob M	|	10.1097/YPG.0000000000000058	|
|	Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications.	|	2012	|	Molecular psychiatry	|	17	|	10	|	1007-16	|	Tan HY and Chen AG and Chen Q and Browne LB and Verchinski B and Kolachana B and Zhang F and Apud J and Callicott JH and Mattay VS and Weinberger DR	|	10.1038/mp.2011.91	|
|	C-reactive protein and cardiovascular risk in bipolar disorder patients: A systematic review.	|	2017	|	Progress in neuro-psychopharmacology & biological psychiatry	|	79	|		|	442-451	|	Marshe VS and Pira S and Mantere O and Bosche B and Looper KJ and Herrmann N and MÃ¼ller DJ and Rej S	|	10.1016/j.pnpbp.2017.07.026	|
|	[Schizophrenia: research perspectives].	|	2013	|	La Revue du praticien	|	63	|	3	|	359-62	|	Delavenne H and Garcia FD and Thibaut F	|		|
|	Predictors of clinical outcome in schizophrenic patients responding to clozapine.	|	2003	|	Journal of clinical psychopharmacology	|	23	|	6	|	660-4	|	Mauri MC and Volonteri LS and Dell'Osso B and Regispani F and Papa P and Baldi M and Bareggi SR	|	10.1097/01.jcp.0000095351.32154.3a	|
|	Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?	|	2021	|	Pharmacogenomics	|	22	|	14	|	913-925	|	Ho AM and Weinshilboum RM and Frye MA and Biernacka JM	|	10.2217/pgs-2021-0041	|
|	Molecular Mechanisms Associated with Antidepressant Treatment on Major Depression.	|	2021	|	Complex psychiatry	|	7	|	3	|	49-59	|	Ramos-da-Silva L and Carlson PT and Silva-Costa LC and Martins-de-Souza D and de Almeida V	|	10.1159/000518098	|
|	Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics.	|	2014	|	Pharmacogenomics	|	15	|	4	|	477-85	|	Roffeei SN and Mohamed Z and Reynolds GP and Said MA and Hatim A and Mohamed EH and Aida SA and Zainal NZ	|	10.2217/pgs.13.220	|
|	A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort).	|	2020	|	Journal of psychopharmacology (Oxford, England)	|	34	|	5	|	524-531	|	Ter Hark SE and Jamain S and Schijven D and Lin BD and Bakker MK and Boland-Auge A and Deleuze JF and Troudet R and Malhotra AK and GÃ¼lÃ¶ksÃ¼z S and Vinkers CH and Ebdrup BH and Kahn RS and Leboyer M and Luykx JJ	|	10.1177/0269881120907972	|
|	The Potential of Polygenic Risk Scores to Predict Antidepressant Treatment Response in Major Depression: A Systematic Review.	|	2022	|	Journal of affective disorders	|	304	|		|	11-Jan	|	Meerman JJ and Ter Hark SE and Janzing JGE and Coenen MJH	|	10.1016/j.jad.2022.02.015	|
|	Case-control association study of ABCB1 gene and major depressive disorder in a local Chinese Han population.	|	2015	|	Neuropsychiatric disease and treatment	|	11	|		|	1967-71	|	Xie WW and Zhang L and Wu RR and Yu Y and Zhao JP and Li LH	|	10.2147/NDT.S87175	|
|	Personalized Pharmacotherapy for Bipolar Disorder: How to Tailor Findings From Randomized Trials to Individual Patient-Level Outcomes.	|	2019	|	Focus (American Psychiatric Publishing)	|	17	|	3	|	206-217	|	Goldberg JF	|	10.1176/appi.focus.20190005	|
|	Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.	|	2008	|	The pharmacogenomics journal	|	8	|	3	|	228-36	|	Smith RC and Segman RH and Golcer-Dubner T and Pavlov V and Lerer B	|	10.1038/sj.tpj.6500474	|
|	An Association Between Functional Polymorphisms of the Interleukin 1 Gene Complex and Schizophrenia Using Transmission Disequilibrium Test.	|	2016	|	Archivum immunologiae et therapiae experimentalis	|	64	|		|	161-168	|	Kapelski P and Skibinska M and Maciukiewicz M and Pawlak J and Dmitrzak-Weglarz M and Szczepankiewicz A and Zaremba D and Twarowska-Hauser J	|	10.1007/s00005-016-0434-6	|
|	Genome-wide association studies of antidepressant outcome: a brief review.	|	2011	|	Progress in neuro-psychopharmacology & biological psychiatry	|	35	|	7	|	1553-7	|	Laje G and McMahon FJ	|	10.1016/j.pnpbp.2010.11.031	|
|	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.	|	2008	|	Genetics in medicine : official journal of the American College of Medical           Genetics	|	10	|	10	|	720-9	|	Grossman I and Sullivan PF and Walley N and Liu Y and Dawson JR and Gumbs C and Gaedigk A and Leeder JS and McEvoy JP and Weale ME and Goldstein DB	|	10.1097/GIM.0b013e3181863239	|
|	Considering medication exposure in genomic association studies of cognition in psychotic disorders.	|	2022	|	Pharmacogenomics	|	23	|	14	|	791-806	|	Eum S and Hill SK and Bishop JR	|	10.2217/pgs-2022-0070	|
|	Association Study of KCNH7 Polymorphisms and Individual Responses to Risperidone Treatment in Schizophrenia.	|	2019	|	Frontiers in psychiatry	|	10	|		|	633	|	Wang X and Su Y and Yan H and Huang Z and Huang Y and Yue W	|	10.3389/fpsyt.2019.00633	|
|	Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status.	|	2020	|	The pharmacogenomics journal	|	20	|	6	|	840-844	|	Gaebler AJ and Schneider KL and Stingl JC and Paulzen M	|	10.1038/s41397-020-0169-y	|
|	Association between serotonin 2A receptor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients.	|	2020	|	The pharmacogenomics journal	|	20	|	3	|	443-450	|	Oz MD and Baskak B and Uckun Z and Artun NY and Ozdemir H and Ozel TK and Ozguven HD and Suzen HS	|	10.1038/s41397-019-0127-8	|
|	Rare copy number variation in treatment-resistant major depressive disorder.	|	2014	|	Biological psychiatry	|	76	|	7	|	536-41	|	O'Dushlaine C and Ripke S and Ruderfer DM and Hamilton SP and Fava M and Iosifescu DV and Kohane IS and Churchill SE and Castro VM and Clements CC and Blumenthal SR and Murphy SN and Smoller JW and Perlis RH	|	10.1016/j.biopsych.2013.10.028	|
|	Recent advances in the genetics of schizophrenia.	|	2002	|	Cellular and molecular life sciences : CMLS	|	59	|	2	|	331-48	|	Waterwort DM and Bassett AS and Brzustowicz LM	|	10.1007/s00018-002-8426-6	|
|	Systematic Review and Meta-Analysis of L-Methylfolate Augmentation in Depressive Disorders.	|	2022	|	Pharmacopsychiatry	|	55	|	3	|	139-147	|	Maruf AA and Poweleit EA and Brown LC and Strawn JR and Bousman CA	|	10.1055/a-1681-2047	|
|	Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms.	|	2009	|	Pharmacogenomics	|	10	|	2	|	277-91	|	Gupta M and Chauhan C and Bhatnagar P and Gupta S and Grover S and Singh PK and Purushottam M and Mukherjee O and Jain S and Brahmachari SK and Kukreti R	|	10.2217/14622416.10.2.277	|
|	Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial).	|	2019	|	Journal of clinical psychopharmacology	|	39	|	6	|	583-590	|	van der Schans J and Hak E and Postma M and Breuning L and Brouwers JRBJ and Ditters K and Jansen PAF and Kok RM and Maring JG and van Marum R and Mulder H and Nanninga J and Oude Voshaar RC and Risselada AJ and Vleugel L and Stek M and van Schaik RHN and Berm EJJ and Wilffert B	|	10.1097/JCP.0000000000001129	|
|	Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine.	|	2010	|	The pharmacogenomics journal	|	10	|	2	|	126-33	|	Glubb DM and McHugh PC and Deng X and Joyce PR and Kennedy MA	|	10.1038/tpj.2009.33	|
|	Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain.	|	2013	|	Human psychopharmacology	|	28	|	2	|	183-7	|	Brandl EJ and Tiwari AK and Lett TA and Shaikh SA and Lieberman JA and Meltzer HY and Kennedy JL and MÃ¼ller DJ	|	10.1002/hup.2288	|
|	Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment.	|	2020	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	183	|	2	|	113-127	|	Hrovatin K and Kunej T and DolÅ¾an V	|	10.1002/ajmg.b.32766	|
|	A pro-inflammatory phenotype is associated with behavioural traits in children with Prader-Willi syndrome.	|	2021	|	European child & adolescent psychiatry	|	30	|	6	|	899-908	|	Krefft M and Frydecka D and Zalsman G and Krzystek-Korpacka M and Åšmigiel R and GÄ™bura K and Bogunia-Kubik K and Misiak B	|	10.1007/s00787-020-01568-7	|
|	Dorsal Anterior Cingulate Lactate and Glutathione Levels in Euthymic Bipolar I Disorder: 1H-MRS Study.	|	2016	|	The international journal of neuropsychopharmacology	|	19	|	8	|		|	Soeiro-de-Souza MG and Pastorello BF and Leite Cda C and Henning A and Moreno RA and Garcia Otaduy MC	|	10.1093/ijnp/pyw032	|
|	The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naÃ¯ve patients with first-episode schizophrenia treated with risperidone.	|	2010	|	European journal of clinical pharmacology	|	66	|	11	|	1109-17	|	JovanoviÄ‡ N and BoÅ¾ina N and LovriÄ‡ M and Medved V and JakovljeviÄ‡ M and PeleÅ¡ AM	|	10.1007/s00228-010-0850-1	|
|	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.	|	2019	|	Schizophrenia research	|	212	|		|	204-212	|	Maciukiewicz M and Tiwari AK and Zai CC and Gorbovskaya I and Laughlin CP and Nurmi EL and Liebermann JA and Meltzer HY and Kennedy JL and MÃ¼ller DJ	|	10.1016/j.schres.2019.07.022	|
|	A review and meta-analysis of gene expression profiles in suicide.	|	2022	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	56	|		|	39-49	|	Piras IS and Huentelman MJ and Pinna F and Paribello P and Solmi M and Murru A and Carpiniello B and Manchia M and Zai CC	|	10.1016/j.euroneuro.2021.12.003	|
|	Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment.	|	2018	|	Pharmacogenomics	|	19	|	2	|	129-143	|	Pisanu C and Katsila T and Patrinos GP and Squassina A	|	10.2217/pgs-2017-0111	|
|	Association Study Between Serotonin Transporter Gene and Fluoxetine Response in Mexican Patients With Major Depressive Disorder.	|	2019	|	Clinical neuropharmacology	|	42	|	1	|	13-Sep	|	Camarena B and Ãlvarez-Icaza D and HernÃ¡ndez S and Aguilar A and MÃ¼nch L and MartÃ­nez C and Becerra-Palars C	|	10.1097/WNF.0000000000000315	|
|	Apolipoprotein D is associated with long-term outcome in patients with schizophrenia.	|	2006	|	The pharmacogenomics journal	|	6	|	2	|	120-5	|	Hansen T and Hemmingsen RP and Wang AG and Olsen L and Timm S and SÃ¸eby K and Jakobsen KD and Fenger M and Parnas J and Rasmussen HB and Werge T	|	10.1038/sj.tpj.6500350	|
|	Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: a meta-analysis.	|	2012	|	International clinical psychopharmacology	|	27	|	6	|	314-20	|	Zhao X and Huang Y and Li J and Ma H and Jin Q and Wang Y and Wu L and Zhu G	|	10.1097/YIC.0b013e32835818bf	|
|	Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.	|	2021	|	Frontiers in psychiatry	|	12	|		|	625935	|	Sneller MH and de Boer N and Everaars S and Schuurmans M and Guloksuz S and Cahn W and Luykx JJ	|	10.3389/fpsyt.2021.625935	|
|	Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes.	|	2008	|	Pharmacogenomics	|	9	|	8	|	1055-68	|	Srivastava V and Deshpande SN and Nimgaonkar VL and Lerer B and Thelma B	|	10.2217/14622416.9.8.1055	|
|	Association of a Single-Nucleotide Variant rs11100494 of the NPY5R Gene with Antipsychotic-Induced Metabolic Disorders.	|	2022	|	Pharmaceutics	|	14	|	2	|		|	Dobrodeeva VS and Shnayder NA and Novitsky MA and Asadullin AR and Vaiman EE and Petrova MM and Limankin OV and Neznanov NG and Garganeeva NP and Nasyrova RF	|	10.3390/pharmaceutics14020222	|
|	Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes.	|	2011	|	Pharmacogenomics	|	12	|	8	|	1127-36	|	Zhang XR and Zhang ZJ and Zhu RX and Yuan YG and Jenkins TA and Reynolds GP	|	10.2217/pgs.11.46	|
|	Prediction of Antidepressant Treatment Response and Remission Using an Ensemble Machine Learning Framework.	|	2020	|	Pharmaceuticals (Basel, Switzerland)	|	13	|	10	|		|	Lin E and Kuo PH and Liu YL and Yu YW and Yang AC and Tsai SJ	|	10.3390/ph13100305	|
|	Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder.	|	2020	|	Frontiers in psychiatry	|	11	|		|	151	|	Xin J and Yuan M and Peng Y and Wang J	|	10.3389/fpsyt.2020.00151	|
|	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.	|	2019	|	The American journal of psychiatry	|	176	|	1	|	21-28	|	Zhang JP and Robinson D and Yu J and Gallego J and Fleischhacker WW and Kahn RS and Crespo-Facorro B and Vazquez-Bourgon J and Kane JM and Malhotra AK and Lencz T	|	10.1176/appi.ajp.2018.17121363	|
|	INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine.	|	2016	|	Pharmacogenomics	|	17	|	18	|	1987-1997	|	Koskinen S and Kampman O and Solismaa A and LyytikÃ¤inen LP and SeppÃ¤lÃ¤ N and Viikki M and HÃ¤mÃ¤lÃ¤inen M and Moilanen E and Mononen N and LehtimÃ¤ki T and Leinonen E	|	10.2217/pgs-2016-0117	|
|	Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis.	|	2019	|	Journal of psychopharmacology (Oxford, England)	|	33	|	10	|	1199-1214	|	Tsugawa S and Noda Y and Tarumi R and Mimura Y and Yoshida K and Iwata Y and Elsalhy M and Kuromiya M and Kurose S and Masuda F and Morita S and Ogyu K and Plitman E and Wada M and Miyazaki T and Graff-Guerrero A and Mimura M and Nakajima S	|	10.1177/0269881119845820	|
|	Gene dosage effect on gamma-secretase component Aph-1b in a rat model for neurodevelopmental disorders.	|	2005	|	Neuron	|	45	|	4	|	497-503	|	Coolen MW and Van Loo KM and Van Bakel NN and Pulford DJ and Serneels L and De Strooper B and Ellenbroek BA and Cools AR and Martens GJ	|	10.1016/j.neuron.2004.12.054	|
|	Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.	|	2009	|	International journal of clinical practice	|	63	|	8	|	1237-48	|	Citrome L	|	10.1111/j.1742-1241.2009.02142.x	|
|	Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis.	|	2010	|	Pharmacogenomics	|	11	|	11	|	1561-71	|	Sicard MN and Zai CC and Tiwari AK and Souza RP and Meltzer HY and Lieberman JA and Kennedy JL and MÃ¼ller DJ	|	10.2217/pgs.10.123	|
|	The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.	|	2020	|	BMC psychiatry	|	20	|	1	|	72	|	Hattori S and Suda A and Miyauchi M and Shiraishi Y and Saeki T and Fukushima T and Fujibayashi M and Tsujita N and Ishii C and Ishii N and Moritani T and Saigusa Y and Kishida I	|	10.1186/s12888-020-02492-5	|
|	Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis.	|	2006	|	Psychiatry research	|	145	|	1	|	61-5	|	Serretti A and Cusin C and Rausch JL and Bondy B and Smeraldi E	|	10.1016/j.psychres.2005.09.020	|
|	Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts.	|	2018	|	PloS one	|	13	|	9	|	e0203896	|	Ward J and Graham N and Strawbridge RJ and Ferguson A and Jenkins G and Chen W and Hodgson K and Frye M and Weinshilboum R and Uher R and Lewis CM and Biernacka J and Smith DJ	|	10.1371/journal.pone.0203896	|
|	Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.	|	2017	|	BMC psychiatry	|	17	|	1	|	250	|	PÃ©rez V and Salavert A and Espadaler J and Tuson M and Saiz-Ruiz J and SÃ¡ez-Navarro C and Bobes J and Baca-GarcÃ­a E and Vieta E and Olivares JM and Rodriguez-Jimenez R and VillagrÃ¡n JM and GascÃ³n J and CaÃ±ete-Crespillo J and SolÃ© M and Saiz PA and IbÃ¡Ã±ez Ã and de Diego-AdeliÃ±o J and MenchÃ³n JM	|	10.1186/s12888-017-1412-1	|
|	Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.	|	2018	|	PloS one	|	13	|	11	|	e0207133	|	Oishi K and Kanahara N and Takase M and Oda Y and Nakata Y and Niitsu T and Ishikawa M and Sato Y and Iyo M	|	10.1371/journal.pone.0207133	|
|	Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients.	|	2015	|	The American journal of managed care	|	21	|	6	|	e357-65	|	Hornberger J and Li Q and Quinn B	|		|
|	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies.	|	2022	|	Molecular psychiatry	|	27	|	1	|	744-757	|	Nakahara T and Tsugawa S and Noda Y and Ueno F and Honda S and Kinjo M and Segawa H and Hondo N and Mori Y and Watanabe H and Nakahara K and Yoshida K and Wada M and Tarumi R and Iwata Y and Plitman E and Moriguchi S and de la Fuente-Sandoval C and Uchida H and Mimura M and Graff-Guerrero A and Nakajima S	|	10.1038/s41380-021-01297-6	|
|	Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: a genome-wide association and polygenic scoring study.	|	2014	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	165	|	5	|	428-37	|	Mullins N and Perroud N and Uher R and Butler AW and Cohen-Woods S and Rivera M and Malki K and Euesden J and Power RA and Tansey KE and Jones L and Jones I and Craddock N and Owen MJ and Korszun A and Gill M and Mors O and Preisig M and Maier W and Rietschel M and Rice JP and MÃ¼ller-Myhsok B and Binder EB and Lucae S and Ising M and Craig IW and Farmer AE and McGuffin P and Breen G and Lewis CM	|	10.1002/ajmg.b.32247	|
|	Effects of BDNF polymorphisms on antidepressant action.	|	2010	|	Psychiatry investigation	|	7	|	4	|	236-42	|	Tsai SJ and Hong CJ and Liou YJ	|	10.4306/pi.2010.7.4.236	|
|	Statistical Binning for Barcoded Reads Improves Downstream Analyses.	|	2018	|	Cell systems	|	7	|	2	|	219-226.e5	|	Shajii A and NumanagiÄ‡ I and Whelan C and Berger B	|	10.1016/j.cels.2018.07.005	|
|	Association study of functional polymorphisms in interleukins and interleukin receptors genes: IL1A, IL1B, IL1RN, IL6, IL6R, IL10, IL10RA and TGFB1 in schizophrenia in Polish population.	|	2015	|	Schizophrenia research	|	169	|	1	|	9-Jan	|	Kapelski P and Skibinska M and Maciukiewicz M and Wilkosc M and Frydecka D and Groszewska A and Narozna B and Dmitrzak-Weglarz M and Czerski P and Pawlak J and Rajewska-Rager A and Leszczynska-Rodziewicz A and Slopien A and Zaremba D and Twarowska-Hauser J	|	10.1016/j.schres.2015.10.008	|
|	Genetic association of LMAN2L gene in schizophrenia and bipolar disorder and its interaction with ANK3 gene polymorphism.	|	2014	|	Progress in neuro-psychopharmacology & biological psychiatry	|	54	|		|	157-62	|	Lim CH and Zain SM and Reynolds GP and Zain MA and Roffeei SN and Zainal NZ and Kanagasundram S and Mohamed Z	|	10.1016/j.pnpbp.2014.05.017	|
|	The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in depressed patients.	|	2022	|	Progress in neuro-psychopharmacology & biological psychiatry	|	119	|		|	110608	|	Chappell K and Colle R and Ait Tayeb AEK and Bouligand J and El-Asmar K and Deflesselle E and FÃ¨ve B and Becquemont L and Corruble E and Verstuyft C	|	10.1016/j.pnpbp.2022.110608	|
|	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.	|	2018	|	Frontiers in psychiatry	|	9	|		|	65	|	Amare AT and Schubert KO and Tekola-Ayele F and Hsu YH and Sangkuhl K and Jenkins G and Whaley RM and Barman P and Batzler A and Altman RB and Arolt V and BrockmÃ¶ller J and Chen CH and Domschke K and Hall-Flavin DK and Hong CJ and Illi A and Ji Y and Kampman O and Kinoshita T and Leinonen E and Liou YJ and Mushiroda T and Nonen S and Skime MK and Wang L and Kato M and Liu YL and Praphanphoj V and Stingl JC and Bobo WV and Tsai SJ and Kubo M and Klein TE and Weinshilboum RM and Biernacka JM and Baune BT	|	10.3389/fpsyt.2018.00065	|
|	DNA hypermethylation of serotonin transporter gene promoter in drug naÃ¯ve patients with schizophrenia.	|	2014	|	Schizophrenia research	|	152	|	2	|	373-80	|	Abdolmaleky HM and Nohesara S and Ghadirivasfi M and Lambert AW and Ahmadkhaniha H and Ozturk S and Wong CK and Shafa R and Mostafavi A and Thiagalingam S	|	10.1016/j.schres.2013.12.007	|
|	Association of CNR1 genotypes with changes in neurocognitive performance after eighteen-month treatment in patients with first-episode psychosis.	|	2019	|	European psychiatry : the journal of the Association of European Psychiatrists	|	61	|		|	88-96	|	Rojnic Kuzman M and Bosnjak Kuharic D and Ganoci L and Makaric P and Kekin I and Rossini Gajsak L and Prpic N and Bozina T and Bajic Z and Bozina N	|	10.1016/j.eurpsy.2019.07.004	|
|	Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.	|	2020	|	JAMA network open	|	3	|	12	|	e2027909	|	JÃ¼rgens G and Andersen SE and Rasmussen HB and Werge T and Jensen HD and Kaas-Hansen BS and Nordentoft M	|	10.1001/jamanetworkopen.2020.27909	|
|	Cannabis Use in People With Obsessive-Compulsive Symptomatology: Results From a Mexican Epidemiological Sample.	|	2021	|	Frontiers in psychiatry	|	12	|		|	664228	|	Nicolini H and MartÃ­nez-MagaÃ±a JJ and Genis-Mendoza AD and Villatoro VelÃ¡zquez JA and Camarena B and Fleiz Bautista C and Bustos-GamiÃ±o M and Aguilar GarcÃ­a A and Lanzagorta N and Medina-Mora ME	|	10.3389/fpsyt.2021.664228	|
|	Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia.	|	2006	|	Sao Paulo medical journal = Revista paulista de medicina	|	124	|	3	|	165-7	|	Cordeiro Q and Miguita K and Miracca E and Elkis H and Vallada H	|	10.1590/s1516-31802006000300013	|
|	Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine.	|	2012	|	The pharmacogenomics journal	|	12	|	6	|	507-12	|	Ono S and Suzuki Y and Fukui N and Sugai T and Watanabe J and Tsuneyama N and Someya T	|	10.1038/tpj.2011.28	|
|	Corticotropin releasing hormone receptor CRHR1 gene is associated with tianeptine antidepressant response in a large sample of outpatients from real-life settings.	|	2020	|	Translational psychiatry	|	10	|	1	|	378	|	Ramoz N and Hoertel N and Nobile B and Voegeli G and Nasr A and Le Strat Y and Courtet P and Gorwood P	|	10.1038/s41398-020-01067-y	|
|	EXPLORATORY ANALYSIS OF RARE AND NOVEL VARIANTS IN MEXICAN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA AND DEMENTIA.	|	2019	|	Revista de investigacion clinica; organo del Hospital de Enfermedades de la           Nutricion	|	71	|	4	|	246-254	|	MartÃ­nez-MagaÃ±a JJ and GenÃ­s-Mendoza AD and GonzÃ¡lez-Covarrubias V and JimÃ©nez-Guenchi J and Galindo-ChÃ¡vez AG and Roche-Bergua A and CastaÃ±eda-GonzÃ¡lez C and Lanzagorta N and SoberÃ³n X and Nicolini H	|	10.24875/RIC.19002923	|
|	Iloperidone: a new option for the treatment of schizophrenia.	|	2009	|	Expert review of neurotherapeutics	|	9	|	12	|	1727-41	|	Cutler AJ	|	10.1002/pmic.200800563	|
|	The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.	|	2010	|	Psychiatria Danubina	|	22	|	1	|	112-6	|	ZivkoviÄ‡ M and MihaljeviÄ‡-Peles A and Sagud M and SiliÄ‡ A and MihanoviÄ‡ M	|		|
|	GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis.	|	2014	|	Pharmacogenomics	|	15	|	11	|	1451-9	|	Kawaguchi DM and Glatt SJ	|	10.2217/pgs.14.96	|
|	Herbal medicines in the treatment of psychiatric disorders: 10-year updated review.	|	2018	|	Phytotherapy research : PTR	|	32	|	7	|	1147-1162	|	Sarris J	|	10.1002/ptr.6055	|
|		|	2016	|		|		|		|		|	Peterson K and Dieperink E and Ferguson L and Anderson J and Helfand M	|		|
|	Heterogeneity amongst 5-HTâ‚ƒ receptor subunits: is this significant?	|	2011	|	Current molecular medicine	|	11	|	1	|	57-68	|	Yaakob N and Malone DT and Exintaris B and Irving HR	|	10.2174/156652411794474392	|
|	Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia.	|	2014	|	The pharmacogenomics journal	|	14	|	5	|	452-6	|	Suzuki Y and Tsuneyama N and Fukui N and Sugai T and Watanabe J and Ono S and Saito M and Inoue Y and Someya T	|	10.1038/tpj.2014.6	|
|	Genetic polymorphisms influencing response to lithium in early-onset Bipolar disorder from south India.	|	2022	|	Asian journal of psychiatry	|	70	|		|	103018	|	Selvarajan S and Srinivasan A and Sakkarabani P and Verma A and Rajendran P and Kandasamy P	|	10.1016/j.ajp.2022.103018	|
|	DNA variation and psychopharmacology of the human serotonin receptor 1B (HTR1B) gene.	|	2002	|	Pharmacogenomics	|	3	|	6	|	745-62	|	Sanders AR and Duan J and Gejman PV	|	10.1517/14622416.3.6.745	|
|	Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia.	|	2013	|	Acta neuropsychiatrica	|	25	|	1	|	11-Feb	|	Rajkumar AP and Poonkuzhali B and Kuruvilla A and Srivastava A and Jacob M and Jacob KS	|	10.1111/j.1601-5215.2012.00638.x	|
|	Effect of Damaging Rare Mutations in Synapse-Related Gene Sets on Response to Short-term Antipsychotic Medication in Chinese Patients With Schizophrenia: A Randomized Clinical Trial.	|	2018	|	JAMA psychiatry	|	75	|	12	|	1261-1269	|	Wang Q and Man Wu H and Yue W and Yan H and Zhang Y and Tan L and Deng W and Chen Q and Yang G and Lu T and Wang L and Zhang F and Yang J and Li K and Lv L and Tan Q and Zhang H and Ma X and Yang F and Li L and Wang C and Ma X and Zhao L and Ren H and Yu H and Wang Y and Hu X and Zhang D and Sham P and Li T	|	10.1001/jamapsychiatry.2018.3039	|
|	The challenge of integrating disparate high-content data: epidemiological, clinical and laboratory data collected during an in-hospital study of chronic fatigue syndrome.	|	2006	|	Pharmacogenomics	|	7	|	3	|	345-54	|	Vernon SD and Reeves WC	|	10.2217/14622416.7.3.345	|
|	St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response.	|	2004	|	Molecular psychiatry	|	9	|	3	|	237-51	|	Wong ML and O'Kirwan F and Hannestad JP and Irizarry KJ and Elashoff D and Licinio J	|	10.1038/sj.mp.4001470	|
|	Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.	|	1998	|	Schizophrenia research	|	32	|	2	|	101-6	|	Kapitany T and Meszaros K and Lenzinger E and Schindler SD and Barnas C and Fuchs K and Sieghart W and Aschauer HN and Kasper S	|	10.1016/s0920-9964(98)00038-3	|
|	A Novel Genotyping Method for Detection of the Muscarinic Receptor M1 Gene rs2067477 Polymorphism and Its Genotype/Allele Frequencies in a Turkish Population.	|	2020	|	Turkish journal of pharmaceutical sciences	|	17	|	6	|	653-658	|	Ã–zdemir F and KÄ±r Y and Tok KC and Baskak B and SÃ¼zen HS	|	10.4274/tjps.galenos.2019.46793	|
|	Integrative Genomic-Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis.	|	2021	|	Pharmaceuticals (Basel, Switzerland)	|	14	|	2	|		|	MayÃ©n-Lobo YG and MartÃ­nez-MagaÃ±a JJ and PÃ©rez-Aldana BE and Ortega-VÃ¡zquez A and Genis-Mendoza AD and DÃ¡vila-Ortiz de Montellano DJ and Soto-Reyes E and Nicolini H and LÃ³pez-LÃ³pez M and Monroy-Jaramillo N	|	10.3390/ph14020118	|
|	The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.	|	2022	|	Journal of affective disorders	|	299	|		|	335-343	|	Poinsignon V and Colle R and Asmar KE and Mendez-David I and David DJ and Ait Tayeb AEK and Chappell K and Gressier F and Herrero H and FÃ¨ve B and Becquemont L and Corruble E and Verstuyft C	|	10.1016/j.jad.2021.12.012	|
|	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.	|	2019	|	BMC medical genetics	|	20	|		|	47	|	Osmanova DZ and Freidin MB and Fedorenko OY and Pozhidaev IV and Boiko AS and Vyalova NM and Tiguntsev VV and Kornetova EG and Loonen AJM and Semke AV and Wilffert B and Bokhan NA and Ivanova SA	|	10.1186/s12881-019-0773-3	|
|	Clinical significance of sodium-dependent lithium transport in affective psychoses.	|	1980	|	Psychiatria clinica	|	13	|	1	|	57-64	|	SzentistvÃ¡nyi I and Janka Z and SzilÃ¡rd J	|	10.1159/000283861	|
|	Sequence Analysis of Drug Target Genes with Suicidal Behavior in Bipolar Disorder Patients.	|	2018	|	Molecular neuropsychiatry	|	4	|	1	|	6-Jan	|	Zai CC and Tiwari AK and Zai GC and de Luca V and Shaikh SA and King N and Strauss J and Kennedy JL and Vincent JB	|	10.1159/000488029	|
|	A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs.	|	2020	|	The pharmacogenomics journal	|	20	|	2	|	260-270	|	Yoshikawa A and Li J and Meltzer HY	|	10.1038/s41397-019-0101-5	|
|	ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.	|	2017	|	Pharmacogenomics and personalized medicine	|	10	|		|	235-242	|	Piatkov I and Caetano D and Assur Y and Lau SL and Jones T and Boyages SC and McLean M	|	10.2147/PGPM.S142314	|
|	Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response.	|	2014	|	The international journal of neuropsychopharmacology	|	17	|	8	|	1167-76	|	Domschke K and Tidow N and Schwarte K and Deckert J and Lesch KP and Arolt V and Zwanzger P and Baune BT	|	10.1017/S146114571400039X	|
|	Damaging coding variants within kainate receptor channel genes are enriched in individuals with schizophrenia, autism and intellectual disabilities.	|	2019	|	Scientific reports	|	9	|	1	|	19215	|	Koromina M and Flitton M and Blockley A and Mellor IR and Knight HM	|	10.1038/s41598-019-55635-4	|
|	Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.	|	2003	|	The pharmacogenomics journal	|	3	|	6	|	356-61	|	Yamanouchi Y and Iwata N and Suzuki T and Kitajima T and Ikeda M and Ozaki N	|	10.1038/sj.tpj.6500211	|
|	Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future.	|	2010	|	Schizophrenia research	|	122	|	1	|	23-Jan	|	Tandon R and Nasrallah HA and Keshavan MS	|	10.1016/j.schres.2010.05.025	|
|	Telomere length in bipolar disorder and lithium response.	|	2017	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	27	|	6	|	560-567	|	Squassina A and Pisanu C and Corbett N and Alda M	|	10.1016/j.euroneuro.2015.10.008	|
|	The ANKS1B gene and its associated phenotypes: focus on CNS drug response.	|	2019	|	Pharmacogenomics	|	20	|	9	|	669-684	|	Younis RM and Taylor RM and Beardsley PM and McClay JL	|	10.2217/pgs-2019-0015	|
|	Iloperidone: in schizophrenia.	|	2009	|	CNS drugs	|	23	|	10	|	867-80	|	Scott LJ	|	10.2165/10489070-000000000-00000	|
|	Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.	|	2006	|	Pharmacogenomics	|	7	|	7	|	987-93	|	Xing Q and Gao R and Li H and Feng G and Xu M and Duan S and Meng J and Zhang A and Qin S and He L	|	10.2217/14622416.7.7.987	|
|	The role of genetic variation across IL-1Î², IL-2, IL-6, and BDNF in antipsychotic-induced weight gain.	|	2015	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	16	|	1	|	45-56	|	Fonseka TM and Tiwari AK and GonÃ§alves VF and Lieberman JA and Meltzer HY and Goldstein BI and Kennedy JL and Kennedy SH and MÃ¼ller DJ	|	10.3109/15622975.2014.984631	|
|	Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia.	|	2012	|	The American journal of psychiatry	|	169	|	7	|	725-34	|	Apud JA and Zhang F and Decot H and Bigos KL and Weinberger DR	|	10.1176/appi.ajp.2012.11081214	|
|	Genome wide study of tardive dyskinesia in schizophrenia.	|	2021	|	Translational psychiatry	|	11	|	1	|	351	|	Lim K and Lam M and Zai C and Tay J and Karlsson N and Deshpande SN and Thelma BK and Ozaki N and Inada T and Sim K and Chong SA and Lencz T and Liu J and Lee J	|	10.1038/s41398-021-01471-y	|
|	Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits.	|	2017	|	PloS one	|	12	|	6	|	e0179020	|	Pinsonneault JK and Frater JT and Kompa B and Mascarenhas R and Wang D and Sadee W	|	10.1371/journal.pone.0179020	|
|	Whole Genome Expression Analyses of miRNAs and mRNAs Suggest the Involvement of miR-320a and miR-155-3p and their Targeted Genes in Lithium Response in Bipolar Disorder.	|	2019	|	International journal of molecular sciences	|	20	|	23	|		|	Pisanu C and Merkouri Papadima E and Melis C and Congiu D and Loizedda A and OrrÃ¹ N and Calza S and OrrÃ¹ S and Carcassi C and Severino G and Ardau R and Chillotti C and Del Zompo M and Squassina A	|	10.3390/ijms20236040	|
|	DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences.	|	2012	|	Epigenomics	|	4	|	3	|	261-8	|	Burghardt KJ and Pilsner JR and Bly MJ and Ellingrod VL	|	10.2217/epi.12.25	|
|	Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms.	|	2009	|	Archives of general psychiatry	|	66	|	11	|	1233-41	|	Kwon JS and Joo YH and Nam HJ and Lim M and Cho EY and Jung MH and Choi JS and Kim B and Kang DH and Oh S and Park T and Hong KS	|	10.1001/archgenpsychiatry.2009.155	|
|	Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.	|	2012	|	The pharmacogenomics journal	|	12	|	1	|	62-7	|	Risselada AJ and Vehof J and Bruggeman R and Wilffert B and Cohen D and Al Hadithy AF and Arends J and Mulder H	|	10.1038/tpj.2010.66	|
|	Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder.	|	2021	|	Frontiers in neuroscience	|	15	|		|	674273	|	Zhou J and Li M and Wang X and He Y and Xia Y and Sweeney JA and Kopp RF and Liu C and Chen C	|	10.3389/fnins.2021.674273	|
|	The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study.	|	2007	|	The pharmacogenomics journal	|	7	|	5	|	318-24	|	Mulder H and Franke B and van der-Beek van der AA and Arends J and Wilmink FW and Egberts AC and Scheffer H	|	10.1038/sj.tpj.6500422	|
|	Head-to-Head Comparison of Sedation and Somnolence Among 37 Antipsychotics in Schizophrenia, Bipolar Disorder, Major Depression, Autism Spectrum Disorders, Delirium, and Repurposed in COVID-19, Infectious Diseases, and Oncology From the FAERS, 2004-2020.	|	2021	|	Frontiers in pharmacology	|	12	|		|	621691	|	Eugene AR and Eugene B and Masiak M and Masiak JS	|	10.3389/fphar.2021.621691	|
|	Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.	|	2012	|	The pharmacogenomics journal	|	12	|	2	|	156-64	|	MÃ¼ller DJ and Zai CC and Sicard M and Remington E and Souza RP and Tiwari AK and Hwang R and Likhodi O and Shaikh S and Freeman N and Arenovich T and Heinz A and Meltzer HY and Lieberman JA and Kennedy JL	|	10.1038/tpj.2010.65	|
|	Astrocytes are direct cellular targets of lithium treatment: novel roles for lysyl oxidase and peroxisome-proliferator activated receptor-Î³ as astroglial targets of lithium.	|	2019	|	Translational psychiatry	|	9	|	1	|	211	|	Rivera AD and Butt AM	|	10.1038/s41398-019-0542-2	|
|	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study.	|	2017	|	The international journal of neuropsychopharmacology	|	20	|	10	|	782-787	|	Schosser A and Carlberg L and Calati R and Serretti A and Massat I and Spindelegger C and Linotte S and Mendlewicz J and Souery D and Zohar J and Montgomery S and Kasper S	|	10.1093/ijnp/pyx028	|
|	[Antipsychotic-induced weight gain--pharmacogenetic studies].	|	2006	|	Psychiatria polska	|	40	|	5	|	1009-20	|	Olajossy-Hilkesberger L and Godlewska B and Marmurowska-MichaÅ‚owskal H and Olajossy M and Landowski J	|		|
|	[DRD4 polymorphism and the association with mental disorders].	|	2005	|	Revista de investigacion clinica; organo del Hospital de Enfermedades de la           Nutricion	|	57	|	1	|	65-75	|	Aguirre-Samudio AJ and Nicolini H	|		|
|	Genetics of migraine.	|	2018	|	Handbook of clinical neurology	|	148	|		|	493-503	|	Anttila V and Wessman M and Kallela M and Palotie A	|	10.1016/B978-0-444-64076-5.00031-4	|
|	Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.	|	2019	|	Basic & clinical pharmacology & toxicology	|	124	|	1	|	94-104	|	Ma L and Zhang X and Xiang Q and Zhou S and Zhao N and Xie Q and Zhao X and Zhou Y and Cui Y	|	10.1111/bcpt.13111	|
|	Genetics of long-term treatment outcome in bipolar disorder.	|	2016	|	Progress in neuro-psychopharmacology & biological psychiatry	|	65	|		|	17-24	|	Fabbri C and Serretti A	|	10.1016/j.pnpbp.2015.08.008	|
|	Mice selected for extremes in stress reactivity reveal key endophenotypes of major depression: a translational approach.	|	2014	|	Psychoneuroendocrinology	|	49	|		|	229-43	|	Heinzmann JM and Kloiber S and Ebling-Mattos G and Bielohuby M and Schmidt MV and Palme R and Holsboer F and Uhr M and Ising M and Touma C	|	10.1016/j.psyneuen.2014.07.008	|
|	Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in Indian populations.	|	2016	|	Molecular genetics & genomic medicine	|	4	|	1	|	18-27	|	Jajodia A and Kaur H and Kumari K and Kanojia N and Gupta M and Baghel R and Sood M and Jain S and Chadda RK and Kukreti R	|	10.1002/mgg3.169	|
|	Pioglitazone could induce remission in major depression: a meta-analysis.	|	2017	|	Neuropsychiatric disease and treatment	|	13	|		|	16-Sep	|	Colle R and de Larminat D and Rotenberg S and Hozer F and Hardy P and Verstuyft C and FÃ¨ve B and Corruble E	|	10.2147/NDT.S121149	|
|	Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia.	|	2014	|	The international journal of neuropsychopharmacology	|	17	|	4	|	645-9	|	Tang H and Dalton CF and Srisawat U and Zhang ZJ and Reynolds GP	|	10.1017/S1461145713001442	|
|	Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients.	|	1999	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	10	|	1	|	17-20	|	Scharfetter J and Chaudhry HR and Hornik K and Fuchs K and Sieghart W and Kasper S and Aschauer HN	|	10.1016/s0924-977x(99)00044-9	|
|	Assay for the simultaneous detection of the *1C and *1F alleles of the CYP1A2 gene by real-time polymerase chain reaction and melting curve analysis.	|	2006	|	Psychiatric genetics	|	16	|	2	|	81-3	|	Casley WL and LeBlanc-Westwood CA	|	10.1097/01.ypg.0000185030.35558.6d	|
|	Integrative mouse and human mRNA studies using WGCNA nominates novel candidate genes involved in the pathogenesis of major depressive disorder.	|	2013	|	Pharmacogenomics	|	14	|	16	|	1979-90	|	Malki K and Tosto MG and Jumabhoy I and Lourdusamy A and Sluyter F and Craig I and Uher R and McGuffin P and Schalkwyk LC	|	10.2217/pgs.13.154	|
|	Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study.	|	2021	|	Journal of psychiatry & neuroscience : JPN	|	46	|	3	|	E358-E368	|	Ciocan D and Cassard AM and Becquemont L and Verstuyft C and Voican CS and El Asmar K and Colle R and David D and Trabado S and Feve B and Chanson P and Perlemuter G and Corruble E	|	10.1503/jpn.200159	|
|	The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.	|	2017	|	Frontiers in neuroscience	|	11	|		|	741	|	Raben AT and Marshe VS and Chintoh A and Gorbovskaya I and MÃ¼ller DJ and Hahn MK	|	10.3389/fnins.2017.00741	|
|	(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population.	|	2006	|	The pharmacogenomics journal	|	6	|	2	|	126-30	|	Ballon N and Leroy S and Roy C and Bourdel MC and Charles-Nicolas A and Krebs MO and Poirier MF	|	10.1038/sj.tpj.6500352	|
|	Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.	|	2007	|	The pharmacogenomics journal	|	7	|	6	|	418-26	|	Molero P and OrtuÃ±o F and Zalacain M and PatiÃ±o-GarcÃ­a A	|	10.1038/sj.tpj.6500441	|
|	Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.	|	2012	|	The pharmacogenomics journal	|	12	|	6	|	513-20	|	Greenbaum L and Alkelai A and Zozulinsky P and Kohn Y and Lerer B	|	10.1038/tpj.2011.32	|
|	Association between genetic polymorphism and antidepressants in major depression: a network meta-analysis.	|	2020	|	Pharmacogenomics	|	21	|	13	|	963-974	|	Du D and Tang Q and Han Q and Zhang J and Liang X and Tan Y and Liu K and Xiang B	|	10.2217/pgs-2020-0037	|
|	Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype.	|	2014	|	Romanian journal of morphology and embryology = Revue roumaine de morphologie et           embryologie	|	55	|	3	|	877-84	|	Nussbaum LA and DumitraÅŸcu V and Tudor A and GrÄƒdinaru R and Andreescu N and Puiu M	|		|
|	Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia.	|	2021	|	Frontiers in pharmacology	|	12	|		|	658734	|	Willcocks IR and Legge SE and Nalmpanti M and Mazzeo L and King A and Jansen J and Helthuis M and Owen MJ and O'Donovan MC and Walters JTR and PardiÃ±as AF	|	10.3389/fphar.2021.658734	|
|	Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.	|	1998	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	19	|	2	|	123-32	|	Masellis M and Basile V and Meltzer HY and Lieberman JA and Sevy S and Macciardi FM and Cola P and Howard A and Badri F and NÃ¶then MM and Kalow W and Kennedy JL	|	10.1016/S0893-133X(98)00007-4	|
|	Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.	|	2012	|	The pharmacogenomics journal	|	12	|	1	|	54-61	|	Liou YJ and Bai YM and Lin E and Chen JY and Chen TT and Hong CJ and Tsai SJ	|	10.1038/tpj.2010.74	|
|	Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.	|	2018	|	Pharmacogenomics	|	19	|	3	|	197-212	|	MontanÃ© Jaime LK and Paul J and Lalla A and Legall G and Gaedigk A	|	10.2217/pgs-2017-0142	|
|	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression.	|	2013	|	Psychiatry investigation	|	10	|	3	|	286-93	|	Han KM and Chang HS and Choi IK and Ham BJ and Lee MS	|	10.4306/pi.2013.10.3.286	|
|	Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol.	|	2017	|	PloS one	|	12	|	4	|	e0174783	|	Rivollier F and Chaumette B and Bendjemaa N and Chayet M and Millet B and Jaafari N and Barhdadi A and Lemieux Perreault LP and Provost S and DubÃ© MP and Gaillard R and Krebs MO and Kebir O	|	10.1371/journal.pone.0174783	|
|	Methylomic changes during conversion to psychosis.	|	2017	|	Molecular psychiatry	|	22	|	4	|	512-518	|	Kebir O and Chaumette B and Rivollier F and Miozzo F and Lemieux Perreault LP and Barhdadi A and Provost S and Plaze M and Bourgin J and Gaillard R and Mezger V and DubÃ© MP and Krebs MO	|	10.1038/mp.2016.53	|
|	Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study.	|	2022	|	Translational psychiatry	|	12	|	1	|	173	|	Zhao M and Ma J and Li M and Zhu W and Zhou W and Shen L and Wu H and Zhang N and Wu S and Fu C and Li X and Yang K and Tang T and Shen R and He L and Huai C and Qin S	|	10.1038/s41398-022-01942-w	|
|	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response.	|	2022	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	55	|		|	86-95	|	Fanelli G and Domschke K and Minelli A and Gennarelli M and Martini P and Bortolomasi M and Maron E and Squassina A and Kasper S and Zohar J and Souery D and Montgomery S and Albani D and Forloni G and Ferentinos P and Rujescu D and Mendlewicz J and De Ronchi D and Baune BT and Serretti A and Fabbri C	|	10.1016/j.euroneuro.2021.11.005	|
|	Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism.	|	2007	|	The pharmacogenomics journal	|	7	|	5	|	305-11	|	Tiwari AK and Deshpande SN and Lerer B and Nimgaonkar VL and Thelma BK	|	10.1038/sj.tpj.6500415	|
|	[Leponex, 10 years after -- a clinical review].	|	2004	|	L'Encephale	|	30	|	5	|	474-91	|	Llorca PM and Pere JJ	|	10.1016/s0013-7006(04)95462-0	|
|	Gene expression effects of lithium and valproic acid in a serotonergic cell line.	|	2019	|	Physiological genomics	|	51	|	2	|	43-50	|	Balasubramanian D and Pearson JF and Kennedy MA	|	10.1152/physiolgenomics.00069.2018	|
|	Towards safer risperidone prescribing in Alzheimer's disease.	|	2021	|	The British journal of psychiatry : the journal of mental science	|	218	|	5	|	268-275	|	Reeves S and Bertrand J and Uchida H and Yoshida K and Otani Y and Ozer M and Liu KY and Bramon E and Bies R and Pollock BG and Howard R	|	10.1192/bjp.2020.225	|
|	HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis.	|	2007	|	Human psychopharmacology	|	22	|	7	|	463-7	|	De Luca V and MÃ¼ller DJ and Hwang R and Lieberman JA and Volavka J and Meltzer HY and Kennedy JL	|	10.1002/hup.868	|
|	The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder.	|	2020	|	Psychopharmacology bulletin	|	50	|	3	|	58-75	|	Zastrozhin and Smirnov and Petukhov and Pankratenko and Zastrozhina and Grishina and Ryzhikova and Bure and Skryabin and Vlasovskih and Bryun and Sychev	|		|
|	Does the 5-HT(1A) rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?	|	2018	|	Therapeutic advances in drug safety	|	9	|	7	|	355-366	|	Scutt G and Overall A and Scott R and Patel B and Hachoumi L and Yeoman M and Wright J	|	10.1177/2042098618770620	|
|	A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain.	|	2017	|	Schizophrenia research	|	187	|		|	67-73	|	Mittal K and GonÃ§alves VF and Harripaul R and Cuperfain AB and Rollins B and Tiwari AK and Zai CC and Maciukiewicz M and MÃ¼ller DJ and Vawter MP and Kennedy JL	|	10.1016/j.schres.2017.06.046	|
|	Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder.	|	2005	|	The pharmacogenomics journal	|	5	|	2	|	89-95	|	Nishiyama T and Ikeda M and Iwata N and Suzuki T and Kitajima T and Yamanouchi Y and Sekine Y and Iyo M and Harano M and Komiyama T and Yamada M and Sora I and Ujike H and Inada T and Furukawa T and Ozaki N	|	10.1038/sj.tpj.6500292	|
|	Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study.	|	2008	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	33	|	2	|	305-11	|	Xuan J and Zhao X and He G and Yu L and Wang L and Tang W and Li X and Gu N and Feng G and Xing Q and He L	|	10.1038/sj.npp.1301418	|
|	Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain.	|	2012	|	Drug metabolism and disposition: the biological fate of chemicals	|	40	|	10	|	1909-16	|	Cremers TI and Flik G and Hofland C and Stratford RE Jr	|	10.1124/dmd.112.045682	|
|	The benefit of diagnostic whole genome sequencing in schizophrenia and other psychotic disorders.	|	2022	|	Molecular psychiatry	|	27	|	3	|	1435-1447	|	Alkelai A and Greenbaum L and Docherty AR and Shabalin AA and Povysil G and Malakar A and Hughes D and Delaney SL and Peabody EP and McNamara J and Gelfman S and Baugh EH and Zoghbi AW and Harms MB and Hwang HS and Grossman-Jonish A and Aggarwal V and Heinzen EL and Jobanputra V and Pulver AE and Lerer B and Goldstein DB	|	10.1038/s41380-021-01383-9	|
|	The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report.	|	2021	|	Annals of general psychiatry	|	20	|	1	|	43	|	Matteo M and Cristian P and Laura M and Federico M and Chiara R and Lorenzo G and Michaela K and Sibilla M and Roberto N and Fabrizia C and Antonios D and Alice C and Enrico C and Beatrice B and Francesca B and Nicoletta V and Alberto P and Silvia I and Massimo C	|	10.1186/s12991-021-00365-z	|
|	The CACNA1C risk allele rs1006737 is associated with age-related prefrontal cortical thinning in bipolar I disorder.	|	2017	|	Translational psychiatry	|	7	|	4	|	e1086	|	Soeiro-de-Souza MG and Lafer B and Moreno RA and Nery FG and Chile T and Chaim K and da Costa Leite C and Machado-Vieira R and Otaduy MC and Vallada H	|	10.1038/tp.2017.57	|
|	Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia.	|	2001	|	American journal of medical genetics	|	105	|	6	|	498-501	|	Schulze TG and Schumacher J and MÃ¼ller DJ and Krauss H and Alfter D and Maroldt A and Ahle G and Maroldt AO and Novo y FernÃ¡ndez A and Weber T and Held T and Propping P and Maier W and NÃ¶then MM and Rietschel M	|	10.1002/ajmg.1472	|
|	New developments in the genetics of bipolar disorder.	|	2014	|	Current psychiatry reports	|	16	|	11	|	493	|	Shinozaki G and Potash JB	|	10.1007/s11920-014-0493-5	|
|	-759C>T Polymorphism of the HTR2C Gene is Associated with Second Generation Antipsychotic-Induced Weight Gain in Female Patients with Schizophrenia.	|	2017	|	Pharmacopsychiatry	|	50	|	1	|	14-18	|	Daray FM and Rodante D and Carosella LG and Silva ME and MartÃ­nez M and FernÃ¡ndez Busch MV and Faccone DF and Rothlin RP and MaffÃ­a PC	|	10.1055/s-0042-110321	|
|	CYP2C19*17 protects against metabolic complications of clozapine treatment.	|	2017	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	18	|	7	|	521-527	|	Piatkov I and Caetano D and Assur Y and Lau SL and Coelho M and Jones T and Nguyen T and Boyages S and McLean M	|	10.1080/15622975.2017.1347712	|
|	Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy.	|	2018	|	The Journal of clinical investigation	|	128	|	11	|	4997-5007	|	Cui D and Peng Y and Zhang C and Li Z and Su Y and Qi Y and Xing M and Li J and Kim GE and Su KN and Xu J and Wang M and Ding W and Piecychna M and Leng L and Hirasawa M and Jiang K and Young L and Xu Y and Qi D and Bucala R	|	10.1172/JCI93090	|
|	Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.	|	2005	|	Schizophrenia research	|	77	|	2	|	253-60	|	Bishop JR and Ellingrod VL and Moline J and Miller D	|	10.1016/j.schres.2005.04.001	|
|	Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.	|	2007	|	Biological psychiatry	|	61	|	6	|	734-42	|	Kraft JB and Peters EJ and Slager SL and Jenkins GD and Reinalda MS and McGrath PJ and Hamilton SP	|	10.1016/j.biopsych.2006.07.017	|
|	The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.	|	2008	|	Movement disorders : official journal of the Movement Disorder Society	|	23	|	4	|	599-602	|	Paus S and GrÃ¼newald A and Klein C and Knapp M and Zimprich A and Janetzky B and MÃ¶ller JC and Klockgether T and WÃ¼llner U	|	10.1002/mds.21901	|
|	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.	|	2018	|	Journal of affective disorders	|	227	|		|	542-549	|	Baskaran A and Farzan F and Milev R and Brenner CA and Alturi S and Pat McAndrews M and Blier P and Evans K and Foster JA and Frey BN and Giacobbe P and Lam RW and Leri F and MacQueen GM and MÃ¼ller DJ and Parikh SV and Rotzinger S and Soares CN and Strother SC and Turecki G and Kennedy SH	|	10.1016/j.jad.2017.10.028	|
|	Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals.	|	2004	|	Psychiatric genetics	|	14	|	3	|	139-42	|	Theisen FM and Hinney A and BrÃ¶mel T and Heinzel-Gutenbrunner M and Martin M and Krieg JC and Remschmidt H and Hebebrand J	|	10.1097/00041444-200409000-00003	|
|	Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms.	|	2021	|	The pharmacogenomics journal	|	21	|	3	|	359-375	|	Sinha P and Cree SL and Miller AL and Pearson JF and Kennedy MA	|	10.1038/s41397-021-00215-x	|
|	-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.	|	2007	|	Progress in neuro-psychopharmacology & biological psychiatry	|	31	|	3	|	673-7	|	Ryu S and Cho EY and Park T and Oh S and Jang WS and Kim SK and Lee D and Hong KS	|	10.1016/j.pnpbp.2006.12.021	|
|	Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A (1)H-MRS study.	|	2018	|	Journal of affective disorders	|	241	|		|	192-199	|	Soeiro-de-Souza MG and Otaduy MCG and Machado-Vieira R and Moreno RA and Nery FG and Leite C and Lafer B	|	10.1016/j.jad.2018.08.039	|
|	Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow.	|	2003	|	The pharmacogenomics journal	|	3	|	4	|	227-34	|	Pereira A and McLaren A and Bell WR and Copolov D and Dean B	|	10.1038/sj.tpj.6500179	|
|	Transcriptomics and the mechanisms of antidepressant efficacy.	|	2016	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	26	|	1	|	105-112	|	Hodgson K and Tansey KE and Powell TR and Coppola G and Uher R and Zvezdana DernovÅ¡ek M and Mors O and Hauser J and Souery D and Maier W and Henigsberg N and Rietschel M and Placentino A and Aitchison KJ and Craig IW and Farmer AE and Breen G and McGuffin P and Dobson R	|	10.1016/j.euroneuro.2015.10.009	|
|	Influence of NOS1AP Risk Variants on the Corrected QT (QTc) Interval in the Pharmacotherapy of Schizophrenia.	|	2022	|	Pharmacopsychiatry	|	55	|	5	|	266-273	|	Esen-Sehir D and Kopf J and HÃ¤gele S and Plichta MM and Reif A and Freudenberg F	|	10.1055/a-1811-7241	|
|	A systematic review of antipsychotic drug effects on human gene expression related to risk factors for cardiovascular disease.	|	2014	|	The pharmacogenomics journal	|	14	|	5	|	446-51	|	Foley DL and Mackinnon A	|	10.1038/tpj.2014.8	|
|	Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.	|	2011	|	Biological psychiatry	|	69	|	1	|	11-Jul	|	Tregellas JR and Tanabe J and Rojas DC and Shatti S and Olincy A and Johnson L and Martin LF and Soti F and Kem WR and Leonard S and Freedman R	|	10.1016/j.biopsych.2010.07.004	|
|	Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment.	|	2006	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	141	|	8	|	939-43	|	Mata I and Crespo-Facorro B and PÃ©rez-Iglesias R and Carrasco-MarÃ­n E and Arranz MJ and Pelayo-TerÃ¡n JM and Leyva-CobÃ­an F and VÃ¡zquez-Barquero JL	|	10.1002/ajmg.b.30405	|
|	Changes in Sertraline Plasma Concentrations Across Pregnancy and Postpartum.	|	2022	|	Clinical pharmacology and therapeutics	|		|		|		|	Stika CS and Wisner KL and George AL Jr and Avram MJ and Zumpf K and Rasmussen-Torvik LJ and Mesches GA and Caritis SN and Venkataramanan R and Costantine MM and West HA and Clark S and Ciolino JD	|	10.1002/cpt.2746	|
|	Search for mutations in the beta 1 GABAA receptor subunit gene in patients with schizophrenia.	|	1994	|	American journal of medical genetics	|	54	|	1	|	20-Dec	|	Coon H and Sobell J and Heston L and Sommer S and Hoff M and Holik J and Umar F and Robertson M and Reimherr F and Wender P and et al.	|	10.1002/ajmg.1320540105	|
|	D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes.	|	2003	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	116	|	1	|	103-25	|	Noble EP	|	10.1002/ajmg.b.10005	|
|	A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders.	|	2008	|	The pharmacogenomics journal	|	8	|	2	|	101-12	|	GratacÃ²s M and Soria V and Urretavizcaya M and GonzÃ¡lez JR and Crespo JM and BayÃ©s M and de Cid R and MenchÃ³n JM and Vallejo J and Estivill X	|	10.1038/sj.tpj.6500460	|
|	Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study.	|	2021	|	General psychiatry	|	34	|	1	|	e100289	|	Yu W and Huang J and He S and Zhang L and Shen Y and Li H	|	10.1136/gpsych-2020-100289	|
|	DRD2 co-expression network and a related polygenic index predict imaging, behavioral and clinical phenotypes linked to schizophrenia.	|	2017	|	Translational psychiatry	|	7	|	1	|	e1006	|	Pergola G and Di Carlo P and D'Ambrosio E and Gelao B and Fazio L and Papalino M and Monda A and Scozia G and Pietrangelo B and Attrotto M and Apud JA and Chen Q and Mattay VS and Rampino A and Caforio G and Weinberger DR and Blasi G and Bertolino A	|	10.1038/tp.2016.253	|
|	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder.	|	2022	|	Journal of personalized medicine	|	12	|	3	|		|	Grant CW and Barreto EF and Kumar R and Kaddurah-Daouk R and Skime M and Mayes T and Carmody T and Biernacka J and Wang L and Weinshilboum R and Trivedi MH and Bobo WV and Croarkin PE and Athreya AP	|	10.3390/jpm12030412	|
|	Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia.	|	2021	|	BJPsych open	|	7	|	4	|	e121	|	Su Y and Yu H and Wang Z and Liu S and Zhao L and Fu Y and Yang Y and Du B and Zhang F and Zhang X and Huang M and Hou C and Huang G and Su Z and Peng M and Yan R and Zhang Y and Yan H and Wang L and Lu T and Jia F and Li K and Lv L and Wang H and Yu S and Wang Q and Tan Y and Xu Y and Zhang D and Yue W	|	10.1192/bjo.2021.945	|
|	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.	|	2019	|	Journal of neural transmission (Vienna, Austria : 1996)	|	126	|	1	|	35-45	|	Amare AT and Schubert KO and Tekola-Ayele F and Hsu YH and Sangkuhl K and Jenkins G and Whaley RM and Barman P and Batzler A and Altman RB and Arolt V and BrockmÃ¶ller J and Chen CH and Domschke K and Hall-Flavin DK and Hong CJ and Illi A and Ji Y and Kampman O and Kinoshita T and Leinonen E and Liou YJ and Mushiroda T and Nonen S and Skime MK and Wang L and Kato M and Liu YL and Praphanphoj V and Stingl JC and Bobo WV and Tsai SJ and Kubo M and Klein TE and Weinshilboum RM and Biernacka JM and Baune BT	|	10.1007/s00702-018-01966-x	|
|	The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis.	|	2010	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	153	|	2	|	387-396	|	Saetre P and Lundmark P and Wang A and Hansen T and Rasmussen HB and Djurovic S and Melle I and Andreassen OA and Werge T and Agartz I and Hall H and Terenius L and JÃ¶nsson EG	|	10.1002/ajmg.b.30991	|
|	BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis.	|	2019	|	The pharmacogenomics journal	|	19	|	3	|	269-276	|	Huang E and Hettige NC and Zai G and Tomasi J and Huang J and Zai CC and Pivac N and Nikolac Perkovic M and Tiwari AK and Kennedy JL	|	10.1038/s41397-018-0041-5	|
|	Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population.	|	2017	|	Frontiers in pharmacology	|	8	|		|	879	|	Koomdee N and Pratoomwun J and Jantararoungtong T and Theeramoke V and Tassaneeyakul W and Klaewsongkram J and Rerkpattanapipat T and Santon S and Puangpetch A and Intusoma U and Tempark T and Deesudchit T and Satapornpong P and Visudtibhan A and Sukasem C	|	10.3389/fphar.2017.00879	|
|	The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples.	|	2022	|	The Lancet regional health. Europe	|	22	|		|	100493	|	Perry BI and Vandenberghe F and Garrido-Torres N and Osimo EF and Piras M and Vazquez-Bourgon J and Upthegrove R and Grosu C and De La Foz VO and Jones PB and Laaboub N and Ruiz-Veguilla M and Stochl J and Dubath C and Canal-Rivero M and Mallikarjun P and Reymond-DelacrÃ©taz A and Ansermot N and Fernandez-Egea E and Crettol S and Gamma F and Plessen KJ and Conus P and Khandaker GM and Murray GK and Eap CB and Crespo-Facorro B	|	10.1016/j.lanepe.2022.100493	|
|	Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.	|	2014	|	Human psychopharmacology	|	29	|	1	|	38-45	|	Roffeei SN and Reynolds GP and Zainal NZ and Said MA and Hatim A and Aida SA and Mohamed Z	|	10.1002/hup.2366	|
|	ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis.	|	2015	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	168	|	4	|	274-83	|	Breitenstein B and BrÃ¼ckl TM and Ising M and MÃ¼ller-Myhsok B and Holsboer F and Czamara D	|	10.1002/ajmg.b.32309	|
|	Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009.	|	2011	|	Journal of clinical psychopharmacology	|	31	|	4	|	411-7	|	Patel MX and Bowskill S and Couchman L and Lay V and Taylor D and Spencer EP and Flanagan RJ	|	10.1097/JCP.0b013e318221b408	|
|	Association of 5-HTR2A T102C and A-1438G polymorphisms with clinical response to atypical antipsychotic treatment in schizophrenia: A meta-analysis.	|	2022	|	Neuroscience letters	|	770	|		|	136395	|	Yan P and Gao B and Wang S and Wang S and Li J and Song M	|	10.1016/j.neulet.2021.136395	|
|	An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective.	|	2020	|	Current neuropharmacology	|	18	|	3	|	168-187	|	Athira KV and Bandopadhyay S and Samudrala PK and Naidu VGM and Lahkar M and Chakravarty S	|	10.2174/1570159X17666191001142934	|
|	Interventions to improve medication adherence in mental health: the update of a systematic review of cost-effectiveness.	|	2020	|	International journal of psychiatry in clinical practice	|	24	|	4	|	416-427	|	GarcÃ­a-PÃ©rez L and LinertovÃ¡ R and Serrano-PÃ©rez P and Trujillo-MartÃ­n M and RodrÃ­guez-RodrÃ­guez L and ValcÃ¡rcel-Nazco C and Del Pino-SedeÃ±o T	|	10.1080/13651501.2020.1782434	|
|	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway.	|	2016	|	BMC psychiatry	|	16	|		|	106	|	Cocchi E and Fabbri C and Han C and Lee SJ and Patkar AA and Masand PS and Pae CU and Serretti A	|	10.1186/s12888-016-0813-x	|
|	Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia.	|	2016	|	Journal of personalized medicine	|	6	|	1	|		|	Nisenbaum LK and Downing AM and Zhao F and Millen BA and Munsie L and Kinon BJ and Adams DH and Gomez JC and Penny MA	|	10.3390/jpm6010009	|
|	DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia.	|	2013	|	The pharmacogenomics journal	|	13	|	1	|	27-34	|	Tanaka S and Syu A and Ishiguro H and Inada T and Horiuchi Y and Ishikawa M and Koga M and Noguchi E and Ozaki N and Someya T and Kakita A and Takahashi H and Nawa H and Arinami T	|	10.1038/tpj.2011.36	|
|	Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens.	|	2007	|	The pharmacogenomics journal	|	7	|	5	|	325-32	|	Dettling M and Cascorbi I and Opgen-Rhein C and Schaub R	|	10.1038/sj.tpj.6500423	|
|	Drug Attitude, Insight, and Patient's Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey.	|	2020	|	Neuropsychiatric disease and treatment	|	16	|		|	781-787	|	Nagai N and Tani H and Yoshida K and Gerretsen P and Suzuki T and Ikai-Tani S and Mimura M and Uchida H	|	10.2147/NDT.S240377	|
|	Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia.	|	2012	|	The pharmacogenomics journal	|	12	|	3	|	260-6	|	Tiwari AK and Zai CC and Likhodi O and Voineskos AN and Meltzer HY and Lieberman JA and Potkin SG and Remington G and MÃ¼ller DJ and Kennedy JL	|	10.1038/tpj.2010.93	|
|	CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.	|	2010	|	Pharmacogenomics	|	11	|	11	|	1535-43	|	Lin KM and Tsou HH and Tsai IJ and Hsiao MC and Hsiao CF and Liu CY and Shen WW and Tang HS and Fang CK and Wu CS and Lu SC and Kuo HW and Liu SC and Chan HW and Hsu YT and Tian JN and Liu YL	|	10.2217/pgs.10.128	|
|	Understanding the genetic aspects of resistance to antidepressants treatment.	|	2020	|	European review for medical and pharmacological sciences	|	24	|	14	|	7784-7795	|	Alqahtani AM and Kumarappan C and Kumar V and Srinivasan R and Krishnaraju V	|	10.26355/eurrev_202007_22281	|
|	Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.	|	2008	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	33	|	12	|	2810-9	|	Perlis RH and Moorjani P and Fagerness J and Purcell S and Trivedi MH and Fava M and Rush AJ and Smoller JW	|	10.1038/npp.2008.6	|
|	Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder.	|	2021	|	Psychopharmacology bulletin	|	51	|	4	|	87-104	|	Zastrozhin MS and Efimova AV and Skryabin V and Smirnov VV and Petukhov AE and Pankratenko EP and Pozdniakov SA and Kaverina EV and Klepikov DA and Grishina EA and Ryzhikova KA and Bure IV and Bryun EA and Sychev DA	|		|
|	Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.	|	2016	|	Frontiers in pharmacology	|	7	|		|	206	|	Ashikawa Y and Nishimura Y and Okabe S and Sasagawa S and Murakami S and Yuge M and Kawaguchi K and Kawase R and Tanaka T	|	10.3389/fphar.2016.00206	|
|	A Novel Sensitive Method to Measure Catechol-O-Methyltransferase Activity Unravels the Presence of This Activity in Extracellular Vesicles Released by Rat Hepatocytes.	|	2016	|	Frontiers in pharmacology	|	7	|		|	501	|	Casal E and Palomo L and Cabrera D and Falcon-Perez JM	|	10.3389/fphar.2016.00501	|
|	Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs.	|	2015	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	25	|	9	|	1437-47	|	Pich EM and Collo G	|	10.1016/j.euroneuro.2015.07.012	|
|	Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: a Belgian patient-control study.	|	2004	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	129	|	1	|	34-5	|	Oswald P and Del-Favero J and Massat I and Souery D and Claes S and Van Broeckhoven C and Mendlewicz J	|	10.1002/ajmg.b.30056	|
|	Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D(2) and Serotonin 1A and 2A Receptors in C. elegans.	|	2022	|	Biomedicines	|	10	|	2	|		|	Jalles A and Vieira C and Pereira-Sousa J and Vilasboas-Campos D and Mota AF and Vasconcelos S and Ferreira-Lomba B and Costa MD and Da Silva JD and Maciel P and Teixeira-Castro A	|	10.3390/biomedicines10020370	|
|	Comparative effectiveness of N95, surgical or medical, and non-medical facemasks in protection against respiratory virus infection: A systematic review and network meta-analysis.	|	2022	|	Reviews in medical virology	|	32	|	5	|	e2336	|	Kim MS and Seong D and Li H and Chung SK and Park Y and Lee M and Lee SW and Yon DK and Kim JH and Lee KH and Solmi M and Dragioti E and Koyanagi A and Jacob L and Kronbichler A and Tizaoui K and Cargnin S and Terrazzino S and Hong SH and Abou Ghayda R and Radua J and Oh H and Kostev K and Ogino S and Lee IM and Giovannucci E and Barnett Y and Butler L and McDermott D and Ilie PC and Shin JI and Smith L	|	10.1002/rmv.2336	|
|	Pharmacological treatment effects on eye movement control.	|	2008	|	Brain and cognition	|	68	|	3	|	415-35	|	Reilly JL and Lencer R and Bishop JR and Keedy S and Sweeney JA	|	10.1016/j.bandc.2008.08.026	|
|	Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome.	|	2008	|	Psychiatric genetics	|	18	|	5	|	248-51	|	Crowley JJ and Lipsky RH and Lucki I and Berrettini WH	|	10.1097/YPG.0b013e3283052ff7	|
|	Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial.	|	2020	|	Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)	|	42	|	2	|	128-135	|	Brunoni AR and Carracedo A and Amigo OM and Pellicer AL and Talib L and Carvalho AF and Lotufo PA and BenseÃ±or IM and Gattaz W and Cappi C	|	10.1590/1516-4446-2019-0620	|
|	Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.	|	2003	|	Human molecular genetics	|	12	|	3	|	205-16	|	Duan J and Wainwright MS and Comeron JM and Saitou N and Sanders AR and Gelernter J and Gejman PV	|	10.1093/hmg/ddg055	|
|	Rare disruptive variants in the DISC1 Interactome and Regulome: association with cognitive ability and schizophrenia.	|	2018	|	Molecular psychiatry	|	23	|	5	|	1270-1277	|	Teng S and Thomson PA and McCarthy S and Kramer M and Muller S and Lihm J and Morris S and Soares DC and Hennah W and Harris S and Camargo LM and Malkov V and McIntosh AM and Millar JK and Blackwood DH and Evans KL and Deary IJ and Porteous DJ and McCombie WR	|	10.1038/mp.2017.115	|
|	Genetic Variation and Autism: A Field Synopsis and Systematic Meta-Analysis.	|	2020	|	Brain sciences	|	10	|	10	|		|	Lee J and Son MJ and Son CY and Jeong GH and Lee KH and Lee KS and Ko Y and Kim JY and Lee JY and Radua J and Eisenhut M and Gressier F and Koyanagi A and Stubbs B and Solmi M and Rais TB and Kronbichler A and Dragioti E and Vasconcelos DFP and Silva FRPD and Tizaoui K and Brunoni AR and Carvalho AF and Cargnin S and Terrazzino S and Stickley A and Smith L and Thompson T and Shin JI and Fusar-Poli P	|	10.3390/brainsci10100692	|
|	More than 25 years of genetic studies of clozapine-induced agranulocytosis.	|	2017	|	The pharmacogenomics journal	|	17	|	4	|	304-311	|	de With SAJ and Pulit SL and Staal WG and Kahn RS and Ophoff RA	|	10.1038/tpj.2017.6	|
|	A genetic network model of cellular responses to lithium treatment and cocaine abuse in bipolar disorder.	|	2010	|	BMC systems biology	|	4	|		|	158	|	McEachin RC and Chen H and Sartor MA and Saccone SF and Keller BJ and Prossin AR and Cavalcoli JD and McInnis MG	|	10.1186/1752-0509-4-158	|
|	Lack of association between 5HT2A receptor gene haplotype, bipolar disorder and its clinical subtypes in a West European sample.	|	2004	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	129	|	1	|	29-33	|	Etain B and Rousseva A and Roy I and Henry C and Malafosse A and Buresi C and Preisig M and Rayah F and Leboyer M and Bellivier F	|	10.1002/ajmg.b.30055	|
|	Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.	|	2017	|	Molecular psychiatry	|	22	|	8	|	1155-1163	|	JukiÄ‡ MM and Opel N and StrÃ¶m J and Carrillo-Roa T and Miksys S and Novalen M and Renblom A and Sim SC and PeÃ±as-LledÃ³ EM and Courtet P and Llerena A and Baune BT and de Quervain DJ and Papassotiropoulos A and Tyndale RF and Binder EB and Dannlowski U and Ingelman-Sundberg M	|	10.1038/mp.2016.204	|
|	Chronic lithium treatment of B lymphoblasts from bipolar disorder patients reduces transient receptor potential channel 3 levels.	|	2004	|	The pharmacogenomics journal	|	4	|	6	|	365-73	|	Andreopoulos S and Wasserman M and Woo K and Li PP and Warsh JJ	|	10.1038/sj.tpj.6500266	|
|	Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene: A Case Report.	|	2015	|	In vivo (Athens, Greece)	|	29	|	5	|	529-31	|	Rizos E and Tournikioti K and Alevyzakis E and Peppa M and Papazaxos K and Zorbas G and Michopoulos I and Liappas I and Papageorgiou C and Douzenis A	|		|
|	Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment.	|	2016	|	International clinical psychopharmacology	|	31	|	3	|	127-33	|	Su YA and Li JT and Dai WJ and Liao XM and Dong LC and Lu TL and Bousman C and Si TM	|	10.1097/YIC.0000000000000115	|
|	Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial.	|	2019	|	Journal of affective disorders	|	245	|		|	1007-1015	|	Sarris J and Byrne GJ and Stough C and Bousman C and Mischoulon D and Murphy J and Macdonald P and Adams L and Nazareth S and Oliver G and Cribb L and Savage K and Menon R and Chamoli S and Berk M and Ng CH	|	10.1016/j.jad.2018.11.092	|
|	Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis.	|	2016	|	Psychoneuroendocrinology	|	72	|		|	10-Jan	|	Miura I and Zhang JP and Hagi K and Lencz T and Kane JM and Yabe H and Malhotra AK and Correll CU	|	10.1016/j.psyneuen.2016.06.002	|
|	CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.	|	2021	|	Frontiers in psychology	|	12	|		|	768748	|	Wannasuphoprasit Y and Andersen SE and Arranz MJ and Catalan R and Jurgens G and Kloosterboer SM and Rasmussen HB and Bhat A and Irizar H and Koller D and Polimanti R and Wang B and Zartaloudi E and Austin-Zimmerman I and Bramon E	|	10.3389/fpsyg.2021.768748	|
|	Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia.	|	2020	|	The application of clinical genetics	|	13	|		|	97-105	|	Pozhidaev IV and Boiko AS and Loonen AJM and Paderina DZ and Fedorenko OY and Tenin G and Kornetova EG and Semke AV and Bokhan NA and Wilffert B and Ivanova SA	|	10.2147/TACG.S247174	|
|	Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial.	|	2019	|	JAMA psychiatry	|	76	|	7	|	691-699	|	Brown HE and Freudenreich O and Fan X and Heard SO and Goff D and Petrides G and Harrington AL and Kane JM and Judge H and Hoeppner B and Fava M and Perlis RH	|	10.1001/jamapsychiatry.2019.0151	|
|	Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene.	|	2013	|	The pharmacogenomics journal	|	13	|	3	|	272-9	|	Chowdhury NI and Tiwari AK and Souza RP and Zai CC and Shaikh SA and Chen S and Liu F and Lieberman JA and Meltzer HY and Malhotra AK and Kennedy JL and MÃ¼ller DJ	|	10.1038/tpj.2011.66	|
|	Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.	|	2009	|	The pharmacogenomics journal	|	9	|	4	|	234-41	|	Godlewska BR and Olajossy-Hilkesberger L and Ciwoniuk M and Olajossy M and Marmurowska-MichaÅ‚owska H and Limon J and Landowski J	|	10.1038/tpj.2009.18	|
|	CYP2C9 gene and susceptibility to major depressive disorder.	|	2003	|	The pharmacogenomics journal	|	3	|	5	|	300-2	|	LLerena A and Berecz R and Dorado P and GonzÃ¡lez AP and PeÃ±as-LLedÃ³ EM and De La Rubia A	|	10.1038/sj.tpj.6500197	|
|	Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol.	|	2010	|	The pharmacogenomics journal	|	10	|	5	|	396-407	|	Kristiana I and Sharpe LJ and Catts VS and Lutze-Mann LH and Brown AJ	|	10.1038/tpj.2009.62	|
|	Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder.	|	2006	|	Psychiatric genetics	|	16	|	1	|	25-9	|	Masoliver E and Menoyo A and PÃ©rez V and Volpini V and Rio ED and PÃ©rez J and Alvarez E and Baiget M	|	10.1097/01.ypg.0000180684.26288.d7	|
|	Prediction of affective psychoses response to lithium prophylaxis. The role of socio-demographic, clinical, psychological and biological variables.	|	1984	|	Acta psychiatrica Scandinavica	|	69	|	1	|	37-44	|	Maj M and Del Vecchio M and Starace F and Pirozzi R and Kemali D	|	10.1111/j.1600-0447.1984.tb04514.x	|
|	Human GABA(B) receptor 1 gene: eight novel sequence variants.	|	2001	|	Human mutation	|	17	|	4	|	349-50	|	Hisama FM and Gruen JR and Choi J and Huseinovic M and Grigorenko EL and Pauls D and Mattson RH and Gelernter J and Wood FB and Goei VL	|	10.1002/humu.34	|
|	Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant.	|	2010	|	The pharmacogenomics journal	|	10	|	3	|	200-18	|	Hwang R and Zai C and Tiwari A and MÃ¼ller DJ and Arranz MJ and Morris AG and McKenna PJ and Munro J and Potkin SG and Lieberman JA and Meltzer HY and Kennedy JL	|	10.1038/tpj.2009.65	|
|	Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance.	|	2010	|	Journal of psychopharmacology (Oxford, England)	|	24	|	12	|	1747-54	|	Mandelli L and Mazza M and Martinotti G and Tavian D and Colombo E and Missaglia S and Di Nicola M and De Ronchi D and Negri G and Colombo R and Janiri L and Serretti A	|	10.1177/0269881109353463	|
|	Oxytocin modulation of self-referential processing is partly replicable and sensitive to oxytocin receptor genotype.	|	2020	|	Progress in neuro-psychopharmacology & biological psychiatry	|	96	|		|	109734	|	Zhao W and Luo R and Sindermann C and Li J and Wei Z and Zhang Y and Liu C and Le J and Quintana DS and Montag C and Becker B and Kendrick KM	|	10.1016/j.pnpbp.2019.109734	|
|	A Bibliometric Analysis of Scientific Production on Second-Generation Anti-Psychotic Drugs in Malaysia.	|	2018	|	The Malaysian journal of medical sciences : MJMS	|	25	|	3	|	40-55	|	LÃ³pez-MuÃ±oz F and Povedano-Montero FJ and Chee KY and Shen WW and FernÃ¡ndez-MartÃ­n P and GarcÃ­a-Pacios J and Rubio G and Ãlamo C	|	10.21315/mjms2018.25.3.5	|
|	Identifying the Common Genetic Basis of Antidepressant Response.	|	2022	|	Biological psychiatry global open science	|	2	|	2	|	115-126	|	Pain O and Hodgson K and Trubetskoy V and Ripke S and Marshe VS and Adams MJ and Byrne EM and Campos AI and Carrillo-Roa T and Cattaneo A and Als TD and Souery D and Dernovsek MZ and Fabbri C and Hayward C and Henigsberg N and Hauser J and Kennedy JL and Lenze EJ and Lewis G and MÃ¼ller DJ and Martin NG and Mulsant BH and Mors O and Perroud N and Porteous DJ and RenterÃ­a ME and Reynolds CF 3rd and Rietschel M and Uher R and Wigmore EM and Maier W and Wray NR and Aitchison KJ and Arolt V and Baune BT and Biernacka JM and Bondolfi G and Domschke K and Kato M and Li QS and Liu YL and Serretti A and Tsai SJ and Turecki G and Weinshilboum R and McIntosh AM and Lewis CM	|	10.1016/j.bpsgos.2021.07.008	|
|	Association of dopamine receptor D1 (DRD1) polymorphisms with risperidone treatment response in Chinese schizophrenia patients.	|	2015	|	Neuroscience letters	|	584	|		|	178-83	|	Huo R and Wei Z and Xiong Y and Jiang J and Liu Y and Yan Y and Shi J and Li W and Cui D and Xing Q and He L and Qin S	|	10.1016/j.neulet.2014.08.041	|
|	DNA methylation and clinical response to antidepressant medication in major depressive disorder: A review and recommendations.	|	2018	|	Neuroscience letters	|	669	|		|	14-23	|	Lisoway AJ and Zai CC and Tiwari AK and Kennedy JL	|	10.1016/j.neulet.2016.12.071	|
|	Analysis of the effects of depression associated polymorphisms on the activity of the BICC1 promoter in amygdala neurones.	|	2016	|	The pharmacogenomics journal	|	16	|	4	|	366-74	|	Davidson S and Shanley L and Cowie P and Lear M and McGuffin P and Quinn JP and Barrett P and MacKenzie A	|	10.1038/tpj.2015.62	|
|	Vitamin D Supplementation Ameliorates Severity of Major Depressive Disorder.	|	2020	|	Journal of molecular neuroscience : MN	|	70	|	2	|	230-235	|	Alghamdi S and Alsulami N and Khoja S and Alsufiani H and Tayeb HO and Tarazi FI	|	10.1007/s12031-019-01461-2	|
|	Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?	|	2005	|	The pharmacogenomics journal	|	5	|	5	|	298-304	|	FernÃ¸ J and Raeder MB and Vik-Mo AO and Skrede S and Glambek M and Tronstad KJ and Breilid H and LÃ¸vlie R and Berge RK and Stansberg C and Steen VM	|	10.1038/sj.tpj.6500323	|
|	Genome-wide association study of suicidal behaviour severity in mood disorders.	|	2021	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|	22	|	9	|	722-731	|	Zai CC and Fabbri C and Hosang GM and Zhang RS and Koyama E and de Luca V and Tiwari AK and King N and Strauss J and Jones I and Jones L and Breen G and Farmer AE and McGuffin P and Vincent JB and Kennedy JL and Lewis CM	|	10.1080/15622975.2021.1907711	|
|	Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling.	|	2012	|	The pharmacogenomics journal	|	12	|	4	|	328-41	|	Gupta A and Schulze TG and Nagarajan V and Akula N and Corona W and Jiang XY and Hunter N and McMahon FJ and Detera-Wadleigh SD	|	10.1038/tpj.2011.9	|
|	[Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].	|	2003	|	Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese           journal of medical genetics	|	20	|	2	|	98-102	|	Zhang Z and Hou G and Zhang X and Yao H and Sha W and Zhang X	|		|
|	Impact of subjective vs. objective remission status on subjective cognitive impairments in depression.	|	2019	|	Journal of affective disorders	|	246	|		|	99-104	|	Sawada K and Yoshida K and Ozawa C and Mizuno Y and Rubinstein EB and Suzuki T and Mimura M and Uchida H	|	10.1016/j.jad.2018.12.049	|
|	Fatal intoxication with antidepressants: a case with many culprits.	|	2018	|	Forensic science, medicine, and pathology	|	14	|	2	|	225-228	|	Goulas A and Raikos N and Krokos D and Mastrogianni O and Orphanidis A and Zisopoulos K and Tsepa A	|	10.1007/s12024-018-9960-3	|
|	Genetics in neural toxicities of drugs.	|	2012	|	Central nervous system agents in medicinal chemistry	|	12	|	4	|	250-3	|	Lu DY and Lu TR and Zhu PP	|	10.2174/187152412803760591	|
|	Gene-Based Association Analysis Suggests Association of HTR2A With Antidepressant Treatment Response in Depressed Patients.	|	2020	|	Frontiers in pharmacology	|	11	|		|	559601	|	Kao CF and Kuo PH and Yu YW and Yang AC and Lin E and Liu YL and Tsai SJ	|	10.3389/fphar.2020.559601	|
|	Clinical factors associated with lithium treatment response in bipolar disorder patients from India.	|	2019	|	Asian journal of psychiatry	|	39	|		|	165-168	|	Kapur V and Nadella RK and Sathur Raghuraman B and Saraf G and Mishra S and Srinivasmurthy N and Jain S and Del Zompo M and Viswanath B	|	10.1016/j.ajp.2018.04.006	|
|	267 Spanish Exomes Reveal Population-Specific Differences in Disease-Related Genetic Variation.	|	2016	|	Molecular biology and evolution	|	33	|	5	|	1205-18	|	Dopazo J and Amadoz A and Bleda M and Garcia-Alonso L and AlemÃ¡n A and GarcÃ­a-GarcÃ­a F and Rodriguez JA and Daub JT and MuntanÃ© G and Rueda A and Vela-Boza A and LÃ³pez-Domingo FJ and Florido JP and Arce P and Ruiz-Ferrer M and MÃ©ndez-Vidal C and Arnold TE and Spleiss O and Alvarez-Tejado M and Navarro A and Bhattacharya SS and Borrego S and Santoyo-LÃ³pez J and AntiÃ±olo G	|	10.1093/molbev/msw005	|
|	Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.	|	2011	|	The pharmacogenomics journal	|	11	|	1	|	35-44	|	Kuzman MR and Medved V and Bozina N and GrubiÅ¡in J and Jovanovic N and Sertic J	|	10.1038/tpj.2010.7	|
|	Cytochrome P450 2D6 genotype variation and venlafaxine dosage.	|	2007	|	Mayo Clinic proceedings	|	82	|	9	|	1065-8	|	McAlpine DE and O'Kane DJ and Black JL and Mrazek DA	|	10.4065/82.9.1065	|
|	Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia.	|	2019	|	Pharmacogenomics and personalized medicine	|	12	|		|	155-166	|	Puangpetch A and Srisawasdi P and Unaharassamee W and Jiratjintana N and Vanavanan S and Punprasit S and Na Nakorn C and Sukasem C and Kroll MH	|	10.2147/PGPM.S210770	|
|	Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population.	|	2010	|	Human psychopharmacology	|	25	|	6	|	481-6	|	Kishi T and Fukuo Y and Yoshimura R and Okochi T and Kitajima T and Naitoh H and Umene-Nakano W and Nakamura J and Ozaki N and Iwata N	|	10.1002/hup.1142	|
|	Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression.	|	2016	|	Translational psychiatry	|	6	|	5	|	e799	|	Williams LM and Debattista C and Duchemin AM and Schatzberg AF and Nemeroff CB	|	10.1038/tp.2016.61	|
|	Integration of genetic, transcriptomic, and clinical data provides insight into 16p11.2 and 22q11.2 CNV genes.	|	2021	|	Genome medicine	|	13	|	1	|	172	|	Vysotskiy M and Zhong X and Miller-Fleming TW and Zhou D and Cox NJ and Weiss LA	|	10.1186/s13073-021-00972-1	|
|	Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.	|	2020	|	The pharmacogenomics journal	|	20	|	2	|	192-201	|	Lesche D and Mostafa S and Everall I and Pantelis C and Bousman CA	|	10.1038/s41397-019-0108-y	|
|	Toward the delineation of mania subtypes in the French National EPIMAN-II Mille Cohort. Comparisons with prior cluster analytic investigations.	|	2008	|	European archives of psychiatry and clinical neuroscience	|	258	|	8	|	497-504	|	Azorin JM and Kaladjian A and Adida M and Hantouche E and Hameg A and Lancrenon S and Akiskal HS	|	10.1007/s00406-008-0823-x	|
|	Contribution of common genetic variants to antidepressant response.	|	2013	|	Biological psychiatry	|	73	|	7	|	679-82	|	Tansey KE and Guipponi M and Hu X and Domenici E and Lewis G and Malafosse A and Wendland JR and Lewis CM and McGuffin P and Uher R	|	10.1016/j.biopsych.2012.10.030	|
|	A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia.	|	2019	|	Molecular psychiatry	|	24	|	3	|	328-337	|	Legge SE and PardiÃ±as AF and Helthuis M and Jansen JA and Jollie K and Knapper S and MacCabe JH and Rujescu D and Collier DA and O'Donovan MC and Owen MJ and Walters JTR	|	10.1038/s41380-018-0335-7	|
|	Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder.	|	2017	|	The Journal of clinical psychiatry	|	78	|	6	|	703-713	|	McIntyre RS and Suppes T and Tandon R and Ostacher M	|	10.4088/JCP.16cs10885	|
|	Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis.	|	2020	|	Journal of clinical medicine	|	9	|	8	|		|	Lee KH and Yoon S and Jeong GH and Kim JY and Han YJ and Hong SH and Ryu S and Kim JS and Lee JY and Yang JW and Lee J and Solmi M and Koyanagi A and Dragioti E and Jacob L and Radua J and Smith L and Oh H and Tizaoui K and Cargnin S and Terrazzino S and Ghayda RA and Kronbichler A and Shin JI	|	10.3390/jcm9082392	|
|	Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients.	|	2021	|	Pharmacogenomics and personalized medicine	|	14	|		|	1123-1131	|	Boiko AS and Pozhidaev IV and Paderina DZ and Bocharova AV and Mednova IA and Fedorenko OY and Kornetova EG and Loonen AJM and Semke AV and Bokhan NA and Ivanova SA	|	10.2147/PGPM.S327353	|
|	Genome-wide association study of antipsychotic-induced QTc interval prolongation.	|	2012	|	The pharmacogenomics journal	|	12	|	2	|	165-72	|	Aberg K and Adkins DE and Liu Y and McClay JL and BukszÃ¡r J and Jia P and Zhao Z and Perkins D and Stroup TS and Lieberman JA and Sullivan PF and van den Oord EJ	|	10.1038/tpj.2010.76	|
|	Genome-wide association study of paliperidone efficacy.	|	2017	|	Pharmacogenetics and genomics	|	27	|	1	|	18-Jul	|	Li Q and Wineinger NE and Fu DJ and Libiger O and Alphs L and Savitz A and Gopal S and Cohen N and Schork NJ	|	10.1097/FPC.0000000000000250	|
|	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.	|	2018	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	28	|	8	|	945-954	|	Fabbri C and Tansey KE and Perlis RH and Hauser J and Henigsberg N and Maier W and Mors O and Placentino A and Rietschel M and Souery D and Breen G and Curtis C and Lee SH and Newhouse S and Patel H and O'Donovan M and Lewis G and Jenkins G and Weinshilboum RM and Farmer A and Aitchison KJ and Craig I and McGuffin P and Schruers K and Biernacka JM and Uher R and Lewis CM	|	10.1016/j.euroneuro.2018.05.009	|
|	Gene-based analysis of genes related to neurotrophic pathway suggests association of BDNF and VEGFA with antidepressant treatment-response in depressed patients.	|	2018	|	Scientific reports	|	8	|	1	|	6983	|	Kao CF and Liu YL and Yu YW and Yang AC and Lin E and Kuo PH and Tsai SJ	|	10.1038/s41598-018-25529-y	|
|	Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression.	|	2021	|	Therapeutic drug monitoring	|	43	|	3	|	436-442	|	Baumann P and Bertschy G and Ramseier F and Nil R	|	10.1097/FTD.0000000000000824	|
|	D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.	|	2010	|	The American journal of psychiatry	|	167	|	7	|	763-72	|	Zhang JP and Lencz T and Malhotra AK	|	10.1176/appi.ajp.2009.09040598	|
|	Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder.	|	2013	|	The pharmacogenomics journal	|	13	|	4	|	354-8	|	Sasayama D and Hiraishi A and Tatsumi M and Kamijima K and Ikeda M and Umene-Nakano W and Yoshimura R and Nakamura J and Iwata N and Kunugi H	|	10.1038/tpj.2012.18	|
|	Association of PDE11A global haplotype with major depression and antidepressant drug response.	|	2009	|	Neuropsychiatric disease and treatment	|	5	|		|	163-70	|	Luo HR and Wu GS and Dong C and Arcos-Burgos M and Ribeiro L and Licinio J and Wong ML	|	10.2147/ndt.s4771	|
|	Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region.	|	2009	|	The pharmacogenomics journal	|	9	|	2	|	103-10	|	Greenbaum L and Smith RC and Rigbi A and Strous R and Teltsh O and Kanyas K and Korner M and Lancet D and Ben-Asher E and Lerer B	|	10.1038/tpj.2008.6	|
|	Identification of novel therapeutics for complex diseases from genome-wide association data.	|	2014	|	BMC medical genomics	|	7	|		|	S8	|	Grover MP and Ballouz S and Mohanasundaram KA and George RA and Sherman CD and Crowley TM and Wouters MA	|	10.1186/1755-8794-7-S1-S8	|
|	Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants.	|	2006	|	Psychiatric genetics	|	16	|	4	|	153-8	|	Smeraldi E and Serretti A and Artioli P and Lorenzi C and Catalano M	|	10.1097/01.ypg.0000218611.53064.a0	|
|	Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.	|	2004	|	The pharmacogenomics journal	|	4	|	4	|	267-73	|	Serretti A and Malitas PN and Mandelli L and Lorenzi C and Ploia C and Alevizos B and Nikolaou C and Boufidou F and Christodoulou GN and Smeraldi E	|	10.1038/sj.tpj.6500252	|
|	Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial.	|	2020	|	BJPsych open	|	6	|	6	|	e126	|	Dai M and Wu Y and Tang Y and Yue W and Yan H and Zhang Y and Tan L and Deng W and Chen Q and Yang G and Lu T and Wang L and Yang F and Zhang F and Yang J and Li K and Lv L and Tan Q and Zhang H and Ma X and Li L and Wang C and Ma X and Zhang D and Yu H and Zhao L and Ren H and Wang Y and Hu X and Zhang G and Du X and Wang Q and Li T	|	10.1192/bjo.2020.105	|
|	Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.	|	2012	|	Archives of general psychiatry	|	69	|	9	|	904-12	|	Malhotra AK and Correll CU and Chowdhury NI and MÃ¼ller DJ and Gregersen PK and Lee AT and Tiwari AK and Kane JM and Fleischhacker WW and Kahn RS and Ophoff RA and Meltzer HY and Lencz T and Kennedy JL	|	10.1001/archgenpsychiatry.2012.191	|
|	GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.	|	2019	|	Medicine	|	98	|	19	|	e15456	|	Sun Q and Yuan F and Yuan R and Ren D and Zhu Y and Bi Y and Hu J and Guo Z and Xu F and Niu W and Ma G and Wu X and Yang F and Wang L and Li X and Yu T and He L and He G	|	10.1097/MD.0000000000015456	|
|	Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.	|	2016	|	CNS drugs	|	30	|	10	|	931-49	|	Malhi GS and Outhred T	|	10.1007/s40263-016-0380-1	|
|	Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.	|	2022	|	The lancet. Psychiatry	|	9	|	1	|	46-58	|	Bugarski-Kirola D and Arango C and Fava M and Nasrallah H and Liu IY and Abbs B and Stankovic S	|	10.1016/S2215-0366(21)00386-2	|
|	Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS).	|	2014	|	The pharmacogenomics journal	|	14	|	2	|	182-91	|	Beech RD and Leffert JJ and Lin A and Sylvia LG and Umlauf S and Mane S and Zhao H and Bowden C and Calabrese JR and Friedman ES and Ketter TA and Iosifescu DV and Reilly-Harrington NA and Ostacher M and Thase ME and Nierenberg A	|	10.1038/tpj.2013.16	|
|	Preliminary examination of microRNA expression profiling in bipolar disorder I patients during antipsychotic treatment.	|	2016	|	American journal of medical genetics. Part B, Neuropsychiatric genetics : the           official publication of the International Society of Psychiatric Genetics	|	171	|	6	|	867-74	|	Lim CH and Zainal NZ and Kanagasundram S and Zain SM and Mohamed Z	|	10.1002/ajmg.b.32457	|
|	cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects.	|	2006	|	The pharmacogenomics journal	|	6	|	2	|	131-40	|	Sondhi S and Castellano JM and Chong VZ and Rogoza RM and Skoblenick KJ and Dyck BA and Gabriele J and Thomas N and Ki K and Pristupa ZB and Singh AN and MacCrimmon D and Voruganti P and Foster J and Mishra RK	|	10.1038/sj.tpj.6500346	|
|	The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.	|	2018	|	The pharmacogenomics journal	|	18	|	3	|	422-430	|	Rafaniello C and Sessa M and Bernardi FF and Pozzi M and Cheli S and Cattaneo D and Baldelli S and Molteni M and Bernardini R and Rossi F and Clementi E and Bravaccio C and Radice S and Capuano A	|	10.1038/tpj.2017.38	|
|	Down-regulation of cholinergic signaling in the habenula induces anhedonia-like behavior.	|	2017	|	Scientific reports	|	7	|	1	|	900	|	Han S and Yang SH and Kim JY and Mo S and Yang E and Song KM and Ham BJ and Mechawar N and Turecki G and Lee HW and Kim H	|	10.1038/s41598-017-01088-6	|
|	Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients.	|	2021	|	European journal of clinical pharmacology	|	77	|	2	|	215-221	|	Tveito M and Smith RL and Molden E and HÃ¸iseth G	|	10.1007/s00228-020-03002-y	|
|	Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.	|	2021	|	The pharmacogenomics journal	|	21	|	5	|	551-558	|	Ammar H and Chadli Z and Mhalla A and Khouadja S and Hannachi I and Alshaikheid M and Slama A and Ben Fredj N and Ben Fadhel N and Ben Romdhane H and Chaabane A and Boughattas NA and Gaha L and Zarrouk L and Aouam K	|	10.1038/s41397-021-00231-x	|
|	Druggable Transcriptional Networks in the Human Neurogenic Epigenome.	|	2019	|	Pharmacological reviews	|	71	|	4	|	520-538	|	Higgins GA and Williams AM and Ade AS and Alam HB and Athey BD	|	10.1124/pr.119.017681	|
|	Analysis of the association of MIR124-1 and its target gene RGS4 polymorphisms with major depressive disorder and antidepressant response.	|	2018	|	Neuropsychiatric disease and treatment	|	14	|		|	715-723	|	Zeng D and He S and Yu S and Li G and Ma C and Wen Y and Shen Y and Yu Y and Li H	|	10.2147/NDT.S155076	|
|	Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice.	|	2012	|	The pharmacogenomics journal	|	12	|	2	|	147-55	|	Crowley JJ and Adkins DE and Pratt AL and Quackenbush CR and van den Oord EJ and Moy SS and Wilhelmsen KC and Cooper TB and Bogue MA and McLeod HL and Sullivan PF	|	10.1038/tpj.2010.82	|
|	Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder.	|	2014	|	Journal of clinical psychopharmacology	|	34	|	4	|	446-54	|	Chang HS and Lee HY and Cha JH and Won ES and Ham BJ and Kim B and Lee MS	|	10.1097/JCP.0000000000000143	|
|	Whole-genome sequencing analysis of clozapine-induced myocarditis.	|	2022	|	The pharmacogenomics journal	|	22	|	3	|	173-179	|	Narang A and Lacaze P and Ronaldson KJ and McNeil JJ and Jayaram M and Thomas N and Sellmer R and Crockford DN and Stowe R and Greenway SC and Pantelis C and Bousman CA	|	10.1038/s41397-022-00271-x	|
|	Gene expression analysis of MAOA and the clock gene ARNTL in individuals with bipolar disorder compared to healthy controls.	|	2021	|	The world journal of biological psychiatry : the official journal of the World           Federation of Societies of Biological Psychiatry	|		|		|	8-Jan	|	Bengesser SA and Hohenberger H and Tropper B and Dalkner N and Birner A and Fellendorf FT and Platzer M and Rieger A and Maget A and Hamm C and Queissner R and Pilz R and Bauer K and Lenger M and MÃ¶rkl S and Wagner-Skacel J and Kapfhammer HP and Meier-Allard N and Stracke A and Holasek SJ and Murphy L and Reininghaus EZ	|	10.1080/15622975.2021.1973816	|
|	High impact child abuse may predict risk of elevated suicidality during antidepressant initiation.	|	2013	|	The Australian and New Zealand journal of psychiatry	|	47	|	12	|	1191-5	|	Singh AB and Bousman CA and Ng CH and Berk M	|	10.1177/0004867413510212	|
|	Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients.	|	2009	|	Journal of affective disorders	|	113	|	1	|	183-7	|	Tsai SJ and Gau YT and Hong CJ and Liou YJ and Yu YW and Chen TJ	|	10.1016/j.jad.2008.04.017	|
|	Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram.	|	2005	|	Neuropsychobiology	|	52	|	3	|	155-62	|	Choi MJ and Kang RH and Ham BJ and Jeong HY and Lee MS	|	10.1159/000087847	|
|	Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania.	|	2015	|	The Journal of clinical psychiatry	|	76	|	2	|	174-80	|	Frye MA and McElroy SL and Prieto ML and Harper KL and Walker DL and Kung S and Chauhan M and Crow S and Sutor B and Galardy CW and Veldic M and Palmer BA and Geske JR and Fuentes M and Cuellar-Barboza AB and Seymour LR and Mori N and Biernacka JM	|	10.4088/JCP.14m09127	|
|	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.	|	2018	|	Translational psychiatry	|	8	|	1	|	280	|	Guo W and Machado-Vieira R and Mathew S and Murrough JW and Charney DS and Grunebaum M and Oquendo MA and Kadriu B and Akula N and Henter I and Yuan P and Merikangas K and Drevets W and Furey M and Mann JJ and McMahon FJ and Zarate CA Jr and Shugart YY	|	10.1038/s41398-018-0311-7	|
|	Serotonin transporter promoter polymorphism in African Americans : allele frequencies and implications for treatment.	|	2003	|	American journal of pharmacogenomics : genomics-related research in drug           development and clinical practice	|	3	|	2	|	145-7	|	Lotrich FE and Pollock BG and Ferrell RE	|	10.2165/00129785-200303020-00007	|
|	Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism.	|	2003	|	The pharmacogenomics journal	|	3	|	2	|	101-4	|	Rousseva A and Henry C and van den Bulke D and Fournier G and Laplanche JL and Leboyer M and Bellivier F and Aubry JM and Baud P and Boucherie M and Buresi C and Ferrero F and Malafosse A	|	10.1038/sj.tpj.6500156	|
|	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.	|	2014	|	Journal of affective disorders	|	168	|		|	91-7	|	Arias B and Fabbri C and Serretti A and Drago A and Mitjans M and GastÃ³ C and CatalÃ¡n R and FaÃ±anÃ¡s L	|	10.1016/j.jad.2014.06.048	|
|	Gender-specific effects of comorbid depression and anxiety on the propensity to drink in negative emotional states.	|	2016	|	Addiction (Abingdon, England)	|	111	|	8	|	1366-75	|	Karpyak VM and Biernacka JM and Geske JR and Abulseoud OA and Brunner MD and Chauhan M and Hall-Flavin DK and Lewis KA and Loukianova LL and Melnyk GJ and Onsrud DA and Proctor BD and Schneekloth TD and Skime MK and Wittkopp JE and Frye MA and Mrazek DA	|	10.1111/add.13386	|
|	The prototypic antidepressant drug, imipramine, but not Hypericum perforatum (St. John's Wort), reduces HPA-axis function in the rat.	|	2003	|	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et           metabolisme	|	35	|	10	|	602-6	|	Frost P and Bornstein S and Ehrhart-Bornstein M and O'Kirwan F and Hutson C and Heber D and Go V and Licinio J and Wong ML	|	10.1055/s-2003-43507	|
|	[Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression].	|	2008	|	Psychiatria polska	|	42	|	6	|	915-23	|	Rajewska-Rager A and SkibiÅ„ska M and Szczepankiewicz A and Kapelski P and Dmitrzak-Weglarz M and LeszczyÅ„ska-Rodziewicz A and Hauser J	|		|
|	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.	|	2021	|	Translational psychiatry	|	11	|	1	|	153	|	MahmoudianDehkordi S and Ahmed AT and Bhattacharyya S and Han X and Baillie RA and Arnold M and Skime MK and John-Williams LS and Moseley MA and Thompson JW and Louie G and Riva-Posse P and Craighead WE and McDonald W and Krishnan R and Rush AJ and Frye MA and Dunlop BW and Weinshilboum RM and Kaddurah-Daouk R	|	10.1038/s41398-020-01097-6	|
|	Analysis of 34 candidate genes in bupropion and placebo remission.	|	2013	|	The international journal of neuropsychopharmacology	|	16	|	4	|	771-81	|	Tiwari AK and Zai CC and Sajeev G and Arenovich T and MÃ¼ller DJ and Kennedy JL	|	10.1017/S1461145712000843	|
|	[Association between polymorphisms of ins/del in the 5-HTT gene and T102C in the 5HTR2A gene and the drug response for escitalopram and nortriptyline in depressed patients].	|	2008	|	Psychiatria polska	|	42	|	6	|	903-14	|	Rajewska-Rager A and Dmitrzak-Weglarz M and Kapelski P and SkibiÅ„ska M and Kaczmarkiewicz-Fass M and Hauser J	|		|
|	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project.	|	2012	|	The pharmacogenomics journal	|	12	|	1	|	68-77	|	Perroud N and Uher R and Ng MY and Guipponi M and Hauser J and Henigsberg N and Maier W and Mors O and Gennarelli M and Rietschel M and Souery D and Dernovsek MZ and Stamp AS and Lathrop M and Farmer A and Breen G and Aitchison KJ and Lewis CM and Craig IW and McGuffin P	|	10.1038/tpj.2010.70	|
|	Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects.	|	2008	|	Journal of neural transmission (Vienna, Austria : 1996)	|	115	|	8	|	1213-9	|	Gorlyn M and Keilp JG and Grunebaum MF and Taylor BP and Oquendo MA and Bruder GE and Stewart JW and Zalsman G and Mann JJ	|	10.1007/s00702-008-0084-x	|
|	Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone.	|	2021	|	BMC psychiatry	|	21	|	1	|	70	|	Lu J and Yang Y and Lu J and Wang Z and He Y and Yan Y and Fu K and Jiang W and Xu Y and Wu R and Liu W and Zhao J	|	10.1186/s12888-020-03034-9	|
|	Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.	|	2020	|	The Journal of clinical psychiatry	|	81	|	3	|		|	Zhang Y and Wang Q and Reynolds GP and Yue W and Deng W and Yan H and Tan L and Wang C and Yang G and Lu T and Wang L and Zhang F and Yang J and Li K and Lv L and Tan Q and Li Y and Yu H and Zhang H and Ma X and Yang F and Li L and Chen Q and Wei W and Zhao L and Wang H and Li X and Guo W and Hu X and Tian Y and Ren H and Ma X and Coid J and Zhang D and Li T	|	10.4088/JCP.19m12785	|
|	Psychiatric Genomics: An Update and an Agenda.	|	2018	|	The American journal of psychiatry	|	175	|	1	|	15-27	|	Sullivan PF and Agrawal A and Bulik CM and Andreassen OA and BÃ¸rglum AD and Breen G and Cichon S and Edenberg HJ and Faraone SV and Gelernter J and Mathews CA and Nievergelt CM and Smoller JW and O'Donovan MC	|	10.1176/appi.ajp.2017.17030283	|
|	Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.	|	2016	|	Pharmacogenetics and genomics	|	26	|	9	|	403-13	|	Nishimura M and Ueda M and Saruwatari J and Nakashima H and Ogusu N and Aoki A and Tsuchimine S and Matsuda K and Iwashita K and Ono T and Oniki K and Shimoda K and Yasui-Furukori N	|	10.1097/FPC.0000000000000228	|
|	Visualizing Patterns of Medication Switching Among Major Depressive Patients with Various Stability and Difficulty to Treatments.	|	2021	|	Neuropsychiatric disease and treatment	|	17	|		|	1953-1963	|	Hung YC and Chen HC and Kuo PH and Lu ML and Huang MC and Chen CH and Wang S and Mao WC and Wu CS and Wu TH	|	10.2147/NDT.S311429	|
|	Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder.	|	2021	|	The pharmacogenomics journal	|	21	|	4	|	498-509	|	Badamasi IM and Lye MS and Ibrahim N and Abdul Razaq NA and Ling KH and Stanslas J	|	10.1038/s41397-021-00228-6	|
|	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.	|	2020	|	Journal of affective disorders	|	264	|		|	90-97	|	Ahmed AT and MahmoudianDehkordi S and Bhattacharyya S and Arnold M and Liu D and Neavin D and Moseley MA and Thompson JW and Williams LSJ and Louie G and Skime MK and Wang L and Riva-Posse P and McDonald WM and Bobo WV and Craighead WE and Krishnan R and Weinshilboum RM and Dunlop BW and Millington DS and Rush AJ and Frye MA and Kaddurah-Daouk R	|	10.1016/j.jad.2019.11.122	|
|	Association between 5HT2A polymorphism and selective serotonin re-uptake inhibitor (SSRI)-induced sexual desire disorder (SDD) among Malaysian women.	|	2013	|	Asia-Pacific psychiatry : official journal of the Pacific Rim College of           Psychiatrists	|	5	|		|	41-9	|	Masiran R and Sidi H and Mohamed Z and Mohamed Saini S and Nik Jaafar NR	|	10.1111/appy.12043	|
|	Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder.	|	2016	|	Translational psychiatry	|	6	|	5	|	e810	|	Young CB and Chen T and Nusslock R and Keller J and Schatzberg AF and Menon V	|	10.1038/tp.2016.80	|
|	Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.	|	2014	|	Journal of clinical psychopharmacology	|	34	|	3	|	318-26	|	BlÃ¡zquez A and Mas S and Plana MT and GassÃ³ P and MÃ©ndez I and Torra M and Arnaiz JA and Lafuente A and LÃ¡zaro L	|	10.1097/JCP.0000000000000121	|
|	Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial.	|	2017	|	Bipolar disorders	|	19	|	6	|	477-486	|	Tunbridge EM and Attenburrow MJ and Gardiner A and Rendell JM and Hinds C and Goodwin GM and Harrison PJ and Geddes JR	|	10.1111/bdi.12531	|
|	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.	|	2022	|	JAMA psychiatry	|	79	|	3	|	260-269	|	PardiÃ±as AF and Smart SE and Willcocks IR and Holmans PA and Dennison CA and Lynham AJ and Legge SE and Baune BT and Bigdeli TB and Cairns MJ and Corvin A and Fanous AH and Frank J and Kelly B and McQuillin A and Melle I and Mortensen PB and Mowry BJ and Pato CN and Periyasamy S and Rietschel M and Rujescu D and Simonsen C and St Clair D and Tooney P and Wu JQ and Andreassen OA and Kowalec K and Sullivan PF and Murray RM and Owen MJ and MacCabe JH and O'Donovan MC and Walters JTR and Ajnakina O and Alameda L and Barnes TRE and Berardi D and Bonora E and Camporesi S and Cleusix M and Conus P and Crespo-Facorro B and D'Andrea G and Demjaha A and Do KQ and Doody GA and Eap CB and Ferchiou A and Di Forti M and Guidi L and Homman L and Jenni R and Joyce EM and Kassoumeri L and Khadimallah I and Lastrina O and Muratori R and Noyan H and O'Neill FA and Pignon B and Restellini R and Richard JR and SchÃ¼rhoff F and Å paniel F and SzÃ¶ke A and Tarricone I and Tortelli A and ÃœÃ§ok A and VÃ¡zquez-Bourgon J	|	10.1001/jamapsychiatry.2021.3799	|
|	CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.	|	2012	|	Journal of psychopharmacology (Oxford, England)	|	26	|	3	|	398-407	|	Huezo-Diaz P and Perroud N and Spencer EP and Smith R and Sim S and Virding S and Uher R and Gunasinghe C and Gray J and Campbell D and Hauser J and Maier W and Marusic A and Rietschel M and Perez J and Giovannini C and Mors O and Mendlewicz J and McGuffin P and Farmer AE and Ingelman-Sundberg M and Craig IW and Aitchison KJ	|	10.1177/0269881111414451	|
|	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study.	|	2019	|	Translational psychiatry	|	9	|	1	|	64	|	Meyer BM and Rabl U and Huemer J and Bartova L and Kalcher K and Provenzano J and Brandner C and Sezen P and Kasper S and Schatzberg AF and Moser E and Chen G and Pezawas L	|	10.1038/s41398-019-0395-8	|
|	Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.	|	2006	|	JAMA	|	296	|	13	|	1609-18	|	Kim H and Lim SW and Kim S and Kim JW and Chang YH and Carroll BJ and Kim DK	|	10.1001/jama.296.13.1609	|
|	Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis.	|	2022	|	Journal of affective disorders	|	304	|		|	59-65	|	Zhou Y and Zhang Z and Wang C and Lan X and Li W and Zhang M and Lao G and Wu K and Chen J and Li G and Ning Y	|	10.1016/j.jad.2022.02.029	|
|	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression.	|	2021	|	Journal of affective disorders	|	279	|		|	722-729	|	Fabbri C and Kasper S and Zohar J and Souery D and Montgomery S and Albani D and Forloni G and Ferentinos P and Rujescu D and Mendlewicz J and Serretti A and Lewis CM	|	10.1016/j.jad.2020.10.049	|
|	Preliminary study of structural magnetic resonance imaging phenotypes related to genetic variation in Interleukin-1Î² rs16944 in adolescents with Bipolar Disorder.	|	2020	|	Journal of psychiatric research	|	122	|		|	33-41	|	Shonibare DO and Patel R and Islam AH and Metcalfe AWS and Fiksenbaum L and Kennedy JL and Freeman N and MacIntosh BJ and Goldstein BI	|	10.1016/j.jpsychires.2019.12.018	|
|	Personalized medicine in Alzheimer's disease and depression.	|	2013	|	Contemporary clinical trials	|	36	|	2	|	616-23	|	Souslova T and Marple TC and Spiekerman AM and Mohammad AA	|	10.1016/j.cct.2013.06.012	|
|	Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients.	|	2019	|	Journal of affective disorders	|	259	|		|	432-439	|	Ochi T and Vyalova NM and Losenkov IS and Levchuk LA and Osmanova DZ and Mikhalitskaya EV and Loonen AJM and Bosker FJ and Simutkin GG and Bokhan NA and Wilffert B and Ivanova SA	|	10.1016/j.jad.2019.08.058	|
|	Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.	|	2021	|	Progress in neuro-psychopharmacology & biological psychiatry	|	104	|		|	110036	|	Bi Y and Ren D and Guo Z and Ma G and Xu F and Chen Z and An L and Zhang N and Ji L and Yuan F and Liu L and Hou B and Yang F and Yu S and Yi Z and Xu Y and He L and Sun X and Dong Z and Wu S and Zhao L and Cai C and Li X and Yu T and Shi Y and He G	|	10.1016/j.pnpbp.2020.110036	|
|	Co-Variation of Peripheral Levels of miR-1202 and Brain Activity and Connectivity During Antidepressant Treatment.	|	2017	|	Neuropsychopharmacology : official publication of the American College of           Neuropsychopharmacology	|	42	|	10	|	2043-2051	|	Lopez JP and Pereira F and Richard-Devantoy S and Berlim M and Chachamovich E and Fiori LM and Niola P and Turecki G and Jollant F	|	10.1038/npp.2017.9	|
|	A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.	|	2007	|	The pharmacogenomics journal	|	7	|	1	|	48-55	|	Kirchheiner J and Nickchen K and Sasse J and Bauer M and Roots I and BrockmÃ¶ller J	|	10.1038/sj.tpj.6500398	|
|	Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.	|	2010	|	Archives of general psychiatry	|	67	|	4	|	369-79	|	Binder EB and Owens MJ and Liu W and Deveau TC and Rush AJ and Trivedi MH and Fava M and Bradley B and Ressler KJ and Nemeroff CB	|	10.1001/archgenpsychiatry.2010.18	|
|	Elevated stress-hemoconcentration in major depression is normalized by antidepressant treatment: secondary analysis from a randomized, double-blind clinical trial and relevance to cardiovascular disease risk.	|	2008	|	PloS one	|	3	|	7	|	e2350	|	Wong ML and Dong C and Esposito K and Thakur S and Liu W and Elashoff RM and Licinio J	|	10.1371/journal.pone.0002350	|
|	Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors.	|	2012	|	Molecular psychiatry	|	17	|	6	|	624-33	|	Wong ML and Dong C and Andreev V and Arcos-Burgos M and Licinio J	|	10.1038/mp.2012.13	|
|	Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression.	|	2021	|	The pharmacogenomics journal	|	21	|	1	|	85-93	|	Shoaib M and Giacopuzzi E and Pain O and Fabbri C and Magri C and Minelli A and Lewis CM and Gennarelli M	|	10.1038/s41397-020-00186-5	|
|	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.	|	2021	|	Translational psychiatry	|	11	|	1	|	513	|	Joyce JB and Grant CW and Liu D and MahmoudianDehkordi S and Kaddurah-Daouk R and Skime M and Biernacka J and Frye MA and Mayes T and Carmody T and Croarkin PE and Wang L and Weinshilboum R and Bobo WV and Trivedi MH and Athreya AP	|	10.1038/s41398-021-01632-z	|
|	FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.	|	2013	|	Pharmacogenetics and genomics	|	23	|	3	|	156-66	|	Ellsworth KA and Moon I and Eckloff BW and Fridley BL and Jenkins GD and Batzler A and Biernacka JM and Abo R and Brisbin A and Ji Y and Hebbring S and Wieben ED and Mrazek DA and Weinshilboum RM and Wang L	|	10.1097/FPC.0b013e32835dc133	|
|	ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder.	|	2013	|	The pharmacogenomics journal	|	13	|	4	|	349-53	|	de Klerk OL and Nolte IM and Bet PM and Bosker FJ and Snieder H and den Boer JA and Bruggeman R and Hoogendijk WJ and Penninx BW	|	10.1038/tpj.2012.16	|
|	BDNF Val66Met genotype and 6-month remission rates in late-life depression.	|	2011	|	The pharmacogenomics journal	|	11	|	2	|	146-54	|	Taylor WD and McQuoid DR and Ashley-Koch A and MacFall JR and Bridgers J and Krishnan RR and Steffens DC	|	10.1038/tpj.2010.12	|
|	A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.	|	2020	|	Psychiatry research	|	284	|		|	112690	|	Yuan F and Yuan R and Ren D and Bi Y and Niu W and Guo Z and Wu X and Xu F and Sun Q and Ma G and Yang F and Zhu Y and Yu T and Li X and He L and Shi L and He G	|	10.1016/j.psychres.2019.112690	|
|	Anxiety Symptoms Questionnaire (ASQ): development and validation.	|	2019	|	General psychiatry	|	32	|	6	|	e100144	|	Baker A and Simon N and Keshaviah A and Farabaugh A and Deckersbach T and Worthington JJ and Hoge E and Fava M and Pollack MP	|	10.1136/gpsych-2019-100144	|
|	Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.	|	2018	|	Depression and anxiety	|	35	|	10	|	992-1000	|	Kelley ME and Dunlop BW and Nemeroff CB and Lori A and Carrillo-Roa T and Binder EB and Kutner MH and Rivera VA and Craighead WE and Mayberg HS	|	10.1002/da.22832	|
|	Posttraumatic stress disorder symptom severity is associated with reduced default mode network connectivity in individuals with elevated genetic risk for psychopathology.	|	2017	|	Depression and anxiety	|	34	|	7	|	632-640	|	Miller DR and Logue MW and Wolf EJ and Maniates H and Robinson ME and Hayes JP and Stone A and Schichman S and McGlinchey RE and Milberg WP and Miller MW	|	10.1002/da.22633	|
|	Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.	|	2017	|	Brain : a journal of neurology	|	140	|	3	|	813-825	|	Hayes JP and Logue MW and Sadeh N and Spielberg JM and Verfaellie M and Hayes SM and Reagan A and Salat DH and Wolf EJ and McGlinchey RE and Milberg WP and Stone A and Schichman SA and Miller MW	|	10.1093/brain/aww344	|
|	Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP.	|	2020	|	The pharmacogenomics journal	|	20	|	2	|	329-341	|	Wigmore EM and Hafferty JD and Hall LS and Howard DM and Clarke TK and Fabbri C and Lewis CM and Uher R and Navrady LB and Adams MJ and Zeng Y and Campbell A and Gibson J and Thomson PA and Hayward C and Smith BH and Hocking LJ and Padmanabhan S and Deary IJ and Porteous DJ and Mors O and Mattheisen M and Nicodemus KK and McIntosh AM	|	10.1038/s41397-019-0067-3	|
|	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.	|	2019	|	Translational psychiatry	|	9	|	1	|	173	|	Bhattacharyya S and Ahmed AT and Arnold M and Liu D and Luo C and Zhu H and Mahmoudiandehkordi S and Neavin D and Louie G and Dunlop BW and Frye MA and Wang L and Weinshilboum RM and Krishnan RR and Rush AJ and Kaddurah-Daouk R	|	10.1038/s41398-019-0507-5	|
|	Moderators of a resiliency group intervention for frontline clinicians during the COVID-19 pandemic.	|	2021	|	Journal of affective disorders	|	293	|		|	373-378	|	Sylvia LG and George N and Rabideau DJ and Streck JM and Albury E and Hall DL and Luberto CM and Mizrach HR and Perez GK and Crute S and Mehta DH and Convery MS and Looby SE and Fricchione G and Fava M and Wilhelm S and Park ER	|	10.1016/j.jad.2021.06.036	|
|	Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder.	|	2015	|	Nature	|	527	|	7576	|	95-9	|	Mertens J and Wang QW and Kim Y and Yu DX and Pham S and Yang B and Zheng Y and Diffenderfer KE and Zhang J and Soltani S and Eames T and Schafer ST and Boyer L and Marchetto MC and Nurnberger JI and Calabrese JR and Ã˜degaard KJ and McCarthy MJ and Zandi PP and Alda M and Nievergelt CM and Mi S and Brennand KJ and Kelsoe JR and Gage FH and Yao J	|	10.1038/nature15526	|
|	Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk.	|	2019	|	International journal of molecular sciences	|	20	|	8	|		|	Srivastava A and Singh P and Gupta H and Kaur H and Kanojia N and Guin D and Sood M and Chadda RK and Yadav J and Vohora D and Saso L and Kukreti R	|	10.3390/ijms20081993	|
|	Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.	|	2020	|	Molecular psychiatry	|	25	|	7	|	1580-1591	|	Fava M and Thase ME and Trivedi MH and Ehrich E and Martin WF and Memisoglu A and Nangia N and Stanford AD and Yu M and Pathak S	|	10.1038/s41380-018-0284-1	|
|	Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder.	|	2020	|	Journal of affective disorders	|	262	|		|	118-125	|	Sakurai H and L Carpenter L and R Tyrka A and Price LH and I Papakostas G and Dording CM and Yeung AS and Cusin C and Ludington E and Bernard-Negron R and Fava M and Mischoulon D	|	10.1016/j.jad.2019.10.040	|
|	ERICH3: vesicular association and antidepressant treatment response.	|	2021	|	Molecular psychiatry	|	26	|	6	|	2415-2428	|	Liu D and Zhuang Y and Zhang L and Gao H and Neavin D and Carrillo-Roa T and Wang Y and Yu J and Qin S and Kim DC and Liu E and Nguyen TTL and Biernacka JM and Kaddurah-Daouk R and Dunlop BW and Craighead WE and Mayberg HS and Binder EB and Frye MA and Wang L and Weinshilboum RM	|	10.1038/s41380-020-00940-y	|
|	Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges.	|	2017	|	Human mutation	|	38	|	9	|	1182-1192	|	Daneshjou R and Wang Y and Bromberg Y and Bovo S and Martelli PL and Babbi G and Lena PD and Casadio R and Edwards M and Gifford D and Jones DT and Sundaram L and Bhat RR and Li X and Pal LR and Kundu K and Yin Y and Moult J and Jiang Y and Pejaver V and Pagel KA and Li B and Mooney SD and Radivojac P and Shah S and Carraro M and Gasparini A and Leonardi E and Giollo M and Ferrari C and Tosatto SCE and Bachar E and Azaria JR and Ofran Y and Unger R and Niroula A and Vihinen M and Chang B and Wang MH and Franke A and Petersen BS and Pirooznia M and Zandi P and McCombie R and Potash JB and Altman RB and Klein TE and Hoskins RA and Repo S and Brenner SE and Morgan AA	|	10.1002/humu.23280	|
|	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.	|	2021	|	European neuropsychopharmacology : the journal of the European College of           Neuropsychopharmacology	|	49	|		|	122-132	|	Feeney A and Hock RS and Freeman MP and Flynn M and Hoeppner B and Iosifescu DV and Trivedi MH and Sanacora G and Mathew SJ and Debattista C and Ionescu DF and Fava M and Papakostas GI	|	10.1016/j.euroneuro.2021.04.024	|
|	Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.	|	2016	|	Human genomics	|	10	|		|	12	|	Srivastava AK and Wang Y and Huang R and Skinner C and Thompson T and Pollard L and Wood T and Luo F and Stevenson R and Polimanti R and Gelernter J and Lin X and Lim IY and Wu Y and Teh AL and Chen L and Aris IM and Soh SE and Tint MT and MacIsaac JL and Yap F and Kwek K and Saw SM and Kobor MS and Meaney MJ and Godfrey KM and Chong YS and Holbrook JD and Lee YS and Gluckman PD and Karnani N and Kapoor A and Lee D and Chakravarti A and Maercker C and Graf F and Boutros M and Stamoulis G and Santoni F and Makrythanasis P and Letourneau A and Guipponi M and Panousis N and Garieri M and Ribaux P and Falconnet E and Borel C and Antonarakis SE and Kumar S and Curran J and Blangero J and Chatterjee S and Kapoor A and Akiyama J and Auer D and Berrios C and Pennacchio L and Chakravarti A and Donti TR and Cappuccio G and Miller M and Atwal P and Kennedy A and Cardon A and Bacino C and Emrick L and Hertecant J and Baumer F and Porter B and Bainbridge M and Bonnen P and Graham B and Sutton R and Sun Q and Elsea S and Hu Z and Wang P and Zhu Y and Zhao J and Xiong M and Bennett DA and Hidalgo-Miranda A and Romero-Cordoba S and Rodriguez-Cuevas S and Rebollar-Vega R and Tagliabue E and Iorio M and Dâ€™Ippolito E and Baroni S and Kaczkowski B and Tanaka Y and Kawaji H and Sandelin A and Andersson R and Itoh M and Lassmann T and Hayashizaki Y and Carninci P and Forrest ARR and Semple CA and Rosenthal EA and Shirts B and Amendola L and Gallego C and Horike-Pyne M and Burt A and Robertson P and Beyers P and Nefcy C and Veenstra D and Hisama F and Bennett R and Dorschner M and Nickerson D and Smith J and Patterson K and Crosslin D and Nassir R and Zubair N and Harrison T and Peters U and Jarvik G and Menghi F and Inaki K and Woo X and Kumar P and Grzeda K and Malhotra A and Kim H and Ucar D and Shreckengast P and Karuturi K and Keck J and Chuang J and Liu ET and Ji B and Tyler A and Ananda G and Carter G and Nikbakht H and Montagne M and Zeinieh M and Harutyunyan A and Mcconechy M and Jabado N and Lavigne P and Majewski J and Goldstein JB and Overman M and Varadhachary G and Shroff R and Wolff R and Javle M and Futreal A and Fogelman D and Bravo L and Fajardo W and Gomez H and Castaneda C and Rolfo C and Pinto JA and Akdemir KC and Chin L and Futreal A and Patterson S and Statz C and Mockus S and Nikolaev SN and Bonilla XI and Parmentier L and King B and Bezrukov F and Kaya G and Zoete V and Seplyarskiy V and Sharpe H and McKee T and Letourneau A and Ribaux P and Popadin K and Basset-Seguin N and Chaabene RB and Santoni F and Andrianova M and Guipponi M and Garieri M and Verdan C and Grosdemange K and Sumara O and Eilers M and Aifantis I and Michielin O and de Sauvage F and Antonarakis S and Likhitrattanapisal S and Lincoln S and Kurian A and Desmond A and Yang S and Kobayashi Y and Ford J and Ellisen L and Peters TL and Alvarez KR and Hollingsworth EF and Lopez-Terrada DH and Hastie A and Dzakula Z and Pang AW and Lam ET and Anantharaman T and Saghbini M and Cao H and Gonzaga-Jauregui C and Ma L and King A and Rosenzweig EB and Krishnan U and Reid JG and Overton JD and Dewey F and Chung WK and Small K and DeLuca A and Cremers F and Lewis RA and Puech V and Bakall B and Silva-Garcia R and Rohrschneider K and Leys M and Shaya FS and Stone E and Sobreira NL and Schiettecatte F and Ling H and Pugh E and Witmer D and Hetrick K and Zhang P and Doheny K and Valle D and Hamosh A and Jhangiani SN and Akdemir ZC and Bainbridge MN and Charng W and Wiszniewski W and Gambin T and Karaca E and Bayram Y and Eldomery MK and Posey J and Doddapaneni H and Hu J and Sutton VR and Muzny DM and Boerwinkle EA and Valle D and Lupski JR and Gibbs RA and Shekar S and Salerno W and English A and Mangubat A and Bruestle J and Thorogood A and Knoppers BM and Takahashi H and Nitta KR and Kozhuharova A and Suzuki AM and Sharma H and Cotella D and Santoro C and Zucchelli S and Gustincich S and Carninci P and Mulvihill JJ and Baynam G and Gahl W and Groft SC and Kosaki K and Lasko P and Melegh B and Taruscio D and Ghosh R and Plon S and Scherer S and Qin X and Sanghvi R and Walker K and Chiang T and Muzny D and Wang L and Black J and Boerwinkle E and Weinshilboum R and Gibbs R and Karpinets T and Calderone T and Wani K and Yu X and Creasy C and Haymaker C and Forget M and Nanda V and Roszik J and Wargo J and Haydu L and Song X and Lazar A and Gershenwald J and Davies M and Bernatchez C and Zhang J and Futreal A and Woodman S and Chesler EJ and Reynolds T and Bubier JA and Phillips C and Langston MA and Baker EJ and Xiong M and Ma L and Lin N and Amos C and Lin N and Wang P and Zhu Y and Zhao J and Calhoun V and Xiong M and Dobretsberger O and Egger M and Leimgruber F and Sadedin S and Oshlack A and Antonio VAA and Ono N and Ahmed Z and Bolisetty M and Zeeshan S and Anguiano E and Ucar D and Sarkar A and Nandineni MR and Zeng C and Shao J and Cao H and Hastie A and Pang AW and Lam ET and Liang T and Pham K and Saghbini M and Dzakula Z and Chee-Wei Y and Dongsheng L and Lai-Ping W and Lian D and Hee ROT and Yunus Y and Aghakhanian F and Mokhtar SS and Lok-Yung CV and Bhak J and Phipps M and Shuhua X and Yik-Ying T and Kumar V and Boon-Peng H and Campbell I and Young MA and James P and Rain M and Mohammad G and Kukreti R and Pasha Q and Akilzhanova AR and Guelly C and Abilova Z and Rakhimova S and Akhmetova A and Kairov U and Trajanoski S and Zhumadilov Z and Bekbossynova M and Schumacher C and Sandhu S and Harkins T and Makarov V and Doddapaneni H and Glenn R and Momin Z and Dilrukshi B and Chao H and Meng Q and Gudenkauf B and Kshitij R and Jayaseelan J and Nessner C and Lee S and Blankenberg K and Lewis L and Hu J and Han Y and Dinh H and Jireh S and Walker K and Boerwinkle E and Muzny D and Gibbs R and Hu J and Walker K and Buhay C and Liu X and Wang Q and Sanghvi R and Doddapaneni H and Ding Y and Veeraraghavan N and Yang Y and Boerwinkle E and Beaudet AL and Eng CM and Muzny DM and Gibbs RA and Worley KCC and Liu Y and Hughes DST and Murali SC and Harris RA and English AC and Qin X and Hampton OA and Larsen P and Beck C and Han Y and Wang M and Doddapaneni H and Kovar CL and Salerno WJ and Yoder A and Richards S and Rogers J and Lupski JR and Muzny DM and Gibbs RA and Meng Q and Bainbridge M and Wang M and Doddapaneni H and Han Y and Muzny D and Gibbs R and Harris RA and Raveenedran M and Xue C and Dahdouli M and Cox L and Fan G and Ferguson B and Hovarth J and Johnson Z and Kanthaswamy S and Kubisch M and Platt M and Smith D and Vallender E and Wiseman R and Liu X and Below J and Muzny D and Gibbs R and Yu F and Rogers J and Lin J and Zhang Y and Ouyang Z and Moore A and Wang Z and Hofmann J and Purdue M and Stolzenberg-Solomon R and Weinstein S and Albanes D and Liu CS and Cheng WL and Lin TT and Lan Q and Rothman N and Berndt S and Chen ES and Bahrami H and Khoshzaban A and Keshal SH and Bahrami H and Khoshzaban A and Keshal SH and Alharbi KKR and Zhalbinova M and Akilzhanova A and Rakhimova S and Bekbosynova M and Myrzakhmetova S and Matar M and Mili N and Molinari R and Ma Y and Guerrier S and Elhawary N and Tayeb M and Bogari N and Qotb N and McClymont SA and Hook PW and Goff LA and McCallion A and Kong Y and Charette JR and Hicks WL and Naggert JK and Zhao L and Nishina PM and Edrees BM and Athar M and Al-Allaf FA and Taher MM and Khan W and Bouazzaoui A and Harbi NA and Safar R and Al-Edressi H and Anazi A and Altayeb N and Ahmed MA and Alansary K and Abduljaleel Z and Kratz A and Beguin P and Poulain S and Kaneko M and Takahiko C and Matsunaga A and Kato S and Suzuki AM and Bertin N and Lassmann T and Vigot R and Carninci P and Plessy C and Launey T and Graur D and Lee D and Kapoor A and Chakravarti A and Friis-Nielsen J and Izarzugaza JM and Brunak S and Chakraborty A and Basak J and Mukhopadhyay A and Soibam BS and Das D and Biswas N and Das S and Sarkar S and Maitra A and Panda C and Majumder P and Morsy H and Gaballah A and Samir M and Shamseya M and Mahrous H and Ghazal A and Arafat W and Hashish M and Gruber JJ and Jaeger N and Snyder M and Patel K and Bowman S and Davis T and Kraushaar D and Emerman A and Russello S and Henig N and Hendrickson C and Zhang K and Rodriguez-Dorantes M and Cruz-Hernandez CD and Garcia-Tobilla CDP and Solorzano-Rosales S and JÃ¤ger N and Chen J and Haile R and Hitchins M and Brooks JD and Snyder M and JimÃ©nez-Morales S and RamÃ­rez M and NuÃ±ez J and Bekker V and Leal Y and JimÃ©nez E and Medina A and Hidalgo A and MejÃ­a J and Halytskiy V and Naggert J and Collin GB and DeMauro K and Hanusek R and Nishina PM and Belhassa K and Belhassan K and Bouguenouch L and Samri I and Sayel H and moufid FZ and El Bouchikhi I and Trhanint S and Hamdaoui H and Elotmani I and Khtiri I and Kettani O and Quibibo L and Ahagoud M and Abbassi M and Ouldim K and Marusin AV and Kornetov AN and Swarovskaya M and Vagaiceva K and Stepanov V and De La Paz EMC and Sy R and Nevado J and Reganit P and Santos L and Magno JD and Punzalan FE and Ona D and Llanes E and Santos-Cortes RL and Tiongco R and Aherrera J and Abrahan L and Pagauitan-Alan P and Morelli KH and Domire JS and Pyne N and Harper S and Burgess R and Zhalbinova M and Akilzhanova A and Rakhimova S and Bekbosynova M and Myrzakhmetova S and Gari MA and Dallol A and Alsehli H and Gari A and Gari M and Abuzenadah A and Thomas M and Sukhai M and Garg S and Misyura M and Zhang T and Schuh A and Stockley T and Kamel-Reid S and Sherry S and Xiao C and Slotta D and Rodarmer K and Feolo M and Kimelman M and Godynskiy G and Oâ€™Sullivan C and Yaschenko E and Xiao C and Yaschenko E and Sherry S and Rangel-EscareÃ±o C and Rueda-Zarate H and Tayubi IA and Mohammed R and Ahmed I and Ahmed T and Seth S and Amin S and Song X and Mao X and Sun H and Verhaak RG and Futreal A and Zhang J and Whiite SJ and Chiang T and English A and Farek J and Kahn Z and Salerno W and Veeraraghavan N and Boerwinkle E and Gibbs R and Kasukawa T and Lizio M and Harshbarger J and Hisashi S and Severin J and Imad A and Sahin S and Freeman TC and Baillie K and Sandelin A and Carninci P and Forrest ARR and Kawaji H and Salerno W and English A and Shekar SN and Mangubat A and Bruestle J and Boerwinkle E and Gibbs RA and Salem AH and Ali M and Ibrahim A and Ibrahim M and Barrera HA and Garza L and Torres JA and Barajas V and Ulloa-Aguirre A and Kershenobich D and Mortaji S and Guizar P and Loera E and Moreno K and De LeÃ³n A and MonsivÃ¡is D and GÃ³mez J and Cardiel R and Fernandez-Lopez JC and Bonifaz-PeÃ±a V and Rangel-EscareÃ±o C and Hidalgo-Miranda A and Contreras AV and Polfus L and Wang X and Philip V and Carter G and Abuzenadah AA and Gari M and Turki R and Dallol A and Uyar A and Kaygun A and Zaman S and Marquez E and George J and Ucar D and Hendrickson CL and Emerman A and Kraushaar D and Bowman S and Henig N and Davis T and Russello S and Patel K and Starr DB and Baird M and Kirkpatrick B and Sheets K and Nitsche R and Prieto-Lafuente L and Landrum M and Lee J and Rubinstein W and Maglott D and Thavanati PKR and de Dios AE and Hernandez REN and Aldrate MEA and Mejia MRR and Kanala KRR and Abduljaleel Z and Khan W and Al-Allaf FA and Athar M and Taher MM and Shahzad N and Bouazzaoui A and Huber E and Dan A and Al-Allaf FA and Herr W and Sprotte G and KÃ¶stler J and Hiergeist A and Gessner A and Andreesen R and Holler E and Al-Allaf F and Alashwal A and Abduljaleel Z and Taher M and Bouazzaoui A and Abalkhail H and Al-Allaf A and Bamardadh R and Athar M and Filiptsova O and Kobets M and Kobets Y and Burlaka I and Timoshyna I and Filiptsova O and Kobets MN and Kobets Y and Burlaka I and Timoshyna I and Filiptsova O and Kobets MN and Kobets Y and Burlaka I and Timoshyna I and Al-allaf FA and Mohiuddin MT and Zainularifeen A and Mohammed A and Abalkhail H and Owaidah T and Bouazzaoui A	|	10.1186/s40246-016-0063-5	|
|	A large-scale genome-wide association study meta-analysis of cannabis use disorder.	|	2020	|	The lancet. Psychiatry	|	7	|	12	|	1032-1045	|	Johnson EC and Demontis D and Thorgeirsson TE and Walters RK and Polimanti R and Hatoum AS and Sanchez-Roige S and Paul SE and Wendt FR and Clarke TK and Lai D and Reginsson GW and Zhou H and He J and Baranger DAA and Gudbjartsson DF and Wedow R and Adkins DE and Adkins AE and Alexander J and Bacanu SA and Bigdeli TB and Boden J and Brown SA and Bucholz KK and Bybjerg-Grauholm J and Corley RP and Degenhardt L and Dick DM and Domingue BW and Fox L and Goate AM and Gordon SD and Hack LM and Hancock DB and Hartz SM and Hickie IB and Hougaard DM and Krauter K and Lind PA and McClintick JN and McQueen MB and Meyers JL and Montgomery GW and Mors O and Mortensen PB and Nordentoft M and Pearson JF and Peterson RE and Reynolds MD and Rice JP and Runarsdottir V and Saccone NL and Sherva R and Silberg JL and Tarter RE and Tyrfingsson T and Wall TL and Webb BT and Werge T and Wetherill L and Wright MJ and Zellers S and Adams MJ and Bierut LJ and Boardman JD and Copeland WE and Farrer LA and Foroud TM and Gillespie NA and Grucza RA and Harris KM and Heath AC and Hesselbrock V and Hewitt JK and Hopfer CJ and Horwood J and Iacono WG and Johnson EO and Kendler KS and Kennedy MA and Kranzler HR and Madden PAF and Maes HH and Maher BS and Martin NG and McGue M and McIntosh AM and Medland SE and Nelson EC and Porjesz B and Riley BP and Stallings MC and Vanyukov MM and Vrieze S and Davis LK and Bogdan R and Gelernter J and Edenberg HJ and Stefansson K and BÃ¸rglum AD and Agrawal A	|	10.1016/S2215-0366(20)30339-4	|
|	Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information.	|	2022	|	Biological psychiatry	|	91	|	7	|	626-636	|	Maihofer AX and Choi KW and Coleman JRI and Daskalakis NP and Denckla CA and Ketema E and Morey RA and Polimanti R and Ratanatharathorn A and Torres K and Wingo AP and Zai CC and Aiello AE and Almli LM and Amstadter AB and Andersen SB and Andreassen OA and Arbisi PA and Ashley-Koch AE and Austin SB and AvdibegoviÄ‡ E and Borglum AD and BabiÄ‡ D and BÃ¦kvad-Hansen M and Baker DG and Beckham JC and Bierut LJ and Bisson JI and Boks MP and Bolger EA and Bradley B and Brashear M and Breen G and Bryant RA and Bustamante AC and Bybjerg-Grauholm J and Calabrese JR and Caldas-de-Almeida JM and Chen CY and Dale AM and Dalvie S and Deckert J and Delahanty DL and Dennis MF and Disner SG and Domschke K and Duncan LE and DÅ¾ubur KulenoviÄ‡ A and Erbes CR and Evans A and Farrer LA and Feeny NC and Flory JD and Forbes D and Franz CE and Galea S and Garrett ME and Gautam A and Gelaye B and Gelernter J and Geuze E and Gillespie CF and GoÃ§i A and Gordon SD and Guffanti G and Hammamieh R and Hauser MA and Heath AC and Hemmings SMJ and Hougaard DM and JakovljeviÄ‡ M and Jett M and Johnson EO and Jones I and Jovanovic T and Qin XJ and Karstoft KI and Kaufman ML and Kessler RC and Khan A and Kimbrel NA and King AP and Koen N and Kranzler HR and Kremen WS and Lawford BR and Lebois LAM and Lewis C and Liberzon I and Linnstaedt SD and Logue MW and Lori A and Lugonja B and Luykx JJ and Lyons MJ and Maples-Keller JL and Marmar C and Martin NG and Maurer D and Mavissakalian MR and McFarlane A and McGlinchey RE and McLaughlin KA and McLean SA and Mehta D and Mellor R and Michopoulos V and Milberg W and Miller MW and Morris CP and Mors O and Mortensen PB and Nelson EC and Nordentoft M and Norman SB and O'Donnell M and Orcutt HK and Panizzon MS and Peters ES and Peterson AL and Peverill M and Pietrzak RH and Polusny MA and Rice JP and Risbrough VB and Roberts AL and Rothbaum AO and Rothbaum BO and Roy-Byrne P and Ruggiero KJ and Rung A and Rutten BPF and Saccone NL and Sanchez SE and Schijven D and Seedat S and Seligowski AV and Seng JS and Sheerin CM and Silove D and Smith AK and Smoller JW and Sponheim SR and Stein DJ and Stevens JS and Teicher MH and Thompson WK and Trapido E and Uddin M and Ursano RJ and van den Heuvel LL and Van Hooff M and Vermetten E and Vinkers CH and Voisey J and Wang Y and Wang Z and Werge T and Williams MA and Williamson DE and Winternitz S and Wolf C and Wolf EJ and Yehuda R and Young KA and Young RM and Zhao H and Zoellner LA and Haas M and Lasseter H and Provost AC and Salem RM and Sebat J and Shaffer RA and Wu T and Ripke S and Daly MJ and Ressler KJ and Koenen KC and Stein MB and Nievergelt CM	|	10.1016/j.biopsych.2021.09.020	|
|	Shared genetic risk between eating disorder- and substance-use-related phenotypes: Evidence from genome-wide association studies.	|	2021	|	Addiction biology	|	26	|	1	|	e12880	|	Munn-Chernoff MA and Johnson EC and Chou YL and Coleman JRI and Thornton LM and Walters RK and Yilmaz Z and Baker JH and HÃ¼bel C and Gordon S and Medland SE and Watson HJ and Gaspar HA and Bryois J and Hinney A and LeppÃ¤ VM and Mattheisen M and Ripke S and Yao S and Giusti-RodrÃ­guez P and Hanscombe KB and Adan RAH and Alfredsson L and Ando T and Andreassen OA and Berrettini WH and Boehm I and Boni C and Boraska Perica V and Buehren K and Burghardt R and Cassina M and Cichon S and Clementi M and Cone RD and Courtet P and Crow S and Crowley JJ and Danner UN and Davis OSP and de Zwaan M and Dedoussis G and Degortes D and DeSocio JE and Dick DM and Dikeos D and Dina C and Dmitrzak-Weglarz M and Docampo E and Duncan LE and Egberts K and Ehrlich S and EscaramÃ­s G and Esko T and Estivill X and Farmer A and Favaro A and FernÃ¡ndez-Aranda F and Fichter MM and Fischer K and FÃ¶cker M and Foretova L and Forstner AJ and Forzan M and Franklin CS and Gallinger S and Giegling I and Giuranna J and Gonidakis F and Gorwood P and Gratacos Mayora M and Guillaume S and Guo Y and Hakonarson H and Hatzikotoulas K and Hauser J and Hebebrand J and Helder SG and Herms S and Herpertz-Dahlmann B and Herzog W and Huckins LM and Hudson JI and Imgart H and Inoko H and Janout V and JimÃ©nez-Murcia S and JuliÃ  A and Kalsi G and KaminskÃ¡ D and Karhunen L and Karwautz A and Kas MJH and Kennedy JL and Keski-Rahkonen A and Kiezebrink K and Kim YR and Klump KL and Knudsen GPS and La Via MC and Le Hellard S and Levitan RD and Li D and Lilenfeld L and Lin BD and Lissowska J and Luykx J and Magistretti PJ and Maj M and Mannik K and Marsal S and Marshall CR and Mattingsdal M and McDevitt S and McGuffin P and Metspalu A and Meulenbelt I and Micali N and Mitchell K and Monteleone AM and Monteleone P and Nacmias B and Navratilova M and Ntalla I and O'Toole JK and Ophoff RA and Padyukov L and Palotie A and Pantel J and Papezova H and Pinto D and Rabionet R and Raevuori A and Ramoz N and Reichborn-Kjennerud T and Ricca V and Ripatti S and Ritschel F and Roberts M and Rotondo A and Rujescu D and Rybakowski F and Santonastaso P and Scherag A and Scherer SW and Schmidt U and Schork NJ and Schosser A and Seitz J and Slachtova L and Slagboom PE and Slof-Op't Landt MCT and Slopien A and Sorbi S and ÅšwiÄ…tkowska B and Szatkiewicz JP and Tachmazidou I and Tenconi E and Tortorella A and Tozzi F and Treasure J and Tsitsika A and Tyszkiewicz-Nwafor M and Tziouvas K and van Elburg AA and van Furth EF and Wagner G and Walton E and Widen E and Zeggini E and Zerwas S and Zipfel S and Bergen AW and Boden JM and Brandt H and Crawford S and Halmi KA and Horwood LJ and Johnson C and Kaplan AS and Kaye WH and Mitchell J and Olsen CM and Pearson JF and Pedersen NL and Strober M and Werge T and Whiteman DC and Woodside DB and Grove J and Henders AK and Larsen JT and Parker R and Petersen LV and Jordan J and Kennedy MA and BirgegÃ¥rd A and Lichtenstein P and Norring C and LandÃ©n M and Mortensen PB and Polimanti R and McClintick JN and Adkins AE and Aliev F and Bacanu SA and Batzler A and Bertelsen S and Biernacka JM and Bigdeli TB and Chen LS and Clarke TK and Degenhardt F and Docherty AR and Edwards AC and Foo JC and Fox L and Frank J and Hack LM and Hartmann AM and Hartz SM and Heilmann-Heimbach S and Hodgkinson C and Hoffmann P and Hottenga JJ and Konte B and Lahti J and Lahti-Pulkkinen M and Lai D and Ligthart L and Loukola A and Maher BS and Mbarek H and McIntosh AM and McQueen MB and Meyers JL and Milaneschi Y and Palviainen T and Peterson RE and Ryu E and Saccone NL and Salvatore JE and Sanchez-Roige S and Schwandt M and Sherva R and Streit F and Strohmaier J and Thomas N and Wang JC and Webb BT and Wedow R and Wetherill L and Wills AG and Zhou H and Boardman JD and Chen D and Choi DS and Copeland WE and Culverhouse RC and Dahmen N and Degenhardt L and Domingue BW and Frye MA and GÃ¤ebel W and Hayward C and Ising M and Keyes M and Kiefer F and Koller G and Kramer J and Kuperman S and Lucae S and Lynskey MT and Maier W and Mann K and MÃ¤nnistÃ¶ S and MÃ¼ller-Myhsok B and Murray AD and Nurnberger JI and Preuss U and RÃ¤ikkÃ¶nen K and Reynolds MD and Ridinger M and Scherbaum N and Schuckit MA and Soyka M and Treutlein J and Witt SH and Wodarz N and Zill P and Adkins DE and Boomsma DI and Bierut LJ and Brown SA and Bucholz KK and Costello EJ and de Wit H and Diazgranados N and Eriksson JG and Farrer LA and Foroud TM and Gillespie NA and Goate AM and Goldman D and Grucza RA and Hancock DB and Harris KM and Hesselbrock V and Hewitt JK and Hopfer CJ and Iacono WG and Johnson EO and Karpyak VM and Kendler KS and Kranzler HR and Krauter K and Lind PA and McGue M and MacKillop J and Madden PAF and Maes HH and Magnusson PKE and Nelson EC and NÃ¶then MM and Palmer AA and Penninx BWJH and Porjesz B and Rice JP and Rietschel M and Riley BP and Rose RJ and Shen PH and Silberg J and Stallings MC and Tarter RE and Vanyukov MM and Vrieze S and Wall TL and Whitfield JB and Zhao H and Neale BM and Wade TD and Heath AC and Montgomery GW and Martin NG and Sullivan PF and Kaprio J and Breen G and Gelernter J and Edenberg HJ and Bulik CM and Agrawal A	|	10.1111/adb.12880	|
|	Genetic association analysis of serotonin 2A receptor gene (HTR2A) with        bipolar disorder and major depressive disorder in the Japanese        population	|	2009	|	NEUROSCIENCE RESEARCH	|	64	|	2	|	231-234	|	Kishi, T and Kitajima, T and Tsunoka, T and Ikeda, M and Yamanouchi, Y and Kinoshita, Y and Kawashima, K and Okochi, T and Okumura, T and Inada, T and Ozaki, N and Iwata, N and Kishi, Taro and Kitajima, Tsuyoshi and Tsunoka, Tomoko and Ikeda, Masashi and Yamanouchi, Yoshio and Kinoshita, Yoko and Kawashima, Kunihiro and Okochi, Tomo and Okumura, Takenori and Inada, Toshiya and Ozaki, Norio and Iwata, Nakao	|	10.1016/j.neures.2009.03.003	|
|	Association study of the TPH2 Gene with Major Depressive Disorder in the        Han Chinese Population	|	2016	|	EUROPEAN JOURNAL OF PSYCHIATRY	|	30	|	2	|	131-140	|	Du, J and Zhang, ZF and Li, WD and He, L and Xu, JH and Shi, YY and Du, Jing and Zhang, Zhaofeng and Li, Weidong and He, Lin and Xu, Jianhua and Shi, Yongyong	|		|
|	Pharmacogenetics of lithium response in bipolar disorder	|	1999	|	JOURNAL OF PSYCHIATRY & NEUROSCIENCE	|	24	|	2	|	154-158	|	Alda, M and Alda, M	|		|
|	Personalized medicine in psychiatry: problems and promises	|	2013	|	BMC MEDICINE	|	11	|		|		|	Ozomaro, U and Wahlestedt, C and Nemeroff, CB and Ozomaro, Uzoezi and Wahlestedt, Claes and Nemeroff, Charles B.	|	10.1186/1741-7015-11-132	|
|	Biomarkers for Major Depressive Disorder: Economic Considerations	|	2016	|	DRUG DEVELOPMENT RESEARCH	|	77	|	7	|	374-378	|	Bogavac-Stanojevic, N and Lakic, D and Bogavac-Stanojevic, Natasa and Lakic, Dragana	|	10.1002/ddr.21330	|
|	GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in        Japanese patients with major depressive disorder	|	2012	|	JOURNAL OF AFFECTIVE DISORDERS	|	142	|	1	|	315-322	|	Kishi, T and Ichinose, H and Yoshimura, R and Fukuo, Y and Kitajima, T and Inada, T and Kunugi, H and Kato, T and Yoshikawa, T and Ujike, H and Musso, GM and Umene-Nakano, W and Nakamura, J and Ozaki, N and Iwata, N and Kishi, Taro and Ichinose, Hiroshi and Yoshimura, Reiji and Fukuo, Yasuhisa and Kitajima, Tsuyoshi and Inada, Toshiya and Kunugi, Hiroshi and Kato, Tadafumi and Yoshikawa, Takeo and Ujike, Hiroshi and Musso, Giovanna M. and Umene-Nakano, Wakako and Nakamura, Jun and Ozaki, Norio and Iwata, Nakao	|	10.1016/j.jad.2012.05.004	|
|	Towards the clinical implementation of pharmacogenetics in bipolar        disorder	|	2014	|	BMC MEDICINE	|	12	|		|		|	Salloum, NC and McCarthy, MJ and Leckband, SG and Kelsoe, JR and Salloum, Naji C. and McCarthy, Michael J. and Leckband, Susan G. and Kelsoe, John R.	|	10.1186/1741-7015-12-90	|
|	Tryptophan hydroxylase 2 gene is associated with major depressive        disorder in a female Chinese population	|	2011	|	JOURNAL OF AFFECTIVE DISORDERS	|	133	|	3	|	619-624	|	Shen, XH and Wu, YF and Qian, MC and Wang, XQ and Hou, ZH and Liu, Y and Sun, JS and Zhong, H and Yang, JH and Lin, M and Li, L and Guan, TF and Shen, ZX and Yuan, YG and Shen, Xinhua and Wu, Yanfeng and Qian, Mingcai and Wang, Xiaoquan and Hou, Zhenghua and Liu, Yang and Sun, Jushui and Zhong, Hua and Yang, Jianhong and Lin, Min and Li, Liang and Guan, Tiefeng and Shen, Zhongxia and Yuan, Yonggui	|	10.1016/j.jad.2011.04.037	|
|	Common Genetic Variation and Antidepressant Efficacy in Major Depressive        Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies	|	2013	|	AMERICAN JOURNAL OF PSYCHIATRY	|	170	|	2	|	207-217	|	Uher, R and Uher, Rudolf and GENDEP Investigators and MARS Investigators and STAR D Investigators	|	10.1176/appi.ajp.2012.12020237	|
|	Length of psychiatric hospitalization is correlated with CYP2D6        functional status in inpatients with major depressive disorder	|	2013	|	BIOMARKERS IN MEDICINE	|	7	|	3	|	429-439	|	Ruano, G and Szarek, BL and Villagra, D and Gorowski, K and Kocherla, M and Seip, RL and Goethe, JW and Schwartz, HI and Ruano, Gualberto and Szarek, Bonnie L. and Villagra, David and Gorowski, Krystyna and Kocherla, Mohan and Seip, Richard L. and Goethe, John W. and Schwartz, Harold I.	|	10.2217/BMM.13.16	|
|	The Ethical Ramifications of Biomarker Use for Mood Disorders	|	2011	|	HANDBOOK OF SCHIZOPHRENIA SPRECTRUM DISORDERS, VOL III: THERAPEUTIC        APPROACHES, COMORBIDITY, AND OUTCOMES	|		|		|	421-437	|	Lakhan, SE and Vieira, KF and Lakhan, Shaheen E. and Vieira, Karen F.	|	10.1007/978-94-007-0834-1_18     D2 10.1007/978-94-007-0834-1	|
|	Logistic ridge regression to predict bipolar disorder using mRNA        expression levels in the N-methyl-D-aspartate receptor genes	|	2022	|	JOURNAL OF AFFECTIVE DISORDERS	|	297	|		|	309-313	|	Lin, E and Lin, CH and Lane, HY and Lin, Eugene and Lin, Chieh-Hsin and Lane, Hsien-Yuan	|	10.1016/j.jad.2021.10.081	|
|	Pretreatment Reward Sensitivity and Frontostriatal Resting-State        Functional Connectivity Are Associated With Response to Bupropion After        Sertraline Nonresponse	|	2020	|	BIOLOGICAL PSYCHIATRY	|	88	|	8	|	657-667	|	Ang, YS and Kaiser, R and Deckersbach, T and Almeida, J and Phillips, ML and Chase, HW and Webb, CA and Parsey, R and Fava, M and McGrath, P and Weissman, M and Adams, P and Deldin, P and Oquendo, MA and McInnis, MG and Carmody, T and Bruder, G and Cooper, CM and Fatt, CRC and Trivedi, MH and Pizzagalli, DA and Ang, Yuen-Siang and Kaiser, Roselinde and Deckersbach, Thilo and Almeida, Jorge and Phillips, Mary L. and Chase, Henry W. and Webb, Christian A. and Parsey, Ramin and Fava, Maurizio and McGrath, Patrick and Weissman, Myrna and Adams, Phil and Deldin, Patricia and Oquendo, Maria A. and McInnis, Melvin G. and Carmody, Thomas and Bruder, Gerard and Cooper, Crystal M. and Fatt, Cherise R. Chin and Trivedi, Madhukar H. and Pizzagalli, Diego A.	|	10.1016/j.biopsych.2020.04.009	|
|	Mapping susceptibility genes for bipolar disorder: a pharmacogenetic        approach based on excellent response to lithium	|	2001	|	MOLECULAR PSYCHIATRY	|	6	|	5	|	570-578	|	Turecki, G and Grof, P and Grof, E and D'Souza, V and Lebuis, L and Marineau, C and Cavazzoni, P and Duffy, A and Betard, C and Zvolsky, P and Robertson, C and Brewer, C and Hudson, TJ and Rouleau, GA and Alda, M and Turecki, G and Grof, P and Grof, E and D'Souza, V and Lebuis, L and Marineau, C and Cavazzoni, P and Duffy, A and Betard, C and Zvolsky, P and Robertson, C and Brewer, C and Hudson, TJ and Rouleau, GA and Alda, M	|	10.1038/sj.mp.4000888	|
|	On naturalistic pharmacogenetic studies: reply from the authors	|	2013	|	BIOMARKERS IN MEDICINE	|	7	|	6	|	917-918	|	Seip, RL and Goethe, JW and Schwartz, HI and Ruano, G and Seip, Richard L. and Goethe, John W. and Schwartz, Harold I. and Ruano, Gualberto	|	10.2217/bmm.13.110	|
|	Genetic and Epigenetic Markers of Lithium Response	|	2022	|	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	|	23	|	3	|		|	Pisanu, C and Meloni, A and Severino, G and Squassina, A and Pisanu, Claudia and Meloni, Anna and Severino, Giovanni and Squassina, Alessio	|	10.3390/ijms23031555	|
|	Machine Learning and Deep Learning for the Pharmacogenomics of        Antidepressant Treatments	|	2021	|	CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE	|	19	|	4	|	577-588	|	Lin, E and Lin, CH and Lane, HY and Lin, Eugene and Lin, Chieh-Hsin and Lane, Hsien-Yuan	|	10.9758/cpn.2021.19.4.577	|
|	Possible relationship between mitochondrial DNA polymorphisms and        lithium response in bipolar disorder	|	2003	|	INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY	|	6	|	4	|	421-424	|	Washizuka, S and Ikeda, A and Kato, N and Kato, T and Washizuka, S and Ikeda, A and Kato, N and Kato, T	|	10.1017/S1461145703003778	|
|	Use of candidate gene markers to guide antipsychotic dosage adjustment	|	2014	|	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	|	54	|		|	315-320	|	Hettige, NC and Zai, C and Hazra, M and Borlido, C and Kennedy, JL and Strauss, J and Le Foll, B and Wong, A and Remington, G and De Luca, V and Hettige, Nuwan C. and Zai, Clement and Hazra, Monica and Borlido, Carol and Kennedy, James L. and Strauss, John and Le Foll, Bernard and Wong, Albert and Remington, Gary and De Luca, Vincenzo	|	10.1016/j.pnpbp.2014.07.001	|
|	Genetic studies of bipolar disorder in patients selected by their        treatment response	|	2008	|	SALUD MENTAL	|	31	|	6	|	431-440	|	Ortiz-Dominguez, A and Alda, M and Ortiz-Dominguez, Abigail and Alda, Martin	|		|
|	Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine        in Patients Diagnosed With Major Depressive Disorder and Comorbid        Alcohol Use Disorders	|	2021	|	JOURNAL OF PSYCHIATRIC PRACTICE	|	27	|	5	|	372-379	|	Zastrozhin, MS and Skryabin, VY and Petukhov, AE and Pankratenko, EP and Grishina, EA and Ryzhikova, KA and Torrado, MV and Shipitsyn, VV and Bryun, EA and Sychev, DA and Zastrozhin, Mikhail S. and Skryabin, Valentin Y. and Petukhov, Alexey E. and Pankratenko, Ekaterina P. and Grishina, Elena A. and Ryzhikova, Kristina A. and Torrado, Marco, V and Shipitsyn, Valery V. and Bryun, Evgeny A. and Sychev, Dmitry A.	|	10.1097/PRA.0000000000000568	|
|	Understanding the molecular mechanisms underlying mood stabilizer        treatments in bipolar disorder: Potential involvement of epigenetics	|	2018	|	NEUROSCIENCE LETTERS	|	669	|		|	24-31	|	Pisanu, C and Papadima, EM and Del Zompo, M and Squassina, A and Pisanu, Claudia and Papadima, Eleni Merkouri and Del Zompo, Maria and Squassina, Alessio	|	10.1016/j.neulet.2016.06.045	|
|	Anxiety symptom remission is associated with genetic variation of PTPRZ1        among patients with major depressive disorder treated with escitalopram	|	2021	|	PHARMACOGENETICS AND GENOMICS	|	31	|	8	|	172-176	|	Su, YA and Bousman, CA and Liu, Q and Lv, XZ and Li, JT and Lin, JY and Yu, X and Tian, L and Si, TM and Su, Yun-Ai and Bousman, Chad A. and Liu, Qi and Lv, Xiao-Zhen and Li, Ji-Tao and Lin, Jing-Yu and Yu, Xin and Tian, Li and Si, Tian-Mei	|	10.1097/FPC.0000000000000437	|
|	Genetic variants associated with response to lithium treatment in        bipolar disorder: a genome-wide association study	|	2016	|	LANCET	|	387	|	10023	|	1085-1093	|	Hou, LP and Heilbronner, U and Degenhardt, F and Adli, M and Akiyama, K and Akula, N and Ardau, R and Arias, B and Backlund, L and Banzato, CEM and Benabarre, A and Bengesser, S and Bhattacharjee, AK and Biernacka, JM and Birner, A and Brichant-Petitjean, C and Bui, ET and Cervantes, P and Chen, GB and Chen, HC and Chillotti, C and Cichon, S and Clark, SR and Colom, F and Cousins, DA and Cruceanu, C and Czerski, PM and Dantas, CR and Dayer, A and Etain, B and Falkai, P and Forstner, AJ and Frisen, L and Fullerton, JM and Gard, S and Garnham, JS and Goes, FS and Grof, P and Gruber, O and Hashimoto, R and Hauser, J and Herms, S and Hoffmann, P and Hofmann, A and Jamain, S and Jimenez, E and Kahn, JP and Kassem, L and Kittel-Schneider, S and Kliwicki, S and Konig, B and Kusumi, I and Lackner, N and Laje, G and Landen, M and Lavebratt, C and Leboyer, M and Leckband, SG and Jaramillo, CAL and MacQueen, G and Manchia, M and Martinsson, L and Mattheisen, M and McCarthy, MJ and McElroy, SL and Mitjans, M and Mondimore, FM and Monteleone, P and Nievergelt, CM and Nothen, MM and Osby, U and Ozaki, N and Perlis, RH and Pfennig, A and Reich-Erkelenz, D and Rouleau, GA and Schofield, PR and Schubert, KO and Schweizer, BW and Seemuller, F and Severino, G and Shekhtman, T and Shilling, PD and Shimoda, K and Simhandl, C and Slaney, CM and Smoller, JW and Squassina, A and Stamm, T and Stopkova, P and Tighe, SK and Tortorella, A and Turecki, G and Volkert, J and Witt, S and Wright, A and Young, LT and Zandi, PP and Potash, JB and DePaulo, JR and Bauer, M and Reininghaus, EZ and Novak, T and Aubry, JM and Maj, M and Baune, BT and Mitchell, PB and Vieta, E and Frye, MA and Rybakowski, JK and Kuo, PH and Kato, T and Grigoroiu-Serbanescu, M and Reif, A and Del Zompo, M and Bellivier, F and Schalling, M and Wray, NR and Kelsoe, JR and Alda, M and Rietschel, M and McMahon, FJ and Schulze, TG and Hou, Liping and Heilbronner, Urs and Degenhardt, Franziska and Adli, Mazda and Akiyama, Kazufumi and Akula, Nirmala and Ardau, Raffaella and Arias, Barbara and Backlund, Lena and Banzato, Claudio E. M. and Benabarre, Antoni and Bengesser, Susanne and Bhattacharjee, Abesh Kumar and Biernacka, Joanna M. and Birner, Armin and Brichant-Petitjean, Clara and Bui, Elise T. and Cervantes, Pablo and Chen, Guo-Bo and Chen, Hsi-Chung and Chillotti, Caterina and Cichon, Sven and Clark, Scott R. and Colom, Francesc and Cousins, David A. and Cruceanu, Cristiana and Czerski, Piotr M. and Dantas, Clarissa R. and Dayer, Alexandre and Etain, Bruno and Falkai, Peter and Forstner, Andreas J. and Frisen, Louise and Fullerton, Janice M. and Gard, Sebastien and Garnham, Julie S. and Goes, Fernando S. and Grof, Paul and Gruber, Oliver and Hashimoto, Ryota and Hauser, Joanna and Herms, Stefan and Hoffmann, Per and Hofmann, Andrea and Jamain, Stephane and Jimenez, Esther and Kahn, Jean-Pierre and Kassem, Layla and Kittel-Schneider, Sarah and Kliwicki, Sebastian and Koenig, Barbara and Kusumi, Ichiro and Lackner, Nina and Laje, Gonzalo and Landen, Mikael and Lavebratt, Catharina and Leboyer, Marion and Leckband, Susan G. and Lopez Jaramillo, Carlos A. and MacQueen, Glenda and Manchia, Mirko and Martinsson, Lina and Mattheisen, Manuel and McCarthy, Michael J. and McElroy, Susan L. and Mitjans, Marina and Mondimore, Francis M. and Monteleone, Palmiero and Nievergelt, Caroline M. and Noethen, Markus M. and Oesby, Urban and Ozaki, Norio and Perlis, Roy H. and Pfennig, Andrea and Reich-Erkelenz, Daniela and Rouleau, Guy A. and Schofield, Peter R. and Schubert, K. Oliver and Schweizer, Barbara W. and Seemueller, Florian and Severino, Giovanni and Shekhtman, Tatyana and Shilling, Paul D. and Shimoda, Kazutaka and Simhandl, Christian and Slaney, Claire M. and Smoller, Jordan W. and Squassina, Alessio and Stamm, Thomas and Stopkova, Pavla and Tighe, Sarah K. and Tortorella, Alfonso and Turecki, Gustavo and Volkert, Julia and Witt, Stephanie and Wright, Adam and Young, L. Trevor and Zandi, Peter P. and Potash, James B. and DePaulo, J. Raymond and Bauer, Michael and Reininghaus, Eva Z. and Novak, Tomas and Aubry, Jean-Michel and Maj, Mario and Baune, Bernhard T. and Mitchell, Philip B. and Vieta, Eduard and Frye, Mark A. and Rybakowski, Janusz K. and Kuo, Po-Hsiu and Kato, Tadafumi and Grigoroiu-Serbanescu, Maria and Reif, Andreas and Del Zompo, Maria and Bellivier, Frank and Schalling, Martin and Wray, Naomi R. and Kelsoe, John R. and Alda, Martin and Rietschel, Marcella and McMahon, Francis J. and Schulze, Thomas G.	|	10.1016/S0140-6736(16)00143-4	|
|	Altered Neuronal Support and Inflammatory Response in Bipolar Disorder        Patient-Derived Astrocytes	|	2021	|	STEM CELL REPORTS	|	16	|	4	|	825-835	|	Vadodaria, KC and Mendes, APD and Mei, A and Racha, V and Erikson, G and Shokhirev, MN and Oefner, R and Heard, KJ and McCarthy, MJ and Eyler, L and Kelsoe, JR and Santos, R and Marchetto, MC and Gage, FH and Vadodaria, Krishna C. and Mendes, Ana P. D. and Mei, Arianna and Racha, Vipula and Erikson, Galina and Shokhirev, Maxim N. and Oefner, Ruth and Heard, Kelly J. and McCarthy, Michael J. and Eyler, Lisa and Kelsoe, John R. and Santos, Renata and Marchetto, Maria C. and Gage, Fred H.	|	10.1016/j.stemcr.2021.02.004     EA APR 2021	|
|	Brain-derived neurotrophic factor gene polymorphisms: influence on        treatment response phenotypes of major depressive disorder	|	2011	|	INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY	|	26	|	1	|	10-Jan	|	Kocabas, NA and Antonijevic, I and Faghel, C and Forray, C and Kasper, S and Lecrubier, Y and Linotte, S and Massat, I and Mendlewicz, J and Noro, M and Montgomery, S and Oswald, P and Snyder, L and Zohar, J and Souery, D and Kocabas, Neslihan Aygun and Antonijevic, Irina and Faghel, Carole and Forray, Carlos and Kasper, Siegfried and Lecrubier, Yves and Linotte, Sylvie and Massat, Isabelle and Mendlewicz, Julien and Noro, Magali and Montgomery, Stuart and Oswald, Pierre and Snyder, Lenore and Zohar, Joseph and Souery, Daniel	|	10.1097/YIC.0b013e32833d18f8	|
|	Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in        major depressive disorder: metabolomics-informed genomics	|	2018	|	TRANSLATIONAL PSYCHIATRY	|	8	|		|		|	Liu, D and Ray, B and Neavin, DR and Zhang, JB and Athreya, AP and Biernacka, JM and Bobo, WV and Hall-Flavin, DK and Skime, MK and Zhu, HJ and Jenkins, GD and Batzler, A and Kalari, KR and Boakye-Agyeman, F and Matson, WR and Bhasin, SS and Mushiroda, T and Nakamura, Y and Kubo, M and Iyer, RK and Wang, LW and Frye, MA and Kaddurah-Daouk, R and Weinshilboum, RM and Liu, Duan and Ray, Balmiki and Neavin, Drew R. and Zhang, Jiabin and Athreya, Arjun P. and Biernacka, Joanna M. and Bobo, William V. and Hall-Flavin, Daniel K. and Skime, Michelle K. and Zhu, Hongjie and Jenkins, Gregory D. and Batzler, Anthony and Kalari, Krishna R. and Boakye-Agyeman, Felix and Matson, Wayne R. and Bhasin, Swati S. and Mushiroda, Taisei and Nakamura, Yusuke and Kubo, Michiaki and Iyer, Ravishankar K. and Wang, Liewei and Frye, Mark A. and Kaddurah-Daouk, Rima and Weinshilboum, Richard M.	|	10.1038/s41398-017-0056-8	|
|	Can an Integrated Science Approach to Precision Medicine Research        Improve Lithium Treatment in Bipolar Disorders?	|	2018	|	FRONTIERS IN PSYCHIATRY	|	9	|		|		|	Scott, J and Etain, B and Bellivier, F and Scott, Jan and Etain, Bruno and Bellivier, Frank	|	10.3389/fpsyt.2018.00360	|
|	Plasma brain-derived neurotrophic factor (BDNF) concentration and the        BDNF Val66Met polymorphism in suicide: a prospective study in patients        with depressive disorder	|	2019	|	PHARMACOGENOMICS & PERSONALIZED MEDICINE	|	12	|		|	97-106	|	Ai, M and Wang, J and Chen, JM and Wang, W and Xu, XM and Gan, Y and Li, XM and Gou, XY and Cao, J and Lv, Z and Chen, XR and Wang, HG and Ma, Q and Kuang, L and Ai, Ming and Wang, Jun and Chen, Jianmei and Wang, Wo and Xu, Xiaoming and Gan, Yao and Li, Xuemei and Gou, Xinyuan and Cao, Jun and Lv, Zhen and Chen, Xiaorong and Wang, Hengguang and Ma, Qing and Kuang, Li	|	10.2147/PGPM.S201187	|
|	Personalized drug therapy in psychiatry: Maybe a little old or a little        new, but the treatment of future	|	2010	|	KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY	|	20	|	4	|	269-273	|	Aricioglu, F and Cetin, M and Aricioglu, Feyza and Cetin, Mesut	|		|
|	Influence of the catechol-O-methyltransferase Val108/158Met polymorphism        on the plasma concentration of catecholamine metabolites and on clinical        features in type I bipolar disorder - A preliminary report	|	2006	|	JOURNAL OF AFFECTIVE DISORDERS	|	92	|	2	|	277-281	|	Davila, R and Zumarraga, M and Basterreche, N and Arrue, A and Zamalloa, MI and Anguiano, JB and Davila, Ricardo and Zumarraga, Mercedes and Basterreche, Nieves and Arrue, Aurora and Zamalloa, M. Isabel and Anguiano, Juan B.	|	10.1016/j.jad.2006.02.009	|
|	CYP2D6 P34S Polymorphism and Mirtazapine Responses in Koreans with Major        Depression	|	2009	|	MOLECULAR & CELLULAR TOXICOLOGY	|	5	|	4	|	346-353	|	Jeon, SO and Chang, HS and Lee, HY and Ham, BJ and Kang, RH and Jeong, YJ and Lee, MS and Jeon, Si-On and Chang, Hun Soo and Lee, Hwa-Young and Ham, Byung-Joo and Kang, Rhee-Hun and Jeong, Yoo-Jung and Lee, Min-Soo	|		|
|	Genetic Predictors of Response to Serotonergic and Noradrenergic        Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of        Individual-Level Data and a Meta-Analysis	|	2012	|	PLOS MEDICINE	|	9	|	10	|		|	Katherine, E and Guipponi, M and Perroud, N and Bondolfi, G and Domenici, E and Evans, D and Hall, SK and Hauser, J and Henigsberg, N and Hu, XL and Jerman, B and Maier, W and Mors, O and O'Donovan, M and Peters, TJ and Placentino, A and Rietschel, M and Souery, D and Aitchison, KJ and Craig, I and Farmer, A and Wendland, JR and Malafosse, A and Holmans, P and Lewis, G and Lewis, CM and Stensbol, TB and Kapur, S and McGuffin, P and Uher, R and Tansey, Katherine E. and Guipponi, Michel and Perroud, Nader and Bondolfi, Guido and Domenici, Enrico and Evans, David and Hall, Stephanie K. and Hauser, Joanna and Henigsberg, Neven and Hu, Xiaolan and Jerman, Borut and Maier, Wolfgang and Mors, Ole and O'Donovan, Michael and Peters, Tim J. and Placentino, Anna and Rietschel, Marcella and Souery, Daniel and Aitchison, Katherine J. and Craig, Ian and Farmer, Anne and Wendland, Jens R. and Malafosse, Alain and Holmans, Peter and Lewis, Glyn and Lewis, Cathryn M. and Stensbol, Tine Bryan and Kapur, Shitij and McGuffin, Peter and Uher, Rudolf	|	10.1371/journal.pmed.1001326	|
|	Association of CRTC1 polymorphisms with obesity markers in subjects from        the general population with lifetime depression	|	2016	|	JOURNAL OF AFFECTIVE DISORDERS	|	198	|		|	43-49	|	Quteineh, L and Preisig, M and Rivera, M and Milaneschi, Y and Castelao, E and Gholam-Rezaee, M and Vandenberghe, F and Saigi-Morgui, N and Delacretaz, A and Cardinaux, JR and Willemsen, G and Boomsma, DI and Penninx, BWJH and Ching-Lopez, A and Conus, P and Eap, CB and Quteineh, Lina and Preisig, Martin and Rivera, Margarita and Milaneschi, Yuri and Castelao, Enrique and Gholam-Rezaee, Mehdi and Vandenberghe, Frederik and Saigi-Morgui, Nuria and Delacretaz, Aurelie and Cardinaux, Jean-Rene and Willemsen, Gonneke and Boomsma, Dorret I. and Penninx, Brenda W. J. H. and Ching-Lopez, Ana and Conus, Philippe and Eap, Chin B.	|	10.1016/j.jad.2016.03.031	|
|	A Cognitive-Emotional Biomarker for Predicting Remission with        Antidepressant Medications: A Report from the iSPOT-D Trial	|	2015	|	NEUROPSYCHOPHARMACOLOGY	|	40	|	6	|	1332-1342	|	Etkin, A and Patenaude, B and Song, YJC and Usherwood, T and Rekshan, W and Schatzberg, AF and Rush, AJ and Williams, LM and Etkin, Amit and Patenaude, Brian and Song, Yun Ju C. and Usherwood, Timothy and Rekshan, William and Schatzberg, Alan F. and Rush, A. John and Williams, Leanne M.	|	10.1038/npp.2014.333	|
|	Harm avoidance involved in mediating the association between nerve        growth factor (NGF) gene polymorphisms and antidepressant efficacy in        patients with major depressive disorder	|	2015	|	JOURNAL OF AFFECTIVE DISORDERS	|	183	|		|	187-194	|	Yeh, YW and Kuo, SC and Chen, CY and Liang, CS and Ho, PS and Yen, CH and Chen, TY and Shyu, JF and Wan, FJ and Lug, RB and Huang, SY and Yeh, Yi-Wei and Kuo, Shin-Chang and Chen, Chun-Yen and Liang, Chih-Sung and Ho, Pei-Shen and Yen, Che-Hung and Chen, Tien-Yu and Shyu, Jia-Fwu and Wan, Fang-Jung and Lug, Ru-Band and Huang, San-Yuan	|	10.1016/j.jad.2015.05.012	|
|	Dysbindin associated with selective serotonin reuptake inhibitor        antidepressant efficacy	|	2007	|	PHARMACOGENETICS AND GENOMICS	|	17	|	1	|	69-75	|	Pae, CU and Serretti, A and Mandelli, L and De Ronchi, D and Patkar, AA and Jun, TY and Kim, JJ and Lee, CU and Lee, SJ and Lee, C and Paik, IH and Pae, Chi-Un and Serretti, Alessandro and Mandelli, Laura and De Ronchi, Diana and Patkar, Ashwin A. and Jun, Tae-Youn and Kim, Jung-Jin and Lee, Chang-Uk and Lee, Soo-Jung and Lee, Chul and Paik, In-Ho	|	10.1097/01.fpc.0000236330.03681.6d	|
|	Biomarkers to Predict Antidepressant Response	|	2010	|	CURRENT PSYCHIATRY REPORTS	|	12	|	6	|	553-562	|	Leuchter, AF and Cook, IA and Hamilton, SP and Narr, KL and Toga, A and Hunter, AM and Faull, K and Whitelegge, J and Andrews, AM and Loo, J and Way, B and Nelson, SF and Horvath, S and Lebowitz, BD and Leuchter, Andrew F. and Cook, Ian A. and Hamilton, Steven P. and Narr, Katherine L. and Toga, Arthur and Hunter, Aimee M. and Faull, Kym and Whitelegge, Julian and Andrews, Anne M. and Loo, Joseph and Way, Baldwin and Nelson, Stanley F. and Horvath, Steven and Lebowitz, Barry D.	|	10.1007/s11920-010-0160-4	|
|	SOD2 genetic polymorphism (rs4880) has no impact on 6-month response to        antidepressant treatment and inflammatory biomarkers in depressed        patients	|	2020	|	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY	|	126	|	3	|	289-295	|	Tayeb, AA and Becquemont, L and El-Asmar, K and Mahmoudi, K and Colle, R and Trabado, S and Gressier, F and Feve, B and Corruble, E and Verstuyft, C and Tayeb, Abd El Kader Ait and Becquemont, Laurent and El-Asmar, Khalil and Mahmoudi, Kaina and Colle, Romain and Trabado, Severine and Gressier, Florence and Feve, Bruno and Corruble, Emmanuelle and Verstuyft, Celine	|	10.1111/bcpt.13385     EA JAN 2020	|
|	Pharmacogenetics of Antipsychotic Treatment in Schizophrenia	|	2014	|	PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT, 2ND EDITION	|	1175	|		|	557-587	|	Pouget, JG and Muller, DJ and Pouget, Jennie G. and Mueller, Daniel J.	|	10.1007/978-1-4939-0956-8_14     D2 10.1007/978-1-4939-0956-8	|
|	Vilazodone, a novel dual-acting serotonergic antidepressant for managing        major depression	|	2009	|	EXPERT OPINION ON INVESTIGATIONAL DRUGS	|	18	|	11	|	1753-1764	|	Khan, A and Khan, Arif	|	10.1517/13543780903286396	|
|	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results	|	2009	|	PSYCHIATRIC SERVICES	|	60	|	11	|	1446-1457	|	Laje, G and Perlis, RH and Rush, AJ and McMahon, FJ and Laje, Gonzalo and Perlis, Roy H. and Rush, A. John and McMahon, Francis J.	|	10.1176/ps.2009.60.11.1446	|
|	Peripheral biomarkers of major depression and antidepressant treatment        response: Current knowledge and future outlooks	|	2018	|	JOURNAL OF AFFECTIVE DISORDERS	|	233	|		|	14-Mar	|	Gadad, BS and Jha, MK and Czysz, A and Furman, JL and Mayes, TL and Emslie, MP and Trivedi, MH and Gadad, Bharathi S. and Jha, Manish K. and Czysz, Andrew and Furman, Jennifer L. and Mayes, Taryn L. and Emslie, Michael P. and Trivedi, Madhukar H.	|	10.1016/j.jad.2017.07.001	|
|	A genetic network model of cellular responses to lithium treatment and        cocaine abuse in bipolar disorder	|	2010	|	BMC SYSTEMS BIOLOGY	|	4	|		|		|	McEachin, RC and Chen, HM and Sartor, MA and Saccone, SF and Keller, BJ and Prossin, AR and Cavalcoli, JD and McInnis, MG and McEachin, Richard C. and Chen, Haiming and Sartor, Maureen A. and Saccone, Scott F. and Keller, Benjamin J. and Prossin, Alan R. and Cavalcoli, James D. and McInnis, Melvin G.	|	10.1186/1752-0509-4-158	|
|	DNA methylation in interleukin-11 predicts clinical response to        antidepressants in GENDEP	|	2013	|	TRANSLATIONAL PSYCHIATRY	|	3	|		|		|	Powell, TR and Smith, RG and Hackinger, S and Schalkwyk, LC and Uher, R and McGuffin, P and Mill, J and Tansey, KE and Powell, T. R. and Smith, R. G. and Hackinger, S. and Schalkwyk, L. C. and Uher, R. and McGuffin, P. and Mill, J. and Tansey, K. E.	|	10.1038/tp.2013.73	|
|	Catechol O-methyltransferase pharmacogenomics and selective serotonin        reuptake inhibitor response	|	2012	|	PHARMACOGENOMICS JOURNAL	|	12	|	1	|	78-85	|	Ji, Y and Biernacka, J and Snyder, K and Drews, M and Pelleymounter, LL and Colby, C and Wang, L and Mrazek, DA and Weinshilboum, RM and Ji, Y. and Biernacka, J. and Snyder, K. and Drews, M. and Pelleymounter, L. L. and Colby, C. and Wang, L. and Mrazek, D. A. and Weinshilboum, R. M.	|	10.1038/tpj.2010.69	|
|	Pharmacogenetics of antidepressant drugs: current clinical practice and        future directions	|	2012	|	PHARMACOGENOMICS	|	13	|	4	|	441-464	|	Narasimhan, S and Lohoff, FW and Narasimhan, Sneha and Lohoff, Falk W.	|	10.2217/PGS.12.1	|
|	Prognostic models in bipolar disorder: can the prediction of the        long-term clinical course rely on the integration of clinical and        molecular data?	|	2014	|	BIOMARKERS IN MEDICINE	|	8	|	3	|	371-374	|	Pinna, M and Manchia, M and Pinna, Martina and Manchia, Mirko	|	10.2217/bmm.13.153	|
|	Pharmacogenetics of antipsychotics: Clinical utility and implementation	|	2021	|	BEHAVIOURAL BRAIN RESEARCH	|	401	|		|		|	Arranz, MJ and Salazar, J and Hernandez, MH and Arranz, Maria J. and Salazar, Juliana and Hernandez, Marta H.	|	10.1016/j.bbr.2020.113058	|
|	Developing the evidence base for applying pharmacogenomics: proceeds        from DIA Workshop IV - Breakout Session 1	|	2009	|	PHARMACOGENOMICS	|	10	|	1	|	117-125	|	Armstrong, M and Bromley, C and Cohen, N and Hunt, CM and O'Neil, R and Power, A and Armstrong, Martin and Bromley, Christina and Cohen, Nadine and Hunt, Christine M. and O'Neil, Robert and Power, Aidan	|	10.2217/14622416.10.1.117	|
|	Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes'        single-nucleotide polymorphism imputation: selective serotonin reuptake        inhibitor response pharmacogenomics	|	2012	|	PHARMACOGENETICS AND GENOMICS	|	22	|	4	|	247-253	|	Abo, R and Hebbring, S and Ji, Y and Zhu, HJ and Zeng, ZB and Batzler, A and Jenkins, GD and Biernacka, J and Snyder, K and Drews, M and Fiehn, O and Fridley, B and Schaid, D and Kamatani, N and Nakamura, Y and Kubo, M and Mushiroda, T and Kaddurah-Daouk, R and Mrazek, DA and Weinshilboum, RM and Abo, Ryan and Hebbring, Scott and Ji, Yuan and Zhu, Hongjie and Zeng, Zhao-Bang and Batzler, Anthony and Jenkins, Gregory D. and Biernacka, Joanna and Snyder, Karen and Drews, Maureen and Fiehn, Oliver and Fridley, Brooke and Schaid, Daniel and Kamatani, Naoyuki and Nakamura, Yusuke and Kubo, Michiaki and Mushiroda, Taisei and Kaddurah-Daouk, Rima and Mrazek, David A. and Weinshilboum, Richard M.	|	10.1097/FPC.0b013e32835001c9	|
|	DRD1 rs4532 polymorphism: A potential pharmacogenomic marker for        treatment response to antipsychotic drugs	|	2012	|	SCHIZOPHRENIA RESEARCH	|	142	|	1	|	206-208	|	Ota, VK and Spindola, LN and Gadelha, A and dos Santos, AF and Santoro, ML and Christofolini, DM and Bellucco, FT and Ribeiro-dos-Santos, AK and Santos, S and Mari, JD and Melaragno, MI and Bressan, RA and Smith, MDC and Belangero, SI and Ota, Vanessa Kiyomi and Spindola, Leticia Nery and Gadelha, Ary and dos Santos Filho, Airton Ferreira and Santoro, Marcos Leite and Christofolini, Denise Maria and Bellucco, Fernanda Teixeira and Ribeiro-dos-Santos, Andrea Kely and Santos, Sidney and Mari, Jair de Jesus and Melaragno, Maria Isabel and Bressan, Rodrigo Affonseca and Cardoso Smith, Marilia de Arruda and Belangero, Sintia Iole	|	10.1016/j.schres.2012.08.003	|
|	Consensus on potential biomarkers developed for use in clinical tests        for schizophrenia	|	2022	|	GENERAL PSYCHIATRY	|	35	|	1	|		|	Lin, P and Sun, JY and Lou, XY and Li, D and Shi, Y and Li, ZH and Ma, PJ and Li, P and Chen, SZ and Jin, WF and Liu, S and Chen, Q and Gao, Q and Zhu, LL and Xu, J and Zhu, MY and Wang, MX and Liang, KY and Zhao, L and Xu, HB and Dong, K and Li, QT and Cheng, XJ and Chen, JH and Guo, XK and Lin, Ping and Sun, Junyu and Lou, Xiaoyan and Li, Dan and Shi, Yun and Li, Zhenhua and Ma, Peijun and Li, Ping and Chen, Shuzi and Jin, Weifeng and Liu, Shuai and Chen, Qing and Gao, Qiong and Zhu, Lili and Xu, Jie and Zhu, Mengyuan and Wang, Mengxia and Liang, Kangyi and Zhao, Ling and Xu, Huabin and Dong, Ke and Li, Qingtian and Cheng, Xunjia and Chen, Jinghong and Guo, Xiaokui	|	10.1136/gpsych-2021-100685	|
|	Genetic Prediction of Antidepressant Drug Response and Nonresponse in        Korean Patients	|	2014	|	PLOS ONE	|	9	|	9	|		|	Lim, SW and Won, HH and Kim, H and Myung, W and Kim, S and Kim, KK and Carroll, BJ and Kim, JW and Kim, DK and Lim, Shinn-Won and Won, Hong-Hee and Kim, Hyeran and Myung, Woojae and Kim, Seonwoo and Kim, Ka-Kyung and Carroll, Bernard J. and Kim, Jong-Won and Kim, Doh Kwan	|	10.1371/journal.pone.0107098	|
|	Pharmacogenomics in the era of next generation sequencing - from byte to        bedside	|	2021	|	DRUG METABOLISM REVIEWS	|	53	|	2	|	253-278	|	Russell, LE and Zhou, YT and Almousa, AA and Sodhi, JK and Nwabufo, CK and Lauschke, VM and Russell, Laura E. and Zhou, Yitian and Almousa, Ahmed A. and Sodhi, Jasleen K. and Nwabufo, Chukwunonso K. and Lauschke, Volker M.	|	10.1080/03602532.2021.1909613     EA MAY 2021	|
|	Intrinsic reward circuit connectivity profiles underlying symptom and        quality of life outcomes following antidepressant medication: a report        from the iSPOT-D trial	|	2021	|	NEUROPSYCHOPHARMACOLOGY	|	46	|	4	|	809-819	|	Fischer, AS and Holt-Gosselin, B and Fleming, SL and Hack, LM and Ball, TM and Schatzberg, AF and Williams, LM and Fischer, Adina S. and Holt-Gosselin, Bailey and Fleming, Scott L. and Hack, Laura M. and Ball, Tali M. and Schatzberg, Alan F. and Williams, Leanne M.	|	10.1038/s41386-020-00905-3     EA NOV 2020	|
|	Polymorphism of RGS2 gene as genetic marker of schizophrenia risk and        pharmacogenetic markers of the efficiency of typical neuroleptics	|	2013	|	MOLECULAR BIOLOGY	|	47	|	6	|	814-820	|	Gareeva, AE and Zakirov, DF and Valinurov, RG and Khusnutdinova, EK and Gareeva, A. E. and Zakirov, D. F. and Valinurov, R. G. and Khusnutdinova, E. K.	|	10.1134/S0026893313060046	|
|	A polygenic-informed approach to a predictive EEG signature empowers        antidepressant treatment prediction: A proof-of-concept study	|	2022	|	EUROPEAN NEUROPSYCHOPHARMACOLOGY	|	62	|		|	49-60	|	Meijs, H and Prentice, A and Lin, BD and De Wilde, B and Van Hecke, J and Niemegeers, P and van Eijk, K and Luykx, JJ and Arns, M and Meijs, Hannah and Prentice, Amourie and Lin, Bochao D. and De Wilde, Bieke and Van Hecke, Jan and Niemegeers, Peter and van Eijk, Kristel and Luykx, Jurjen J. and Arns, Martijn	|	10.1016/j.euroneuro.2022.07.006	|
|	Escitalopram and Neuroendocrine Response in Healthy First-Degree        Relatives to Depressed Patients - A Randomized Placebo-Controlled Trial	|	2011	|	PLOS ONE	|	6	|	6	|		|	Knorr, U and Vinberg, M and Hansen, A and Klose, M and Feldt-Rasmussen, U and Hilsted, L and Hasselstrom, J and Gether, U and Winkel, P and Gluud, C and Wetterslev, J and Kessing, LV and Knorr, Ulla and Vinberg, Maj and Hansen, Allan and Klose, Marianne and Feldt-Rasmussen, Ulla and Hilsted, Linda and Hasselstrom, Jorgen and Gether, Ulrik and Winkel, Per and Gluud, Christian and Wetterslev, Jorn and Kessing, Lars Vedel	|	10.1371/journal.pone.0021224	|
|	Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms        of Drug Metabolizing Enzymes and Transporters	|	2021	|	PHARMACEUTICALS	|	14	|	3	|		|	Iannaccone, T and Sellitto, C and Manzo, V and Colucci, F and Giudice, V and Stefanelli, B and Iuliano, A and Corrivetti, G and Filippelli, A and Iannaccone, Teresa and Sellitto, Carmine and Manzo, Valentina and Colucci, Francesca and Giudice, Valentina and Stefanelli, Berenice and Iuliano, Antonio and Corrivetti, Giulio and Filippelli, Amelia	|	10.3390/ph14030204	|
|	Pharmacogenetics of mood disorders: what clinicians need to know	|	2013	|	CNS SPECTRUMS	|	18	|	5	|	272-284	|	Laje, G and Laje, Gonzalo	|	10.1017/S1092852913000278	|
|	Pharmacogenetics of second-generation antipsychotics	|	2014	|	PHARMACOGENOMICS	|	15	|	6	|	869-884	|	Brennan, MD and Brennan, Mark D.	|	10.2217/PGS.14.50	|
|	Clinical application of antidepressant pharmacogenetics: Considerations        for the design of future studies	|	2020	|	NEUROSCIENCE LETTERS	|	726	|		|		|	Fabbri, C and Serretti, A and Fabbri, Chiara and Serretti, Alessandro	|	10.1016/j.neulet.2018.06.020	|
|	Polymorphism of brain neurotransmitter system genes: Search for        pharmacogenetic markers of haloperidol efficiency in Russians and Tatars	|	2015	|	MOLECULAR BIOLOGY	|	49	|	6	|	858-866	|	Gareeva, AE and Kinyasheva, KO and Galaktionova, DY and Sabirov, ET and Valinourov, RG and Chudinov, AV and Zasedatelev, AS and Nasedkina, TV and Khusnutdinova, EK and Gareeva, A. E. and Kinyasheva, K. O. and Galaktionova, D. Yu. and Sabirov, E. T. and Valinourov, R. G. and Chudinov, A. V. and Zasedatelev, A. S. and Nasedkina, T. V. and Khusnutdinova, E. K.	|	10.1134/S0026893315050076	|
|	Data Science Approaches to Pharmacogenetics	|	2014	|	CURRENT MOLECULAR MEDICINE	|	14	|	7	|	805-813	|	Penrod, NM and Moore, JH and Penrod, N. M. and Moore, J. H.	|	10.2174/1566524014666140811112438	|
|	Understanding the pharmacogenetics of selective serotonin reuptake        inhibitors	|	2014	|	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	|	10	|	8	|	1093-1118	|	Fabbri, C and Minarini, A and Niitsu, T and Serretti, A and Fabbri, Chiara and Minarini, Alessandro and Niitsu, Tomihisa and Serretti, Alessandro	|	10.1517/17425255.2014.928693	|
|	Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders	|	2009	|	NEUROPSYCHOPHARMACOLOGY	|	34	|	1	|	159-172	|	de Leon, J and de Leon, Jose	|	10.1038/npp.2008.147	|
|	A pharmacogenetic study of risperidone on histamine H3 receptor gene        (HRH3) in Chinese Han schizophrenia patients	|	2012	|	JOURNAL OF PSYCHOPHARMACOLOGY	|	26	|	6	|	813-818	|	Wei, ZY and Wang, L and Zhang, MM and Xuan, JK and Wang, Y and Liu, BC and Shao, LY and Li, J and Zeng, Z and Li, T and Liu, J and Wang, T and Zhang, M and Qin, SY and Xu, YF and Feng, GY and He, L and Xing, QH and Wei, Zhiyun and Wang, Lei and Zhang, Mengmeng and Xuan, Jiekun and Wang, Yang and Liu, Baocheng and Shao, Liyan and Li, Jun and Zeng, Zhen and Li, Tao and Liu, Jie and Wang, Ti and Zhang, Ming and Qin, Shengying and Xu, Yifeng and Feng, Guoyin and He, Lin and Xing, Qinghe	|	10.1177/0269881111405358	|
|	Analysis of treatment-resistant schizophrenia and 384 markers from        candidate genes	|	2012	|	PHARMACOGENETICS AND GENOMICS	|	22	|	11	|	807-811	|	Teo, C and Zai, C and Borlido, C and Tomasetti, C and Strauss, J and Shinkai, T and Le Foll, B and Wong, A and Kennedy, JL and De Luca, V and Teo, Celine and Zai, Clement and Borlido, Carol and Tomasetti, Carmine and Strauss, John and Shinkai, Takahiro and Le Foll, Bernard and Wong, Albert and Kennedy, James L. and De Luca, Vincenzo	|	10.1097/FPC.0b013e3283586c04	|
|	Pharmacogenomics in Psychiatric Disorders	|	2020	|	BRAIN-BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE	|	11	|	1	|	57-66	|	Tauser, RG and Tauser, Roxana-Georgiana	|	10.18662/brain/11.1Sup2/39	|
|	Variation in the gene encoding the serotonin 2A receptor is associated        with outcome of antidepressant treatment	|	2006	|	AMERICAN JOURNAL OF HUMAN GENETICS	|	78	|	5	|	804-814	|	McMahon, FJ and Buervenich, S and Charney, D and Lipsky, R and Rush, AJ and Wilson, AF and Sorant, AJM and Papanicolaou, GJ and Laje, G and Fava, M and Trivedi, MH and Wisniewski, SR and Manji, H and McMahon, FJ and Buervenich, S and Charney, D and Lipsky, R and Rush, AJ and Wilson, AF and Sorant, AJM and Papanicolaou, GJ and Laje, G and Fava, M and Trivedi, MH and Wisniewski, SR and Manji, H	|	10.1086/503820	|
|	Clinical and pharmacogenetic determinants for the discontinuation of        non-ergoline dopamine agonists in Parkinson's disease	|	2009	|	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	|	65	|	12	|	1245-1251	|	Arbouw, MEL and Movig, KLL and Egberts, TCG and Poels, PJE and van Vugt, JPP and Wessels, JAM and van der Straaten, RJHM and Neef, C and Guchelaar, HJ and Arbouw, Maurits E. L. and Movig, Kris L. L. and Egberts, Toine C. G. and Poels, Petra J. E. and van Vugt, Jeroen P. P. and Wessels, Judith A. M. and van der Straaten, R. J. H. M. and Neef, Cees and Guchelaar, Henk-Jan	|	10.1007/s00228-009-0708-6	|
|	Recent Progress in Pharmacogenomics of Antipsychotic Drug Response	|	2018	|	CURRENT PSYCHIATRY REPORTS	|	20	|	4	|		|	Zhang, JP and Malhotra, AK and Zhang, Jian-Ping and Malhotra, Anil K.	|	10.1007/s11920-018-0886-y	|
|	Diverse Facets of COMT: From a Plausible Predictive Marker to a        Potential Drug Target for Schizophrenia	|	2011	|	CURRENT MOLECULAR MEDICINE	|	11	|	9	|	732-743	|	Gupta, M and Kaur, H and Jajodia, A and Jain, S and Satyamoorthy, K and Mukerji, M and Thirthalli, J and Kukreti, R and Gupta, M. and Kaur, H. and Jajodia, A. and Jain, S. and Satyamoorthy, K. and Mukerji, M. and Thirthalli, J. and Kukreti, R. and Indian Genome Variation Consortium	|	10.2174/156652411798062386	|
|	Research Progress and Clinical Application of Psychiatric Imaging        Pharmacogenomics	|	2019	|	PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS	|	46	|	1	|	51-62	|	Zhang, YZ and Chen, TL and Gong, QY and Zhang Ying-Zhe and Chen Tao-Lin and Gong Qi-Yong	|	10.16476/j.pibb.2018.0137	|
|	Biomarkers predicting treatment outcome in depression: what is        clinically significant?	|	2012	|	PHARMACOGENOMICS	|	13	|	2	|	233-240	|	Uher, R and Tansey, KE and Malki, K and Perlis, RH and Uher, Rudolf and Tansey, Katherine E. and Malki, Karim and Perlis, Roy H.	|	10.2217/PGS.11.161	|
|	Schizophrenia risk genes: Implications for future drug development and        discovery	|	2011	|	BIOCHEMICAL PHARMACOLOGY	|	81	|	12	|	1367-1373	|	O'Connell, G and Lawrie, SM and McIntosh, AM and Hall, J and O'Connell, Garret and Lawrie, Stephen M. and McIntosh, Andrew M. and Hall, Jeremy	|	10.1016/j.bcp.2010.11.009	|
|	Association between type-three metabotropic glutamate receptor gene        (GRM3) variants and symptom presentation in treatment refractory        schizophrenia	|	2011	|	HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL	|	26	|	1	|	28-34	|	Bishop, JR and Miller, DD and Ellingrod, VL and Holman, T and Bishop, Jeffrey R. and Miller, Del D. and Ellingrod, Vicki L. and Holman, Timothy	|	10.1002/hup.1163	|
|	The efficacies of clozapine and haloperidol in refractory schizophrenia        are related to DTNBP1 variation	|	2009	|	PHARMACOGENETICS AND GENOMICS	|	19	|	6	|	437-446	|	Zuo, LJ and Luo, XG and Krystal, JH and Cramer, J and Charney, DS and Gelernter, J and Zuo, Lingjun and Luo, Xinaguang and Krystal, John H. and Cramer, Joyce and Charney, Dennis S. and Gelernter, Joel	|	10.1097/FPC.0b013e32832b9cfc	|
|	Asthma pharmacogenetic study using finite mixture models to handle        drug-response heterogeneity	|	2009	|	PHARMACOGENOMICS	|	10	|	5	|	753-767	|	York, TP and Vargas-Irwin, C and Anderson, WH and van den Oord, EJCG and York, Timothy P. and Vargas-Irwin, Cristina and Anderson, Wayne H. and van den Oord, Edwin J. C. G.	|	10.2217/PGS.09.19	|
|	Schizophrenia Genetics	|	2018	|	RUSSIAN JOURNAL OF GENETICS	|	54	|	6	|	593-603	|	Gareeva, AE and Khusnutdinova, EK and Gareeva, A. E. and Khusnutdinova, E. K.	|	10.1134/S1022795418050046	|
|	Putative role of pharmacogenetics to elucidate the mechanism of tardive        dyskinesia in schizophrenia	|	2019	|	PHARMACOGENOMICS	|	20	|	17	|	1199-1223	|	Loonen, AJM and Wilffert, B and Ivanova, SA and Loonen, Anton J. M. and Wilffert, Bob and Ivanova, Svetlana A.	|	10.2217/pgs-2019-0100	|
|	Association of HTR2A Polymorphisms with Risperidone Efficacy in Chinese        Han Schizophrenia Patients	|	2015	|	KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY	|	25	|	1	|	11-Apr	|	Yan, YC and Wei, ZY and Xiong, YY and Jiang, J and Huo, R and Shen, L and Sun, LY and Liu, YC and Cui, DH and Li, WQ and Zhao, JY and He, L and Xing, QH and Qin, SY and Yan, Yucai and Wei, Zhiyun and Xiong, Yuyu and Jiang, Jie and Huo, Ran and Shen, Lu and Sun, Liya and Liu, Yichen and Cui, Donghong and Li, Wenqiang and Zhao, Jingyuan and He, Lin and Xing, Qinghe and Qin, Shengying	|	10.5455/bcp.20140802124158	|
|	Response to fluoxetine in children and adolescents: a weighted gene        co-expression network analysis of peripheral blood	|	2020	|	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH	|	12	|	5	|	2028-2040	|	Torres, T and Boloc, D and Rodriguez, N and Blazquez, A and Plana, MT and Varela, E and Gasso, P and Martinez-Pinteno, A and Lazaro, L and Arnaiz, JA and Mas, S and Torres, Teresa and Boloc, Daniel and Rodriguez, Natalia and Blazquez, Ana and Teresa Plana, Maria and Varela, Eva and Gasso, Patricia and Martinez-Pinteno, Albert and Lazaro, Luisa and Albert Arnaiz, Joan and Mas, Sergi	|		|
|	The putative functional rs1045881 marker of neurexin-1 in schizophrenia        and clozapine response	|	2011	|	SCHIZOPHRENIA RESEARCH	|	132	|	2	|	121-124	|	Lett, TAP and Tiwari, AK and Meltzer, HY and Lieberman, JA and Potkin, SG and Voineskos, AN and Kennedy, JL and Muller, DJ and Lett, Tristram A. P. and Tiwari, Arun K. and Meltzer, Herbert Y. and Lieberman, Jeffrey A. and Potkin, Steven G. and Voineskos, Aristotle N. and Kennedy, James L. and Mueller, Daniel J.	|	10.1016/j.schres.2011.08.007	|
|	TRYPTOPHAN METABOLITE RATIO PHARMACOGENOMICS AND PHARMACOMETABOLOMICS:        SOD2 AS A MARKER FOR SSRI RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE        DISORDER (MDD).	|	2015	|	CLINICAL PHARMACOLOGY & THERAPEUTICS	|	97	|		|	S15-S15	|	Neavin, D and Taddei, A and Ray, B and Biernacka, J and Zhu, H and Jenkins, G and Kalari, K and Mushiroda, T and Nakamura, Y and Kubo, M and Matson, W and Wang, L and Kaddurah-Daouk, R and Weinshilboum, R and Neavin, D. and Taddei, A. and Ray, B. and Biernacka, J. and Zhu, H. and Jenkins, G. and Kalari, K. and Mushiroda, T. and Nakamura, Y. and Kubo, M. and Matson, W. and Wang, L. and Kaddurah-Daouk, R. and Weinshilboum, R.	|		|
|	Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in        patients with schizophrenia	|	2017	|	PHYSIOLOGY AND PHARMACOLOGY	|	21	|	1	|	25-33	|	Fedorenko, OY and Loonen, AJM and Vyalova, NM and Boiko, AS and Pozhidaev, IV and Osmanova, DZ and Rakhmazova, LD and Bokhan, NA and Ivanov, MV and Freidin, MB and Ivanova, SA and Fedorenko, Olga Yu. and Loonen, Anton J. M. and Vyalova, Natalya M. and Boiko, Anastasiya S. and Pozhidaev, Ivan V. and Osmanova, Diana Z. and Rakhmazova, Lyubov D. and Bokhan, Nikolay A. and Ivanov, Mikhail V. and Freidin, Maxim B. and Ivanova, Svetlana A.	|		|
|	Genetic determinants of selective serotonin reuptake inhibitor related        sexual dysfunction	|	2014	|	PHARMACOGENOMICS	|	15	|	14	|	1791-1806	|	Stevenson, JM and Bishop, JR and Stevenson, James M. and Bishop, Jeffrey R.	|	10.2217/pgs.14.114	|
|	The influences of CYP2D6 genotypes and drug interactions on the        pharmacokinetics of venlafaxine: exploring predictive biomarkers for        treatment outcomes	|	2015	|	PSYCHOPHARMACOLOGY	|	232	|	11	|	1899-1909	|	Jiang, F and Kim, HD and Na, HS and Lee, SY and Seo, DW and Choi, JY and Ha, JH and Shin, HJ and Kim, YH and Chung, MW and Jiang, Fen and Kim, Hae-Deun and Na, Han-Sung and Lee, Seok-Yong and Seo, Doo-Won and Choi, Jong-Yeol and Ha, Ji-Hye and Shin, Hee-Jung and Kim, Young-Hoon and Chung, Myeon-Woo	|	10.1007/s00213-014-3825-6	|
|	ADME pharmacogenetics: current practices and future outlook	|	2009	|	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY	|	5	|	5	|	449-462	|	Grossman, I and Grossman, Iris	|	10.1517/17425250902902322	|
|	Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme        and Transporter Genes Associated with Steady-State Plasma Concentrations        of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder        Patients	|	2016	|	FRONTIERS IN PHARMACOLOGY	|	7	|		|		|	Medhasi, S and Pinthong, D and Pasomsub, E and Vanwong, N and Ngamsamut, N and Puangpetch, A and Chamnanphon, M and Hongkaew, Y and Pratoomwun, J and Limsila, P and Sukasem, C and Medhasi, Sadeep and Pinthong, Darawan and Pasomsub, Ekawat and Vanwong, Natchaya and Ngamsamut, Nattawat and Puangpetch, Apichaya and Chamnanphon, Monpat and Hongkaew, Yaowaluck and Pratoomwun, Jirawat and Limsila, Penkhae and Sukasem, Chonlaphat	|	10.3389/fphar.2016.00475	|
|	From Pharmacogenomics and Systems Biology to Personalized Care: A        Framework of Systems and Dynamical Medicine	|	2014	|	PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT, 2ND EDITION	|	1175	|		|	17-Mar	|	Yan, Q and Yan, Qing	|	10.1007/978-1-4939-0956-8_1     D2 10.1007/978-1-4939-0956-8	|
|	Two Novel Loci of RELN Associated With Antipsychotics Response in        Chinese Han Population	|	2020	|	FRONTIERS IN PHARMACOLOGY	|	11	|		|		|	Xu, QQ and Li, M and Qin, SY and Li, YJ and Ning, AL and Fu, YM and Wang, DX and Zeng, D and Li, HF and Yu, WJ and Yu, SY and Xu, Qingqing and Li, Mo and Qin, Shengying and Li, Yaojing and Ning, Ailing and Fu, Yingmei and Wang, Dongxiang and Zeng, Duan and Li, Huafang and Yu, Wenjuan and Yu, Shunying	|	10.3389/fphar.2020.00007	|
|	Association between Global Assessment of Functioning scores and        indicators of functioning, severity, and prognosis in first-time        schizophrenia	|	2016	|	CLINICAL EPIDEMIOLOGY	|	8	|		|	323-+	|	Kohler, O and Horsdal, HT and Baandrup, L and Mors, O and Gasse, C and Kohler, Ole and Horsdal, Henriette Thisted and Baandrup, Lone and Mors, Ole and Gasse, Christiane	|	10.2147/CLEP.S109036	|
|	Variants of GRM7 as risk factor and response to antipsychotic therapy in        schizophrenia	|	2020	|	TRANSLATIONAL PSYCHIATRY	|	10	|	1	|		|	Liang, W and Yu, H and Su, Y and Lu, TL and Yan, H and Yue, WH and Zhang, D and Liang, Wei and Yu, Hao and Su, Yi and Lu, Tianlan and Yan, Hao and Yue, Weihua and Zhang, Dai	|	10.1038/s41398-020-0763-4	|
|	Pharmacogenomics of neuropsychiatric disorders: analysis of genetic        variability in 162 identified neuroreceptors using 1000 Genomes Project        data	|	2014	|	PHARMACOGENOMICS	|	15	|	12	|	1575-1587	|	Kaur, H and Jajodia, A and Grover, S and Agarwal, N and Baghel, R and Kukreti, R and Kaur, Harpreet and Jajodia, Ajay and Grover, Sandeep and Agarwal, Nidhi and Baghel, Ruchi and Kukreti, Ritushree	|	10.2217/PGS.14.113	|
|	A systematic meta-review of predictors of antidepressant treatment        outcome in major depressive disorder	|	2019	|	JOURNAL OF AFFECTIVE DISORDERS	|	243	|		|	503-515	|	Perlman, K and Benrimoh, D and Israel, S and Rollins, C and Brown, E and Tunteng, JF and You, R and You, E and Tanguay-Sela, M and Snook, E and Miresco, M and Berlim, MT and Perlman, Kelly and Benrimoh, David and Israel, Sonia and Rollins, Colleen and Brown, Eleanor and Tunteng, Jingla-Fri and You, Raymond and You, Eunice and Tanguay-Sela, Myriam and Snook, Emily and Miresco, Marc and Berlim, Marcelo T.	|	10.1016/j.jad.2018.09.067	|
|	Calorimetric monitoring of the serum proteome in schizophrenia patients	|	2013	|	THERMOCHIMICA ACTA	|	572	|		|	59-64	|	Krumova, S and Rukova, B and Todinova, S and Gartcheva, L and Milanova, V and Toncheva, D and Taneva, SG and Krumova, Sashka and Rukova, Blaga and Todinova, Svetla and Gartcheva, Lidia and Milanova, Vihra and Toncheva, Draga and Taneva, Stefka G.	|	10.1016/j.tca.2013.09.015	|
|	Towards precision medicine in generalized anxiety disorder: Review of        genetics and pharmaco(epi)genetics	|	2019	|	JOURNAL OF PSYCHIATRIC RESEARCH	|	119	|		|	33-47	|	Tomasi, J and Lisoway, AJ and Zai, CC and Harripaul, R and Muller, DJ and Zai, GCM and McCabe, RE and Richter, MA and Kennedy, JL and Tiwari, AK and Tomasi, Julia and Lisoway, Amanda J. and Zai, Clement C. and Harripaul, Ricardo and Muller, Daniel J. and Zai, Gwyneth C. M. and McCabe, Randi E. and Richter, Margaret A. and Kennedy, James L. and Tiwari, Arun K.	|	10.1016/j.jpsychires.2019.09.002	|
|	PPP3CC gene: a putative modulator of antidepressant response through the        B-cell receptor signaling pathway	|	2014	|	PHARMACOGENOMICS JOURNAL	|	14	|	5	|	463-472	|	Fabbri, C and Marsano, A and Albani, D and Chierchia, A and Calati, R and Drago, A and Crisafull, C and Calabro, M and Kasper, S and Lanzenberger, R and Zohar, J and Juven-Wetzler, A and Souery, D and Montgomery, S and Mendlewicz, J and Serretti, A and Fabbri, C. and Marsano, A. and Albani, D. and Chierchia, A. and Calati, R. and Drago, A. and Crisafull, C. and Calabro, M. and Kasper, S. and Lanzenberger, R. and Zohar, J. and Juven-Wetzler, A. and Souery, D. and Montgomery, S. and Mendlewicz, J. and Serretti, A.	|	10.1038/tpj.2014.15	|
|	Genome-wide approaches to antidepressant treatment: working towards        understanding and predicting response	|	2012	|	GENOME MEDICINE	|	4	|		|		|	Hodgson, K and Mufti, SJ and Uher, R and McGuffin, P and Hodgson, Karen and Mufti, Shaista Jeelani and Uher, Rudolf and McGuffin, Peter	|	10.1186/gm351	|
|	Molecular genetics of schizophrenia: a critical review	|	2003	|	JOURNAL OF PSYCHIATRY & NEUROSCIENCE	|	28	|	6	|	415-429	|	Berry, N and Jobanputra, V and Pal, H and Berry, N and Jobanputra, V and Pal, H	|		|
|	The impact of COMT gene polymorphisms on suicidality in treatment        resistant major depressive disorder - A European Multicenter Study	|	2012	|	EUROPEAN NEUROPSYCHOPHARMACOLOGY	|	22	|	4	|	259-266	|	Schosser, A and Calati, R and Serretti, A and Massat, I and Kocabas, NA and Papageorgiou, K and Linotte, S and Mendlewicz, J and Souery, D and Zohar, J and Juven-Wetzler, A and Montgomery, S and Kasper, S and Schosser, A. and Calati, R. and Serretti, A. and Massat, I. and Kocabas, N. A. and Papageorgiou, K. and Linotte, S. and Mendlewicz, J. and Souery, D. and Zohar, J. and Juven-Wetzler, A. and Montgomery, S. and Kasper, S.	|	10.1016/j.euroneuro.2011.08.007	|
|	Correlations Between Neuroendocrine Disorders and Biochemical Brain        Metabolites Alterations in Antidepressant Treatment	|	2018	|	REVISTA DE CHIMIE	|	69	|	3	|	621-626	|	Ageu, L and Talpos, C and Kanalas, G and Crisan, S and Zamfir, CL and Poroch, V and Anghel, M and Ageu, Luminita and Talpos, Cristina and Kanalas, Ghizela and Crisan, Simina and Zamfir, Carmen Lacramioara and Poroch, Vladimir and Anghel, Mirela	|		|
|	Knowledge Engineering for PharmacoGenomic Molecular Imaging of the Brain	|	2009	|	2009 FIFTH INTERNATIONAL CONFERENCE ON SEMANTICS, KNOWLEDGE AND GRID        (SKG 2009)	|		|		|	26-33	|	Taswell, C and Taswell, Carl     GP IEEE	|	10.1109/SKG.2009.101	|
|	Routine pharmacogenetic testing in clinical practice: dream or reality?	|	2007	|	PHARMACOGENOMICS	|	8	|	10	|	1449-1459	|	Grossman, I and Grossman, Iris	|	10.2217/14622416.8.10.1449	|
|	Prediction of functional outcomes of schizophrenia with genetic        biomarkers using a bagging ensemble machine learning method with feature        selection	|	2021	|	SCIENTIFIC REPORTS	|	11	|	1	|		|	Lin, E and Lin, CH and Lane, HY and Lin, Eugene and Lin, Chieh-Hsin and Lane, Hsien-Yuan	|	10.1038/s41598-021-89540-6	|
|	Association analysis of serotonin receptor 7 gene (HTR7) and risperidone        response in Chinese schizophrenia patients	|	2009	|	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	|	33	|	3	|	547-551	|	Wei, ZY and Wang, L and Xuan, JK and Che, RL and Du, J and Qin, SY and Xing, Y and Gu, B and Yang, L and Li, H and Li, J and Feng, GY and He, L and Xing, QH and Wei, Zhiyun and Wang, Lei and Xuan, Jiekun and Che, Ronglin and Du, Jing and Qin, Shengying and Xing, Yi and Gu, Bo and Yang, Lun and Li, Huafang and Li, Jun and Feng, Guoyin and He, Lin and Xing, Qinghe	|	10.1016/j.pnpbp.2009.02.008	|
|	Polymorphism of DISC1 and GAD2 genes: genetic markers of risk for        schizophrenia and pharmacogenetic markers of haloperidol efficiency	|	2015	|	EUROPEAN NEUROPSYCHOPHARMACOLOGY	|	25	|		|	S520-S520	|	Kinyasheva, KO and Sabirov, ET and Gareeva, AE and Khusnutdinova, EK and Kinyasheva, K. O. and Sabirov, E. T. and Gareeva, A. E. and Khusnutdinova, E. K.	|	10.1016/S0924-977X(15)30716-1	|
|	Identifying the genetic risk factors for treatment response to        lurasidone by genome-wide association study: A meta-analysis of samples        from three independent clinical trials	|	2018	|	SCHIZOPHRENIA RESEARCH	|	199	|		|	203-213	|	Li, J and Loebel, A and Meltzer, HY and Li, Jiang and Loebel, Antony and Meltzer, Herbert Y.	|	10.1016/j.schres.2018.04.006	|
|	Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response	|	2010	|	HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL	|	25	|	7	|	582-585	|	Souza, RP and Meltzer, HY and Lieberman, JA and Le Foll, B and Kennedy, JL and Souza, Renan P. and Meltzer, Herbert Y. and Lieberman, Jeffrey A. and Le Foll, Bernard and Kennedy, James L.	|	10.1002/hup.1146	|
|	DNA Methylation of Fluoxetine Response in Child and Adolescence:        Preliminary Results	|	2021	|	PHARMACOGENOMICS & PERSONALIZED MEDICINE	|	14	|		|	459-467	|	Martinez-Pinteno, A and Rodriguez, N and Blazquez, A and Plana, MT and Varela, E and Gasso, P and Lafuente, A and Lazaro, L and Mas, S and Martinez-Pinteno, Albert and Rodriguez, Natalia and Blazquez, Ana and Plana, Maria Teresa and Varela, Eva and Gasso, Patricia and Lafuente, Amalia and Lazaro, Luisa and Mas, Sergi	|	10.2147/PGPM.S289480	|
|	Common genetic variation in the indoleamine-2,3-dioxygenase genes and        antidepressant treatment outcome in major depressive disorder	|	2012	|	JOURNAL OF PSYCHOPHARMACOLOGY	|	26	|	3	|	360-367	|	Cutler, JA and Rush, AJ and McMahon, FJ and Laje, G and Cutler, Jessica A. and Rush, A. John and McMahon, Francis J. and Laje, Gonzalo	|	10.1177/0269881111434622	|
|	Methodological and Statistical Issues in the Use of Biomarkers in        Clinical and Research Studies	|	2009	|	HANDBOOK OF NEUROPSYCHIATRIC BIOMARKERS, ENDOPHENOTYPES AND GENES, VOL        1: NEUROPSYCHOLOGICAL ENDOPHENOTYPES AND BIOMARKERS	|		|		|	23-39	|	Van Lieshout, RJ and Szatmari, P and Van Lieshout, Ryan J. and Szatmari, Peter	|		|
|	Relationship between CYP2D6 genotype and haloperidol pharmacokinetics        and extrapyramidal symptoms in healthy volunteers	|	2013	|	PHARMACOGENOMICS	|	14	|	13	|	1551-1563	|	Gasso, P and Papagianni, K and Mas, S and de Bobadilla, RF and Arnaiz, JA and Bernardo, M and Lafuente, A and Gasso, Patricia and Papagianni, Katerina and Mas, Sergi and Fernandez de Bobadilla, Ramon and Albert Arnaiz, Joan and Bernardo, Miquel and Lafuente, Amalia	|	10.2217/pgs.13.150	|
|	Evidence for a possible association of neurotrophin receptor (NTRK-3)        gene polymorphisms with hippocampal function and schizophrenia	|	2009	|	NEUROBIOLOGY OF DISEASE	|	34	|	3	|	518-524	|	Otnaess, MK and Djurovic, S and Rimol, LM and Kulle, B and Kahler, AK and Jonsson, EG and Agartz, I and Sundet, K and Hall, H and Timm, S and Hansen, T and Callicott, JH and Melle, I and Werge, T and Andreassen, OA and Otnaess, Mona K. and Djurovic, Srdjan and Rimol, Lars M. and Kulle, Bettina and Kahler, Anna K. and Jonsson, Erik G. and Agartz, Ingrid and Sundet, Kjetil and Hall, Hakan and Timm, Sally and Hansen, Thomas and Callicott, Joseph H. and Melle, Ingrid and Werge, Thomas and Andreassen, Ole A.	|	10.1016/j.nbd.2009.03.011	|
|	Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating        in schizophrenia: A proof-of-mechanism study	|	2013	|	NEUROPHARMACOLOGY	|	64	|		|	197-204	|	Winterer, G and Gallinat, J and Brinkmeyer, J and Musso, F and Kornhuber, J and Thuerauf, N and Rujescu, D and Favis, R and Sun, Y and Franc, MA and Ouwerkerk-Mahadevan, S and Janssens, L and Timmers, M and Streffer, JR and Winterer, Georg and Gallinat, Juergen and Brinkmeyer, Juergen and Musso, Francesco and Kornhuber, Johannes and Thuerauf, Norbert and Rujescu, Dan and Favis, Reyna and Sun, Yu and Franc, Monique A. and Ouwerkerk-Mahadevan, Sivi and Janssens, Luc and Timmers, Maarten and Streffer, Johannes R.	|	10.1016/j.neuropharm.2012.06.040	|
|	Pharmacogenetics analysis of serotonin receptor gene variants and        clinical response to risperidone in Han Chinese schizophrenic patients	|	2018	|	NEUROSCIENCE LETTERS	|	683	|		|	202-206	|	Zhou, W and Chang, WS and Yan, YC and Shen, L and Li, WQ and Yi, ZH and Qin, SY and Zhou, Wei and Chang, Wushao and Yan, Yucai and Shen, Lu and Li, Wenqiang and Yi, Zhenghui and Qin, Shengying	|	10.1016/j.neulet.2018.08.002	|
|	Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers        Reviewed	|	2014	|	CURRENT PSYCHIATRY REPORTS	|	16	|	10	|		|	Shams, TA and Muller, DJ and Shams, Tahireh A. and Mueller, Daniel J.	|	10.1007/s11920-014-0473-9	|
|	Association Analysis of Schizophrenia on 18 Genes Involved in Neuronal        Migration: MDGA1 as a New Susceptibility Gene	|	2008	|	AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS	|	147	|	7	|	1089-1100	|	Kahler, AK and Djurovic, S and Kulle, B and Jonsson, EG and Agartz, I and Hall, H and Opjordsmoen, S and Jakobsen, KD and Hansen, T and Melle, I and Werge, T and Steen, VM and Andreassen, OA and Kahler, Anna K. and Djurovic, Srdjan and Kulle, Bettina and Jonsson, Erik G. and Agartz, Ingrid and Hall, Hakan and Opjordsmoen, Stein and Jakobsen, Klaus D. and Hansen, Thomas and Melle, Ingrid and Werge, Thomas and Steen, Vidar M. and Andreassen, Ole A.	|	10.1002/ajmg.b.30726	|
|	How Can Pharmacogenomics Biomarkers Be Translated into Patient Benefit	|	2015	|	EUROPEAN PSYCHIATRY	|	30	|		|		|	Collier, D and Achilla, E and Breen, G and Curran, S and Dima, D and Flanagan, R and Frank, J and Frangou, S and Gasse, C and Giegling, I and Rietschel, M and Rujescu, D and Helthuis, M and Maccabe, J and McCrone, P and Mill, J and Sigurdsson, E and Stefansson, H and Walters, J and Verbelen, M and Collier, D. and Achilla, E. and Breen, G. and Curran, S. and Dima, D. and Flanagan, R. and Frank, J. and Frangou, S. and Gasse, C. and Giegling, I. and Rietschel, M. and Rujescu, D. and Helthuis, M. and Maccabe, J. and McCrone, P. and Mill, J. and Sigurdsson, E. and Stefansson, H. and Walters, J. and Verbelen, M.	|	10.1016/S0924-9338(15)30078-X	|
|	Genetic Markers for Later Remission in Response to Early Improvement of        Antidepressants	|	2020	|	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	|	21	|	14	|		|	Kang, HJ and Kim, KT and Yoo, KH and Park, Y and Kim, JW and Kim, SW and Shin, IS and Kim, JH and Kim, JM and Kang, Hee-Ju and Kim, Ki-Tae and Yoo, Kyung-Hun and Park, Yoomi and Kim, Ju-Wan and Kim, Sung-Wan and Shin, Il-Seon and Kim, Ju Han and Kim, Jae-Min	|	10.3390/ijms21144884	|
|	Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic        association and decreased frontal cortex mRNA levels	|	2012	|	INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY	|	15	|	6	|	727-737	|	Bromberg, A and Lerer, E and Udawela, M and Scarr, E and Dean, B and Belmaker, RH and Ebstein, R and Agam, G and Bromberg, Anna and Lerer, Elad and Udawela, Madhara and Scarr, Elizabeth and Dean, Brian and Belmaker, R. H. and Ebstein, Richard and Agam, Galila	|	10.1017/S1461145711001179	|
|	Association of HSPA1B genotypes with psychopathology and neurocognition        in patients with the first episode of psychosis: a longitudinal 18-month        follow-up study	|	2020	|	PHARMACOGENOMICS JOURNAL	|	20	|	5	|	638-646	|	Kuharic, DB and Bozina, N and Ganoci, L and Makaric, P and Kekin, I and Prpic, N and Bozina, T and Kuzman, MR and Bosnjak Kuharic, Dina and Bozina, Nada and Ganoci, Lana and Makaric, Porin and Kekin, Ivana and Prpic, Nikola and Bozina, Tamara and Rojnic Kuzman, Martina	|	10.1038/s41397-020-0150-9     EA FEB 2020	|
|	Investigation of Epistasis Between DAOA and 5HTR1A Variants on Clinical        Outcomes in Patients with Schizophrenia	|	2013	|	GENETIC TESTING AND MOLECULAR BIOMARKERS	|	17	|	6	|	504-507	|	Chiesa, A and Lia, L and Han, C and Lee, SJ and Pae, CU and Serretti, A and Chiesa, Alberto and Lia, Loredana and Han, Changsu and Lee, Soo-Jung and Pae, Chi-Un and Serretti, Alessandro	|	10.1089/gtmb.2012.0484	|
|	Combined HTR2C-LEP Genotype as a Determinant of Obesity in Patients        Using Antipsychotic Medication	|	2010	|	JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY	|	30	|	6	|	702-705	|	Gregoor, JG and Mulder, H and Cohen, D and van Megen, HJGM and Egberts, TCG and Heerdink, ER and van der Weide, J and Gregoor, Jochem G. and Mulder, Hans and Cohen, Dan and van Megen, Harold J. G. M. and Egberts, Toine C. G. and Heerdink, Eibert R. and van der Weide, Jan	|	10.1097/JCP.0b013e3181fa05a2	|
|	Polymorphism of the glutamate receptor genes and risk of paranoid        schizophrenia in Russians and Tatars from the Republic of Bashkortostan	|	2014	|	MOLECULAR BIOLOGY	|	48	|	5	|	671-680	|	Gareeva, AE and Khusnutdinova, EK and Gareeva, A. E. and Khusnutdinova, E. K.	|	10.1134/S0026893314050033	|
|	Precision psychiatry in clinical practice	|	2021	|	INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE	|	25	|	1	|	19-27	|	Zanardi, R and Prestifilippo, D and Fabbri, C and Colombo, C and Maron, E and Serretti, A and Zanardi, Raffaella and Prestifilippo, Dario and Fabbri, Chiara and Colombo, Cristina and Maron, Eduard and Serretti, Alessandro	|	10.1080/13651501.2020.1809680     EA AUG 2020	|
|	Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine        response and evidence of lower weight gain in the high response group	|	2014	|	PHARMACOGENOMICS	|	15	|	7	|	933-939	|	Ramsey, TL and Liu, Q and Brennan, MD and Ramsey, Timothy L. and Liu, Qian and Brennan, Mark D.	|	10.2217/pgs.14.54	|
|	Towards precision medicine for stress disorders: diagnostic biomarkers        and targeted drugs	|	2020	|	MOLECULAR PSYCHIATRY	|	25	|	5	|	918-938	|	Le-Niculescu, H and Roseberry, K and Levey, DF and Rogers, J and Kosary, K and Prabha, S and Jones, T and Judd, S and McCormick, MA and Wessel, AR and Williams, A and Phalen, PL and Mamdani, F and Sequeira, A and Kurian, SM and Niculescu, AB and Le-Niculescu, H. and Roseberry, K. and Levey, D. F. and Rogers, J. and Kosary, K. and Prabha, S. and Jones, T. and Judd, S. and McCormick, M. A. and Wessel, A. R. and Williams, A. and Phalen, P. L. and Mamdani, F. and Sequeira, A. and Kurian, S. M. and Niculescu, A. B.	|	10.1038/s41380-019-0370-z	|
|	Investigating aberrantly expressed microRNAs in peripheral blood        mononuclear cells from patients with treatment-resistant schizophrenia        using miRNA sequencing and integrated bioinformatics	|	2020	|	MOLECULAR MEDICINE REPORTS	|	22	|	5	|	4340-4350	|	You, X and Zhang, YQ and Long, Q and Liu, ZJ and Ma, X and Lu, ZX and Yang, W and Feng, ZQ and Zhang, WY and Teng, ZW and Zeng, Y and You, Xu and Zhang, Yunqiao and Long, Qing and Liu, Zijun and Ma, Xiao and Lu, Zixiang and Yang, Wei and Feng, Ziqiao and Zhang, Wengyu and Teng, Zhaowei and Zeng, Yong	|	10.3892/mmr.2020.11513	|
|	Analysis of 250 Candidate Gene Markers to Optimize Antipsychotic Dosage	|	2015	|	BIOLOGICAL PSYCHIATRY	|	77	|	9	|		|	Hettige, N and Matmari, M and De Luca, V and Hettige, Nuwan and Matmari, Michelle and De Luca, Vincenzo	|		|
|	Early antidepressant efficacy modulation by glutamatergic gene variants        in the STAR*D	|	2013	|	EUROPEAN NEUROPSYCHOPHARMACOLOGY	|	23	|	7	|	612-621	|	Fabbri, C and Drago, A and Serretti, A and Fabbri, Chiara and Drago, Antonio and Serretti, Alessandro	|	10.1016/j.euroneuro.2012.07.006	|
|	Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment        with Lithium and Clozapine	|	2021	|	CURRENT PHARMACEUTICAL DESIGN	|	27	|	30	|	3293-3304	|	De Berardis, D and Vellante, F and Pettorruso, M and Lucidi, L and Tambelli, A and Di Muzio, I and Gianfelice, G and Ventriglio, A and Fornaro, M and Serafini, G and Pompili, M and Perna, G and Fraticelli, S and Martinotti, G and di Giannantonio, M and De Berardis, Domenico and Vellante, Federica and Pettorruso, Mauro and Lucidi, Lorenza and Tambelli, Antonio and Di Muzio, Ilenia and Gianfelice, Giulia and Ventriglio, Antonio and Fornaro, Michele and Serafini, Gianluca and Pompili, Maurizio and Perna, Giampaolo and Fraticelli, Silvia and Martinotti, Giovanni and di Giannantonio, Massimo	|	10.2174/1381612827666210603143353	|
|	Tumor necrosis factor and its targets in the inflammatory cytokine        pathway are identified as putative transcriptomic biomarkers for        escitalopram response	|	2013	|	EUROPEAN NEUROPSYCHOPHARMACOLOGY	|	23	|	9	|	1105-1114	|	Powell, TR and Schalkwyk, LC and Heffernan, AL and Breen, G and Lawrence, T and Price, T and Farmer, AE and Aitchison, KJ and Craig, IW and Danese, A and Lewis, C and McGuffin, P and Uher, R and Tansey, KE and D'Souza, UM and Powell, Timothy R. and Schalkwyk, Leonard C. and Heffernan, Andrew L. and Breen, Gerome and Lawrence, Timothy and Price, Tom and Farmer, Anne E. and Aitchison, Katherine J. and Craig, Ian W. and Danese, Andrea and Lewis, Cathryn and McGuffin, Peter and Uher, Rudolf and Tansey, Katherine E. and D'Souza, Ursula M.	|	10.1016/j.euroneuro.2012.09.009	|
|	Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to        risperidone	|	2003	|	PHARMACOGENOMICS JOURNAL	|	3	|	6	|	356-361	|	Yamanouchi, Y and Iwata, N and Suzuki, T and Kitajima, T and Ikeda, M and Ozaki, N and Yamanouchi, Y and Iwata, N and Suzuki, T and Kitajima, T and Ikeda, M and Ozaki, N	|	10.1038/sj.tpj.6500211	|
|	Metabolic Abnormalities and Spectroscopy Biochemical Cerebral Compounds        Modifications in Children and Adolescents with Antipsychotic Treatment	|	2017	|	REVISTA DE CHIMIE	|	68	|	12	|	3022-3026	|	Talpos, C and Ageu, L and Crisan, S and Zamfir, CL and Poroch, V and Anghel, M and Talpos, Cristina and Ageu, Luminita and Crisan, Simina and Zamfir, Carmen Lacramioara and Poroch, Vladimir and Anghel, Mirela	|		|
|	An Ensemble Approach to Predict Schizophrenia Using Protein Data in the        N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways	|	2020	|	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY	|	8	|		|		|	Lin, E and Lin, CH and Hung, CC and Lane, HY and Lin, Eugene and Lin, Chieh-Hsin and Hung, Chung-Chieh and Lane, Hsien-Yuan	|	10.3389/fbioe.2020.00569	|
|	Sensitivity to the dopaminergic regulation of prepulse inhibition in        rats: Evidence for genetic, but not environmental determinants	|	2001	|	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR	|	70	|	2	|	219-226	|	Swerdlow, NR and Platten, A and Kim, YK and Gaudet, I and Shoemaker, J and Pitcher, L and Auerbach, P and Swerdlow, NR and Platten, A and Kim, YK and Gaudet, I and Shoemaker, J and Pitcher, L and Auerbach, P	|	10.1016/S0091-3057(01)00598-6	|
|	The microbiome-gut-brain axis: implications for schizophrenia and        antipsychotic induced weight gain	|	2018	|	EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE	|	268	|	1	|	15-Mar	|	Kanji, S and Fonseka, TM and Marshe, VS and Sriretnakumar, V and Hahn, MK and Muller, DJ and Kanji, S. and Fonseka, T. M. and Marshe, V. S. and Sriretnakumar, V. and Hahn, M. K. and Muller, D. J.	|	10.1007/s00406-017-0820-z	|
|	The Genetic Determinants of Clozapine-Induced Agranulocytosis: A        Systematic Review and Meta-Analysis	|	2021	|	BIOLOGICAL PSYCHIATRY	|	89	|	9	|	S341-S341	|	Islam, F and Hain, D and Lewis, D and Law, R and Brown, L and Tanner, JA and Mueller, DJ and Islam, Farhana and Hain, Daniel and Lewis, David and Law, Rebecca and Brown, Lisa and Tanner, Julie-Anne and Mueller, Daniel J.	|		|
|	Human catechol-O-methyltransferase pharmacogenetics: Description of a        functional polymorphism and its potential application to        neuropsychiatric disorders	|	1996	|	PHARMACOGENETICS	|	6	|	3	|	243-250	|	Lachman, HM and Papolos, DF and Saito, T and Yu, YM and Szumlanski, CL and Weinshilboum, RM and Lachman, HM and Papolos, DF and Saito, T and Yu, YM and Szumlanski, CL and Weinshilboum, RM	|	10.1097/00008571-199606000-00007	|
|	Association Study of Serotonin 3 Receptor Subunit Gene Variants in        Antipsychotic-Induced Weight Gain	|	2016	|	NEUROPSYCHOBIOLOGY	|	74	|	3	|	169-175	|	Zai, CC and Tiwari, AK and Chowdhury, NI and Brandl, EJ and Shaikh, SA and Freeman, N and Lieberman, JA and Meltzer, HY and Kennedy, JL and Muller, DJ and Zai, Clement C. and Tiwari, Arun K. and Chowdhury, Nabilah I. and Brandl, Eva J. and Shaikh, Sajid A. and Freeman, Natalie and Lieberman, Jeffrey A. and Meltzer, Herbert Y. and Kennedy, James L. and Mueller, Daniel J.	|	10.1159/000457903	|
|	Dopamine receptor D2 gene is associated with weight gain in        schizophrenic patients under long-term atypical antipsychotic treatment	|	2010	|	PHARMACOGENETICS AND GENOMICS	|	20	|	6	|	359-366	|	Hong, CJ and Liou, YJ and Bai, YM and Chen, TT and Wang, YC and Tsai, SJ and Hong, Chen-Jee and Liou, Ying-Jay and Bai, Ya Mei and Chen, Tzu-Ting and Wang, Ying-Chieh and Tsai, Shih-Jen	|	10.1097/FPC.0b013e3283397d06	|
|	The role of brain-derived neurotrophic factor (BDNF) gene variants in        antipsychotic response and antipsychotic-induced weight gain	|	2012	|	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	|	39	|	1	|	96-101	|	Zai, GCM and Zai, CCH and Chowdhury, NI and Tiwari, AK and Souza, RP and Lieberman, JA and Meltzer, HY and Potkin, SG and Muller, DJ and Kennedy, JL and Zai, Gwyneth C. M. and Zai, Clement C. H. and Chowdhury, Nabilah I. and Tiwari, Arun K. and Souza, Renan P. and Lieberman, Jeffrey A. and Meltzer, Herbert Y. and Potkin, Steven G. and Mueller, Daniel J. and Kennedy, James L.	|	10.1016/j.pnpbp.2012.05.014	|
|	Iloperidone - A novel atypical antipsychotic for the treatment of        schizophrenia	|	2008	|	FORMULARY	|	43	|	6	|	190-+	|	Ehret, MJ and Sopko, MA and Levine, A and Ehret, Megan J. and Sopko, Michael A., Jr. and Levine, Alexander	|		|
|	Sample Size Requirements for Multivariate Models to Predict        Between-Patient Differences in Best Treatments of Major Depressive        Disorder	|	2019	|	CLINICAL PSYCHOLOGICAL SCIENCE	|	7	|	3	|	445-461	|	Luedtke, A and Sadikova, E and Kessler, RC and Luedtke, Alex and Sadikova, Ekaterina and Kessler, Ronald C.	|	10.1177/2167702618815466	|
|	The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment        Effect and Response (MAKE BETTER) Study: Design and Methodology	|	2018	|	PSYCHIATRY INVESTIGATION	|	15	|	5	|	538-545	|	Kang, HJ and Kim, JW and Kim, SY and Kim, SW and Shin, HY and Shin, MG and Kim, JM and Kang, Hee-Ju and Kim, Ju-Wan and Kim, Seon-Young and Kim, Sung-Wan and Shin, Hee-Young and Shin, Myung-Geun and Kim, Jae-Min	|	10.30773/pi.2017.10.2	|
|	Association Study of GABA(A) alpha 2 Receptor Subunit Gene Variants in        Antipsychotic-Associated Weight Gain	|	2015	|	JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY	|	35	|	1	|	12-Jul	|	Zai, CCH and Tiwari, AK and Chowdhury, NI and Brandl, EJ and Shaikh, SA and Freeman, N and Lieberman, JA and Meltzer, HY and Muller, DJ and Kennedy, JL and Zai, Clement C. H. and Tiwari, Arun K. and Chowdhury, Nabilah I. and Brandl, Eva J. and Shaikh, Sajid A. and Freeman, Natalie and Lieberman, Jeffrey A. and Meltzer, Herbert Y. and Mueller, Daniel J. and Kennedy, James L.	|	10.1097/JCP.0000000000000261	|
|	A functional polymorphism in the ATP-Binding Cassette B1 transporter        predicts pharmacologic response to combination of nortriptyline and        morphine in neuropathic pain patients	|	2020	|	PAIN	|	161	|	3	|	619-629	|	Benavides, R and Vsevolozhskaya, O and Cattaneo, S and Zaykin, D and Brenton, A and Parisien, M and Verma, V and Khoury, S and Gilron, I and Diatchenko, L and Benavides, Rodrigo and Vsevolozhskaya, Olga and Cattaneo, Stefano and Zaykin, Dmitri and Brenton, Ashley and Parisien, Marc and Verma, Vivek and Khoury, Samar and Gilron, Ian and Diatchenko, Luda	|	10.1097/j.pain.0000000000001750	|
|	Lithium long-term treatment in mood disorders: clinical and genetic        predictors	|	2002	|	PHARMACOGENOMICS	|	3	|	1	|	117-129	|	Serretti, A and Serretti, A	|	10.1517/14622416.3.1.117	|
|	Iloperidone for schizophrenia: a review of the efficacy and safety        profile for this newly commercialised second-generation antipsychotic	|	2009	|	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE	|	63	|	8	|	1237-1248	|	Citrome, L and Citrome, L.	|	10.1111/j.1742-1241.2009.02142.x	|
|	The Role of Intergenic Interactions of Neurotrophic and Neurotransmitter        System Genes in the Development of Susceptibility to Paranoid        Schizophrenia	|	2020	|	RUSSIAN JOURNAL OF GENETICS	|	56	|	1	|	79-87	|	Gareeva, AE and Khusnutdinova, EK and Gareeva, A. E. and Khusnutdinova, E. K.	|	10.1134/S1022795420010056	|
|	Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering        from Post-traumatic Stress Disorder	|	2017	|	CURRENT NEUROPHARMACOLOGY	|	15	|	6	|	831-860	|	Nass, J and Efferth, T and Nass, Janine and Efferth, Thomas	|	10.2174/1570159X15666161111113514	|
|	How can we realize the promise of personalized antidepressant medicines?	|	2008	|	NATURE REVIEWS NEUROSCIENCE	|	9	|	8	|	638-U14	|	Holsboer, F and Holsboer, Florian	|	10.1038/nrn2453	|
|	Genome-wide association study identifies genetic loci associated with        body mass index and high density lipoprotein-cholesterol levels during        psychopharmacological treatment - a cross-sectional naturalistic study	|	2012	|	PSYCHIATRY RESEARCH	|	197	|	3	|	327-336	|	Athanasiu, L and Brown, AA and Birkenaes, AB and Mattingsdal, M and Agartz, I and Melle, I and Steen, VM and Andreassen, OA and Djurovic, S and Athanasiu, Lavinia and Brown, Andrew A. and Birkenaes, Astrid B. and Mattingsdal, Morten and Agartz, Ingrid and Melle, Ingrid and Steen, Vidar M. and Andreassen, Ole A. and Djurovic, Srdjan	|	10.1016/j.psychres.2011.12.036	|
|	Ventral midbrain correlation between genetic variation and expression of        the dopamine transporter gene in cocaine-abusing versus non-abusing        subjects	|	2014	|	ADDICTION BIOLOGY	|	19	|	1	|	122-131	|	Zhou, YH and Michelhaugh, SK and Schmidt, CJ and Liu, JS and Bannon, MJ and Lin, ZC and Zhou, Yanhong and Michelhaugh, Sharon K. and Schmidt, Carl J. and Liu, Jun S. and Bannon, Michael J. and Lin, Zhicheng	|	10.1111/j.1369-1600.2011.00391.x	|
|	The role of dopamine D-3, 5-HT2(A) and 5-HT2(C) receptor variants as        pharmacogenetic determinants in tardive dyskinesia in African-Caribbean        patients under chronic antipsychotic treatment Curacao extrapyramidal        syndromes study IX	|	2009	|	JOURNAL OF PSYCHOPHARMACOLOGY	|	23	|	6	|	652-659	|	Wilffert, B and Al Hadithy, AFY and Sing, VJ and Matroos, G and Hoek, HW and van Os, J and Bruggeman, R and Brouwers, JRBJ and van Harten, PN and Wilffert, B. and Al Hadithy, A. F. Y. and Sing, V. J. and Matroos, G. and Hoek, H. W. and van Os, J. and Bruggeman, R. and Brouwers, J. R. B. J. and van Harten, P. N.	|	10.1177/0269881108091594	|
|	Emergent biomarker derived from next-generation sequencing to identify        pain patients requiring uncommonly high opioid doses	|	2017	|	PHARMACOGENOMICS JOURNAL	|	17	|	5	|	419-426	|	Kringel, D and Ultsch, A and Zimmermann, M and Jansen, JP and Ilias, W and Freynhagen, R and Griessinger, N and Kopf, A and Stein, C and Doehring, A and Resch, E and Lotsch, J and Kringel, D. and Ultsch, A. and Zimmermann, M. and Jansen, J-P and Ilias, W. and Freynhagen, R. and Griessinger, N. and Kopf, A. and Stein, C. and Doehring, A. and Resch, E. and Loetsch, J.	|	10.1038/tpj.2016.28	|
|	Association of the HTR2A T102C SNP with Weight Gain and Changes in        Biochemical Markers in Patients Receiving Antipsychotics	|	2018	|	INTERNATIONAL JOURNAL OF BIOMEDICINE	|	8	|	3	|	186-191	|	Tolmachev, MY and Akhmetova, LS and Shnayder, NA and Ershov, EE and Bugorsky, AV and Kravtsov, VV and Taraskina, AE and Andreev, BV and Yakhin, KK and Neznanov, NG and Nasyrova, RF and Tolmachev, Mikhail Yu. and Akhmetova, Liliya Sch and Shnayder, Natalia A. and Ershov, Evgeny E. and Bugorsky, Alexander V. and Kravtsov, Vladimir V. and Taraskina, Anastasia E. and Andreev, Boris V. and Yakhin, Kausar K. and Neznanov, Nikolay G. and Nasyrova, Regina F.	|	10.21103/Article8(3)_OA3	|
|	Pharmacometabolomics: Implications for Clinical Pharmacology and Systems        Pharmacology	|	2014	|	CLINICAL PHARMACOLOGY & THERAPEUTICS	|	95	|	2	|	154-167	|	Kaddurah-Daouk, R and Weinshilboum, RM and Kaddurah-Daouk, R. and Weinshilboum, R. M. and Pharmacometabol Res Network	|	10.1038/clpt.2013.217	|
|	Gene expression and response prediction to amisulpride in the OPTiMiSE        first episode psychoses	|	2020	|	NEUROPSYCHOPHARMACOLOGY	|	45	|	10	|	1637-1644	|	Troudet, R and Ali, WBH and Bacq-Daian, D and van Rossum, IW and Boland-Auge, A and Battail, C and Barau, C and Rujescu, D and McGuire, P and Kahn, RS and Deleuze, JF and Leboyer, M and Jamain, S and Troudet, Rejane and Ali, Wafa Bel Haj and Bacq-Daian, Delphine and van Rossum, Inge Winter and Boland-Auge, Anne and Battail, Christophe and Barau, Caroline and Rujescu, Dan and McGuire, Philip and Kahn, Rene S. and Deleuze, Jean-Francois and Leboyer, Marion and Jamain, Stephane and OPTiMiSE Study Grp	|	10.1038/s41386-020-0703-2     EA MAY 2020	|
|	Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in        patients using antipsychotic medication in a naturalistic setting	|	2011	|	PHARMACOGENOMICS	|	12	|	6	|	919-923	|	Gregoor, JG and van der Weide, J and Loovers, HM and van Megen, HJGM and Egberts, TCG and Heerdink, ER and Gregoor, Jochem G. and van der Weide, Jan and Loovers, Harriet M. and van Megen, Harold J. G. M. and Egberts, Toine C. G. and Heerdink, Eibert R.	|	10.2217/PGS.11.40	|
|	Personalized medicine in psychiatry	|	2017	|	NORDIC JOURNAL OF PSYCHIATRY	|	71	|	1	|	19-Dec	|	Wium-Andersen, IK and Vinberg, M and Kessing, LV and McIntyre, RS and Wium-Andersen, Ida Kim and Vinberg, Maj and Kessing, Lars Vedel and McIntyre, Roger S.	|	10.1080/08039488.2016.1216163	|
|	Prediction of treatment outcomes in psychiatry-where do we stand?	|	2014	|	DIALOGUES IN CLINICAL NEUROSCIENCE	|	16	|	4	|	455-464	|	McMahon, FJ and McMahon, Francis J.	|		|
|	Association of DNA methylation in BDNF with escitalopram treatment        response in depressed Chinese Han patients	|	2018	|	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	|	74	|	8	|	1011-1020	|	Wang, PP and Zhang, CZ and Lv, QY and Bao, CX and Sun, H and Ma, G and Fang, YR and Yi, ZH and Cai, WM and Wang, Peipei and Zhang, Cuizhen and Lv, Qinyu and Bao, Chenxi and Sun, Hong and Ma, Guo and Fang, Yiru and Yi, Zhenghui and Cai, Weimin	|	10.1007/s00228-018-2463-z	|
|	Opening up new horizons for psychiatric genetics in the Russian        Federation: moving toward a national consortium	|	2019	|	MOLECULAR PSYCHIATRY	|	24	|	8	|	1099-1111	|	Fedorenko, OY and Golimbet, VE and Ivanova, SA and Levchenko, A and Gainetdinov, RR and Semke, AV and Simutkin, GG and Gareeva, AE and Glotov, AS and Gryaznova, A and Iourov, IY and Krupitsky, EM and Lebedev, IN and Mazo, GE and Kaleda, VG and Abramova, LI and Oleichik, IV and Nasykhova, YA and Nasyrova, RF and Nikolishin, AE and Kasyanov, ED and Rukavishnikov, GV and Timerbulatov, IF and Brodyansky, VM and Vorsanova, SG and Yurov, YB and Zhilyaeva, TV and Sergeeva, AV and Blokhina, EA and Zvartau, EE and Blagonravova, AS and Aftanas, LI and Bokhan, NA and Kekelidze, ZI and Klimenko, TV and Anokhina, IP and Khusnutdinova, EK and Klyushnik, TP and Neznanov, NG and Stepanov, VA and Schulze, TG and Kibitov, AO and Fedorenko, Olga Yu. and Golimbet, Vera E. and Ivanova, Svetlana A. and Levchenko, Anastasia and Gainetdinov, Raul R. and Semke, Arkady V. and Simutkin, German G. and Gareeva, Anna E. and Glotov, Andrey S. and Gryaznova, Anna and Iourov, Ivan Y. and Krupitsky, Evgeny M. and Lebedev, Igor N. and Mazo, Galina E. and Kaleda, Vasily G. and Abramova, Lilia I. and Oleichik, Igor V. and Nasykhova, Yulia A. and Nasyrova, Regina F. and Nikolishin, Anton E. and Kasyanov, Evgeny D. and Rukavishnikov, Grigory V. and Timerbulatov, Ilgiz F. and Brodyansky, Vadim M. and Vorsanova, Svetlana G. and Yurov, Yury B. and Zhilyaeva, Tatyana V. and Sergeeva, Anzhelika V. and Blokhina, Elena A. and Zvartau, Edwin E. and Blagonravova, Anna S. and Aftanas, Lyubomir I. and Bokhan, Nikolay A. and Kekelidze, Zurab I. and Klimenko, Tatyana V. and Anokhina, Irina P. and Khusnutdinova, Elza K. and Klyushnik, Tatyana P. and Neznanov, Nikolay G. and Stepanov, Vadim A. and Schulze, Thomas G. and Kibitov, Aleksandr O.	|	10.1038/s41380-019-0354-z	|
|	Complex haplotype structure of the human GNAS gene identifies a        recombination hotspot centred on a single nucleotide polymorphism widely        used in association studies	|	2004	|	PHARMACOGENETICS	|	14	|	11	|	741-747	|	Yang, WL and Whitea, B and Spicer, EK and Weinstein, BL and Hildebrandt, JD and Yang, WL and Whitea, B and Spicer, EK and Weinstein, BL and Hildebrandt, JD	|	10.1097/00008571-200411000-00005	|
|	Association study of the GSK-3B gene with tardive dyskinesia in European        Caucasians	|	2010	|	EUROPEAN NEUROPSYCHOPHARMACOLOGY	|	20	|	10	|	688-694	|	Souza, RP and Remington, G and Chowdhury, NI and Lau, MK and Voineskos, AN and Lieberman, JA and Meltzer, HY and Kennedy, JL and Souza, Renan P. and Remington, Gary and Chowdhury, Nabilah I. and Lau, Matthew K. and Voineskos, Aristotle N. and Lieberman, Jeffrey A. and Meltzer, Herbert Y. and Kennedy, James L.	|	10.1016/j.euroneuro.2010.05.002	|
|	Psychotropic prescription practices in east Asia: looking back and        peering ahead	|	2008	|	CURRENT OPINION IN PSYCHIATRY	|	21	|	6	|	645-650	|	Tan, CH and Shinfuku, N and Sim, K and Tan, Chay-Hoon and Shinfuku, Naotaka and Sim, Kang	|	10.1097/YCO.0b013e32830e6dc4	|
|	Sample size considerations in genetic polymorphism studies	|	2001	|	HUMAN HEREDITY	|	52	|	4	|	191-200	|	B-Rao, C and B-Rao, C	|	10.1159/000053376	|
|	Genetic landscape of the people of India: a canvas for disease gene        exploration	|	2008	|	JOURNAL OF GENETICS	|	87	|	1	|	20-Mar	|	Brahmachari, SK and Majunder, PP and Mukerji, M and Habib, S and Dash, D and Ray, K and Bahl, S and Brahmachari, Samir K. and Majunder, Partha P. and Mukerji, Mitali and Habib, Saman and Dash, Debasis and Ray, Kunal and Bahl, Samira and Indian Genome Variat Consortium	|		|
|	Mapping depression rating scale phenotypes onto research domain criteria        (RDoC) to inform biological research in mood disorders	|	2018	|	JOURNAL OF AFFECTIVE DISORDERS	|	238	|		|	7-Jan	|	Ahmed, AT and Frye, MA and Rush, AJ and Biernacka, JM and Craighead, WE and McDonald, WM and Bobo, WV and Riva-Posse, P and Tye, SJ and Mayberg, HS and Hall-Flavin, DK and Skime, MK and Jenkins, GD and Wang, LW and Krishnan, RR and Weinshilboum, RM and Kaddurah-Daouk, R and Dunlop, BW and Ahmed, T. Ahmed and Frye, Mark A. and Rush, A. John and Biernacka, Joanna M. and Craighead, W. Edward and McDonald, William M. and Bobo, William V. and Riva-Posse, Patricio and Tye, Susannah J. and Mayberg, Helen S. and Hall-Flavin, Daniel K. and Skime, Michelle K. and Jenkins, Greg D. and Wang, Liewei and Krishnan, Ranga Rama and Weinshilboum, Richard M. and Kaddurah-Daouk, Rima and Dunlop, Boadie W. and Mood Disorders Precision Med Conso	|	10.1016/j.jad.2018.05.005	|
|	Association between COMT gene and Chinese male schizophrenic patients        with violent behavior	|	2009	|	MEDICAL SCIENCE MONITOR	|	15	|	9	|	CR484-CR489	|	Gu, Y and Yun, LB and Tian, YY and Hu, ZQ and Gu, Yan and Yun, Libing and Tian, Yuanyuan and Hu, Zeqing	|		|
|	Identifying genetic loci associated with antidepressant drug response        with drug-gene interaction models in a population-based study	|	2015	|	JOURNAL OF PSYCHIATRIC RESEARCH	|	62	|		|	31-37	|	Noordam, R and Direk, N and Sitlani, CM and Aarts, N and Tiemeier, H and Hofman, A and Uitterlinden, AG and Psaty, BM and Stricker, BH and Visser, LE and Noordam, Raymond and Direk, Nese and Sitlani, Colleen M. and Aarts, Nikkie and Tiemeier, Henning and Hofman, Albert and Uitterlinden, Andre G. and Psaty, Bruce M. and Stricker, Bruno H. and Visser, Loes E.	|	10.1016/j.jpsychires.2015.01.005	|
|	Role of polymorphisms in dopamine synthesis and metabolism genes and        association of DBH haplotypes with Parkinson's disease among North        Indians	|	2010	|	PHARMACOGENETICS AND GENOMICS	|	20	|	7	|	435-441	|	Punia, S and Das, M and Behari, M and Mishra, BK and Sahani, AK and Govindappa, ST and Jayaram, S and Muthane, UB and Thelma, BK and Juyal, RC and Punia, Sohan and Das, Mitashree and Behari, Madhuri and Mishra, Bikash K. and Sahani, Asish K. and Govindappa, Shyla T. and Jayaram, Sachi and Muthane, Uday B. and Thelma, B. K. and Juyal, Ramesh C.	|	10.1097/FPC.0b013e32833ad3bb	|
|	Phenotype of Mice With Inducible Ablation of GluA1 AMPA Receptors During        Late Adolescence: Relevance for Mental Disorders	|	2014	|	HIPPOCAMPUS	|	24	|	4	|	424-435	|	Inta, D and Vogt, MA and Elkin, H and Weber, T and Lima-Ojeda, JM and Schneider, M and Luoni, A and Riva, MA and Gertz, K and Hellmann-Regen, J and Kronenberg, G and Meyer-Lindenberg, A and Sprengel, R and Gass, P and Inta, Dragos and Vogt, Miriam A. and Elkin, Hasan and Weber, Tillmann and Lima-Ojeda, Juan M. and Schneider, Miriam and Luoni, Alessia and Riva, Marco A. and Gertz, Karen and Hellmann-Regen, Julian and Kronenberg, Golo and Meyer-Lindenberg, Andreas and Sprengel, Rolf and Gass, Peter	|	10.1002/hipo.22236	|
|	Prediction of early weight gain during psychotropic treatment using a        combinatorial model with clinical and genetic markers	|	2016	|	PHARMACOGENETICS AND GENOMICS	|	26	|	12	|	547-557	|	Vandenberghe, F and Saigi-Morgui, N and Delacretaz, A and Quteineh, L and Crettol, S and Ansermot, N and Gholam-Rezaee, M and von Gunten, A and Conus, P and Eap, CB and Vandenberghe, Frederik and Saigi-Morgui, Nuria and Delacretaz, Aurelie and Quteineh, Lina and Crettol, Severine and Ansermot, Nicolas and Gholam-Rezaee, Mehdi and von Gunten, Armin and Conus, Philippe and Eap, Chin B.	|	10.1097/FPC.0000000000000249	|
|	Pharmacodynamic genetic variants related to antipsychotic adverse        reactions in healthy volunteers	|	2013	|	PHARMACOGENOMICS	|	14	|	10	|	1203-1214	|	Lopez-Rodriguez, R and Cabaleiro, T and Ochoa, D and Roman, M and Borobia, AM and Carcas, AJ and Ayuso, C and Novalbos, J and Abad-Santos, F and Lopez-Rodriguez, Rosario and Cabaleiro, Teresa and Ochoa, Dolores and Roman, Manuel and Borobia, Alberto M. and Carcas, Antonio J. and Ayuso, Carmen and Novalbos, Jesus and Abad-Santos, Francisco	|	10.2217/PGS.13.106	|
|	The effect of polymorphisms in startle-related genes on anxiety symptom        severity	|	2020	|	JOURNAL OF PSYCHIATRIC RESEARCH	|	125	|		|	144-151	|	Tomasi, J and Zai, CC and Zai, G and Herbert, D and King, N and Freeman, N and Kennedy, JL and Tiwari, AK and Tomasi, Julia and Zai, Clement C. and Zai, Gwyneth and Herbert, Deanna and King, Nicole and Freeman, Natalie and Kennedy, James L. and Tiwari, Arun K.	|	10.1016/j.jpsychires.2020.03.019	|
|	Pharmacoepigenomics: a key determinant in resolving epigenomic        parameters in pathogenesis, and treatment response in complex diseases	|	2021	|	PHARMACOGENOMICS	|	23	|	2	|	81-84	|	Banerjee, M and Banerjee, Moinak	|	10.2217/pgs-2021-0140     EA NOV 2021	|
|	Genomewide interaction and enrichment analysis on antidepressant        response	|	2014	|	PSYCHOLOGICAL MEDICINE	|	44	|	4	|	753-765	|	Antypa, N and Drago, A and Serretti, A and Antypa, N. and Drago, A. and Serretti, A.	|	10.1017/S0033291713001554	|
|	Development of a Diverse Learning Experience for Diverse Psychiatry        Resident Needs: A Four-Year Biological Psychiatry Curriculum        Incorporating Principles of Neurobiology, Psychopharmacology, and        Evidence-Based Practice	|	2017	|	PSYCHIATRY INVESTIGATION	|	14	|	3	|	289-297	|	Muzyk, AJ and Gagliardi, JR and Rakesh, G and Jiroutek, MR and Radhakrishnan, R and Pae, CU and Masand, PS and Szabo, ST and Muzyk, Andrew J. and Gagliardi, Jane R. and Rakesh, Gopalkumar and Jiroutek, Michael R. and Radhakrishnan, Rajiv and Pae, Chi-Un and Masand, Prakash S. and Szabo, Steven T.	|	10.4306/pi.2017.14.3.289	|
|	Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms        in a South African cohort	|	2015	|	APPLIED AND TRANSLATIONAL GENOMICS	|	5	|		|	40-46	|	Dodgen, TM and Eloff, A and Mataboge, C and Roos, L and van Staden, W and Pepper, MS and Dodgen, Tyren M. and Eloff, Arinda and Mataboge, Connie and Roos, Louw (J. L. ) and van Staden, Werdie (C. W. ) and Pepper, Michael S.	|	10.1016/j.atg.2015.05.001	|
|	The association between CYP2D6 genotype and switching antipsychotic        medication to clozapine	|	2013	|	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	|	69	|	11	|	1927-1932	|	Gregoor, JG and van der Weide, K and van der Weide, J and van Megen, HJGM and Egberts, ACG and Heerdink, ER and Gregoor, Jochem G. and van der Weide, Karen and van der Weide, Jan and van Megen, Harold J. G. M. and Egberts, Antoine C. G. and Heerdink, Eibert R.	|	10.1007/s00228-013-1553-1	|
|	Precision pharmacotherapy: psychiatry's future direction in preventing,        diagnosing, and treating mental disorders	|	2018	|	PHARMACOGENOMICS & PERSONALIZED MEDICINE	|	11	|		|	211-222	|	Menke, A and Menke, Andreas	|	10.2147/PGPM.S146110	|
|	Deep sequencing identifies novel regulatory variants in the distal        promoter region of the dopamine-beta-hydroxylase gene	|	2016	|	PHARMACOGENETICS AND GENOMICS	|	26	|	7	|	311-323	|	Punchaichira, TJ and Prasad, S and Deshpande, SN and Thelma, BK and Punchaichira, Toyanji J. and Prasad, Suman and Deshpande, Smita N. and Thelma, B. K.	|	10.1097/FPC.0000000000000214	|
|	Interaction between the Val158Met catechol-O-methyltransferase gene        variant and second-generation antipsychotic treatment on blood pressure        in children	|	2015	|	PHARMACOGENOMICS JOURNAL	|	15	|	1	|	95-100	|	Cote, AT and Panagiotopoulos, C and Devlin, AM and Cote, A. T. and Panagiotopoulos, C. and Devlin, A. M.	|	10.1038/tpj.2014.35	|
|	Weight gain during a double-blind multiclosage clozapine study	|	2007	|	JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY	|	27	|	1	|	22-27	|	de Leon, J and Diaz, FJ and Josiassen, RC and Cooper, TB and Simpson, GM and de Leon, Jose and Diaz, Francisco J. and Josiassen, Richard C. and Cooper, Thomas B. and Simpson, George M.	|	10.1097/JCP.0b013e31802e513a	|
|	Precision and personalized assessment, diagnosis and treatment in        psychiatry	|	2021	|	CNS SPECTRUMS	|	26	|	4	|	326-332	|	Fountoulakis, KN and Stahl, SM and Fountoulakis, Konstantinos N. and Stahl, Stephen M.	|	10.1017/S1092852920000139	|
|	Influence of polygenic risk scores on lipid levels and dyslipidemia in a        psychiatric population receiving weight gain-inducing psychotropic drugs	|	2017	|	PHARMACOGENETICS AND GENOMICS	|	27	|	12	|	464-472	|	Delacretaza, A and Santos, PL and Morgui, NS and Vandenberghe, F and Glatard, A and Gholam-Rezaee, M and von Gunten, A and Conus, P and Eap, CB and Delacretaza, Aurelie and Santos, Patricia Lagares and Morgui, Nuria Saigi and Vandenberghe, Frederik and Glatard, Anais and Gholam-Rezaee, Mehdi and von Gunten, Armin and Conus, Philippe and Eap, Chin B.	|	10.1097/FPC.0000000000000313	|
|	Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B        receptor gene polymorphisms in Parkinson's disease	|	2003	|	PHARMACOGENETICS	|	13	|	6	|	365-369	|	Wang, J and Si, YM and Liu, ZL and Yu, L and Wang, J and Si, YM and Liu, ZL and Yu, L	|	10.1097/00008571-200306000-00008	|
|	Common genetic background in anorexia nervosa and obsessive compulsive        disorder: Preliminary results from an association study	|	2013	|	JOURNAL OF PSYCHIATRIC RESEARCH	|	47	|	6	|	747-754	|	Mas, S and Plana, MT and Castro-Fornieles, J and Gasso, P and Lafuente, A and Moreno, E and Martinez, E and Mila, M and Lazaro, L and Mas, Sergi and Teresa Plana, Maria and Castro-Fornieles, Josefina and Gasso, Patricia and Lafuente, Amalia and Moreno, Elena and Martinez, Esteban and Mila, Montserrat and Lazaro, Luisa	|	10.1016/j.jpsychires.2012.12.015	|
|	Association study of polymorphisms in leptin and leptin receptor genes        with antipsychotic-induced body weight gain	|	2012	|	PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY	|	38	|	2	|	134-141	|	Brandl, EJ and Frydrychowicz, C and Tiwari, AK and Lett, TAP and Kitzrow, W and Buttner, S and Ehrlich, S and Meltzer, HY and Lieberman, JA and Kennedy, JL and Muller, DJ and Puls, I and Brandl, E. J. and Frydrychowicz, C. and Tiwari, A. K. and Lett, T. A. P. and Kitzrow, W. and Buettner, S. and Ehrlich, S. and Meltzer, H. Y. and Lieberman, J. A. and Kennedy, J. L. and Mueller, D. J. and Puls, I.	|	10.1016/j.pnpbp.2012.03.001	|
|	The-759C/T polymorphism of the 5-HT2C receptor is associated with type 2        diabetes in male and female Caucasians	|	2008	|	PHARMACOGENETICS AND GENOMICS	|	18	|	2	|	153-159	|	Lordanidou, M and Tavridou, A and Vasiliadis, MV and Arvanitidis, KI and Petridis, J and Christakidis, D and Vargemezis, V and Bougloukas, G and Manolopoulos, VG and Lordanidou, Maria and Tavridou, Anna and Vasiliadis, Michalis V. and Arvanitidis, Kostas I. and Petridis, John and Christakidis, Dimitrios and Vargemezis, Vassilios and Bougloukas, George and Manolopoulos, Vangelis G.	|	10.1097/FPC.0b013e3282f4ae93	|
|	Effects of cytochrome P450 2D6 and 3A5 genotypes and possible        coadministered medicines on the metabolic clearance of antidepressant        mirtazapine in Japanese patients	|	2015	|	BIOCHEMICAL PHARMACOLOGY	|	93	|	1	|	104-109	|	Okubo, M and Murayama, N and Miura, J and Chiba, Y and Yamazaki, H and Okubo, Maho and Murayama, Norie and Miura, Jun and Chiba, Yasuji and Yamazaki, Hiroshi	|	10.1016/j.bcp.2014.11.011	|
|	Inflammatory dysregulation of monocytes in pediatric patients with        obsessive-compulsive disorder	|	2017	|	JOURNAL OF NEUROINFLAMMATION	|	14	|		|		|	Rodriguez, N and Morer, A and Gonzalez-Navarro, EA and Serra-Pages, C and Boloc, D and Torres, T and Garcia-Cerro, S and Mas, S and Gasso, P and Lazaro, L and Rodriguez, Natalia and Morer, Astrid and Azucena Gonzalez-Navarro, E. and Serra-Pages, Carles and Boloc, Daniel and Torres, Teresa and Garcia-Cerro, Susana and Mas, Sergi and Gasso, Patricia and Lazaro, Luisa	|	10.1186/s12974-017-1042-z	|
|	Transancestral GWAS of alcohol dependence reveals common genetic        underpinnings with psychiatric disorders	|	2018	|	NATURE NEUROSCIENCE	|	21	|	12	|	1656-+	|	Walters, RK and Polimanti, R and Johnson, EC and McClintick, JN and Adams, MJ and Adkins, AE and Aliev, F and Bacanu, SA and Batzler, A and Bertelsen, S and Biernacka, JM and Bigdeli, TB and Chen, LS and Clarke, TK and Chou, YL and Degenhardt, F and Docherty, AR and Edwards, AC and Fontanillas, P and Foo, JC and Fox, L and Frank, J and Giegling, I and Gordon, S and Hack, LM and Hartmann, AM and Hartz, SM and Heilmann-Heimbach, S and Herms, S and Hodgkinson, C and Hoffmann, P and Hottenga, JJ and Kennedy, MA and Alanne-Kinnunen, M and Konte, B and Lahti, J and Lahti-Pulkkinen, M and Lai, DB and Ligthart, L and Loukola, A and Maher, BS and Mbarek, H and McIntosh, AM and McQueen, MB and Meyers, JL and Milaneschi, Y and Palviainen, T and Pearson, JF and Peterson, RE and Ripatti, S and Ryu, E and Saccone, NL and Salvatore, JE and Sanchez-Roige, S and Schwandt, M and Sherva, R and Streit, F and Strohmaier, J and Thomas, N and Wang, JC and Webb, BT and Wedow, R and Wetherill, L and Wills, AG and Boardman, JD and Chen, DF and Choi, DS and Copeland, WE and Culverhouse, RC and Dahmen, N and Degenhardt, L and Domingue, BW and Elson, SL and Frye, MA and Gabel, W and Hayward, C and Ising, M and Keyes, M and Kiefer, F and Kramer, J and Kuperman, S and Lucae, S and Lynskey, MT and Maier, W and Mann, K and Mannisto, S and Muller-Myhsok, B and Murray, AD and Nurnberger, JI and Palotie, A and Preuss, U and Raikkonen, K and Reynolds, MD and Ridinger, M and Scherbaum, N and Schuckit, MA and Soyka, M and Treutlein, J and Witt, S and Wodarz, N and Zill, P and Adkins, DE and Boden, JM and Boomsma, DI and Bierut, LJ and Brown, SA and Bucholz, KK and Cichon, S and Costello, EJ and De Wit, H and Diazgranados, N and Dick, DM and Eriksson, JG and Farrer, LA and Foroud, TM and Gillespie, NA and Goate, AM and Goldman, D and Grucza, RA and Hancock, DB and Harris, KM and Heath, AC and Hesselbrock, V and Hewitt, JK and Hopfer, CJ and Horwood, J and Iacono, W and Johnson, EO and Kaprio, JA and Karpyak, VM and Kendler, KS and Kranzler, HR and Krauter, K and Lichtenstein, P and Lind, PA and McGue, M and MacKillop, J and Madden, PAF and Maes, HH and Magnusson, P and Martin, NG and Medland, SE and Montgomery, GW and Nelson, EC and Nothen, MM and Palmer, AA and Pedersen, NL and Penninx, BWJH and Porjesz, B and Rice, JP and Rietschel, M and Riley, BP and Rose, R and Rujescu, D and Shen, PH and Silberg, J and Stallings, MC and Tarter, RE and Vanyukov, MM and Vrieze, S and Wall, TL and Whitfield, JB and Zhao, HY and Neale, BM and Gelernter, J and Edenberg, HJ and Agrawal, A and Walters, Raymond K. and Polimanti, Renato and Johnson, Emma C. and McClintick, Jeanette N. and Adams, Mark J. and Adkins, Amy E. and Aliev, Fazil and Bacanu, Silviu-Alin and Batzler, Anthony and Bertelsen, Sarah and Biernacka, Joanna M. and Bigdeli, Tim B. and Chen, Li-Shiun and Clarke, Toni-Kim and Chou, Yi-Ling and Degenhardt, Franziska and Docherty, Anna R. and Edwards, Alexis C. and Fontanillas, Pierre and Foo, Jerome C. and Fox, Louis and Frank, Josef and Giegling, Ina and Gordon, Scott and Hack, Laura M. and Hartmann, Annette M. and Hartz, Sarah M. and Heilmann-Heimbach, Stefanie and Herms, Stefan and Hodgkinson, Colin and Hoffmann, Per and Hottenga, Jouke Jan and Kennedy, Martin A. and Alanne-Kinnunen, Mervi and Konte, Bettina and Lahti, Jari and Lahti-Pulkkinen, Marius and Lai, Dongbing and Ligthart, Lannie and Loukola, Anu and Maher, Brion S. and Mbarek, Hamdi and McIntosh, Andrew M. and McQueen, Matthew B. and Meyers, Jacquelyn L. and Milaneschi, Yuri and Palviainen, Teemu and Pearson, John F. and Peterson, Roseann E. and Ripatti, Samuli and Ryu, Euijung and Saccone, Nancy L. and Salvatore, Jessica E. and Sanchez-Roige, Sandra and Schwandt, Melanie and Sherva, Richard and Streit, Fabian and Strohmaier, Jana and Thomas, Nathaniel and Wang, Jen-Chyong and Webb, Bradley T. and Wedow, Robbee and Wetherill, Leah and Wills, Amanda G. and Boardman, Jason D. and Chen, Danfeng and Choi, Doo-Sup and Copeland, William E. and Culverhouse, Robert C. and Dahmen, Norbert and Degenhardt, Louisa and Domingue, Benjamin W. and Elson, Sarah L. and Frye, Mark A. and Gaebel, Wolfgang and Hayward, Caroline and Ising, Marcus and Keyes, Margaret and Kiefer, Falk and Kramer, John and Kuperman, Samuel and Lucae, Susanne and Lynskey, Michael T. and Maier, Wolfgang and Mann, Karl and Mannisto, Satu and Muller-Myhsok, Bertram and Murray, Alison D. and Nurnberger, John I. and Palotie, Aarno and Preuss, Ulrich and Raikkonen, Katri and Reynolds, Maureen D. and Ridinger, Monika and Scherbaum, Norbert and Schuckit, Marc A. and Soyka, Michael and Treutlein, Jens and Witt, Stephanie and Wodarz, Norbert and Zill, Peter and Adkins, Daniel E. and Boden, Joseph M. and Boomsma, Dorret I. and Bierut, Laura J. and Brown, Sandra A. and Bucholz, Kathleen K. and Cichon, Sven and Costello, E. Jane and De Wit, Harriet and Diazgranados, Nancy and Dick, Danielle M. and Eriksson, Johan G. and Farrer, Lindsay A. and Foroud, Tatiana M. and Gillespie, Nathan A. and Goate, Alison M. and Goldman, David and Grucza, Richard A. and Hancock, Dana B. and Harris, Kathleen Mullan and Heath, Andrew C. and Hesselbrock, Victor and Hewitt, John K. and Hopfer, Christian J. and Horwood, John and Iacono, William and Johnson, Eric O. and Kaprio, Jaakko A. and Karpyak, Victor M. and Kendler, Kenneth S. and Kranzler, Henry R. and Krauter, Kenneth and Lichtenstein, Paul and Lind, Penelope A. and McGue, Matt and MacKillop, James and Madden, Pamela A. F. and Maes, Hermine H. and Magnusson, Patrik and Martin, Nicholas G. and Medland, Sarah E. and Montgomery, Grant W. and Nelson, Elliot C. and Noethen, Markus M. and Palmer, Abraham A. and Pedersen, Nancy L. and Penninx, Brenda W. J. H. and Porjesz, Bernice and Rice, John P. and Rietschel, Marcella and Riley, Brien P. and Rose, Richard and Rujescu, Dan and Shen, Pei-Hong and Silberg, Judy and Stallings, Michael C. and Tarter, Ralph E. and Vanyukov, Michael M. and Vrieze, Scott and Wall, Tamara L. and Whitfield, John B. and Zhao, Hongyu and Neale, Benjamin M. and Gelernter, Joel and Edenberg, Howard J. and Agrawal, Arpana and 23Andme Res Team	|	10.1038/s41593-018-0275-1	|
|	Gene expression study in monocytes: evidence of inflammatory        dysregulation in early-onset obsessive-compulsive disorder	|	2022	|	TRANSLATIONAL PSYCHIATRY	|	12	|	1	|		|	Rodriguez, N and Lazaro, L and Ortiz, AE and Morer, A and Martinez-Pinteno, A and Segura, AG and Gasso, P and Mas, S and Rodriguez, Natalia and Lazaro, Luisa and Ortiz, Ana E. and Morer, Astrid and Martinez-Pinteno, Albert and Segura, Alex G. and Gasso, Patricia and Mas, Sergi	|	10.1038/s41398-022-01905-1	|
|	Genetic Polymorphism of the Serotonin Transporter Gene, SLC6A4        rs16965628, Is Associated with Obsessive Compulsive Disorder	|	2015	|	GENETIC TESTING AND MOLECULAR BIOMARKERS	|	19	|	5	|	228-234	|	Cengiz, M and Okutan, SN and Bayoglu, B and Kani, AS and Bayar, R and Kocabasoglu, N and Cengiz, Mujgan and Okutan, Saide Nur and Bayoglu, Burcu and Kani, Ayse Sakalli and Bayar, Reha and Kocabasoglu, Nese	|	10.1089/gtmb.2014.0319	|
|	Tracking the impact of translational research in psychiatry: state of        the art and perspectives	|	2012	|	JOURNAL OF TRANSLATIONAL MEDICINE	|	10	|		|		|	Machado-Vieira, R and Machado-Vieira, Rodrigo	|	10.1186/1479-5876-10-175	|
|	Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis	|	2022	|	Current Drug Safety	|	17	|	1	|	40-46	|	Sivagourounadin, K. and Rajendran, P. and Selvarajan, S. and Ganesapandian, M.	|	10.2174/1574886316666210611160123	|
|	Editorial: A fresh look at mood and anxiety disorders: Recent developments and emerging concepts	|	2022	|	Current Opinion in Psychiatry	|	35	|	1	|		|	Chaturvedi, S.K. and Berk, M. and Marx, W.	|	10.1097/YCO.0000000000000767	|
|	Applying an equity lens to pharmacogenetic research and translation to under-represented populations	|	2021	|	Clinical and Translational Science	|	14	|	6	|	2117-2123	|	Luczak, T. and Stenehjem, D. and Brown, J.	|	10.1111/cts.13110	|
|	Artificial intelligence and sleep: Advancing sleep medicine	|	2021	|	Sleep Medicine Reviews	|	59	|		|		|	Watson, N.F. and Fernandez, C.R.	|	10.1016/j.smrv.2021.101512	|
|	Mini review: Recent advances on epigenetic effects of lithium	|	2021	|	Neuroscience Letters	|	761	|		|		|	Marie-Claire, C. and Etain, B. and Bellivier, F.	|	10.1016/j.neulet.2021.136116	|
|	Changes in RNA expression levels during antidepressant treatment: a systematic review	|	2021	|	Journal of Neural Transmission	|	128	|	9	|	1461-1477	|	Kim, H.K. and Zai, G. and Hennings, J.M. and MÃ¼ller, D.J. and Kloiber, S.	|	10.1007/s00702-021-02394-0	|
|	Investigation of genetic loci shared between bipolar disorder and risk-taking propensity: potential implications for pharmacological interventions	|	2021	|	Neuropsychopharmacology	|	46	|	9	|	1680-1692	|	Pisanu, C. and Congiu, D. and Severino, G. and Ardau, R. and Chillotti, C. and Del Zompo, M. and Baune, B.T. and Squassina, A.	|	10.1038/s41386-021-01045-y	|
|	Current Developments of Clinical Sequencing and the Clinical Utility of Polygenic Risk Scores in Inflammatory Diseases	|	2021	|	Frontiers in Immunology	|	11	|		|		|	HÃ¼benthal, M. and LÃ¶scher, B.-S. and Erdmann, J. and Franke, A. and Gola, D. and KÃ¶nig, I.R. and Emmert, H.	|	10.3389/fimmu.2020.577677	|
|	Biological markers affecting the efficacy and safety of pharmacotherapy in schizophrenia. Review	|	2021	|	Psychiatry, Psychotherapy and Clinical Psychology	|	12	|	4	|	742-748	|	Golubeva, T. and Dokukina, T. and Objedkov, V. and Gilep, A. and Gaidukevich, I. and Bashko, N. and Bokut, O. and Moroz, A.	|	10.34883/PI.2021.12.4.016	|
|	Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies	|	2021	|	Expert Opinion on Drug Metabolism and Toxicology	|	17	|	10	|	1211-1221	|	Molden, E.	|	10.1080/17425255.2021.1974400	|
|	Genetic Inheritance and Its Contribution to Tinnitus	|	2021	|	Current Topics in Behavioral Neurosciences	|	51	|		|	29-47	|	Amanat, S. and Gallego-Martinez, A. and Lopez-Escamez, J.A.	|	10.1007/7854_2020_155	|
|	Ethnic variations are still underrepresented in neuropharmacogenomics: A systematic review	|	2021	|	Revista Ecuatoriana de Neurologia	|	30	|	1	|	91-103	|	GonzÃ¡lez-Andrade, F. and Michelena, S. and Pibaque, R. and Aguinaga-Romero, G.	|	10.46997/REVECUATNEUROL30100091	|
|	Genetics of schizophrenia and bipolar disorder: Potential clinical applications	|	2021	|	Psychiatric Annals	|	51	|	4	|	158-164	|	Gupta, R. and Bigdeli, T.B. and Buckley, P.F. and Fanous, A.H.	|	10.3928/00485713-20210310-01	|
|	The Role of Genetics in Bipolar Disorder	|	2021	|	Current Topics in Behavioral Neurosciences	|	48	|		|	41-60	|	Fabbri, C.	|	10.1007/7854_2020_153	|
|	Good, better, best: Clinical scenarios for the use of L-methylfolate in patients with MDD	|	2020	|	CNS Spectrums	|	25	|	6	|	750-764	|	Jain, R. and Manning, S. and Cutler, A.J.	|	10.1017/S1092852919001469	|
|	Facing the methodological challenge in dissecting the genetics of ADHD: A case for deep phenotyping and heterogeneity reduction	|	2020	|	Journal of the Canadian Academy of Child and Adolescent Psychiatry	|	29	|	3	|	188-201	|	Sengupta, S.M. and Grizenko, N. and Fortier, M.-Ãˆ. and Ter-Stepanian, M. and Joober, R.	|		|
|	Pharmacogenomics of Alzheimer's and Parkinson's diseases	|	2020	|	Neuroscience Letters	|	726	|		|		|	Cacabelos, R.	|	10.1016/j.neulet.2018.09.018	|
|	Neuroimaging biomarkers for predicting treatment response and recurrence of major depressive disorder	|	2020	|	International Journal of Molecular Sciences	|	21	|	6	|		|	Kang, S.-G. and Cho, S.-E.	|	10.3390/ijms21062148	|
|	The genetics of bipolar disorder	|	2020	|	Molecular Psychiatry	|	25	|	3	|	544-559	|	Gordovez, F.J.A. and McMahon, F.J.	|	10.1038/s41380-019-0634-7	|
|	Gene expression signature of antidepressant treatment response/non-response in Flinders Sensitive Line rats subjected to maternal separation	|	2020	|	European Neuropsychopharmacology	|	31	|		|	69-85	|	Marchetti, L. and Lauria, M. and Caberlotto, L. and Musazzi, L. and Popoli, M. and MathÃ©, A.A. and Domenici, E. and Carboni, L.	|	10.1016/j.euroneuro.2019.11.004	|
|	Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: Implications for clinical pharmacogenomics	|	2020	|	Human Genomics	|	14	|	1	|		|	Koromina, M. and Koutsilieri, S. and Patrinos, G.P.	|	10.1186/s40246-019-0254-y	|
|	Pharmacogenomics of bipolar disorder	|	2020	|	Neurobiology of Bipolar Disorder: Road to Novel Therapeutics	|		|		|	135-142	|	Pisanu, C. and Squassina, A.	|	10.1016/B978-0-12-819182-8.00012-0	|
|	Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline	|	2019	|	Expert Opinion on Drug Metabolism and Toxicology	|	15	|	9	|	751-765	|	Miscio, G. and Paroni, G. and Bisceglia, P. and Gravina, C. and Urbano, M. and Lozupone, M. and Piccininni, C. and Prisciandaro, M. and Ciavarella, G. and Daniele, A. and Bellomo, A. and Panza, F. and Di Mauro, L. and Greco, A. and Seripa, D.	|	10.1080/17425255.2019.1658742	|
|	Pharmacogenetics and depression: A critical perspective	|	2019	|	Psychiatry Investigation	|	16	|	9	|	645-653	|	Corponi, F. and Fabbri, C. and Serretti, A.	|	10.30773/pi.2019.06.16	|
|	Results of the European Group for the Study of Resistant Depression (GSRD) â€” basis for further research and clinical practice	|	2019	|	World Journal of Biological Psychiatry	|	20	|	6	|	427-448	|	Bartova, L. and Dold, M. and Kautzky, A. and Fabbri, C. and Spies, M. and Serretti, A. and Souery, D. and Mendlewicz, J. and Zohar, J. and Montgomery, S. and Schosser, A. and Kasper, S.	|	10.1080/15622975.2019.1635270	|
|	RNA sequencing of bipolar disorder lymphoblastoid cell lines implicates the neurotrophic factor HRP-3 in lithiumâ€™s clinical efficacy	|	2019	|	World Journal of Biological Psychiatry	|	20	|	6	|	449-461	|	Milanesi, E. and Voinsky, I. and Hadar, A. and Srouji, A. and Maj, C. and Shekhtman, T. and Gershovits, M. and Gilad, S. and Chillotti, C. and Squassina, A. and Potash, J.B. and Schulze, T.G. and Goes, F.S. and Zandi, P. and Kelsoe, J.R. and Gurwitz, D.	|	10.1080/15622975.2017.1372629	|
|	Understanding and managing cognitive impairment in bipolar disorder in older people	|	2019	|	BJPsych Advances	|	25	|	3	|	150-156	|	Rubinsztein, J.S. and Sahakian, B.J. and O'Brien, J.T.	|	10.1192/bja.2018.74	|
|	Study of 45 candidate genes suggests CACNG2 may be associated with lithium response in bipolar disorder	|	2019	|	Journal of Affective Disorders	|	248	|		|	175-179	|	Miranda, A. and Shekhtman, T. and McCarthy, M. and DeModena, A. and Leckband, S.G. and Kelsoe, J.R.	|	10.1016/j.jad.2019.01.010	|
|	Pharmacoepigenetics of Major Depression	|	2019	|	Pharmacoepigenetics	|		|		|	747-754	|	Fries, G.R. and Eyre, H.A. and Bousman, C. and Quevedo, J. and Baune, B.T.	|	10.1016/B978-0-12-813939-4.00027-9	|
|	Treating depression in the era of precision medicine: Challenges and perspectives	|	2019	|	Neurobiology of Depression: Road to Novel Therapeutics	|		|		|	265-275	|	Musker, M. and Wong, M.-L.	|	10.1016/B978-0-12-813333-0.00023-8	|
|	Personalized treatment in bipolar disorder	|	2019	|	Personalized Psychiatry	|		|		|	423-436	|	Salagre, E. and Vieta, E. and Grande, I.	|	10.1016/B978-0-12-813176-3.00035-3	|
|	Pharmacoepigenetics and pharmacoepigenomics: An overview	|	2019	|	Current Drug Discovery Technologies	|	16	|	4	|	392-399	|	Peedicayil, J.	|	10.2174/1570163815666180419154633	|
|	Genomics and the future of psychopharmacology: MicroRNAs offer novel therapeutics	|	2019	|	Dialogues in Clinical Neuroscience	|	21	|	2	|	131-138	|	Gurwitz, D.	|	10.31887/DCNS.2019.21.2/dgurwitz	|
|	MiRNAs in drug response variability: Potential utility as biomarkers for personalized medicine	|	2019	|	Pharmacogenomics	|	20	|	14	|	1049-1059	|	Latini, A. and Borgiani, P. and Novelli, G. and Ciccacci, C.	|	10.2217/pgs-2019-0089	|
|	High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: A case report	|	2019	|	Pharmacogenomics	|	20	|	8	|	567-570	|	Mian, P. and Somers, M. and Berg, M.T. and Cahn, W. and Wilting, I. and Schaik, R.V.	|	10.2217/pgs-2019-0037	|
|	The application of machine learning techniques in clinical drug therapy	|	2019	|	Current Computer-Aided Drug Design	|	15	|	2	|	111-119	|	Meng, H.-Y. and Jin, W.-L. and Yan, C.-K. and Yang, H.	|	10.2174/1573409914666180525124608	|
|	The Role of Biomarkers in Psychiatry	|	2019	|	Advances in Experimental Medicine and Biology	|	1118	|		|	135-162	|	Lozupone, M. and La Montagna, M. and Dâ€™Urso, F. and Daniele, A. and Greco, A. and Seripa, D. and Logroscino, G. and Bellomo, A. and Panza, F.	|	10.1007/978-3-030-05542-4_7	|
|	Pharmacogenomics in Parkinson's disease: Which perspective for developing a personalized medicine?	|	2019	|	Neural Regeneration Research	|	14	|	1	|	75-76	|	Ciccacci, C. and Borgiani, P.	|	10.4103/1673-5374.243706	|
|	Temporal trends and patterns in carbamazepine use, related severe cutaneous adverse reactions, and HLA-B*15:02 screening: A nationwide study	|	2018	|	Epilepsia	|	59	|	12	|	2325-2339	|	Lin, C.-W. and Huang, W.-I. and Chao, P.-H. and Chen, W.-W. and Hsiao, F.-Y.	|	10.1111/epi.14599	|
|	Successes and Challenges in Precision Medicine in Psychiatry	|	2018	|	JAMA Psychiatry	|	75	|	12	|	1301	|	Van Den Oord, E.J.C.G. and Chan, R.F. and Aberg, K.A.	|	10.1001/jamapsychiatry.2018.2897	|
|	Lithium-associated transcriptional regulation of CRMP1 in patient-derived olfactory neurons and symptom changes in bipolar disorder	|	2018	|	Translational Psychiatry	|	8	|	1	|		|	McLean, C.K. and Narayan, S. and Lin, S.Y. and Rai, N. and Chung, Y. and Hipolito, M.S. and Cascella, N.G. and Nurnberger, J.I. and Ishizuka, K. and Sawa, A.S. and Nwulia, E.A.	|	10.1038/s41398-018-0126-6	|
|	Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials	|	2018	|	Schizophrenia Research	|	199	|		|	203-213	|	Li, J. and Loebel, A. and Meltzer, H.Y.	|	10.1016/j.schres.2018.04.006	|
|	Herbal medicines in the treatment of psychiatric disorders: 10-year updated review	|	2018	|	Phytotherapy Research	|	32	|	7	|	1147-1162	|	Sarris, J.	|	10.1002/ptr.6055	|
|	Blood biomarkers and treatment response in major depression	|	2018	|	Expert Review of Molecular Diagnostics	|	18	|	6	|	513-529	|	Mora, C. and Zonca, V. and Riva, M.A. and Cattaneo, A.	|	10.1080/14737159.2018.1470927	|
|	Leveraging the Power of Genetics to Bring Precision Medicine to Psychiatry: Too Little of a Good Thing?	|	2018	|	Biological Psychiatry	|	83	|	8	|	e45-e46	|	Moreno-De-Luca, D. and Ross, M.E. and Ross, D.A.	|	10.1016/j.biopsych.2018.02.013	|
|	The genetics of antipsychotic response in schizophrenia	|	2018	|	The Lancet Psychiatry	|	5	|	4	|	291-292	|	Ikeda, M. and Mushiroda, T.	|	10.1016/S2215-0366(18)30064-6	|
|	Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients	|	2018	|	Neuropsychopharmacology	|	43	|	4	|	708-717	|	Swerdlow, N.R. and Bhakta, S.G. and Talledo, J.A. and Franz, D.M. and Hughes, E.L. and Rana, B.K. and Light, G.A.	|	10.1038/npp.2017.285	|
|	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance	|	2018	|	Progress in Neuro-Psychopharmacology and Biological Psychiatry	|	81	|		|	203-210	|	Fabbri, C. and Corponi, F. and Albani, D. and Raimondi, I. and Forloni, G. and Schruers, K. and Kasper, S. and Kautzky, A. and Zohar, J. and Souery, D. and Montgomery, S. and Cristalli, C.P. and Mantovani, V. and Mendlewicz, J. and Serretti, A.	|	10.1016/j.pnpbp.2017.10.005	|
|	Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia	|	2018	|	Neuropsychiatric Disease and Treatment	|	14	|		|	2981-2987	|	Escamilla, R. and Camarena, B. and Saracco-Alvarez, R. and FresÃ¡n, A. and HernÃ¡ndez, S. and Aguilar-GarcÃ­a, A.	|	10.2147/NDT.S176455	|
|	An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers	|	2018	|	F1000Research	|	7	|		|		|	Eugene, A.R. and Eugene, B.	|	10.12688/F1000RESEARCH.14970.2	|
|	Potential diagnostic markers of olanzapine efficiency for acute psychosis: A focus on peripheral biogenic amines	|	2017	|	BMC Psychiatry	|	17	|	1	|		|	Taraskina, A.E. and Nasyrova, R.F. and Zabotina, A.M. and Sosin, D.N. and Sosina, K.A. and Ershov, E.E. and Grunina, M.N. and Krupitsky, E.M.	|	10.1186/s12888-017-1562-1	|
|	The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia	|	2017	|	Schizophrenia Research	|	190	|		|	182-183	|	Takase, M. and Kanahara, N. and Oda, Y. and Niitsu, T. and Watanabe, H. and Iyo, M.	|	10.1016/j.schres.2017.03.014	|
|	Genetics and Antipsychotic Response in Schizophrenia: an Update	|	2017	|	Current Behavioral Neuroscience Reports	|	4	|	3	|	221-230	|	Foster, A. and Nisar, A. and Sanchez, G. and Trieu, M.	|	10.1007/s40473-017-0119-4	|
|	Preventing aggressive/violent behavior: A role for biomarkers?	|	2017	|	Biomarkers in Medicine	|	11	|	9	|	701-704	|	Pinna, M. and Manchia, M.	|	10.2217/bmm-2017-0135	|
|	Precision medicine for suicidality: From universality to subtypes and personalization	|	2017	|	Molecular Psychiatry	|	22	|	9	|	1250-1273	|	Niculescu, A.B. and Le-Niculescu, H. and Levey, D.F. and Phalen, P.L. and Dainton, H.L. and Roseberry, K. and Niculescu, E.M. and Niezer, J.O. and Williams, A. and Graham, D.L. and Jones, T.J. and Venugopal, V. and Ballew, A. and Yard, M. and Gelbart, T. and Kurian, S.M. and Shekhar, A. and Schork, N.J. and Sandusky, G.E. and Salomon, D.R.	|	10.1038/mp.2017.128	|
|	Pharmacogenomics of Antipsychotic Drugs	|	2017	|	Current Treatment Options in Psychiatry	|	4	|	2	|	127-138	|	Zhang, J.-P. and Malhotra, A.K.	|	10.1007/s40501-017-0113-1	|
|	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes	|	2017	|	Nature Communications	|	8	|		|		|	Lopez, J.P. and Fiori, L.M. and Cruceanu, C. and Lin, R. and Labonte, B. and Cates, H.M. and Heller, E.A. and Vialou, V. and Ku, S.M. and Gerald, C. and Han, M.-H. and Foster, J. and Frey, B.N. and Soares, C.N. and MÃ¼ller, D.J. and Farzan, F. and Leri, F. and Macqueen, G.M. and Feilotter, H. and Tyryshkin, K. and Evans, K.R. and Giacobbe, P. and Blier, P. and Lam, R.W. and Milev, R. and Parikh, S.V. and Rotzinger, S. and Strother, S.C. and Lewis, C.M. and Aitchison, K.J. and Wittenberg, G.M. and Mechawar, N. and Nestler, E.J. and Uher, R. and Kennedy, S.H. and Turecki, G.	|	10.1038/ncomms15497	|
|	Drug-induced akathisia in patients with schizophrenia: Literature review	|	2017	|	Psychiatry, Psychotherapy and Clinical Psychology	|	8	|	3	|	422-431	|	Gorgun, O.V. and Goloenko, I.M. and Obiedkov, V.G.	|		|
|	Personalized Medicine and Nonmotor Symptoms in Parkinson's Disease	|	2017	|	International Review of Neurobiology	|	134	|		|	1257-1281	|	Titova, N. and Chaudhuri, K.R.	|	10.1016/bs.irn.2017.05.015	|
|	Recent advances in predicting responses to antidepressant treatment	|	2017	|	F1000Research	|	6	|		|		|	Frodl, T.	|	10.12688/f1000research.10300.1	|
|	Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia	|	2017	|	Physiology and Pharmacology	|	21	|	1	|	25-33	|	Fedorenko, O.Y. and Loonen, A.J.M. and Vyalova, N.M. and Boiko, Ð.S. and Pozhidaev, I.V. and Osmanova, D.Z. and Rakhmazova, L.D. and Bokhan, N.Ð. and Ivanov, M.V. and Freidin, M.B. and Ivanova, S.Ð.	|		|
|	Modern treatment approaches in psychoses. Pharmacogenetic, neuroimagistic and clinical implications	|	2017	|	Farmacia	|	65	|	1	|	75-81	|	Nussbaum, L. and Hogea, L.M. and CÄƒlina, D. and Andreescu, N. and GrÄƒdinaru, R. and È˜tefÄƒnescu, R. and Puiu, M.	|		|
|	Rapporteur summaries of plenary, symposia, and oral sessions from the XXIIIrd World Congress of Psychiatric Genetics Meeting in Toronto, Canada, 16-20 October 2015	|	2016	|	Psychiatric Genetics	|	26	|	6	|	229-257	|	Zai, G. and Alberry, B. and Arloth, J. and BÃ¡nlaki, Z. and Bares, C. and Boot, E. and Camilo, C. and Chadha, K. and Chen, Q. and Cole, C.B. and Cost, K.T. and Crow, M. and Ekpor, I. and Fischer, S.B. and Flatau, L. and Gagliano, S. and Kirli, U. and Kukshal, P. and Labrie, V. and Lang, M. and Lett, T.A. and Maffioletti, E. and Maier, R. and Mihaljevic, M. and Mittal, K. and Monson, E.T. and O'brien, N.L. and Ã˜stergaard, SÃ¸.D. and Ovenden, E. and Patel, S. and Peterson, R.E. and Pouget, J.G. and Rovaris, D.L. and Seaman, L. and Shankarappa, B. and Tsetsos, F. and Vereczkei, A. and Wang, C. and Xulu, K. and Yuen, R.K.C. and Zhao, J. and Zai, C.C. and Kennedy, J.L.	|	10.1097/YPG.0000000000000148	|
|	Abandoning personalization to get to precision in the pharmacotherapy of depression	|	2016	|	World Psychiatry	|	15	|	3	|	228-235	|	Perlis, R.H.	|	10.1002/wps.20345	|
|	Person-centered measurement-based care for depression	|	2016	|	World Psychiatry	|	15	|	3	|	238-239	|	Uher, R.	|	10.1002/wps.20363	|
|	From metabonomics to pharmacometabonomics: The role of metabolic profiling in personalized medicine	|	2016	|	Frontiers in Pharmacology	|	7	|		|		|	Everett, J.R.	|	10.3389/fphar.2016.00297	|
|	Pharmacogenomics in Psychiatric Practice	|	2016	|	Clinics in Laboratory Medicine	|	36	|	3	|	507-523	|	El-Mallakh, R.S. and Roberts, R.J. and El-Mallakh, P.L. and Findlay, L.J. and Reynolds, K.K.	|	10.1016/j.cll.2016.05.001	|
|	Circadian genes and lithium response in bipolar disorders: associations with PPARGC1A (PGC-1Î±) and RORA	|	2016	|	Genes, Brain and Behavior	|	15	|	7	|	660-668	|	Geoffroy, P.A. and Etain, B. and Lajnef, M. and Zerdazi, E.-H. and Brichant-Petitjean, C. and Heilbronner, U. and Hou, L. and Degenhardt, F. and Rietschel, M. and McMahon, F.J. and Schulze, T.G. and Jamain, S. and Marie-Claire, C. and Bellivier, F.	|	10.1111/gbb.12306	|
|	Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population	|	2016	|	Pharmacogenomics Journal	|	16	|	4	|	357-365	|	Xu, Q. and Wu, X. and Li, M. and Huang, H. and Minica, C. and Yi, Z. and Wang, G. and Shen, L. and Xing, Q. and Shi, Y. and He, L. and Qin, S.	|	10.1038/tpj.2015.61	|
|	Metabolomics of Schizophrenia	|	2016	|	The Neurobiology of Schizophrenia	|		|		|	167-177	|	Rujescu, D. and Giegling, I.	|	10.1016/B978-0-12-801829-3.00018-5	|
|	The Limitations of Genetic Testing in Psychiatry	|	2016	|	Psychotherapy and Psychosomatics	|	85	|	3	|	129-135	|	Dubovsky, S.L.	|	10.1159/000443512	|
|	Advances in the genetics of schizophrenia: Toward a network and pathway view for drug discovery	|	2016	|	Annals of the New York Academy of Sciences	|	1366	|	1	|	61-75	|	Collier, D.A. and Eastwood, B.J. and Malki, K. and Mokrab, Y.	|	10.1111/nyas.13066	|
|	Genetic influences on response to drug treatment for major psychiatric disorders	|	2016	|	Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders	|		|		|	1-117	|	Rybakowski, J.K. and Serretti, A.	|	10.1007/978-3-319-27040-1	|
|	The genetic basis of bipolar disorder	|	2016	|	Milestones in Drug Therapy	|		|		|	73-92	|	Hou, L. and McMahon, F.J.	|	10.1007/978-3-319-31689-5_5	|
|	Pharmacogenetic tests for antipsychotic medications: Clinical implications and considerations	|	2016	|	Dialogues in Clinical Neuroscience	|	18	|	3	|	323-337	|	Eum, S. and Lee, A.M. and Bishop, J.R.	|		|
|	Personalised approaches to pharmacotherapy for schizophrenia	|	2016	|	BJ Psych Advances	|	22	|	2	|	78-86	|	Lally, J. and MacCabe, J.H.	|	10.1192/apt.bp.114.013433	|
|	Association of genetic risk scores with body mass index in Swiss psychiatric cohorts	|	2016	|	Pharmacogenetics and Genomics	|	26	|	5	|	208-217	|	Saigi-Morgui, N. and Vandenberghe, F. and DelacrÃ©taz, A. and Quteineh, L. and Gholamrezaee, M. and Aubry, J.-M. and Von Gunten, A. and Kutalik, Z. and Conus, P. and Eap, C.B.	|	10.1097/FPC.0000000000000210	|
|	Making progress toward individualized medicine in the treatment of psychosis	|	2016	|	American Journal of Psychiatry	|	173	|	1	|	7-May	|	Lahti, A.C.	|	10.1176/appi.ajp.2016.15101320	|
|	Pharmacometabolomics: Applications and challenges	|	2015	|	Current Pharmacogenomics and Personalized Medicine	|	13	|	1	|	13-Sep	|	Katsila, T. and Patrinos, G.P.	|	10.2174/1875692113666150818221334	|
|	Let us promote bio-banking in India for translational research	|	2015	|	Neurology India	|	63	|	5	|	644-646	|	Shankar, S.K.	|	10.4103/0028-3886.166573	|
|	Applicability of gene expression and systems biology to develop pharmacogenetic predictors; Antipsychotic-induced extrapyramidal symptoms as an example	|	2015	|	Pharmacogenomics	|	16	|	17	|	1975-1988	|	Mas, S. and GassÃ³, P. and Lafuente, A.	|	10.2217/pgs.15.134	|
|	Systems medicine, personalized health and therapy	|	2015	|	Pharmacogenomics	|	16	|	14	|	1527-1539	|	Siest, G. and Auffray, C. and Taniguchi, N. and Ingelman-Sundberg, M. and Murray, H. and Visvikis-Siest, S. and Ansari, M. and Marc, J. and Jacobs, P. and Meyer, U. and Van Schaik, R.H.N. and MÃ¼ller, M.M. and Wevers, R.A. and Simmaco, M. and Kussmann, M. and Manolopoulos, V.G. and Alizadeh, B.Z. and Beastall, G. and NÃ©meth, G.	|	10.2217/pgs.15.103	|
|	Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs	|	2015	|	Journal of Psychopharmacology	|	29	|	8	|	884-891	|	Athanasiu, L. and Smorr, L.-L.H. and Tesli, M. and RÃ¸ssberg, J.I. and SÃ¸nderby, I.E. and Spigset, O. and Djurovic, S. and Andreassen, O.A.	|	10.1177/0269881115584469	|
|	Clinically useful genetic markers of antidepressant response: How do we get there from here?	|	2015	|	American Journal of Psychiatry	|	172	|	8	|	697-699	|	McMahon, F.J.	|	10.1176/appi.ajp.2015.15050644	|
|	Taking personalized medicine seriously: Biomarker approaches in phase IIb/III studies in major depression and schizophrenia	|	2015	|	Innovations in Clinical Neuroscience	|	12	|	3	|	26S-40S	|	Murck, H. and Laughren, T. and Lamers, F. and Picard, R. and Walther, S. and Goff, D. and Sainati, S.	|		|
|	Genomic biomarkers related to drug response in Venezuelan populations	|	2015	|	Drug Metabolism and Personalized Therapy	|	30	|	1	|	33-41	|	Chiurillo, M.A.	|	10.1515/dmdi-2014-0019	|
|	Association study of GABAA Î±2 receptor subunit gene variants in antipsychotic-associated weight gain	|	2015	|	Journal of Clinical Psychopharmacology	|	35	|	1	|	12-Jul	|	Zai, C.C.H. and Tiwari, A.K. and Chowdhury, N.I. and Brandl, E.J. and Shaikh, S.A. and Freeman, N. and Lieberman, J.A. and Meltzer, H.Y. and MÃ¼ller, D.J. and Kennedy, J.L.	|	10.1097/JCP.0000000000000261	|
|	Personalized therapies in psychiatry: promises, pitfalls and perspectives	|	2015	|	Journal of Neural Transmission	|	122	|	1	|		|	Domschke, K. and MÃ¼ller, D.J. and Serretti, A.	|	10.1007/s00702-014-1340-x	|
|	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients	|	2015	|	Journal of Neural Transmission	|	122	|	1	|	43-58	|	Fabbri, C. and Souery, D. and Calati, R. and Crisafulli, C. and Chierchia, A. and Albani, D. and Forloni, G. and Chiesa, A. and Martines, R. and Sentissi, O. and Mendlewicz, J. and De Girolamo, G. and Serretti, A.	|	10.1007/s00702-014-1290-3	|
|	Role of neurogenomics in the development of personalized neurology	|	2015	|	Neuromethods	|	97	|		|	137-153	|	Jain, K.K.	|	10.1007/978-1-4939-2247-5_6	|
|	Complementary versus companion diagnostics: Apples and oranges?	|	2015	|	Biomarkers in Medicine	|	9	|	1	|	25-34	|	Milne, C.-P. and Bryan, C. and Garafalo, S. and McKiernan, M.	|	10.2217/bmm.14.84	|
|	Genome-wide association study: A useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics	|	2014	|	Clinical Cancer Research	|	20	|	10	|	2541-2552	|	Low, S.-K. and Takahashi, A. and Mushiroda, T. and Kubo, M.	|	10.1158/1078-0432.CCR-13-2755	|
|	Pharmacogenetics in the treatment of schizophrenia	|	2014	|	Schizophrenia: Recent Advances in Diagnosis and Treatment	|		|		|	161-173	|	Massey, B.W. and Li, J. and Meltzer, H.Y.	|	10.1007/978-1-4939-0656-7_9	|
|	Pharmacogenetics and treatment-resistant schizophrenia	|	2014	|	Treatment-Refractory Schizophrenia: A Clinical Conundrum	|		|		|	179-194	|	Foster, A. and Buckley, P.F.	|	10.1007/978-3-642-45257-4_12	|
|	Person-oriented perspectives in neurology	|	2014	|	Acta Clinica Croatica	|	53	|	4	|	423-429	|	Lisak, M. and Demarin, V. and Trkanjec, Z. and Zavoreo, I. and Kes, V.B.	|		|
|	Antipsychotic treatment modulates glutamate transport and NMDA receptor expression	|	2014	|	European Archives of Psychiatry and Clinical Neuroscience	|	264	|	1	|	67-82	|	Zink, M. and Englisch, S. and Schmitt, A.	|	10.1007/s00406-014-0534-4	|
|	Pharmacogenetics and molecular medicine: "So close and yet so far"	|	2014	|	Current Molecular Medicine	|	14	|	7	|	803-804	|	Moore, J.H. and Hwa, J.	|	10.2174/1566524014666140811122704	|
|	Genetics: A window into the biology of the mind	|	2014	|	Current Psychiatry Reviews	|	10	|	2	|	89-90	|	Bawor, M. and Dennis, B.B. and Samaan, Z.	|	10.2174/157340051002140707092402	|
|	ConLiGen-A consortium investigating the genetic underpinnings of lithium response in bipolar disorder	|	2014	|	Annales Medico-Psychologiques	|	172	|	3	|	197-198	|	Heilbronner, U. and Schulze, T.G.	|	10.1016/j.amp.2014.02.017	|
|	The clinical application of ABCB1 genotyping in antidepressant treatment: A pilot study	|	2014	|	CNS Spectrums	|	19	|	2	|	165-175	|	Breitenstein, B. and Scheuer, S. and Pfister, H. and Uhr, M. and Lucae, S. and Holsboer, F. and Ising, M. and BrÃ¼ckl, T.M.	|	10.1017/S1092852913000436	|
|	Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients	|	2014	|	European Journal of Clinical Pharmacology	|	70	|	6	|	695-699	|	Mannheimer, B. and Holm, J. and Koukel, L. and Bertilsson, L. and Ã–sby, U. and Eliasson, E.	|	10.1007/s00228-014-1664-3	|
|	Circadian abnormalities as markers of susceptibility in bipolar disorders	|	2014	|	Frontiers in Bioscience - Scholar	|	6	|	1	|	120-137	|	Milhiet, V. and Boudebesse, C. and Bellivier, F. and Drouot, X. and Henry, C. and Leboyer, M. and Etain, B.	|		|
|	Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients	|	2014	|	Neuropsychobiology	|	69	|	2	|	76-82	|	Drago, A. and Monti, B. and De Ronchi, D. and Serretti, A.	|	10.1159/000356971	|
|	Problems and solutions to filling the drying drug pipeline for psychiatric disorders: A report from the inaugural 2012 CINP Think Tank	|	2014	|	International Journal of Neuropsychopharmacology	|	17	|	1	|	137-148	|	Dean, B. and Moller, H.-J. and Svensson, T.H. and Geyer, M.A. and Rujescu, D. and Scarr, E. and Millan, M.J.	|	10.1017/S1461145713001077	|
|	Improving clinical outcomes for naltrexone as a management of problem alcohol use	|	2013	|	British Journal of Clinical Pharmacology	|	76	|	5	|	632-641	|	Hulse, G.K.	|	10.1111/j.1365-2125.2012.04452.x	|
|	Relationship between the serotonin receptor 1A polymorphism with treatment response to escitalopram in patients with major depresive disorder	|	2013	|	Clinical Neuropsychiatry	|	10	|	3	|	148-154	|	Soo Chang, H. and Choi, I.-K. and Lee, H.-Y. and Jeong, Y.-J. and Kim, B. and Lee, M.-S.	|		|
|	Anti-Parkinson's disease drugs and pharmacogenetic considerations	|	2013	|	Expert Opinion on Drug Metabolism and Toxicology	|	9	|	7	|	859-874	|	AgÃºndez, J.A.G. and GarcÃ­a-MartÃ­n, E. and Alonso-Navarro, H. and JimÃ©nez-JimÃ©nez, F.J.	|	10.1517/17425255.2013.789018	|
|	Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels	|	2013	|	European Neuropsychopharmacology	|	23	|	7	|	653-662	|	Kloiber, S. and Ripke, S. and Kohli, M.A. and Reppermund, S. and Salyakina, D. and Uher, R. and McGuffin, P. and Perlis, R.H. and Hamilton, S.P. and PÃ¼tz, B. and Hennings, J. and BrÃ¼ckl, T. and Klengel, T. and Bettecken, T. and Ising, M. and Uhr, M. and Dose, T. and Unschuld, P.G. and Zihl, J. and Binder, E. and MÃ¼ller-Myhsok, B. and Holsboer, F. and Lucae, S.	|	10.1016/j.euroneuro.2012.08.010	|
|	Purposeful reprofiling	|	2013	|	EBR - European Biopharmaceutical Review	|		|		|	24-29	|	Meighan-Mantha, R.	|		|
|	Acute lymphoblastic leukaemia	|	2013	|	The Lancet	|	381	|	9881	|	1943-1955	|	Inaba, H. and Greaves, M. and Mullighan, C.G.	|	10.1016/S0140-6736(12)62187-4	|
|	Cholinergic muscarinic M4 receptor gene polymorphisms: A potential risk factor and pharmacogenomic marker for schizophrenia	|	2013	|	Schizophrenia Research	|	146	|	1	|	279-284	|	Scarr, E. and Um, J.Y. and Cowie, T.F. and Dean, B.	|	10.1016/j.schres.2013.01.023	|
|	Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: Associations and functional implications	|	2013	|	Progress in Neuro-Psychopharmacology and Biological Psychiatry	|	42	|		|	49-62	|	Debnath, M. and Cannon, D.M. and Venkatasubramanian, G.	|	10.1016/j.pnpbp.2012.07.009	|
|	GeneÃ—environment interactions in the prediction of response to antidepressant treatment	|	2013	|	International Journal of Neuropsychopharmacology	|	16	|	3	|	701-711	|	Klengel, T. and Binder, E.B.	|	10.1017/S1461145712001459	|
|	[Polymorphism of RGS2 gene: genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency]	|	2013	|	Molekuliarnaia biologiia	|	47	|	6	|	934-941	|	Gareeva, A.E. and Zakirov, D.F. and Valinurov, R.G. and Khusnutdinova, E.K.	|	10.7868/s0026898413060049	|
|	Pharmacogenetics and genomics of antipsychotic-induced weight gain and obesity: An integrated review	|	2013	|	Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention	|		|		|	175-217	|	Chagnon, Y.C.	|		|
|	Pharmacogenetics of clinical response to risperidone	|	2013	|	Pharmacogenomics	|	14	|	2	|	177-194	|	Llerena, A. and Berecz, R. and PeÃ±as-LledÃ³, E. and SÃ¼veges, Ã. and FariÃ±as, H.	|	10.2217/pgs.12.201	|
|	Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder	|	2012	|	Psychiatry Research	|	200	|	1	|	63-65	|	Houston, J.P. and Zou, W. and Aris, V. and Fijal, B. and Chen, P. and Heinloth, A.N. and Martinez, J.	|	10.1016/j.psychres.2012.06.002	|
|	Novel diagnostics R&amp;D for public health and personalized medicine in Taiwan: Current state, challenges and opportunities	|	2012	|	Current Pharmacogenomics and Personalized Medicine	|	10	|	3	|	239-246	|	Lin, E. and Tsai, S.-J.	|	10.2174/187569212802510049	|
|	Pharmacogenetics in psychiatry: Translating research into clinical practice	|	2012	|	Molecular Psychiatry	|	17	|	8	|	760-769	|	Malhotra, A.K. and Zhang, J.-P. and Lencz, T.	|	10.1038/mp.2011.146	|
|	Genome-wide approaches in pharmacogenomics: Heritability estimation and pharmacoethnicity as primary challenges	|	2012	|	Pharmacogenomics	|	13	|	10	|	1101-1104	|	Gamazon, E.R. and Perera, M.	|	10.2217/pgs.12.88	|
|	Challenges in the codevelopment of companion diagnostics	|	2012	|	Personalized Medicine	|	9	|	5	|	485-496	|	Moore, M.W. and Babu, D. and Cotter, P.D.	|	10.2217/pme.12.60	|
|	Pharmacogenomics and Personalized Medicine in Neuropsychiatry	|	2012	|	Neuron	|	74	|	5	|	773-776	|	McMahon, F.J. and Insel, T.R.	|	10.1016/j.neuron.2012.05.004	|
|	From basic to clinical neuropharmacology: Targetophilia or pharmacodynamics?	|	2012	|	British Journal of Clinical Pharmacology	|	73	|	6	|	959-967	|	Green, A.R. and Aronson, J.K.	|	10.1111/j.1365-2125.2012.04246.x	|
|	Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration	|	2012	|	Progress in Neuro-Psychopharmacology and Biological Psychiatry	|	37	|	1	|	62-75	|	Hwang, R. and Tiwari, A.K. and Zai, C.C. and Felsky, D. and Remington, E. and Wallace, T. and Tong, R.P. and Souza, R.P. and Oh, G. and Potkin, S.G. and Lieberman, J.A. and Meltzer, H.Y. and Kennedy, J.L.	|	10.1016/j.pnpbp.2011.11.018	|
|	Conference Scene: Golden Helix Pharmacogenomics Days: Educational activities on pharmacogenomics and personalized medicine	|	2012	|	Pharmacogenomics	|	13	|	5	|	525-528	|	Squassina, A. and Severino, G. and Grech, G. and Fenech, A. and Borg, J. and Patrinos, G.P.	|	10.2217/pgs.12.22	|
|	Pharmacogenetics of drugs withdrawn from the market	|	2012	|	Pharmacogenomics	|	13	|	2	|	223-231	|	Zhang, W. and Roederer, M.W. and Chen, W.-Q. and Fan, L. and Zhou, H.-H.	|	10.2217/pgs.11.137	|
|	Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)	|	2012	|	Drug Metabolism and Pharmacokinetics	|	27	|	1	|	85-105	|	Ieiri, I.	|	10.2133/dmpk.DMPK-11-RV-098	|
|	Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance	|	2012	|	Drug Metabolism and Pharmacokinetics	|	27	|	1	|	55-67	|	Teh, L.K. and Bertilsson, L.	|	10.2133/dmpk.DMPK-11-RV-121	|
|	Influence of a genetic signature on therapeutic effects of clozapine in schizophrenia subjects from South China	|	2011	|	ITME 2011 - Proceedings: 2011 IEEE International Symposium on IT in Medicine and Education	|	1	|		|	501-504	|	Gong, D. and Li, Z. and Li, B. and Gan, C. and Wang, X.	|	10.1109/ITiME.2011.6130885	|
|	Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: Implication for pharmacogenetics and disease	|	2011	|	Drug Metabolism and Drug Interactions	|	26	|	4	|	169-179	|	Silverton, L. and Dean, M. and Moitra, K.	|	10.1515/DMDI.2011.027	|
|	Integrative genomics strategies to elucidate the complexity of drug response	|	2011	|	Pharmacogenomics	|	12	|	12	|	1695-1715	|	Kasarskis, A. and Yang, X. and Schadt, E.	|	10.2217/pgs.11.115	|
|	Biomarkers in development of psychotropic drugs	|	2011	|	Dialogues in Clinical Neuroscience	|	13	|	2	|	225-234	|	Wiedemann, K.	|		|
|	Pharmacogenomics in neurology: Current state and future steps	|	2011	|	Annals of Neurology	|	70	|	5	|	684-697	|	Chan, A. and Pirmohamed, M. and Comabella, M.	|	10.1002/ana.22502	|
|	Direct-to-consumer personalized genomic testing	|	2011	|	Human Molecular Genetics	|	20	|		|	132-141	|	Bloss, C.S. and Darst, B.F. and Topol, E.J. and Schork, N.J.	|	10.1093/hmg/ddr349	|
|	Mechanisms and genetics of antipsychotic-associated weight gain	|	2011	|	Clinical Pharmacology and Therapeutics	|	90	|	1	|	179-183	|	Balt, S.L. and Galloway, G.P. and Baggott, M.J. and Schwartz, Z. and Mendelson, J.	|	10.1038/clpt.2011.97	|
|	Emerging biosignature of brain function and intervention in pediatric bipolar disorder	|	2011	|	Minerva Pediatrica	|	63	|	3	|	183-200	|	Mayanil, T. and Wegbreit, E. and Fitzgerald, J. and Pavuluri, M.	|		|
|	Evidence of involvement of the human Par-4 (PAWR) gene in major depressive disorder	|	2011	|	World Journal of Biological Psychiatry	|	12	|	4	|	288-295	|	Liou, Y.-J. and Chen, T.-J. and Tsai, S.-J. and Yu, Y.W.-Y. and Chen, S.-Y. and Cheng, C.-Y. and Hong, C.-J.	|	10.3109/15622975.2010.509451	|
|	Introduction	|	2011	|	Harvard Review of Psychiatry	|	19	|	3	|	99-101	|	Roffman, J.L.	|	10.3109/10673229.2011.586547	|
|	Betting on biomarkers	|	2011	|	American Journal of Psychiatry	|	168	|	3	|	234-236	|	Perlis, R.H.	|	10.1176/appi.ajp.2010.10121738	|
|	Genetics of depression: Implications for clinical practice yet?	|	2011	|	Clinical Neuropsychiatry	|	8	|	1	|	37-46	|	Garriock, H.A. and Moreno, F.A.	|		|
|	High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug	|	2011	|	Journal of Clinical Psychopharmacology	|	31	|	1	|	9-Apr	|	Skogh, E. and SjÃ¶din, I. and Josefsson, M. and Dahl, M.-L.	|	10.1097/JCP.0b013e318204d9e2	|
|	Personalized Medicine for Schizophrenia	|	2011	|	Integrative Neuroscience and Personalized Medicine	|		|		|		|	Ballon, J.S. and Girgis, R.R. and Lieberman, J.A.	|	10.1093/acprof:oso/9780195393804.003.0006	|
|	Toward Personalized Medicine in the Neuropsychiatric Field	|	2011	|	International Review of Neurobiology	|	101	|		|	329-349	|	Wong, E.H.F. and Fox, J.C. and Ng, M.Y.M. and Lee, C.-M.	|	10.1016/B978-0-12-387718-5.00013-4	|
|	Pharmacoproteomics applications for drug target discovery in CNS disorders	|	2011	|	Current Pharmacogenomics and Personalized Medicine	|	9	|	2	|	102-122	|	Park, S.	|	10.2174/187569211795508484	|
|	Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome - clozapine-induced agranulocytosis as a case study	|	2011	|	PLoS Computational Biology	|	7	|	3	|		|	Yang, L. and Wang, K. and Chen, J. and Jegga, A.G. and Luo, H. and Shi, L. and Wan, C. and Guo, X. and Qin, S. and He, G. and Feng, G. and He, L.	|	10.1371/journal.pcbi.1002016	|
|	Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: Old thoughts revisited from a genetic perspective	|	2011	|	Human Psychopharmacology	|	26	|	1	|	21-27	|	Souza, R.P. and Meltzer, H.Y. and Lieberman, J.A. and Voineskos, A.N. and Remington, G. and Kennedy, J.L.	|	10.1002/hup.1161	|
|	Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics-informed pharmacogenomics	|	2011	|	Clinical Pharmacology and Therapeutics	|	89	|	1	|	97-104	|	Ji, Y. and Hebbring, S. and Zhu, H. and Jenkins, G.D. and Biernacka, J. and Snyder, K. and Drews, M. and Fiehn, O. and Zeng, Z. and Schaid, D. and Mrazek, D.A. and Kaddurah-Daouk, R. and Weinshilboum, R.M.	|	10.1038/clpt.2010.250	|
|	Pharmacogenetics in medico-legal context	|	2010	|	Forensic Science International	|	203	|	1	|	44-52	|	Sajantila, A. and Palo, J.U. and OjanperÃ¤, I. and Davis, C. and Budowle, B.	|	10.1016/j.forsciint.2010.09.011	|
|	Whole genome association studies in complex diseases: Where do we stand?	|	2010	|	Dialogues in Clinical Neuroscience	|	12	|	1	|	34-43	|	Need, A.C. and Goldstein, D.B.	|		|
|	Cost effectiveness of pharmacogenomics: A critical and systematic review	|	2010	|	PharmacoEconomics	|	28	|	11	|	1001-1013	|	Wong, W.B. and Carlson, J.J. and Thariani, R. and Veenstra, D.L.	|	10.2165/11537410-000000000-00000	|
|	Pharmacogenetics of adverse effects due to antiretroviral drugs	|	2010	|	AIDS Reviews	|	12	|	1	|	15-30	|	Vidal, F. and GutiÃ©rrez, F. and GutiÃ©rrez, M. and Olona, M. and SÃ¡nchez, V. and Mateo, G. and Peraire, J. and ViladÃ©s, C. and Veloso, S. and LÃ³pez-Dupla, M. and Domingo, P.	|		|
|	No influence of DTNBP1 polymorphisms on the response to aripiprazole	|	2010	|	Neuropsychobiology	|	62	|	4	|	245-249	|	Pae, C.-U. and Chiesa, A. and Mandelli, L. and Serretti, A.	|	10.1159/000320863	|
|	The catechol-O-methyl-transferase gene in tardive dyskinesia	|	2010	|	World Journal of Biological Psychiatry	|	11	|	6	|	803-812	|	Zai, C.C. and Tiwari, A.K. and MÃ¼ller, D.J. and De Luca, V. and Shinkai, T. and Shaikh, S. and Ni, X. and Sibony, D. and Voineskos, A.N. and Meltzer, H.Y. and Lieberman, J.A. and Potkin, S.G. and Remington, G. and Kennedy, J.L.	|	10.3109/15622975.2010.486043	|
|	No association between genetic markers in BDNF gene and lithium prophylaxis in a Greek sample	|	2010	|	International Journal of Psychiatry in Clinical Practice	|	14	|	2	|	154-157	|	Drago, A. and Serretti, A. and Smith, R. and Huezo-Diaz, P. and Malitas, P. and Albani, D. and Ronchi, D.D. and Pae, C.-U. and Aitchison, K.J.	|	10.3109/13651501003706717	|
|	Sixty years of lithium responders	|	2010	|	Neuropsychobiology	|	62	|	1	|	16-Aug	|	Grof, P.	|	10.1159/000314305	|
|	Use of biomarkers from the prospective of pharmaceutical industry	|	2010	|	Japanese Journal of Clinical Pharmacology and Therapeutics	|	41	|	3	|	107-112	|	Liou, S.-Y.	|	10.3999/jscpt.41.107	|
|	The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action	|	2010	|	Pharmacology and Therapeutics	|	126	|	2	|	173-185	|	Wong, E.H.F. and Tarazi, F.I. and Shahid, M.	|	10.1016/j.pharmthera.2010.02.001	|
|	A selected review of recent biological psychiatric research in China (translated version)	|	2010	|	East Asian Archives of Psychiatry	|	20	|	1	|	44-50	|	Fu, Y. and Hu, S.H. and Lam, L.C.W.	|		|
|	Pharmacogenetic considerations in the treatment of psychiatric disorders	|	2010	|	Expert Opinion on Pharmacotherapy	|	11	|	3	|	423-439	|	Lohoff, F.W. and Ferraro, T.N.	|	10.1517/14656560903508762	|
|	Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants	|	2010	|	Pharmaceuticals	|	3	|	10	|	3040-3100	|	Cacabelos, R. and FernÃ¡ndez-Novoa, L. and MartÃ­nez-Bouza, R. and McKay, A. and Carril, J.C. and Lombardi, V. and Corzo, L. and Carrera, I. and Tellado, I. and Nebril, L. and Alcaraz, M. and RodrÃ­guez, S. and Casas, A. and Couceiro, V. and Ãlvarez, A.	|	10.3390/ph3103040	|
|	Iloperidone: An old tune variation or the first implementation of personalized medicine into psychiatry?	|	2010	|	Psychiatrie	|	14	|	3	|	153-158	|	Mohr, P.	|		|
|	Does response to prophylactic lithium characterize a distinct form of bipolar disorder?	|	2009	|	Psychiatrie	|	13	|		|	131-136	|	Alda, M.	|		|
|	Knowledge engineering for pharmacogenomic molecular imaging of the brain	|	2009	|	SKG 2009 - 5th International Conference on Semantics, Knowledge, and Grid	|		|		|	26-33	|	Taswell, C.	|	10.1109/SKG.2009.101	|
|	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms	|	2009	|	Pharmacogenomics Journal	|	9	|	6	|	404-410	|	GassÃ³, P. and Mas, S. and Bernardo, M. and Lvarez, S. and Parellada, E. and Lafuente, A.	|	10.1038/tpj.2009.26	|
|	Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease	|	2009	|	European Journal of Clinical Pharmacology	|	65	|	12	|	1245-1251	|	Arbouw, M.E.L. and Movig, K.L.L. and Egberts, T.C.G. and Poels, P.J.E. and Van Vugt, J.P.P. and Wessels, J.A.M. and Van Der Straaten, R.J.H.M. and Neef, C. and Guchelaar, H.-J.	|	10.1007/s00228-009-0708-6	|
|	Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression	|	2009	|	Expert Opinion on Investigational Drugs	|	18	|	11	|	1753-1764	|	Khan, A.	|	10.1517/13543780903286396	|
|	Extracting a needle from a haystack: Reanalysis of whole genome data reveals a readily translatable finding	|	2009	|	Psychological Medicine	|	39	|	8	|	1231-1235	|	Keers, R. and Farmer, A.E. and Aitchison, K.J.	|	10.1017/S0033291708005084	|
|	Iloperidone for schizophrenia: A review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic	|	2009	|	International Journal of Clinical Practice	|	63	|	8	|	1237-1248	|	Citrome, L.	|	10.1111/j.1742-1241.2009.02142.x	|
|	Influence of TAAR6 polymorphisms on response to aripiprazole	|	2009	|	Progress in Neuro-Psychopharmacology and Biological Psychiatry	|	33	|	5	|	822-826	|	Serretti, A. and Pae, C.-U. and Chiesa, A. and Mandelli, L. and De Ronchi, D.	|	10.1016/j.pnpbp.2009.03.032	|
|	Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response	|	2009	|	Progress in Neuro-Psychopharmacology and Biological Psychiatry	|	33	|	4	|	637-641	|	Tsai, S.-J. and Hong, C.-J. and Liou, Y.-J. and Yu, Y.W.-Y. and Chen, T.-J. and Hou, S.-J. and Yen, F.-C.	|	10.1016/j.pnpbp.2009.02.020	|
|	Developing the evidence base for applying pharmacogenomics: Proceeds from DIA workshop IV - Breakout session 1	|	2009	|	Pharmacogenomics	|	10	|	1	|	117-125	|	Amstrong, M. and Bromley, C. and Cohen, N. and Hunt, C.M. and O'Neill, R. and Power, A.C.	|	10.2217/14622416.10.1.117	|
|	Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia	|	2009	|	European Neuropsychopharmacology	|	19	|	5	|	317-328	|	Zai, C.C. and Tiwari, A.K. and De Luca, V. and MÃ¼ller, D.J. and Bulgin, N. and Hwang, R. and Zai, G.C. and King, N. and Voineskos, A.N. and Meltzer, H.Y. and Lieberman, J.A. and Potkin, S.G. and Remington, G. and Kennedy, J.L.	|	10.1016/j.euroneuro.2009.01.001	|
|	Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication	|	2009	|	Journal of Clinical Psychopharmacology	|	29	|	1	|	21-25	|	Gregoor, J.G. and Van Der Weide, J. and Mulder, H. and Cohen, D. and Van Megen, H.J.G.M. and Egberts, A.C.G. and Heerdink, E.R.	|	10.1097/JCP.0b013e31819359be	|
|	Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder	|	2009	|	American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics	|	150	|	1	|	115-123	|	Kato, M. and Fukuda, T. and Wakeno, M. and Okugawa, G. and Takekita, Y. and Watanabe, S. and Yamashita, M. and Hosoi, Y. and Azuma, J. and Kinoshita, T. and Serretti, A.	|	10.1002/ajmg.b.30783	|
|	Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment	|	2009	|	Pharmacogenomics	|	10	|	3	|	385-397	|	Gupta, M. and Bhatnagar, P. and Grover, S. and Kaur, H. and Baghel, R. and Bhasin, Y. and Chauhan, C. and Verma, B. and Manduva, V. and Mukherjee, O. and Purushottam, M. and Sharma, A. and Jain, S. and Brahmachari, S.K. and Kukreti, R.	|	10.2217/14622416.10.3.385	|
|	Identifying blood biomarkers for mood disorders using convergent functional genomics	|	2009	|	Molecular Psychiatry	|	14	|	2	|	156-174	|	Le-Niculescu, H. and Kurian, S.M. and Yehyawi, N. and Dike, C. and Patel, S.D. and Edenberg, H.J. and Tsuang, M.T. and Salomon, D.R. and Nurnberger Jr., J.I. and Niculescu, A.B.	|	10.1038/mp.2008.11	|
|	Target identification for CNS diseases by transcriptional profiling	|	2009	|	Neuropsychopharmacology	|	34	|	1	|	18-54	|	Altar, C.A. and Vawter, M.P. and Ginsberg, S.D.	|	10.1038/npp.2008.172	|
|	Personalized medicine: Pharmacogenetics in psychiatry	|	2008	|	Current Pharmacogenomics and Personalized Medicine	|	6	|	1	|	11-Jan	|	Hinrichs, J.W.J. and van der Weide, J.	|	10.2174/187569208784017548	|
|	Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia	|	2008	|	NeuroMolecular Medicine	|	10	|	4	|	362-367	|	Shinkai, T. and De Luca, V. and Utsunomiya, K. and Sakata, S. and Inoue, Y. and Fukunaka, Y. and Hwang, R. and Ohmori, O. and Kennedy, J.L. and Nakamura, J.	|	10.1007/s12017-008-8041-2	|
|	Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations	|	2008	|	Pharmacogenomics	|	9	|	10	|	1543-1546	|	Ferrell Jr., P.B. and McLeod, H.L.	|	10.2217/14622416.9.10.1543	|
|	Evidence for association between genetic variants of p75 neurotrophin receptor (p75NTR) gene and antidepressant treatment response in Chinese major depressive disorder	|	2008	|	American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics	|	147	|	5	|	594-599	|	Gau, Y.-T.A. and Liou, Y.-J. and Yu, Y.W.-Y. and Chen, T.-J. and Lin, M.-W. and Tsai, S.-J. and Hong, C.-J.	|	10.1002/ajmg.b.30646	|
|	Iloperidone: A novel atypical antipsychotic for the treatment of schizophrenia	|	2008	|	Formulary	|	43	|	6	|	190-196+203	|	Ehret, M.J. and Sopko Jr., M.A. and Levine, A.	|		|
|	Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics	|	2008	|	BMC Psychiatry	|	8	|		|		|	Benmessaoud, D. and Hamdani, N. and Boni, C. and Ramoz, N. and Hamon, M. and Kacha, F. and Gorwood, P.	|	10.1186/1471-244X-8-40	|
|	Association of RGS2 and RGS5 variants with schizophrenia symptom severity	|	2008	|	Schizophrenia Research	|	101	|	1	|	67-75	|	Campbell, D.B. and Lange, L.A. and Skelly, T. and Lieberman, J. and Levitt, P. and Sullivan, P.F.	|	10.1016/j.schres.2008.01.006	|
|	Progress in neurotherapeutics and neuropsychopharmacology 2008	|	2008	|	Progress in Neurotherapeutics and Neuropsychopharmacology	|	3	|	1	|	11-Jan	|	Cummings, J.L.	|	10.1017/S1748232107000183	|
|	Integrating functional brain neuroimaging and developmental cognitive neuroscience in child psychiatry research	|	2008	|	Journal of the American Academy of Child and Adolescent Psychiatry	|	47	|	11	|	1273-1288	|	Pavuluri, M.N. and Sweeney, J.A.	|	10.1097/CHI.0b013e318185d2d1	|
|	Treating a psychotic syndrome in 2007	|	2008	|	Therapie	|	63	|	3	|	165-175	|	OliÃ©, J.-P.	|	10.2515/therapie:2008027	|
|	Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder	|	2008	|	Psychiatry Investigation	|	5	|	2	|	102-105	|	Yun, D.-H. and Pae, C.-U. and Drago, A. and Mandelli, L. and De Ronchi, D. and Patkar, A.A. and Paik, I.H. and Serretti, A. and Kim, J.-J.	|	10.4306/pi.2008.5.2.102	|
|	Cardiac side effects of psychiatric drugs	|	2008	|	Human Psychopharmacology	|	23	|		|	14-Mar	|	Mackin, P.	|	10.1002/hup.915	|
|	Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia	|	2008	|	Biological Psychiatry	|	63	|	1	|	32-41	|	Campbell, D.B. and Ebert, P.J. and Skelly, T. and Stroup, T.S. and Lieberman, J. and Levitt, P. and Sullivan, P.F.	|	10.1016/j.biopsych.2007.04.018	|
|	Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders	|	2007	|	Journal of Child and Adolescent Psychopharmacology	|	17	|	6	|	741-750	|	Kronenberg, S. and Apter, A. and Brent, D. and Schirman, S. and Melhem, N. and Pick, N. and Gothelf, D. and Carmel, M. and Frisch, A. and Weizman, A.	|	10.1089/cap.2006.0144	|
|	Use of whole-genome association scans in disease gene identification, drug discovery and development	|	2007	|	IDrugs	|	10	|	11	|	797-804	|	Roses, A.D. and St Jean, P.L. and Ehm, M.G.	|		|
|	Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response	|	2007	|	Journal of Psychopharmacology	|	21	|	7	|	718-727	|	Hwang, R. and Shinkai, T. and De Luca, V. and Ni, X. and Potkin, S.G. and Lieberman, J.A. and Meltzer, H.Y. and Kennedy, J.L.	|	10.1177/0269881106072341	|
|	The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans	|	2007	|	NeuroReport	|	18	|	12	|	1291-1293	|	Ribeiro, L. and Busnello, J.V. and Cantor, R.M. and Whelan, F. and Whittaker, P. and Deloukas, P. and Wong, M.-L. and Licinio, J.	|	10.1097/WNR.0b013e328273bcb0	|
|	Current status of applied pharmacogenetics in clinical practice	|	2007	|	Personalized Medicine	|	4	|	2	|	221-225	|	Reynolds, K.K. and Bukaveckas, B.L.	|	10.2217/17410541.4.2.221	|
|	Integrating genomics and neuromarkers for the era of brain-related personalized medicine	|	2007	|	Personalized Medicine	|	4	|	2	|	201-215	|	Gordon, E.	|	10.2217/17410541.4.2.201	|
|	Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia	|	2007	|	Psychiatry and Clinical Neurosciences	|	61	|	2	|	174-180	|	Sakumoto, N. and Kondo, T. and Mihara, K. and Suzuki, A. and Yasui-Furukori, N.	|	10.1111/j.1440-1819.2007.01633.x	|
|	Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders	|	2007	|	Neuroscience Letters	|	414	|	2	|	155-158	|	Liu, Z. and Zhu, F. and Wang, G. and Xiao, Z. and Tang, J. and Liu, W. and Wang, H. and Liu, H. and Wang, X. and Wu, Y. and Cao, Z. and Li, W.	|	10.1016/j.neulet.2006.12.013	|
|	Meeting report: From human genetic variations to prediction of risks and responses to drugs and the environment	|	2007	|	Clinical Chemistry and Laboratory Medicine	|	45	|	3	|	427-436	|	Siest, G. and Bastien, B. and Benachour, H. and Herbeth, B. and Jeannesson, E. and Lambert, D. and Samara, A. and Visvikis-Siest, S.	|	10.1515/CCLM.2007.076	|
|	Pharmacogenetics of antiparkinsonian drug treatment: A systematic review	|	2007	|	Pharmacogenomics	|	8	|	2	|	159-176	|	Arbouw, M.E.L. and van Vugt, J.P.P. and Egberts, T.C.G. and Guchelaar, H.-J.	|	10.2217/14622416.8.2.159	|
|	Pattern-recognition techniques with haplotype analysis in pharmacogenomics	|	2007	|	Pharmacogenomics	|	8	|	1	|	75-83	|	Lin, E. and Hwang, Y. and Liang, K.-H. and Chen, E.Y.	|	10.2217/14622416.8.1.75	|
|	Pharmacogenetics and drug therapy in psychiatry - The role of the CYP2D6 polymorphism	|	2007	|	Current Pharmaceutical Design	|	13	|	2	|	241-250	|	Vandel, P. and Talon, J.M. and Haffen, E. and Sechter, D.	|	10.2174/138161207779313704	|
|	Delirium as destiny: Clinical precision and genetic risk	|	2007	|	Critical Care Medicine	|	35	|	1	|	304-305	|	Skrobik, Y.	|	10.1097/01.CCM.0000251293.38217.85	|
|	Major depressive disorders: Depressive disorders	|	2006	|	Psychopharmacogenetics	|		|		|	45-73	|	Serretti, A. and Artioli, P.	|	10.1007/0-387-34577-2_3	|
|	Drug-induced movement disorders	|	2006	|	Psychopharmacogenetics	|		|		|	495-514	|	Goetz, C.G.	|	10.1007/0-387-34577-2_18	|
|	Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts	|	2006	|	Nervenarzt	|	77	|		|	S65-S76	|	Falkai, P. and Maier, W.	|	10.1007/s00115-006-2197-5	|
|	Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders	|	2006	|	European Neuropsychopharmacology	|	16	|	7	|	498-503	|	Yu, Y.W.-Y. and Tsai, S.-J. and Liou, Y.-J. and Hong, C.-J. and Chen, T.-J.	|	10.1016/j.euroneuro.2005.12.004	|
|	Pharmacogenetics in affective disorders: A drug response approach	|	2006	|	Current Pharmacogenomics	|	4	|	3	|	191-208	|	Lefebvre, R. and Del-Favero, J.	|	10.2174/157016006778195061	|
|	Biomarker world congress 2006. 16-18 May 2006, Philadelphia, PA, USA	|	2006	|	IDrugs	|	9	|	7	|	478-480	|	Paterson, D.A.	|		|
|	EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetics basis of adverse drug reactions	|	2006	|	Pharmacogenomics	|	7	|	4	|	633-639	|	Molokhia, M. and McKeigue, P.	|	10.2217/14622416.7.4.633	|
|	The role of fMRI in drug discovery	|	2006	|	Journal of Magnetic Resonance Imaging	|	23	|	6	|	862-876	|	Wise, R.G. and Tracey, I.	|	10.1002/jmri.20584	|
|	Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment	|	2006	|	European Neuropsychopharmacology	|	16	|	4	|	248-259	|	Hwang, R. and Shinkai, T. and Deluca, V. and Macciardi, F. and Potkin, S. and Meltzer, H.Y. and Kennedy, J.L.	|	10.1016/j.euroneuro.2005.09.004	|
|	Bioactive lipids in schizophrenia	|	2006	|	International Review of Psychiatry	|	18	|	2	|	85-98	|	Berger, G.E. and Smesny, S. and Amminger, G.P.	|	10.1080/09540260600583072	|
|	Metabolic profiling of patients with schizophrenia	|	2006	|	PLoS Medicine	|	3	|	8	|	1222-1223	|	Kaddurah-Daouk, R.	|	10.1371/journal.pmed.0030363	|
|	Pharmacogenetics for off-patent antipsychotics: Reframing the risk for tardive dyskinesia and access to essential medicines	|	2006	|	Expert Opinion on Pharmacotherapy	|	7	|	2	|	119-133	|	Ozdemir, V. and Aklillu, E. and Mee, S. and Bertilsson, L. and Albers, L.J. and Graham, J.E. and Caligiuri, M. and Lohr, J.B. and Reist, C.	|	10.1517/14656566.7.2.119	|
|	Pharmacogenetics and the concept of individualized medicine	|	2006	|	Pharmacogenomics Journal	|	6	|	1	|	16-21	|	Shastry, B.S.	|	10.1038/sj.tpj.6500338	|
|	Psychiatric genetics - The new era: Genetic research and some clinical implications	|	2005	|	British Medical Bulletin	|	73	|		|	107-122	|	Prathikanti, S. and Weinberger, D.R.	|	10.1093/bmb/ldh055	|
|	A candidate pathway strategy for integration of pharmacogenomic components of variability in antipsychotic treatment outcomes: A focus on aripiprazole	|	2005	|	Current Pharmacogenomics	|	3	|	4	|	305-317	|	Reist, C. and Albers, L.J. and Marder, S.R. and Williams-Jones, B. and Wu, J.C. and Mee, S. and Shimoda, K. and Someya, T. and Ozdemir, V.	|	10.2174/157016005774913194	|
|	Clustering of metabolic comorbidity in schizophrenia: A genetic contribution?	|	2005	|	Journal of Psychopharmacology	|	19	|	6	|	47-55	|	Gough, S.C.L. and O'Donovan, M.C.	|	10.1177/0269881105058380	|
|	Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations	|	2005	|	Psychopharmacology	|	181	|	1	|	179-187	|	Hwang, R. and Shinkai, T. and De Luca, V. and MÃ¼ller, D.J. and Ni, X. and Macciardi, F. and Potkin, S. and Lieberman, J.A. and Meltzer, H.Y. and Kennedy, J.L.	|	10.1007/s00213-005-2223-5	|
|	Pharmacogenetic studies of psychotropic drug-induced adverse effects	|	2005	|	Current Pharmacogenomics	|	3	|	2	|	157-164	|	Tsai, S.-J. and Hong, C.-J.	|	10.2174/1570160054022944	|
|	Influence ofCYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients	|	2005	|	Pharmacogenetics and Genomics	|	15	|	1	|	5-Jan	|	Rotger, M. and Colombo, S. and Furrer, H. and Bleiber, G. and Buclin, T. and Lee, B.L. and Keiser, O. and Biollaz, J. and DÃ©costerd, L. and Telenti, A. and Battegay, M. and Bernard, M.-C. and Bernasconi, E. and Bucher, H. and Burgisser, P. and Egger, M. and Erb, P. and Fierz, W. and Flepp, M. and Francioli, P. and Furrer, H.J. and Gorgievski, M. and nthard, H.G. and Grob, P. and Hirschel, B. and Kind, C. and Klimkait, T. and Ledergerber, B. and Lauper, U. and Opravil, M. and Paccaud, F. and Pantaleo, G. and Perrin, L. and Piffaretti, J.-C. and Rickenbach, M. and Rudin, C. and Schupbach, J. and Telenti, A. and Vernazza, P. and Wagels, T. and Weber, R.	|	10.1097/01213011-200501000-00001	|
|	The dopamine D4 receptor and your association with mental disorders	|	2005	|	Revista de Investigacion Clinica	|	57	|	1	|	65-75	|	Aguirre-Samudio, A.J. and Nicolini, H.	|		|
|	Recursive partitioning analysis of complex disease pharmacogenetic studies. I. Motivation and overview	|	2005	|	Pharmacogenomics	|	6	|	1	|	65-75	|	Young, S.S. and Ge, N.	|	10.1517/14622416.6.1.65	|
|	Neuregulin genotype and medication response in Finnish patients with schizophrenia	|	2004	|	NeuroReport	|	15	|	16	|	2517-2520	|	Kampman, O. and Anttila, S. and Illi, A. and Saarela, M. and Rontu, R. and Mattila, K.M. and Leinonen, E. and LehtimÃ¤ki, T.	|	10.1097/00001756-200411150-00017	|
|	Pharmacogenetics	|	2004	|	SENDROM	|	16	|	8	|	42-54	|	Bozok-Ã‡etintaÅŸ, V. and Kosova, B.	|		|
|	The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions	|	2004	|	Current Drug Targets	|	5	|	6	|	573-579	|	Berecz, R. and Dorado, P. and De La Rubia, A. and CÃ¡ceres, M.C. and Degrell, I. and Llerena, A.	|	10.2174/1389450043345263	|
|	Genetics of depression. Current knowledge and perspectives	|	2004	|	Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz	|	47	|	5	|	487-492	|	Maier, W.	|	10.1007/s00103-003-0773-4	|
|	Pharmacogenetics of antipsychoatics.	|	2004	|	Nagoya journal of medical science	|	67	|	1	|	7-Jan	|	Ozaki, N.	|		|
|	A Perspective on Progress in Pharmacogenomics	|	2003	|	American Journal of PharmacoGenomics	|	3	|	6	|	371-373	|	Kerwin, R.W.	|	10.2165/00129785-200303060-00003	|
|	Refining pharmacogenetic research in schizophrenia: Control for patient-related variables	|	2003	|	Drug Development Research	|	60	|	2	|	164-171	|	Lane, H.-Y. and Chang, Y.-C. and Huang, C.-L. and Chang, W.-H.	|	10.1002/ddr.10295	|
|	Biological predictors of lithium response in bipolar disorder	|	2003	|	Psychiatry and Clinical Neurosciences	|	57	|	3	|	243-250	|	Ikeda, A. and Kato, T.	|	10.1046/j.1440-1819.2003.01112.x	|
|	The human genome sequence: Impact on health care	|	2003	|	Indian Journal of Medical Research	|	117	|		|	43-65	|	Bashyam, M.D. and Hasnain, S.E.	|		|
|	Genetics of inflammatory bowel disease: Scientific and clinical implications	|	2003	|	Bailliere's Best Practice and Research in Clinical Gastroenterology	|	17	|	1	|	18-Mar	|	Satsangi, J. and Morecroft, J. and Shah, N.B. and Nimmo, E.	|	10.1053/bega.2002.0349	|
|	Pharmacogenomics	|	2002	|	Medical Science Monitor	|	8	|	7	|	RA152-RA163	|	Tribut, O. and Lessard, Y. and Reymann, J.-M. and Allain, H. and BentuÃ©-Ferrer, D.	|		|
|	Psychiatric genomics, Inc	|	2002	|	Pharmacogenomics	|	3	|	3	|	417-420	|	Palfreyman, M.G.	|	10.1517/14622416.3.3.417	|
|	Pharmacogenetics of lithium prophylaxis in mood disorders: Analysis of COMT, MAO-A, and GÎ²3 variants	|	2002	|	American Journal of Medical Genetics - Neuropsychiatric Genetics	|	114	|	4	|	370-379	|	Serretti, A. and Lorenzi, C. and Lilli, R. and Mandelli, L. and Pirovano, A. and Smeraldi, E.	|	10.1002/ajmg.10357	|
|	The frustrating search for schizophrenia genes	|	2000	|	American Journal of Medical Genetics - Seminars in Medical Genetics	|	97	|	1	|	3-Jan	|	Tsuang, M.T. and Paraone, S.V.	|	10.1002/(SICI)1096-8628(200021)97:1<1::AID-AJMG1>3.0.CO;2-P	|
|	Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype	|	1997	|	British Journal of Psychiatry	|	170	|		|	23-26	|	Armstrong, M. and Daly, A.K. and Blennerhassett, R. and Ferrier, N. and Idle, J.R.	|	10.1192/bjp.170.1.23	|
|	Genetic correlations with ethanol withdrawal severity	|	1983	|	Pharmacology, Biochemistry and Behavior	|	18	|		|	541-547	|	Crabbe Jr., J.C. and Young, E.R. and Kosobud, A.	|	10.1016/0091-3057(83)90233-2	|
|	Behavioral Toxicity to Medications in a Six-Year-Old Boy: A Genetic Marker?	|	1983	|	Journal of the American Academy of Child Psychiatry	|	22	|	5	|	492-494	|	WATERS, B.G.H. and SIMEON, J.	|	10.1016/S0002-7138(09)61516-8	|
|	Dextroamphetamine and arecoline as pharmacogenetic probes in normals and remitted bipolar patients	|	1981	|	Psychopharmacology Bulletin	|	17	|	3	|	80-82	|	Nurnberger Jr., J.I. and Gershon, E.S. and Sitaram, N.	|		|
|	The contribution of genetics to biological psychiatry	|	1976	|	Neuropsychobiology	|	2	|	2	|	65-73	|	Mendlewicz, J.	|	10.1159/000117532	|
|	Pharmacogenetic tests and depressive	|	2019	|	Pharmacogenomics	|	20	|	2	|		|	Bousman, A. C.	|	10.2217/pgs-2018-0142	|
|	Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review	|	2021	|	Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review	|	17	|		|		|	Aboelbaha, S	|	10.2147/NDT.S312966	|
|	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study	|	2019	|	J Psychiatr Res	|	111	|		|	59-67	|	Greden, J. F.	|	10.1016/j.jpsychires.2019.01.003	|
|	A Pharmacogenomic-based Antidepressant Treatment for Patients	|	2018	|	Clinical Psychopharmacology and Neuroscience	|	16	|	4	|	469-480	|	Han, C.	|	10.9758/cpn.2018.16.1.469	|
|	Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial	|	2017	|	BMC psychiatry	|	17	|	1	|		|	Pérez, V.	|	10.1186/s12888-017-1412-1	|
|	Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder	|	2020	|	Depress Anxiety	|	37	|	9	|	834-841	|	Perlis, R. H.	|	10.1002/da.23029	|
|	Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report	|	2015	|	Clin Psychopharmacol Neurosci	|	13	|	2	|	150-6	|	Singh, A. B.	|	10.9758/cpn.2015.13.2.150	|
|	A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder	|	2013	|	Discov Med	|	16	|	89	|	219-27	|	Winner, J. G.	|		|
